<html lang="en"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <link rel="shortcut icon" href="./favicon.png">
    <link rel="preload" href="./static/media/SourceSansPro-Regular.DZLUzqI4.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-SemiBold.sKQIyTMz.woff2" as="font" type="font/woff2" crossorigin="">
    <link rel="preload" href="./static/media/SourceSansPro-Bold.-6c9oR8J.woff2" as="font" type="font/woff2" crossorigin="">

    <title>app</title>

    <!-- initialize window.prerenderReady to false and then set to true in React app when app is ready for indexing -->
    <script>
      window.prerenderReady = false
    </script>
    <script type="module" crossorigin="" src="./static/js/index.BlylrL8P.js"></script>
    <link rel="stylesheet" crossorigin="" href="./static/css/index.DpJG_94W.css">
  <style media=""></style><style data-emotion="st-emotion-cache-global" data-s=""></style><style data-emotion="st-emotion-cache" data-s=""></style><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.BqlD3NTA.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/index.DW_MHI2K.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FormClearHelper.UtDFKbpT.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/FileHelper.DV2KuUj6.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/ProgressBar.BtMHwdZZ.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/Hooks.YZgOFmbn.js"><link rel="modulepreload" as="script" crossorigin="" href="https://pieree369-olmocr.hf.space/static/js/UploadFileInfo.C-jY39rj.js"></head>
  <body>
    <noscript>You need to enable JavaScript to run this app.</noscript>
    <div id="root"><div class=""><div class="withScreencast" data-testid="stScreencast"><div class="stApp stAppEmbeddingId-t797t1oningx st-emotion-cache-1r4qj8v ee4bbma0" data-testid="stApp" data-test-script-state="notRunning" data-test-connection-state="CONNECTED"><header tabindex="-1" class="stAppHeader st-emotion-cache-12fmjuu e4hpqof0" data-testid="stHeader"><div class="stDecoration st-emotion-cache-1dp5vir e4hpqof1" data-testid="stDecoration" id="stDecoration"></div><div class="stAppToolbar st-emotion-cache-15ecox0 e4hpqof2" data-testid="stToolbar"><div class="stToolbarActions st-emotion-cache-1p1m4ay e1i26tt72" data-testid="stToolbarActions"></div><span id="MainMenu" class="stMainMenu st-emotion-cache-czk5ss ev04twb8" data-testid="stMainMenu" aria-haspopup="true" aria-expanded="false"><button kind="headerNoPadding" data-testid="stBaseButton-headerNoPadding" aria-label="" class="st-emotion-cache-l1ktzw em9zgd018"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M12 8c1.1 0 2-.9 2-2s-.9-2-2-2-2 .9-2 2 .9 2 2 2zm0 2c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2zm0 6c-1.1 0-2 .9-2 2s.9 2 2 2 2-.9 2-2-.9-2-2-2z"></path></svg></button></span></div></header><div class="stAppViewContainer appview-container st-emotion-cache-1yiq2ps eht7o1d0" data-testid="stAppViewContainer" data-layout="narrow"><section tabindex="0" class="stMain st-emotion-cache-bm2z3a eht7o1d1" data-testid="stMain"><div class="stMainBlockContainer block-container st-emotion-cache-mtjnbi eht7o1d4" data-testid="stMainBlockContainer"><div data-testid="stVerticalBlockBorderWrapper" data-test-scroll-behavior="normal" class="st-emotion-cache-0 eu6p4el5"><div class="st-emotion-cache-b95f0i eu6p4el4"><div class="stVerticalBlock st-emotion-cache-1n76uvr eu6p4el3" data-testid="stVerticalBlock" width="704"><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stHeading" data-testid="stHeading"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 id="olmocr">OLMOCR<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#olmocr" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="st-emotion-cache-8atqhb e1mlolmg0"><div class="stFileUploader st-emotion-cache-0 e17y52ym15" data-testid="stFileUploader" width="704"><label data-testid="stWidgetLabel" aria-hidden="true" class="st-emotion-cache-1s2v671 e1dx5vew0"><div data-testid="stMarkdownContainer" class="st-emotion-cache-wq5ihp e1icttdg0"><p>Upload a PDF or Image</p></div></label><section role="presentation" data-testid="stFileUploaderDropzone" aria-label="Upload a PDF or Image" class="st-emotion-cache-1gulkj5 e17y52ym0" tabindex="0"><input data-testid="stFileUploaderDropzoneInput" accept="application/streamlit,.pdf,.png,.jpg,.jpeg" type="file" style="border: 0px; clip: rect(0px, 0px, 0px, 0px); clip-path: inset(50%); height: 1px; margin: 0px -1px -1px 0px; overflow: hidden; padding: 0px; position: absolute; width: 1px; white-space: nowrap;" tabindex="-1"><div data-testid="stFileUploaderDropzoneInstructions" class="st-emotion-cache-u8hs99 e17y52ym1"><span class="st-emotion-cache-nwtri e17y52ym2"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-6rlrad ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19.35 10.04A7.49 7.49 0 0012 4C9.11 4 6.6 5.64 5.35 8.04A5.994 5.994 0 000 14c0 3.31 2.69 6 6 6h13c2.76 0 5-2.24 5-5 0-2.64-2.05-4.78-4.65-4.96zM19 18H6c-2.21 0-4-1.79-4-4 0-2.05 1.53-3.76 3.56-3.97l1.07-.11.5-.95A5.469 5.469 0 0112 6c2.62 0 4.88 1.86 5.39 4.43l.3 1.5 1.53.11A2.98 2.98 0 0122 15c0 1.65-1.35 3-3 3zM8 13h2.55v3h2.9v-3H16l-4-4z"></path></svg></span><div class="st-emotion-cache-j7qwjs e17y52ym4"><span class="st-emotion-cache-9ycgxx e17y52ym3">Drag and drop file here</span><small class="st-emotion-cache-1rpn56r ejh2rmr0">Limit 200MB per file • PDF, PNG, JPG, JPEG</small></div></div><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02">Browse files</button></section><div class="st-emotion-cache-fis6aj e17y52ym5"><ul class="st-emotion-cache-14m29r0 e17y52ym6"><li class="st-emotion-cache-1l95nvm e17y52ym7"><div class="stFileUploaderFile st-emotion-cache-12xsiil e17y52ym10" data-testid="stFileUploaderFile"><div class="st-emotion-cache-10ix4kq e17y52ym12"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-4mjat2 ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zM6 20V4h7v5h5v11H6z"></path></svg></div><div class="stFileUploaderFileData st-emotion-cache-1l4firl e17y52ym8"><div class="stFileUploaderFileName st-emotion-cache-1uixxvy e17y52ym9" data-testid="stFileUploaderFileName" title="501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf">501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</div><small class="st-emotion-cache-1rpn56r ejh2rmr0">8.4MB</small></div><div data-testid="stFileUploaderDeleteBtn"><button kind="minimal" data-testid="stBaseButton-minimal" aria-label="" class="st-emotion-cache-8ccstr em9zgd06"><svg viewBox="0 0 24 24" aria-hidden="true" focusable="false" fill="currentColor" xmlns="http://www.w3.org/2000/svg" class="e144pc0f1 st-emotion-cache-1pbsqtx ex0cdmw0"><path fill="none" d="M0 0h24v24H0V0z"></path><path d="M19 6.41L17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41z"></path></svg></button></div></div></li></ul></div></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stButton st-emotion-cache-8atqhb e1mlolmg0" data-testid="stButton"><button kind="secondary" data-testid="stBaseButton-secondary" aria-label="" class="st-emotion-cache-ocsh0s em9zgd02"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1hyd1ho e1icttdg0"><p>Submit</p></div></button></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p><strong>Processing file:</strong> 501_PDFsam_Pharmacology_and_Pharmacotherapeutics,_24e_etc_Z_Library.pdf</p></div></div></div><div class="stElementContainer element-container st-emotion-cache-kj6hex eu6p4el1" data-testid="stElementContainer" data-stale="false" width="auto"><div class="stMarkdown" data-testid="stMarkdown"><div data-testid="stMarkdownContainer" class="st-emotion-cache-1104ytp e1icttdg0"><p>having a poor ability to hydrolyse succinylcholine, or acquired deficiency of normal pseudocholinesterase as in liver disease, predisposes to its development. Metabolic acidosis can also precipitate succinylcholine apnoea. It is treated by artificial respiration and fresh blood transfusion. No antidote is available.</p>
<ul>
<li>Malignant hyperthermia: The drug can rarely trigger serious malignant hyperthermic crisis in patients receiving ether or halothane.</li>
<li>Miscellaneous: Muscle soreness is a frequent complaint following succinylcholine. Increase in intraocular tension can also occur.</li>
<li>Drug interactions: They are similar to those of d-tubocurarine. AntiChE drugs, however, act synergistically with depolarising blockers.
Preparations and dosage: Succinylcholine chloride 50 mg per ml . Dose: 1 mg per kg given slowly IV, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> as needed.
Therapeutic uses of peripheral skeletal muscle relaxants:</li>
<li>Adjuvant to anaesthesia: The main use of skeletal muscle relaxants is to promote skeletal muscle relaxation during abdominal surgery, orthopaedic manipulations, and various brief procedures like laryngoscopy, bronchoscopy and oesophagoscopy. When the procedure involved is of short duration, succinylcholine or mivacurium is the drug of choice.</li>
<li>In electroconvulsive therapy: Succinylcholine or mivacurium is often administered along with diazepam to protect the patient from injury during electroconvulsive therapy.</li>
<li>In spastic disorders: The curarimimetic skeletal muscle relaxants have been used to treat the severe spasms of tetanus. This use, however, involves risk and needs expert supervision.
III Drugs which inhibit ACh release from motor nerve terminals.
BOTULINUM TOXIN TYPE A is produced by Clostridium botulinum. It binds irreversibly to presynaptic, cholinergic sites and inhibits the release of ACh from the motor nerve terminals. Local injection of the toxin weakens the overactive muscle and decreases the hypersecretion of glands innervated by cholinergic neurons. It has been used to treat:
(1) Spastic conditions such as spasmodic torticolis, hemifacial spasm, strabismus, blepharospasm, dystonias, lower esophageal spasm and painful anal fissure;
(2) Wrinkles on the face and neck;
(3) Palmar hyperhidrosis.
(4) Overactive bladder (Chapter 20). It appears to be safe and effective in these conditions. Its action lasts for 3-4 months.
Adverse reactions include ptosis, diplopia, reduced blinking leading to dry eyes, minor bruises and lid swelling; reversible muscle atrophy can occur after repeated administration.</li>
</ul>
<p>Botulinum toxin Type B can be used in patients who have become resistant to Type A toxin.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-acting-directly-on-skeletal-muscle">Drugs Acting Directly on Skeletal Muscle<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-acting-directly-on-skeletal-muscle" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>DANTROLENE: This phenytoin analogue relaxes the skeletal muscles by binding to the ryanodine receptors (RYR) on the sarcoplasmic reticulum, blocking their opening. This prevents the release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the sarcoplasmic stores. Thus, the muscle contraction is weakened without muscle paralysis. It does not alter the neuromuscular transmission. It has relatively little effect on cardiac and smooth muscle. Given orally, it is incompletely (about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> ) absorbed and is largely metabolised in the liver. It can also be given IV. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi></mrow><annotation encoding="application/x-tex">25 \mathrm{mg} / \mathrm{d}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span></span></span></span></span>, increased weekly to a maximum of 100 mg bid or qid.</p>
<p>Adverse reactions: These include generalised muscle weakness, dizziness, drowsiness, fatigue and diarrhoea. Rarely, it may cause serious hepatotoxicity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Spasticity: The drug is particularly useful for the treatment of spasticity (especially cerebral spasticity) in patients in whom nursing care is made difficult by muscle spasm. Patients in whom spastic, dystonic stiffness is useful as a sort of protective endogenous crutch should not be treated with dantrolene.</li>
<li>Malignant hyperthermia: Intravenous dantrolene ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, bolus, repeated if required to a maximum total dose of 100 mg ) is life-saving in this rare, fatal and familial, genetic disorder of skeletal muscle triggered by any potent inhalation anaesthetic, depolarising muscle relaxant, curare-like neuromuscular blocking agent and even by stress. In susceptible individuals, these can cause excessive release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the sarcoplasmic reticulum, leading to muscle rigidity, hyperpyrexia (temperature more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>42</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">42^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">4</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> ), hyperkalemia, tachycardia and metabolic acidosis. It is a medical emergency.
It must be noted that management of the patient with spasticity implies more than just treatment of the spasticity. For many patients the increased tone is not harmful and may even be helpful. Active measures to reduce spasticity are only justified where the reflex hyperexcitability interferes with function, making rehabilitation, physiotherapy and nursing care difficult.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-v-br-other-biogenic-amines-and-polypeptides">SECTION V &lt;br&gt; Other Biogenic Amines and Polypeptides<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-v-br-other-biogenic-amines-and-polypeptides" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 23: Histamine and Antihistaminic Drugs
Chapter 24: 5-Hydroxytryptamine (Serotonin), its Agonists and Antagonists; and Treatment of Migraine
Chapter 25: Angiotensin, Kinins, Leukotrienes, Prostaglandins and Cytokines</p>
<p>23</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine-and-antihistaminic-drugs">Histamine and Antihistaminic Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine-and-antihistaminic-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HISTAMINE ('tissue amine'), a potent biogenic amine, was synthesised even before its isolation from plants and animals by Windaus and Vogt in 1907. The compound was isolated from ergot extracts by Barger and Dale in 1910 and reports regarding its pharmacological actions were published by Dale and Laidlaw in 1910-1911. The role of this extremely potent natural substance in the genesis of allergic and anaphylactic manifestations was forecast by the brilliant work of Lewis.</p>
<p>Distribution and synthesis: Histamine, an imidazole compound, is widely distributed in plant and animal tissues, and is also present in the venom of bees and wasps. Almost all tissues in mammals synthesise histamine, from amino acid histidine by decarboxylation with the help of histidine decarboxylase (Fig 23.1). Histamine is also synthesised by the microflora in the GI tract from dietary histidine. Very little, however, reaches the circulation as most of what is absorbed is rapidly metabolised in the intestinal wall and the liver.
<img src="assets/images/image-20251214-941ae906.jpeg" alt="img-0.jpeg"></p>
<p>Histamine is present in various biological fluids, and in platelets, leucocytes, basophils and mast cells. A major portion of histamine is stored in mast cells and circulating basophils. These cells possess histidine decarboxylase, and also contain specialised granules, wherein histamine is stored in an inactive form. In the mast cells of majority of animals, histamine is stored along with heparin, and in rodents, along with 5-HT. Tissues devoid of mast cells, e.g., human epidermis, gastric mucosa and CNS neurons also contain a significant concentration of histamine. Within the gut, the histamine concentration is highest in the stomach wall and gastric and intestinal glands. In the CNS, the area postrema, mast cells (histaminocytes) and histaminergic neurons of the pituitary stalk and the hypothalamus contain significant amounts of histamine.</p>
<p>Mechanism of action: Four types of receptors, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub><mo separator="true">,</mo><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}, \mathrm{H}_{2}, \mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> have been identified and cloned. All these receptors belong to the family of GPCR (G protein coupled receptors). (Table 23.1).</p>
<p>Table 23.1
Histamine receptors and their functions</p>
<table><thead><tr><th style="text-align: center;">Receptor</th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></th></tr></thead><tbody><tr><td style="text-align: center;">Distribution</td><td style="text-align: center;">Widespread in the neuronal system, smooth muscles, endothelium and other cells</td><td style="text-align: center;">Widespread - gastric mucosa, smooth muscle, heart, brain and mast cells</td><td style="text-align: center;">Mainly in the histaminergic neurons and myenteric plexus</td><td style="text-align: center;">Mainly bone marrow and eosinophils, neutrophils and CD4 T cells</td></tr><tr><td style="text-align: center;">General role</td><td style="text-align: center;">On stimulation: itching, pain, vasodilatation, tachycardia, hypotension, increased permeability, bronchoconstriction, cough</td><td style="text-align: center;">Increased gastric acidity, vascular permeability (hypotension); and chronotropic, inotropic actions on heart; increased airway mucus production</td><td style="text-align: center;">Prevent excessive bronchoconstriction; mediate pruritus</td><td style="text-align: center;">Differentiation of myeloblasts and promyelocytes</td></tr><tr><td style="text-align: center;">Role in CNS</td><td style="text-align: center;">Control: sleep-awake cycle, food intake, temperature regulation, emotional behaviour, memory and learning (Feedback inhibitor)</td><td style="text-align: center;">Neuroendocrine regulation</td><td style="text-align: center;">Presynaptic heteroreceptor; decrease histamine, NA, DA, 5HT and ACh release</td><td style="text-align: center;">Not known</td></tr><tr><td style="text-align: center;">Role in allergy and immune modulation</td><td style="text-align: center;">Increased release of histamine and other mediators; promote chemotaxis of eosinophils and neutrophils; block humoral immunity and IgE production. Induction of cellular immunity</td><td style="text-align: center;">Decrease neutrophil and eosinophil chemotaxis; induce humoral immunity; suppress cellular immunity; induce IL-10 and suppress IL-12</td><td style="text-align: center;">Control neurogenic inflammation; proinflammatory activity</td><td style="text-align: center;">Increase eosinophil chemotaxis and IL-16 production</td></tr><tr><td style="text-align: center;">Antagonists (see text)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers</td><td style="text-align: center;">Under evaluation</td><td style="text-align: center;">Under evaluation</td></tr></tbody></table>
<ul>
<li>Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors causes pain, pruritus, bronchoconstriction, vasodilatation, increase in vascular permeability and in secretions. It is associated with increase in intracellular cyclic guanosine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><mo separator="true">,</mo><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime}, 5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9463em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span> monophosphate (cGMP). In the tissues, histamine serves as a chemotactic agent for neutrophils and eosinophils.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor effects can be competitively blocked specifically by the conventional antihistaminics ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers).</li>
<li>Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors increases the gastric acid secretion and myocardial contractility. These effects are not blocked by the conventional antihistaminics but are specifically blocked by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">H_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists such as cimetidine. Impromidine is a potent <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonist and behaves as a competitive antagonist at the autoinhibitory receptors. Both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">H_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors appear to be involved in vascular dilatation, hypotension and edema formation.</li>
<li>For <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, see Table 23.1.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions-of-histamine">Pharmacological actions of histamine:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions-of-histamine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-system">Cardiovascular system:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Blood vessels: Although histamine may produce pulmonary and systemic vasoconstriction in certain herbivores like rabbits and guinea pigs, it causes marked vasodilatation in human beings. In man, the pulmonary vessels are dilated by histamine, producing a fall in pulmonary artery pressure. The cerebral blood vessels are dilated in majority of the species. It produces throbbing headache, palpable temporal pulsations, and a transient increase in the CSF pressure. The headache is attributed to stretching of sensory nerve endings around the cranial arteries. Histamine constricts large veins.</li>
</ul>
<p>It acts on the blood vessels in several ways:
(a) Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors on the endothelial cells causes rapid and short-lived</p>
<p>vasodilatation, mainly of arterioles through the release of NO.
(b) Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the vascular smooth muscle causes slower but more prolonged vasodilatation, and
(c) Direct relaxation of the smooth muscle of the arterioles and capillaries leads to their dilatation and fall in BP.
In man, histamine causes marked flushing, a sense of warmth; and marked increase in capillary permeability after large doses, which causes edema and reduction in plasma volume.</p>
<ul>
<li>Blood pressure: Hypotension, induced by moderate doses of histamine is transient due to its rapid degradation and the presence of protective reflexes. Large doses, however, produce prolonged hypotension. Histamine-induced hypotension can be prevented but only partially reversed by antihistaminic agents. However, it can be reversed by adrenaline (Physiological antagonism).
Triple response: When a pointed object is drawn lightly over the skin, the stroke line becomes blanched, i.e. white reaction, owing to contraction of the precapillary sphincters. It lasts for about 15 seconds.
When histamine ( 20 mcg ) is injected ID or the skin is stroked firmly with the pointed object in man, a triple response develops at the site. It comprises sequentially:
(a) Flush or red reaction which is a red line/spot developing within 10 seconds, owing to local dilatation of capillaries and venules; then
(b) Wheal which is local swelling due to edema, and mottled reddening around the injury, and lasts for about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span></span></span></span></span> minute; it is due to increased permeability of capillaries and post capillary venules, with consequent extravasation of fluid; and finally
(c) Flare in which the redness with irregular margins spreads out from the injury.</li>
</ul>
<p>The triple response (Lewis response) is a part of the normal reaction to injury. Its prevention is used to evaluate antihistaminic activity of a new drug.</p>
<ul>
<li>Heart: Histamine increases the sinus rate (positive chronotropic action); increases the amplitude of ventricular contraction (positive inotropic action); decreases A-V conduction time and increases coronary blood flow. High concentrations induce ventricular fibrillation.
Smooth muscle: Histamine stimulates the smooth muscle of various tissues directly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> action). However, the individual tissue responses show a marked variation. The bronchial and the uterine smooth muscle is highly sensitive to histamine. Its action on the pregnant uterus is, however, not significant. Individuals suffering from bronchial asthma and certain other pulmonary diseases develop a sharp fall in vital capacity and considerable respiratory embarrassment in response to histamine. Histamine-induced bronchospasm is antagonised by adrenaline, isoprenaline and aminophylline but not by antihistaminics or atropine.</li>
</ul>
<p>The GI and the ureteral smooth muscles respond moderately to histamine. Histamine, through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors, causes gall bladder contraction while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-receptors mediate gall bladder relaxation.</p>
<p>Exocrine glands: Histamine is an important physiological mediator of gastric acid secretion. It acts by activating <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors (Chapter 43). It is blocked by the specific <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists.</p>
<p>Central nervous system: Histamine does not readily cross the BBB. The histamine</p>
<p>receptors in the brain mediate the actions of locally synthesised, stored and released histamine. There are two types of histamine containing cells in the brain: (1) Histaminergic neurons and (2) Mast cells. Histamine is thought to be a waking amine within the brain and is believed to act by "increasing the sensitivity of large cerebral areas to excitatory inputs". It acts through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which release intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which release intracellular cyclic AMP. Competitive blocking of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">H_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0813em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors by the 'classical' antihistaminic drugs and of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors by cimetidine causes drowsiness as an adverse effect.</p>
<p>Histamine also modulates the release of neurotransmitters via presynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors located on histaminergic and non-histaminergic neurons in the central and peripheral nervous systems. The evidence suggests a role of histamine as a neurotransmitter in the CNS.</p>
<p>Immunomodulation: All the four histamine receptors are involved in immunomodulation (Table 23.1).</p>
<p>Miscellaneous actions: Histamine, on intra-epidermal injection, evokes itching and pain.
Histamine has an effect on lymphocytes via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors and it also inhibits the secretory activity of the mast cells and the basophils by a negative feedback via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. It facilitates pro-inflammatory activity through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. It also probably plays a part in embryonic development and wound healing.</p>
<p>Absorption, fate and excretion: Histamine is a very stable compound and is absorbed from all sites. However, only a small quantity of oral histamine reaches the circulation because of its first pass metabolism. Histamine metabolism varies according to the animal species, sex and the organ studied. In man, it is mainly converted into methylhistamine by an enzyme imidazole-n-methyltransferase and then further converted by MAO-B into 1methylimidazole acetic acid. In some species like rats, it is mainly metabolised by oxidative deamination by the enzyme diamine oxidase (histaminase) present in the liver, kidney and intestinal mucosa.</p>
<p>Adverse reactions: These are due to its pharmacological actions and include hypotension, flushing, angioedema, headache, visual disturbances, diarrhoea and dyspnea due to bronchospasm. Man and guinea pig are extremely sensitive to histamine while rats and mice are highly resistant. Large quantities of histamine may be formed by bacteria in the small intestine acting on spoiled fish which may have high histidine content. Ingestion of such fish may lead to severe nausea, griping, headache and sweating. Similar reaction may be observed in susceptible subjects after consumption of red wine.</p>
<p>Uses: It was used to study gastric acid secretion.
BETAHISTINE HYDROCHLORIDE: is a histamine substitute, claimed to reduce the frequency of episodes of vertigo in some patients with Meniere's syndrome. The drug causes vasodilatation and improves blood flow to the labyrinth and brainstem. The improvement is short lived. The compound may aggravate peptic ulcer and bronchial asthma. It can cause drowsiness.</p>
<p>Histamine liberators: Various agents can release tissue histamine and may thus cause histamine reactions. They are:
I Those which release histamine mainly from the mast cells with minimal tissue damage:</p>
<ul>
<li>Proteolytic enzymes like Trypsin, certain Venoms, Food products, e.g. Crabs, Lobsters and Fish.</li>
</ul>
<ul>
<li>Surface tension reducing substances like Bile salts, Anionic and Cationic surfactants.</li>
<li>Substances with a high molecular weight like Dextran, and Polyvinyl pyrrollidone.</li>
<li>Drugs, particularly organic bases such as quaternary ammonium compounds, dTubocurarine, Morphine, Pethidine, Amphetamine, Hydralazine, Tolazoline, basic polypeptides (Polymyxin B) and a few Antihistaminic drugs; and</li>
<li>The polybasic compound 48/40 and the compound 19/35L, the most potent histamine liberators, used in animal experiments.
II Those which release histamine accompanied by substantial tissue damage:</li>
<li>Trauma due to cold and chemical, thermal or radiant energy.</li>
<li>Antigen-antibody reactions (Chapter 2).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="histamine-anaphylaxis-and-allergy">Histamine, Anaphylaxis and Allergy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#histamine-anaphylaxis-and-allergy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The term anaphylaxis is used clinically to describe a medical emergency caused by allergy to a variety of agents such as drugs, foods, plants, chemicals, latex and insect/reptile bites. It is mediated by IgE (Chapter 2), and histamine is the most important mediator involved in it. The clinical features in man are due to laryngeal edema, bronchospasm and hypotension (anaphylactic shock). An anaphylactic reaction may progress either slowly or rapidly, the latter especially after parenteral drug administration.</p>
<p>The term anaphylactoid is used for a similar condition, not IgE induced, commonly caused by vancomycin, quinolone antibiotics, opioids and iodine containing contrast dyes. It is, however, safer to assume that all such reactions are immune mediated, and avoid future exposure to the same agent.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="treatment-of-anaphylactic-shock">Treatment of anaphylactic shock:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-anaphylactic-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Anaphylactic shock needs immediate treatment for laryngeal edema, bronchospasm and hypotension:</p>
<ul>
<li>Lay the patient flat and raise his legs.</li>
<li>When possible, apply a tourniquet to obstruct the draining blood flow from the site of deposition of the antigen or inciting medication.</li>
<li>Attend to the airway.</li>
<li>Administer adrenaline: Adrenaline, 1:1000 solution IM, produces a dramatic reversal of the hypotension, bronchospasm and laryngeal edema and is life-saving. It may be repeated cautiously after 15 to 20 minutes, if necessary. When the patient is severely ill and there is doubt about the adequacy of circulation and absorption from the IM site, adrenaline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>10</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 10,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>; never <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>:</mo><mn>1</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">1: 1,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>; solution) may be injected IV, slowly, in the dose of 500 mcg , at the rate of 100 mcg per minute. (Table 23.2).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-23-2">Table 23.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-23-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Adrenaline doses in anaphylaxis</p>
<ul>
<li>Adults: 0.5 ml of a 1:1000 solution IM. or 3-5 ml of a 1:10000 solution IM or slowly IV.</li>
<li>Children: 0.01 ml of a 1:1000 solution per kg IM or 0.1 ml a 1:10000 solution per kg slowly IV.</li>
</ul>
<p>Rapid IV injection of adrenaline or IV injection of the 1:1000 solution can induce lethal cardiac arrhythmias like fibrillations.
In patients on a non-selective beta blocker, severe anaphylaxis may not respond to adrenaline and may need additional IV salbutamol.</p>
<ul>
<li>
<p>IV fluids: Hypotension associated with anaphylactic shock should be corrected by immediate IV administration of large quantities of fluids (preferably colloids). If necessary, dopamine or norepinephrine can be infused IV. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker has been used in refractory cases.</p>
</li>
<li>
<p>Glucocorticoids: Glucocorticoids are routinely administered in the treatment of anaphylactic shock, as they inhibit the late phase of an allergic reaction (Chapter 27). Hydrocortisone hemisuccinate 100 mg is given IV, followed by oral prednisolone. They do not inhibit the early phase of the anaphylactic reactions and are not a substitute for adrenaline which is the drug of first choice.</p>
</li>
<li>
<p>Antihistaminic drugs: The antihistaminic drugs do not counter the hypotension and bronchospasm characteristic of anaphylactic shock. This is due to involvement of mediators other than histamine in the genesis of anaphylaxis or to release of histamine in intimate contact with cells not accessible to conventional antihistaminics. However, an antihistaminic such as chlorpheniramine, 10-20 mg over one minute by slow IV injection, and repeated for upto 24-48 hours, may prevent late manifestations of allergy. It must be given after adrenaline.
Injection of an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist e.g. ranitidine 50 mg , IV over 3-5 min may be helpful.
Bronchodilators: Aminophylline IV or nebulised salbutamol may be needed in patients with resistant bronchospasm.</p>
</li>
<li>
<p>Supportive measures: These include oxygen and assisted ventilation.</p>
</li>
</ul>
<p>The methods of countering the actions of histamine in the body are listed in Table 23.3.
Table 23.3
Methods of countering the actions of histamine</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="9e682e6e"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#9e682e6e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In 1933, Fourneau and Bovet showed that certain phenolic ethers possessed antihistamine properties. Since then, many specific, competitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists with different chemical structures have been synthesised; the term antihistaminics, unless qualified, refers to these agents. In addition to their antihistaminic activity, many of them also have CNS and ANS actions.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antihistaminic agents can be classified either clinically or chemically.
Clinical classification: (Table 23.4)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-23-4">Table 23.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-23-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor blocking antihistaminic agents</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Adult oral dose (mg)</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Potent and sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Diphenhydramine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCl}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8362em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8362em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">25 to 50 (parenteral: 10)</td><td style="text-align: center;">Moderate antispasmodic, antimuscarinic.</td></tr><tr><td style="text-align: center;">Dimenhydrinate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">25 to 100</td><td style="text-align: center;">Mainly used for motion sickness.</td></tr><tr><td style="text-align: center;">Promethazine HCl*</td><td style="text-align: center;">12.5 to 25</td><td style="text-align: center;">Marked antimuscarinic action.</td></tr><tr><td style="text-align: center;">Promethazine chloro- &lt;br&gt; theophyllinate</td><td style="text-align: center;">25 to 75</td><td style="text-align: center;">Marked antimuscarinic action; used mainly in motion sickness. Superiority over promethazine HCl is doubtful</td></tr><tr><td style="text-align: center;">Pheniramine maleate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{* *}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">25 to 75</td><td style="text-align: center;">Antimuscarinic</td></tr><tr><td style="text-align: center;">Trimeprazine **</td><td style="text-align: center;">5 to10</td><td style="text-align: center;">Mainly anti-pruritic.</td></tr><tr><td style="text-align: center;">Doxylamine</td><td style="text-align: center;">25</td><td style="text-align: center;">Anti-allergic. OTC sleep-aid</td></tr><tr><td style="text-align: center;">Potent and less sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>b</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">b</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Chlorpheniramine maleate *</td><td style="text-align: center;">4 to 20 (parenteral: 5 to &lt;br&gt; 20)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Triprolidine **</td><td style="text-align: center;">2.5 to 5.0</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cyclizine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mtext>*&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">\mathrm{HCl}^{\text {* }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9723em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HCl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.9723em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">*&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">50</td><td style="text-align: center;">Used in motion sickness.</td></tr><tr><td style="text-align: center;">Meclizine HCl **</td><td style="text-align: center;">25 to 50</td><td style="text-align: center;">Mainly used for motion sickness.</td></tr><tr><td style="text-align: center;">Buclizine</td><td style="text-align: center;">25 to 75</td><td style="text-align: center;">Antiemetic</td></tr><tr><td style="text-align: center;">Less potent and less sedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>b</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{b}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">b</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Mepyramine maleate: *</td><td style="text-align: center;">50 to 100 (parenteral: 25 to 50)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Antazoline HCl</td><td style="text-align: center;">50 to 100</td><td style="text-align: center;">Moderately active; antiarrhythmic</td></tr><tr><td style="text-align: center;">Cinnarizine *</td><td style="text-align: center;">25</td><td style="text-align: center;">Anti-vertigo; to treat EP reactions</td></tr><tr><td style="text-align: center;">Flunarizine</td><td style="text-align: center;">5 to 10</td><td style="text-align: center;">Anti-vertigo; to treat EP reactions</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Non-sedative (Second generation)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Loratadine **</td><td style="text-align: center;">10 (once daily)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Desloratadine</td><td style="text-align: center;">5 (once daily)</td><td style="text-align: center;">Less antimuscarinic and relatively</td></tr><tr><td style="text-align: center;">Fexofenadine **</td><td style="text-align: center;">120 (once daily)</td><td style="text-align: center;">free from cardiac toxicity.</td></tr><tr><td style="text-align: center;">Acrivastine *</td><td style="text-align: center;">8 (tid)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cetirizine **</td><td style="text-align: center;">5-10 (once daily)</td><td style="text-align: center;">May cause some sedation</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> First generation or classical
*Short acting;
*Long acting.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-potent-and-sedative-ii-potent-but-less-sedative">I Potent and sedative II Potent but less sedative<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-potent-and-sedative-ii-potent-but-less-sedative" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>III Less potent and less sedative
IV Non-sedative They do not cross the BBB in significant amounts.</p>
<p>Chemical classification: Most of the antihistaminic agents can be represented by the general formula:
<img src="assets/images/image-20251214-0b737f1f.jpeg" alt="img-1.jpeg"></p>
<p>Depending upon the configuration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi></mrow><annotation encoding="application/x-tex">X</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span></span></span></span></span>, the antihistaminic agents can be classified as: I Ethanolamines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo><mi>O</mi></mrow><annotation encoding="application/x-tex">X=O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span>, e.g. Diphenhydramine and Doxylamine II Ethylenediamines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo><mi>N</mi></mrow><annotation encoding="application/x-tex">X=N</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.10903em;">N</span></span></span></span></span>, e.g., Tripelennamine, Mepyramine and Antazoline. They have negligible anticholinergic and antiemetic effects.
III Alkylamines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo><mi>C</mi></mrow><annotation encoding="application/x-tex">X=C</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">C</span></span></span></span></span>, e.g. Chlorpheniramine, Triprolidine, Acrivastine.
IV Piperazines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">X=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> carbon in conjunction with a piperazine ring, e.g., Hydroxyzine, Buclizine, Meclizine, Cinnarizine, Cetirizine.
V Phenothiazines where <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">X=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> nitrogen as a part of phenothiazine nucleus, e.g., Promethazine, Trimeprazine. They have potent antiemetic effect.
VI Piperidines: Cyproheptadine, Loratadine, Fexofenadine and Ketotifen.
VII Dibenzoxepines: Doxepin, an anti-depressant, with potent antihistaminic properties. Pharmacological actions of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists:</p>
<ul>
<li>Antihistaminic actions: The anti-histaminics competitively block histamine actions at many sites. Thus, they antagonise the stimulant action of histamine on the smooth muscle of the GI tract, the bronchi, the uterus and the blood vessels and inhibit histamine-augmented salivary secretion. They also reduce histamine-induced triple response and itching, but fail to produce resorption of the edema fluid. Antihistaminics prevent the itching, edema, urticaria and increased gastric motility and to a lesser extent, the hypotension produced by the histamine releasing drugs.
Antiallergic and anti-inflammatory actions involve (a) inhibition of the release of mediators from mast cells and basophils and (b) downregulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. Pretreatment with an oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistamic reduces the early response to an allergen challenge in the conjunctiva, nose, lower airways and skin. However, as described above, the bronchospasm and hypotension during anaphylaxis are not adequately reversed by them. This is probably because of the other mediators released during the reaction. These agents do not antagonise the cardiovascular actions of histamine.
Other actions: These actions vary according to the drug used and are related to their blocking of muscarinic, 5-HT as well as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptors. They are:</li>
<li>Sedation and hypnosis: CNS depression is a common side effect with the classical (first generation) antihistaminics. They induce varying degrees of sedation, drowsiness and sleep. Sedation is sometimes beneficial, particularly in the treatment of allergic reactions. Drugs like promethazine and diphen-hydramine are potent sedativehypnotics. Sedation is often accompanied by inability to concentrate, dizziness and disturbances of co-ordination, and thus may interfere with daily work. Sedation is negligible with Second generation antihistaminics such as fexofenadine and</li>
</ul>
<p>desloratadine.</p>
<ul>
<li>CNS stimulation: Stimulation is less commonly encountered than depression. Conventional doses of a few drugs such as promethazine may occasionally produce paradoxical restlessness, tremors and insomnia.</li>
<li>Autonomic nervous system: Majority of the first generation antihistaminics exhibit muscarinic blocking activity. Dryness of mouth is common. Antihistaminics, such as antazoline and promethazine, exert an alpha adrenergic blocking effect. The second generation antihistaminics usually do not have these actions.</li>
<li>Antiemetic and anti-motion sickness effects: Motion sickness, attributed commonly to vestibular disturbances, is benefited to a considerable extent by diphenhydramine, dimenhydrinate, promethazine and the piperazine antihistaminics. They block the histaminergic signals from the vestibular nucleus to the vomiting centre. Vomiting due to other labyrinthine disturbances, such as labyrinthitis and fenestration operation also responds to antihistaminics. These agents, except the phenothiazine antihistaminics, however, are of limited value in treating emesis due to jaundice, radiation, and alkylating agents (Chapter 41).</li>
<li>Antiparkinsonian effect: Central anti-muscarinic actions of some antihistaminics, such as diphenhydramine or promethazine, are useful in treating parkinsonism. (Chapter 15).</li>
<li>Cardiovascular system: Although therapeutic doses of antihistaminics fail to affect the cardiovascular system, rapid IV administration of diphenhydramine, antazoline, and tripelennamine may cause dose related prolongation of QT interval due to their membrane stabilising action.</li>
<li>Local anaesthesia: Antihistaminics such as promethazine and diphenhydramine exhibit some local anaesthetic activity due to blockade of sodium channels.
Absorption, fate and excretion: They are absorbed well orally and parenterally; the antihistaminic effect starts within 15 to 30 minutes, peaks by 1 hour and lasts for 3 to 6 hours. The actions of medizine, however, persist for 12 to 24 hours. All first generation compounds are mainly metabolised in the liver by CYP3A4, and the products are eliminated in urine. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists can induce hepatic microsomal enzymes, facilitating their own metabolism.</li>
</ul>
<p>Adverse reactions: They are as a rule mild and can be grouped as follows:</p>
<ul>
<li>CNS: The first generation antihistaminics commonly cause sedation, hypnosis and fatigue. Individuals taking antihistaminics should not drive vehicles because of drowsiness and impaired motor coordination. Extrapyramidal reactions (Table 23.4), excitement and delirium may occur rarely. In children less than 2 years, promethazine may cause apnoea.</li>
<li>Antimuscarinic effects: The commonest effects are dry mouth, blurring of vision, bladder disturbances and rarely impotence, seen with first generation drugs.</li>
<li>GI: Nausea, vomiting, and epigastric distress may occur rarely.</li>
<li>Miscellaneous: The antihistaminics, in spite of their antiallergic properties, may themselves produce allergic manifestations, especially after topical use.
Acute, first generation antihistaminic poisoning is characterised by marked central stimulation. In children the clinical picture often resembles that of atropine intoxication, while in adults, fever and flushing are uncommon, and drowsiness often precedes the development of delirium and convulsion. Blood pressure and respiration are usually well</li>
</ul>
<p>maintained. Death is due to central depression leading to cardiorespiratory collapse and coma. The treatment is symptomatic and supportive. Diazepam can control convulsions.</p>
<p>Preparations and dosage: The number of antihistaminic drugs available in the market far exceeds their utility. Only the commonly available antihistaminics are listed in Table 23.4.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic disorders: The antihistaminics are beneficial in the suppression of allergic manifestations like polinosis and urticaria. They are extremely effective in the treatment of seasonal hay fever, where they reduce the sneezing, rhinorrhoea, and other manifestations associated with this condition. Their efficacy in the treatment of perennial vasomotor rhinitis, however, is much less (Chapter 27).
Antihistaminics effectively counter the pruritus and urticaria in atopic and contact dermatitis and that induced by various drugs, chemicals and plants. They partially control the pruritus of eczema. Combination of a phenothiazine such as chlorpromazine with an antihistaminic may give better results in severe pruritus than the antihistaminic alone. Systemic administration also controls, to some extent, the pain and the itch due to bee or wasp stings. The antipruritic action of the antihistaminics is probably nonspecific. Their topical use is not recommended owing to the risk of sensitisation and tendency to cause eczema.
Adequate treatment of pruritus (Chapter 71) depends upon recognition of the local and/or systemic factor(s) responsible for it. For example, adequate treatment of scabies would generally relieve the itching in this condition. The itching in elderly patients, which is due to dryness of the skin, is best treated by moisturising the skin by applying a little edible oil or moisturising cream to the affected area immediately after bath and by minimising the use of soap for washing and bathing. Itching due to inflammatory skin conditions can be relieved by a combination of a weak corticosteroid applied locally and a systemically administered antihistaminic. Antihistaminics, however, are ineffective in itching of clinically normal skin.
Reaginic allergy (Chapter 2) is known to be familial. A period of relative immunodeficiency may precede frank development of allergic illness in genetically predisposed children. Infants of allergic parents kept on "allergen avoidance regimen" (avoidance of exposure to cow's milk, dairy products, eggs, house dust and pets) for first six months of life may have strikingly low incidence of eczema.
Antihistaminics are of some value in controlling mild blood transfusion reactions but not pyrexia or hemolysis (Chapter 32). Weak atropine like activity of the classical antihistaminics and the occasional superimposition of acute cold on chronic allergic rhinitis may account for the beneficial effects of antihistaminic drugs on rhinorrhoea in a few cases of common cold (Chapter 27).
Allergic conjunctivitis is a common condition and causes itching. Local treatment with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists (emedastine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>, levocabastine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.05</mn><mi mathvariant="normal">%</mi><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.05 \%)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.05%</span><span class="mclose">)</span></span></span></span></span>, mast cell stabilisers (cromolyn sodium 4%, nedocromil sodium 2%; Chapter 27) and drugs having both actions (ketotifen <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.025</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.025 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.025%</span></span></span></span></span>; Chapter 27) can give symptomatic relief. Their use is safe. The adverse reactions are mild and include ocular irritation, burning and stinging; headache may occur. Routine long term use of local glucocorticoids (Chapter 66) is not justified for fear of causing cataract and raised intraocular pressure.
Antihistaminics are effective in the treatment of urticaria and angioedema. Urticaria</li>
</ul>
<p>may occur as acute episodes but is considered chronic when it lasts longer than six weeks. It may occur in a person with atopic history (Chapter 27) but often such history is absent. In a few cases, an allergen (fish, seafood, nuts, eggs; food additives such as citric acid, preservatives and colouring agents like tartrazine; drugs such as aspirin and other NSAID; vegetable gums), an offending physical agent (mechanical trauma, cold, heat), history of insect bites and stings, or underlying disease (infection, connective tissue disorder) may be identified. However, no such factor is found in majority of cases. A detailed history and thorough physical examination must precede laboratory tests. If a causative agent can be identified, it must be avoided if possible and treated if it is a systemic disease. But, a witch-hunt for a 'septic focus' is unrewarding.
The treatment of choice for acute urticaria (and acute angioedema) is a SC injection of adrenaline (1:1000 aqueous solution) in the dose of 0.3 ml , repeated if necessary. If adrenaline is contraindicated, an antihistaminic ( 50 mg of diphenhydramine IM or IV) may be used. Ecallantide, a selective and reversible Kallikrein inhibitor is approved for acute attacks of hereditary angioedema (see Chapter 33).
Oral antihistaminics are the drugs of choice in chronic urticarias; they are more effective when given, prophylactically on a regular basis, than after urticarial lesions start; the non-sedative antihistaminics may be preferred. Alternatives to the antihistaminics are cyproheptadine, doxepin (an antidepressant with a potent antihistaminic action) or a beta adrenergic agonist such as ephedrine. In resistant cases, an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker such as cimetidine or ranitidine may be added to the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker. Very few patients need corticosteroids and then, they should be used for the shortest possible period. Topical application of calamine lotion is useful for its cooling and soothing effects and can be used alone in mild cases.</p>
<ul>
<li>Mastocytosis: This rare disease is characterised by an abnormal increase in mast cells in the body leading to an increase in the production of mast cell mediators mainly histamine. This gives rise to symptoms such as pruritus, diarrhoea and anaphylaxis. Partial symptomatic relief can be obtained by a combination of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists.</li>
<li>Other uses:
(i) As hypnotics e.g., Diphenhydramine and Promethazine.
(ii) As antiemetics, e.g., Dimenhydrinate and Meclizine and Doxylamine. (Chapter 41)
(iii) In parkinsonism e.g., Diphenhydramine and Promethazine (Chapter 15).
(iv) In motion sickness and vertigo (Chapter 41).
(v) As antitussives e.g. Diphenhydramine.
(vi) In drug-induced acute dystonias Diphenhydramine, Promethazine (Chapter 15).</li>
</ul>
<p>Drug interactions: Sedation is enhanced when the sedative antihistaminics are used concurrently with alcohol, barbiturates, benzodiazepines or tricyclic antidepressants.</p>
<p>Nonsedative <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistaminics (second generation): Most of the classical <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocking drugs (antihistaminics) are highly lipid soluble and have marked CNS adverse effects. They also have anticholinergic, antiserotoninergic and antibradykinin effects.</p>
<p>A second generation competitive <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers, which poorly cross the BBB, are available. They are:</p>
<ul>
<li>
<p>The highly specific <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists.</p>
</li>
<li>
<p>Non-sedating in therapeutic doses.</p>
</li>
<li>
<p>Devoid of antimuscarinic, anti-serotonergic and antibradykinin action;</p>
</li>
<li>
<p>Less prone to clinically relevant drug interactions.</p>
</li>
<li>
<p>More expensive.</p>
</li>
</ul>
<p>Preparations and dosage: See Table 23.4.
Cetirizine is largely excreted as such in the urine; fexofenadine is primarily excreted in the feces. Fexofenadine is an active metabolite of terfenadine whereas cetirizine is an active metabolite of hydroxyzine.</p>
<p>Adverse reactions: Astemizole and terfenadine cause prolongation of QT interval with potential for lethal ventricular arrhythmias.</p>
<p>They are no more used. Fexofenadine and desloratadine are relatively safer.
Therapeutic uses:</p>
<ul>
<li>Allergic rhinitis but not vasomotor rhinitis (Chapter 27).</li>
<li>Urticaria; and</li>
<li>Dermographia.</li>
</ul>
<p>In practice, the choice of an antihistaminic drug depends upon efficacy, onset and duration of action, adverse effects and cost. These vary among different preparations, and among individuals. Sedative-hypnotic property may be beneficial, particularly when sleep is disturbed. None of the preparations available is ideal for all conditions in all the patients.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ecf8b38c"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptor Antagonists<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ecf8b38c" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors (Table 23.1) are responsible for histamine induced gastric acid secretion and are useful in the treatment of peptic ulcer (see Chapter 43). Experimentally, they block positive chronotropic action of histamine, counter the enhanced automaticity of atria and ventricles, and prevent ventricular tachyarrhythmias induced by histamine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fe4732e"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> Receptors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fe4732e" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are thought to be presynaptic heteroreceptors that exert a tonic autoinhibitory control on histamine synthesis and release within the brain. Betahistine, a weak, partial agonist at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, behaves as a weak <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist. For <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors, see Table 23.1.</p>
<p>24</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="5-hydroxytryptamine-serotonin-its-agonists-and-antagonists-and-treatment-of-migraine">5-Hydroxytryptamine (Serotonin), its Agonists and Antagonists; and Treatment of Migraine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#5-hydroxytryptamine-serotonin-its-agonists-and-antagonists-and-treatment-of-migraine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>5-HYDROXYTRYPTAMINE (5-HT), also termed serotonin (Fig 24.1), was isolated in 1948. The same compound, studied earlier independently, termed enteramine by Erspamer and co-workers, was found to have a wide tissue distribution and a variety of pharmacological actions.
<img src="assets/images/image-20251214-5e922b9e.jpeg" alt="img-2.jpeg"></p>
<p>FIG. 24.1 5-Hydroxytryptamine
Distribution and synthesis: 5-HT is widely distributed in plants and in animal tissues, mast cells and platelets. In the mammalian tissues, the highest concentration ( 60 to 180 micrograms per g) is present in the pineal gland, where it serves as a precursor for the synthesis of the hormone melatonin. It is also present in the venoms of wasps, bees and scorpions. Fruits like pineapples, bananas, tomatoes, plums and various nuts contain considerable amounts of 5-HT. However, it largely undergoes metabolic degradation on entering the circulation.</p>
<p>The compound is synthesised from the essential amino acid tryptophan (Fig. 24.2). The enzyme L-aromatic amino acid decarboxylase also decarboxylates histidine and DOPA. Within the CNS and the GI tract, 5-HT is stored in the chromaffin granules.
<img src="assets/images/image-20251214-9545336c.jpeg" alt="img-3.jpeg"></p>
<p>5-HT receptors: Four 5-HT receptor groups with defined functions have been identified:</p>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub><mo separator="true">,</mo><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}, 5-\mathrm{HT}_{2}, 5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, with further subdivision into several subtypes. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub><mo separator="true">,</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}, 5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors belong to G-protein-coupled receptor (GPCR) families, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">5-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is a ligand-operated ion channel receptor.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor has six subtypes. Of these, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is found in the raphe cell bodies and dendrites, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> on the axon terminals (presynaptic). They function as autoreceptors and regulate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">HT</span></span></span></span></span></span> release. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is also found in the substantia nigra and basal ganglia.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor has three subtypes. Of these, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are found in the frontal cortex, clustrum, GI tract and platelets.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor is a monoamine neurotransmitter receptor, located at the cholinergic terminals in the GI tract, nucleus solitarius and in the area postrema. Both the CNS and GI tract <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors participate in the process of vomiting.</p>
<p>The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn mathvariant="bold">5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{5}-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord mathbf">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor are widely distributed throughout the body, including the CNS, smooth muscles and secretory cells. Their stimulation causes increased mucus secretion in the GI tract and facilitates the peristaltic process.</p>
<p>Although <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>5</mn></msub><mo separator="true">,</mo><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>6</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{5}, 5-\mathrm{HT}_{6}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">6</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>7</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">7</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors have been described, their exact function is not known.</p>
<p>The handling of 5-HT at the receptor level is similar to that of NA. Thus a large portion of 5-HT released from the neuronal endings is retaken up (Uptake 1) and stored in the granules by the neurons (Fig. 24.3). It is metabolised by the enzyme MAO. The metabolite 5-Hydroxy-indole-acetic-acid (5-HIAA) is actively transported out of the brain by a process which can be blocked by probenecid.
<img src="assets/images/image-20251214-b1878099.jpeg" alt="img-4.jpeg"></p>
<p>FIG. 24.3 Synthesis and metabolism of 5-HT at serotonergic neuronal endings
*Autoreceptors Dotted line indicates inhibition of release of the transmitter
Functions of various 5-HT receptors are summarised in Table 24.1.</p>
<p>Table 24.1
Important 5-HT receptors and their functions</p>
<table><thead><tr><th style="text-align: center;">Receptor</th><th style="text-align: center;">Signal transduction</th><th style="text-align: center;">Subtype</th><th style="text-align: center;">Location</th><th style="text-align: center;">Functions</th></tr></thead><tbody><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">G-protein coupled. Inhibits AC</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Raphe nuclei, hippocampus,</td><td style="text-align: center;">Mood and behaviour : anxiety sleep, feeding, thermoregulation. Autoreceptor regulating 5-HT release</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Substantia nigra and basal ganglia; vascular smooth muscles</td><td style="text-align: center;">Autoreceptors (may be regulating dopamine release); locomotor function. Behaviour; pulmonary vasoconstriction</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">CNS; cerebral vessels</td><td style="text-align: center;">Cerebral vasoconstriction: migraine</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">G-protein coupled.</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Frontal cortex, clustrum, platelets, smooth muscles, autonomic neurons</td><td style="text-align: center;">Neural excitation; behavioral effects (of LSD); platelet aggregation; smooth muscle contraction (GI tract, bronchi, bladder)</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Activates PLC</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Gastric fundus</td><td style="text-align: center;">Contraction</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Choroid plexus</td><td style="text-align: center;">CSF secretion</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Ligand operated ion channels</td><td style="text-align: center;"></td><td style="text-align: center;">Cholinergic terminals of GI tract; tractus solitarius; area postrema; hippocampus</td><td style="text-align: center;">Emesis &lt;br&gt; Behaviour: anxiety Neuronal excitation (autonomic, nociceptive neurons)</td></tr><tr><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">G-protein coupled. Activates AC</td><td style="text-align: center;"></td><td style="text-align: center;">Hippocampus; myenteric neurons; smooth muscles of esophagus, secretory cells</td><td style="text-align: center;">Neuronal excitation; contraction of muscle; stimulation of secretion</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{AC}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">AC</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Adenylyl cyclase
PLC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Phospholipase C
Significance of 5-HT: The available data on this subject has not yet been synthesised into a unitary hypothesis. However, 5-HT
(i) Plays a major role in the regulation of GI motility,
(ii) Acts as a central neurotransmitter and
(iii) Serves as an autocoid in the peripheral vascular system.</p>
<ul>
<li>Neurohumoral transmission: 5-HT is present in the nervous system of all the vertebrates and many invertebrates. It is a chemical transmitter released by 'tryptaminergic' neurons widely distributed in the brain. One of the important functions attributed to the tryptaminergic dorsal raphe neurons is dampening of over-reactiveness to various stimuli, and 5-HT is involved in some way in regulation of the state of consciousness. Altered tryptaminergic function may be responsible for disturbances in sleep, appetite, mood, sexual behaviour, motor activity, perception and for migraine. These neurons are also involved in other functions such as temperature regulation, endocrine control and extra-pyramidal activity. 5-HT receptors have been identified in brain areas implicated in learning and memory. Many centrally acting drugs are known to influence responses to 5-HT or alter its reuptake, synthesis, storage, release or catabolism. Prominent among these are anti-psychotic drugs like chlorpromazine, reserpine, antidepressants, hallucinogens like LSD, mescaline and even analgesics like morphine.</li>
<li>Sleep: 5-HT controls sleep-wakefulness cycle; depletion of 5-HT causes insomnia, which can be reversed by 5-hydroxytryptophan.</li>
<li>Behaviour: Disturbances in the brain 5-HT metabolism are suspected as a cause of certain psychiatric disorders such as schizophrenia and affective disorders. 5- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors present in brain in limbic and cortical areas are known to be involved in controlling mood, emotion, reward and memory. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists reduce the increased psychomotor drive associated with a mesolimbic dopamine excess. Low CSF 5HIAA is associated with impulsive, violent and suicidal behaviour, and 5-HT reuptake inhibitors (SSRI) are used to treat mental depression (Chapter 14). 5-HT receptor</li>
</ul>
<p>function is altered in anorexia nervosa and bulimia, the major eating disorders.</p>
<ul>
<li>Emesis and migraine: Antiemetic activity has generally been associated with dopamine antagonist drugs such as metoclopramide but studies in animals indicate that selective 5<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonists can prevent emesis associated with anti-cancer drugs and radiotherapy. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are present in high densities on afferent vagus nerves and in the area postrema and dorsal vagal complex of animals.
Role of 5-HT in migraine has been suspected for a long time. 5-HT metabolism is abnormal in patients with migraine and IV administration of 5-HT can alleviate migraine attacks. It is not clear if the relevant 5-HT receptors are vascular or neural in location. However, sumatriptan, a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist, is used to treat acute attacks of migraine. (see later).</li>
<li>Gastrointestinal tract: Entero-chromaffin cells in the GI tract synthesise 5-HT which forms the major source of circulating 5-HT. A part of it is metabolised by the hepatic MAO during its first pass through the liver. 5-HT released by mechanical or vagal stimulation from the neuronal endings acts locally to regulate the GI motility. 5-HT is believed to act as a local hormone for the initiation and sustenance of intestinal peristalsis.
It reduces the volume, acidity, and pepsin content of the gastric juice and promotes the production of mucus.</li>
<li>Cardiovascular system: 5-HT constricts the renal, pulmonary, splanchnic and cerebral blood vessels. It also has some positive inotropic and chronotropic action on the heart.</li>
<li>Platelets: Platelets do not synthesize 5-HT but take it up from the circulation and store it. 5-HT release, following a vascular injury along with other mediators of injury, activates platelets, which then promote vascular occlusion and vasoconstriction.</li>
<li>Hormone secretion: There is some evidence to suggest that tryptaminergic mechanisms are involved in the control of release of certain hormones. Sex hormones may affect mood and the mental state by activating the central 5-HT receptors.</li>
<li>Carcinoid syndrome: This clinical syndrome is associated with argentaffin cell tumours of the GI tract which secrete 5-HT. These tumours are locally invasive and may occasionally metastasize. Carcinoid syndrome is characterised by intermittent attacks of flushing, hypotension, bronchospasm, colic and diarrhoea. Associated tricuspid incompetence and pulmonary stenosis are occasionally observed. Some of these manifestations are due to excessive production of 5-HT. The diagnosis is usually confirmed by demonstrating high plasma 5-HT and high urinary HIAA levels. The drug, parachlorophenylalanine (PCPA) inhibits 5-HT synthesis by inhibiting tryptophan hydroxylase. PCPA administration results in almost complete inhibition of this enzyme leading to stoppage of diarrhoea, cramps and decrease in 5-HIAA excretion in urine. The toxicity of PCPA includes allergic reactions, tinnitus, fatigue, dizziness and mental changes. Marked hypothermia following PCPA has been reported. Some benefit may also be achieved by cyproheptadine and methysergide. However, treatment of choice is surgery.
It appears that 5-HT is a mediator of acute inflammation only in rats and mice. Unlike with histamine the human skin does not contain significant amounts of 5-HT and the 5-HT antagonists are not effective in controlling inflammation in human skin.
Pharmacological actions:</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiovascular-system">Cardiovascular system:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-system" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Peripheral blood vessels: 5-HT constricts majority of blood vessels including the renal, splanchnic, meningeal and pulmonary arteries, while it dilates the blood vessels of skeletal muscles, the coronaries and the capillaries of the skin. In several species, the cerebral blood vessels are constricted. It also constricts the veins and venules. Administration of 5-HT in humans results in cutaneous vasodilatation, producing initially a bright red flush, that may be converted to cyanosis.</li>
<li>Heart: 5-HT has weak direct positive inotropic and chronotropic effects on the myocardium; these, however, are usually not demonstrable in human beings, as it also causes reflex bradycardia.</li>
<li>Blood pressure: A characteristic 'triphasic response' is observed in BP after IV injection of 5-HT in majority of the species including man. It consists of:
(a) Initial transient depression of BP due to increased vagal activity following stimulation of carotid chemoreceptors;
(b) Rise in BP due to peripheral vasoconstriction; and finally
(c) Sustained hypotension which is due to dilatation of skeletal muscle blood vessels.</li>
</ul>
<p>Central nervous system: Considerable quantities of 5-HT are found in the midbrain, the limbic system, hypothalamus, caudate nucleus and pituitary gland. 5-HT, administered exogenously, does not readily cross the BBB. The barrier, however, does not exist for its precursor, 5-HTP. Intraventricular administration of 5-HT in an unanaesthetised cat evokes tremors and muscular weakness, and sometimes profuse salivation. The cat becomes catatonic but not sleepy.</p>
<p>Smooth muscle: 5-HT stimulates smooth muscles; the most significant effect is seen on the small intestine. After stimulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the GI tract, both the tone and the motility are initially augmented followed by an inhibition of the spontaneous activity. 5-HT also evokes bronchoconstriction.</p>
<p>Absorption, fate and excretion: 5-HT is not significantly absorbed orally as it is degraded rapidly within the GI tract. Although platelets cannot synthesise 5-HT, they do have the capacity for its uptake and storage. It is mainly metabolised by the hepatic enzyme MAO and excreted as 5-HIAA in the urine (Fig. 24.4). The upper limit of normal urinary 5-HIAA in man is about 10 mg per day.</p>
<p><img src="assets/images/image-20251214-8d20d5da.jpeg" alt="img-5.jpeg"></p>
<p>Uses: 5-HT is not used therapeutically. However, many drugs act by manipulating 5-HT at various receptor sites, centrally as well as peripherally. Drugs can also act directly on 5HT receptors as agonists or antagonists; because of multiple types of 5-HT receptors, their actions and therapeutic uses vary. Further, some drugs in addition act on histaminergic, dopaminergic and adrenergic receptors. Some of the drugs acting through 5-HT receptors are summarised in Table 24.2.</p>
<p>Table 24.2
5-Hydroxytryptamine and drugs</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">5-HT receptor subtype</th><th style="text-align: center;">Other receptors</th><th style="text-align: center;">Uses</th></tr></thead><tbody><tr><td style="text-align: center;">Agonists:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ergotamine</td><td style="text-align: center;">All 5-HT, 2A,2B</td><td style="text-align: center;">Dopamine; alpha-adrenergic agonist</td><td style="text-align: center;">Acute attack of migraine</td></tr><tr><td style="text-align: center;">LSD</td><td style="text-align: center;">2A,2C,1A</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Hallucinogen</td></tr><tr><td style="text-align: center;">Triptans</td><td style="text-align: center;">1B,1D</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Acute attack of migraine</td></tr><tr><td style="text-align: center;">Buspirone</td><td style="text-align: center;">1A (partial agonist)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Anxiety states</td></tr><tr><td style="text-align: center;">Cisapride</td><td style="text-align: center;">4</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Gastroesophageal reflux disease (GERD)</td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">4</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">D_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.02778em;">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0278em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker</td><td style="text-align: center;">GERD, gastroparesis</td></tr><tr><td style="text-align: center;">Antagonists:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Cyproheptadine</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker Antimuscarinic</td><td style="text-align: center;">Migraine prophylaxis; carcinoid syndrome; postgastrectomy dumping syndrome</td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker</td><td style="text-align: center;">Antiemetic</td></tr><tr><td style="text-align: center;">Methysergide</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Carcinoid syndrome; migraine prophylaxis</td></tr><tr><td style="text-align: center;">Ketanserin</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic blocker</td><td style="text-align: center;">Migraine, hypertension</td></tr><tr><td style="text-align: center;">Mianserin</td><td style="text-align: center;">3, 2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic blocker</td><td style="text-align: center;">Antidepressant</td></tr><tr><td style="text-align: center;">Atypical antipsychotics:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Clozapine</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist</td><td style="text-align: center;">Schizophrenia</td></tr><tr><td style="text-align: center;">Risperidone</td><td style="text-align: center;">2A, 2C</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">D</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{D}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist</td><td style="text-align: center;">Schizophrenia</td></tr><tr><td style="text-align: center;">Others</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Alosetron</td><td style="text-align: center;">3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Irritable bowel syndrome</td></tr><tr><td style="text-align: center;">Ondansetron</td><td style="text-align: center;">3</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo></mrow><annotation encoding="application/x-tex">-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span></span></span></span></span></td><td style="text-align: center;">Antiemetic</td></tr><tr><td style="text-align: center;">5-HT uptake inhibitors:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">(a) Selective (SSRI) &lt;br&gt; (Chapter 14)</td><td style="text-align: center;"></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, antimuscarinic</td><td style="text-align: center;">Antidepressant Obsessive compulsive disorder; Panic disorder</td></tr><tr><td style="text-align: center;">(b) Nonselective (Chapter &lt;br&gt; 14)</td><td style="text-align: center;"></td><td style="text-align: center;">NA- reuptake inhibitor</td><td style="text-align: center;">Antidepressant Obsessive compulsive disorder</td></tr><tr><td style="text-align: center;">5-HT depletors:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Reserpine</td><td style="text-align: center;">Depletion of intraneuronal stores of 5-HT and NA</td><td style="text-align: center;"></td><td style="text-align: center;">Antihypertensive; antipsychotic</td></tr></tbody></table>
<p>NA = Noradrenaline
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">H</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{H}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">H</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Histamine
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">D</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{D}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">D</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Dopamine
5-HT-receptor agonists: These compounds differ in their chemical structures and actions. The important agents are:
(1) 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists e.g. Buspirone used as an antianxiety agent (Chapter 14).
(2) 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor agonists e.g. Sumatriptan used in the treatment of migraine (see later).
(3) 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists e.g. Cisapride used in the treatment of gastroesophageal reflux disease.
(4) Non-selective 5-HT agonists e.g. LSD (Chapter 14).</p>
<p>SUMATRIPTAN: This drug, an indole derivative (Fig 24.5), is a selective agonist of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors located in cranial blood vessels and nerve terminals. Activation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo></mrow><annotation encoding="application/x-tex">5-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{HT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors leads to (a) blocking the release of several vasodilator neuropeptides, and (b) selective constriction of extracerebral, intracranial blood vessels. It also constricts other blood vessels such as the coronary. Triptans also reduce the increased concentration of</p>
<p>CGRP in migraine attacks (see later). Given orally, sumatriptan is highly effective in treating acute attacks of migraine.
<img src="assets/images/image-20251214-cc4c0ad7.jpeg" alt="img-6.jpeg"></p>
<p>Absorption, fate, excretion: The oral bioavailability is only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">14 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">14%</span></span></span></span></span>. It can also be given by nasal spray and SC. The drug is metabolised in the liver by MAO-A enzyme to an inactive metabolite. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 2 hours. It does not cross the BB barrier.</p>
<p>Adverse reactions: These are usually mild to moderate in intensity. It may cause a sensation of flushing and heat at the injection site, neck pain, dizziness, asthenia and tingling in the hands. Occasionally it may cause myocardial ischemia due to coronary vasoconstriction. It is, therefore, contraindicated in patients with symptomatic IHD, angina or hypertension. It should not be combined with ergotamine and other vasoconstrictor drugs.</p>
<p>Although analogues of sumatriptan (triptans) such as Zolmitriptan, Rizatriptan, Almotriptan, Frovatriptan and Naratriptan, have been introduced, their superiority over sumatriptan has not been established. They differ in their other pharmacokinetic properties but cross the BB barrier.</p>
<p>Ergotamine: See Chapter 44.
Cisapride: This substituted piperidinyl benzamide compound is a prokinetic agent used previously for the treatment of gastroesophageal reflux disease and gastroparesis (Chapter 40). It is banned because of its cardiac toxicity.</p>
<p>5-HT antagonists: Apart from PCPA, 5-HT synthesis can be inhibited by alpha methyldopa, some halogenated tryptophans, and phenylalanine.</p>
<p>A number of compounds antagonise the actions of 5-HT on the tissues. These include lysergic acid diethylamide (LSD) and its derivative 2-brom LSD or BOL (Chapter 14). By acting as agonists on the inhibitory 5-HT autoreceptors, they inhibit the release of 5-HT from the neurons in the raphe nuclei. Other compounds like chlorpromazine, and yohimbine block the actions of 5-HT. Since there are multiple types of 5-HT receptors, a drug acting as an antagonist at one site may not act similarly at others. The 5-HT antagonists of therapeutic importance are:</p>
<p>METHYSERGIDE: Methysergide, a congener of LSD, is a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist. It is an effective prophylactic agent in the management of migrainous headaches. The protective effect of the drug develops within 24 to 48 hours after administration and persists for a similar period after its withdrawal. Rebound headaches may occur after sudden cessation of therapy. It is indicated for use in patients with resistant migraine but is of no value in treating an acute attack.</p>
<p>Methysergide is not used for diarrhoea due to carcinoid syndrome, because it has no action against the kinins released by the carcinoid tumour. Instead, somatostatin analogue octreotide (Chapter 63) which inhibits all the mediators released by the tumour is</p>
<p>preferred.
Adverse reactions: Significant toxicity is observed in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of the patients on chronic therapy. The serious toxic effects include peripheral arterial insufficiency, precipitation of angina, retroperitoneal fibrosis with obstruction of the urinary tract, pleuro-pulmonary fibrosis and cardiac valve damage. It is now rarely used because of its toxicity.</p>
<p>CYPROHEPTADINE: This compound (Fig 24.6), with structural resemblance to phenothiazines, is a potent antagonist of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors and to a certain extent of histamine and acetylcholine. As a central depressant it exhibits anticonvulsant and antitremor activities. Cyproheptadine is satisfactorily absorbed from the GI tract. The metabolic fate of the compound is not known.
<img src="assets/images/image-20251214-04b56320.jpeg" alt="img-7.jpeg"></p>
<p>It stimulates appetite probably by acting directly on the hypothalamus. Weight is gained rapidly during the first few weeks of therapy and is lost when the drug is stopped. There is evidence that 5-HT is involved in the control of ACTH secretion, possibly by stimulating corticotropin releasing factor (CRF) secretion from the hypothalamus. Administration of cyproheptadine can block the release of hydrocortisone and has, in fact, been used in the treatment of ACTH dependent Cushing's disease. It also suppresses aldosterone production in idiopathic aldosteronism.</p>
<p>The drug is available as 4 mg tablets. Dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4-20 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in divided doses.
Adverse reactions: The common adverse effect is transient drowsiness which seldom necessitates withdrawal of the drug. Other adverse reactions include dryness of mouth, mental confusion, ataxia, dizziness, headache and visual hallucinations.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Migraine prophylaxis: See later.</li>
<li>Treatment of postgastrectomy dumping syndrome and carcinoid syndrome; its 5-HT antagonizing action is probably useful.</li>
<li>Relief of pruritus associated with allergic dermatitis, urticaria and neurodermatosis. This action is probably due to its antihistaminic effect as the human skin does not contain significant quantities of 5-HT.</li>
<li>For symptomatic relief in seasonal and perennial pollinosis.</li>
<li>As an appetite stimulant in certain conditions.</li>
</ul>
<p>However, its promotion as a general appetite stimulant or tonic is not justifiable.</p>
<ul>
<li>In certain cases of Cushing's disease.</li>
</ul>
<p>PIZOTIFEN: This is an antihistaminic and 5-HT antagonist, structurally related to tricyclic antidepressants. It is effective in the prophylaxis of migraine and other vascular headaches. It may cause drowsiness, weight gain and urinary retention due to antimuscarinic action. Dose: 0.5 to 2.0 mg as a single dose at bedtime.</p>
<p>KETANSERIN: Ketanserin blocks 5-HT receptors, mainly 5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>2</mn><mi>A</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{2 A}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight">A</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and thereby antagonises vasoconstriction, platelet aggregation and bronchoconstriction. It has affinity for adrenergic alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which it blocks. It can cause lowering of blood pressure. The drug is used to improve digital circulation in patients with vasospastic conditions such as Raynaud's syndrome.</p>
<p>ONDANSETRON: This is a specific <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist and is particularly useful as an antiemetic in nausea and vomiting following cytotoxic drugs and radiotherapy. Its action is partly central and partly peripheral. It is given orally in the dose of 8 mg 1 - 2 hours before treatment and in the same dose 12 hourly thereafter. The drug can also be given by slow IV infusion and as mouth dissolving tablets. It sometimes causes headache, constipation, allergic reaction and chest pain. Unlike phenothiazine, it causes neither sedation nor EPR (Chapter 41).</p>
<p>Granisetron, Alosetron and Palanosetron have similar antiemetic properties as ondansetron</p>
<p>CLOZAPINE: This atypical antipsychotic drug acts as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">A</mi></mrow><mi mathvariant="normal">/</mi><mn>2</mn><mi mathvariant="normal">C</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{2 \mathrm{~A} / 2 \mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0385em; vertical-align: -0.3552em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3448em;"><span style="top: -2.5198em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">A</span></span><span class="mord mtight">/2</span><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.3552em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist and is used in the treatment of schizophrenia. Many other antipsychotic drugs have 5-HT antagonist action (Chapter 13).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-migraine">Pharmacotherapy of Migraine<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-migraine" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Migraine, tension type of headache and cluster headache are grouped as primary headaches which occur without any exogenous cause. Migraine is an episodic headache, unilateral or bilateral, throbbing in quality and exacerbated by physical activity. It may be associated with GI, autonomic or behavioural disturbances. It is common in females. It shows a strong hereditary tendency. In practice, it is one of the most underdiagnosed and undertreated neurological disorders. It is classified as:</p>
<ul>
<li>Migraine with aura (classical migraine);. and</li>
<li>Migraine without aura (common migraine).</li>
</ul>
<p>Attacks of headache may be triggered by factors like food (chocolate, cheese) visual stimuli, impending menstruation, stress and relaxation after emotional tension. Classically, the headache is unilateral and may vary in duration from a few minutes to days. In 10-15% of cases, it is preceded by visual and neurologic phenomena such as scintillating scotomata and visual field defects. These are often accompanied by nausea, vomiting, diarrhoea and prostration. Rarely, migrainous headaches are due to structural lesions in the CNS like an aneurysm or an angioma.</p>
<p>Pathophysiology: Migraine is a neurovascular disorder where there is an interaction between the intracranial nerves and blood vessels. Its exact mechanism is not known. According to the current concept, migraine involves abnormal cortical activity leading to dilatation of meningeal blood vessels and activation of perivascular trigeminal nerve terminals. Activated nerve terminals release vasoactive neuropeptides within the meninges. Those peptides give rise to inflammation characterised by vasodilatation, mast cell degranulation and vessel leakage. In addition, they are also involved in the genesis of pain. The throbbing headache is mostly due to dilatation of pain- sensitive arteries.</p>
<p>Evidence suggests that calcitonin gene related peptide (CGRP) released from the trigeminal nerve terminals plays an important role in the genesis of migraine and other vascular headaches. The peptide is present in peripheral and central nervous systems. It is a potent vasodilator of the meningeal and cerebral blood vessels, and is probably important in regulating blood flow to the brain and the pain-sensitive meninges. It is also capable of causing the release of pro-inflammatory cytokines from the meningeal mast cells. Infusion of CGRP causes migrainous headache in susceptible subjects. Triptans which block the release of CGRP rapidly relieve the headache.</p>
<p>The aims of treatment of migraine are:</p>
<ul>
<li>To produce quick symptomatic relief by nonspecific analgesics.</li>
<li>To suppress the attack, using a specific triptan.</li>
<li>Prevention of further attacks by behavioural or pharmacological means.</li>
</ul>
<p>Non-pharmacological means for prevention include:
(a) Avoidance of precipitating factors such as loud noise, bright light, stress, certain foods and hypoglycaemia and
(b) The use of cognitive behaviour and relaxation therapy.</p>
<p>The behavioural approach involves education of the patient about the precipitating causes of attacks and their avoidance; a regular lifestyle with moderation in everything including regular meal hours, adequate but not excessive sleep, and minimising work-related and family stress.</p>
<p>Treatment of acute attacks: See Table 24.3. In all cases of migraine, aspirin (300-600 mg) or paracetamol ( 500 mg ) with or without metoclopramide should be tried in the first instance. If taken at the very onset of headache and repeated every 4 hours till the headache subsides, many patients may not need any more medication. Opioids such as codeine are considered unsuitable for routine use because of their dependence liability. If nausea is prominent, an antiemetic such as chlorpromazine or prochlorperazine may be added to the above medication. An adequate dose of one of the other NSAID (ibuprofen) is as effective as aspirin in relieving an acute attack of migraine. The NSAID may be used prophylactically if headaches are predictable, as in menstrual migraine. NSAID act by inhibiting PG synthesis, thus preventing neurologically mediated inflammation in the trigemino-vascular system. Prolonged, excessive use of any of the above medication can lead to chronic daily headache.</p>
<p>Table 24.3
Drugs used for treatment of migraine attacks</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Dose (mg)</th></tr></thead><tbody><tr><td style="text-align: center;">Analgesic</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Aspirin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><mn>600</mn></mrow><annotation encoding="application/x-tex">300-600</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">600</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Paracetamol</td><td style="text-align: center;">600</td></tr><tr><td style="text-align: center;">Codeine"</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">15-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td></tr><tr><td style="text-align: center;">NSAID</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Naproxen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn></mrow><annotation encoding="application/x-tex">250-500</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">500</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Ibuprofen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn></mrow><annotation encoding="application/x-tex">400-800</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">800</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Diclofenac (IM)</td><td style="text-align: center;">75</td></tr><tr><td style="text-align: center;">Ketorolac (IM)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">30-120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td></tr><tr><td style="text-align: center;">5-HT <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mrow><mn>1</mn><mi>D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">{ }_{1 D}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4783em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathnormal mtight" style="margin-right: 0.02778em;">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sumatriptan</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">25-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span></td></tr><tr><td style="text-align: center;">SC</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">4-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Nasal Spray</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">10-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span></td></tr><tr><td style="text-align: center;">5-HT partial agonists/antagonists</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Ergotamine</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Oral</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">1-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Sublingual</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">1-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span></td></tr><tr><td style="text-align: center;">DHE (IV/IM-SC/Nasal Spray)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mi mathvariant="normal">/</mi><mn>1</mn><mo>−</mo><mn>3</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2 / 1-3 / 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2/1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3/2</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dopamine antagonists (Oral/IV)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Metoclopramide</td><td style="text-align: center;">10</td></tr><tr><td style="text-align: center;">Haloperidol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">5-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Prochlorperazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">/</mi><mn>10</mn></mrow><annotation encoding="application/x-tex">25 / 10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">25/10</span></span></span></span></span></td></tr></tbody></table>
<p>'Oral, unless specified
"For occasional use only.
Ergotamine tartrate ( 1 mg ) with or without caffeine ( 100 mg ) constitutes specific therapy. It is a partial agonist of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mi mathvariant="normal">D</mi></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{D}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mathrm mtight">D</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mrow><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">B</mi></mrow></mrow></msub></mrow><annotation encoding="application/x-tex">5-\mathrm{HT}_{1 \mathrm{~B}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span><span class="mord mtight"><span class="mspace nobreak mtight"><span class="mtight">&nbsp;</span></span><span class="mord mathrm mtight">B</span></span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. A tablet is chewed and swallowed early during an attack, preferably during the preheadache aura phase. A repeat dose is</p>
<p>taken 45 min . later, if necessary. Not more than four tablets should be taken in 24 hours, nor more than 12 tablets per week. The drug can also be given rectally. Ergotamine may make the nausea of migraine worse; this may be pretreated with an antiemetic drug. It is also available in sublingual form ( 2 mg ). Dihydroergotamine (DHE) 1 mg SC together with pretreatment with an antiemetic is effective in many cases; its main disadvantage is the need for an injection. As the tissue binding effect of ergotamine on arteries persists as long as 24 hours, repeated doses may cause a cumulative effect. The drug can precipitate angina. Persistent, chronic headache may be a symptom of overtreatment with ergot preparations.</p>
<p>Ergot preparations are contraindicated in the presence of peripheral vascular disease or coronary artery disease. They should be avoided in hypertension, during pregnancy, and in hepatic and renal disease. Ergotamine should never be used in migraine prophylaxis.</p>
<p>The triptans are highly effective in the specific treatment of an acute attack of migraine and are now preferred in a moderate to severe attack. They are given orally, SC or by nasal spray. Orally, it is given in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, which may be repeated every 2 hours, if necessary, to the maximum total dose of 300 mg within 24 hours. It can also be given by nasal spray in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, repeated after 2 hours, if needed. It may be given SC in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">4-6 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> It is effective in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of patients within 2 hours. Sumatriptan and zolmitriptan nasal sprays have a faster onset of action. A triptan should not be used until 24 hours after the last dose of ergotamine.</p>
<p>In resistant acute attacks, a 5-HT antagonist, either prochlorperazine 10 mg IV or haloperidol IM may be useful.</p>
<p>Telcagepant: This CGRP receptor antagonist is effective orally. It blocks the CGRP-receptor complex at several sites in CNS including trigeminal nucleus. It does not cause vasoconstriction. However manufacturers have terminated its further clinical development.</p>
<p>Migraine Prophylaxis: See Table 24.4. Preventive treatment is considered when attacks occur oftener than 2-3 times a month or are severe enough to limit normal activity; and when symptomatic therapy causes serious ADR. Medications containing vasodilators should be discontinued, if possible. Therapy is started with small doses, and the lowest effective maintenance dose be used; it may take as much as 3 months to show the desired result. If the therapy is effective, the attacks become less frequent and milder in intensity. Overuse of acute medication may reduce the efficacy of the preventive medication. If the response is good, the medication may be tapered gradually after 9-12 months. If headaches recur, the treatment should be restarted. Propranolol if used, should not be stopped abruptly.</p>
<p>Table 24.4
Drugs used for prevention of migraine attacks</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: center;">Dose (mg)</th></tr></thead><tbody><tr><td style="text-align: left;">5-HT antagonists:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Pizotifen</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.5</mn></mrow><annotation encoding="application/x-tex">0.5-1.5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1.5</span></span></span></span></span> OD</td></tr><tr><td style="text-align: left;">Beta-adrenergic antagonists:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Propranolol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><msup><mn>240</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">40-240^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">24</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Atenolol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">25-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> OD</td></tr><tr><td style="text-align: left;">Antidepressants:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Amitripty line</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">10-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> OD</td></tr><tr><td style="text-align: left;">Calcium channel blockers:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Verapamil</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><msup><mn>200</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">100-200^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">20</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Anticonvulsants:</td><td style="text-align: center;"></td></tr><tr><td style="text-align: left;">Valproic acid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>300</mn><mo>−</mo><msup><mn>600</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">300-600^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">300</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">60</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Gabapentin</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1800</mn><mo>−</mo><msup><mn>2400</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">1800-2400^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1800</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6741em;"></span><span class="mord">240</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Topiramate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">25-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> bid</td></tr></tbody></table>
<p>'Daily-divided
The 5-HT antagonists methysergide and pizotifen (discussed earlier) and the tricyclic antidepressant amitriptyline (Chapter 14) are effective for prophylaxis. Methysergide is a toxic drug and should be used only in resistant cases. Amitriptyline in the low dose of 5-10 mg at bedtime daily is especially useful in patients who have concomitant depression. Propranolol, a beta adrenergic blocker (Chapter 18), is considered the drug of choice in patients with attacks related to stress. Valproic acid and topiramate have been reported to be useful in some patients.</p>
<p>Menstrual migraine (attacks occurring during menses) is generally refractory and may need prophylactic treatment with amitriptyline/beta blocker, plus NSAID/ergotamine at the onset of menses. Oral diuretics are sometimes helpful in such cases as they counter fluid retention.</p>
<p>25</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-kinins-leukotrienes-prostaglandins-and-cytokines">Angiotensin, Kinins, Leukotrienes, Prostaglandins and Cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-kinins-leukotrienes-prostaglandins-and-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ANGIOTENSINS are peptide hormones derived from a protein precursor angiotensinogen (a serum globulin, also called renin substrate) by the sequential actions of proteolyltic enzymes in the circulation and several tissues. Angiotensinogen, synthesised by the liver, is converted by the circulating renin from the kidney into angiotensin I, a decapeptide. By itself, the latter is inactive. It is converted by angiotensin converting enzyme (ACE) located in the plasma and the capillary endothelial cells mainly in the lungs into the octapeptide angiotensin II. Angiotensin II is further converted to either angiotensin III or angiotensin IV. ACE is also found in various tissues including the brain, kidney and the adrenals. Local renin-angiotensin system in the tissues exists independently of the renal-hepatic based system.</p>
<p>ACE is nonspecific and it also acts on other natural substrates such as bradykinin, which it inactivates.</p>
<p>Angiotensin II is the most potent angiotensin. It can also be synthesised by a pathway that does not require ACE. It acts through G protein coupled receptors, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>Angiotensin III acts on the same <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors.
Most of the classic actions of angiotensin are mediated by the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. Thus:</p>
<ul>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors
(i) mediate the vasoconstrictor action
(ii) stimulate aldosterone production and
(iii) promote cell growth and hypertrophy of the arterial and the ventricular wall muscle in the diseased and failing heart.</li>
<li><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors ameliorate the adverse effects of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor activation by inhibiting cell growth and hypertrophy. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors abound in several tissues in fetal life and may be involved in fetal tissue development and cell differentiation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors are less abundant in adults; they are present in brain, adrenal medulla, vascular endothelium and reproductive tissues.
Actions of angiotensin II: It acts at several sites in the body (Table 25.1). It increases the peripheral resistance, prevents renal sodium excretion and modulates cardiovascular morphological structure. It is a 40-50 times more potent vasoconstrictor than NA on molar basis:</li>
</ul>
<p>Table 25.1
Actions of Angiotensin II via <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors</p>
<table><thead><tr><th style="text-align: left;">Tissue</th><th style="text-align: left;">Action(s)</th></tr></thead><tbody><tr><td style="text-align: left;">- Artery</td><td style="text-align: left;">Contraction and growth</td></tr><tr><td style="text-align: left;">- Heart</td><td style="text-align: left;">Contraction and ventricular hypertrophy</td></tr><tr><td style="text-align: left;">- Adrenal</td><td style="text-align: left;">Stimulates aldosterone biosynthesis</td></tr><tr><td style="text-align: left;">- Kidney</td><td style="text-align: left;">Inhibits renin release; stimulates sodium reabsorption; stimulates vasoconstriction (efferent glomerular arterioles in low concentrations, and &lt;br&gt; both afferent and efferent in higher concentrations); releases PGE</td></tr><tr><td style="text-align: left;">- Sympathetic &lt;br&gt; nervous system</td><td style="text-align: left;">Increased release of NA and adrenaline from autonomic ganglia and adrenal medulla respectively. Facilitates peripheral transmission</td></tr></tbody></table>
<ul>
<li>It causes rapid regulation of arterial BP in response to acute fall in BP, by constricting the arterioles, and to a smaller extent, venules.</li>
<li>Long term maintenance of BP (slow response) is mediated by regulation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> excretion by the kidney. Angiotensin II directly promotes renal <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>reabsorption in the proximal tubules, and also causes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>retention through the release of aldosterone.</li>
<li>It also causes hypertrophy of the heart and thickening of the blood vessels (Chapter 66). Angiotensin II contributes to the pathogenesis of hypertension, cardiac hypertrophy, heart failure and diabetic renal disease. The direct action of angiotensin on some tissues stimulates the formation of counterregulatory substances, including vasodilating prostaglandins and nitric oxide. On the other hand, the target organs may release substances such as catecholamines, endothelin and growth factors, which may amplify the effects of angiotensin. The balance between the vasoconstrictors and the vasodilators determines the response of blood vessels to angiotensin II.</li>
<li>It stimulates vasopressin (ADH) and ACTH release. It increases the thirst.</li>
</ul>
<p>The ill effects of excess angiotensin II can be countered by:
(a) Angiotensin Converting Enzyme Inhibitors (ACEI) and
(b) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blockers (ARBs) (Chapter 30).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="kinins">Kinins<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#kinins" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The kinins are vasoactive polypetides released from an alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> globulin fraction of the plasma, termed as kininogens, by the action of enzymes termed kallikreins. Kininogens are present in two forms: (1) Low molecular weight kininogen (LMWK); and (2) High molecular weight kininogen (HMWK). HMWK is limited to the blood stream whereas LMWK can reach the tissues.</p>
<p>The kallikreins (Kallikreas, the Greek name for pancreas) are highly specific proteases, and exist in two forms: (a) plasma kallikreins, and (b) tissue kallikreins. Both normally exist in inactive forms called prekallikreins (PK).</p>
<p>Plasma prekallikrein is bound to its substrate HMWK; the protease inhibitors present in plasma prevent its proteolysis. When this system binds to a receptor complex on the endothelial cell membrane, it gets activated to kallikrein. The generated kallikrein activates clotting factor XII and cleaves HMWK to a nonapeptide, bradykinin.</p>
<p>Tissue prekallikrein is present in epithelial or secretory cells of salivary glands, pancreas, prostate, distal nephron and human neutrophils. The activation sequence of this tissue form is not well delineated but the active tissue kallikrein acts locally near the site of its origin. It converts HMWK and LMWK to a decapeptide, kallidin (lysyl bradykinin) (Fig. 25.1). Various factors such as tissue damage, infection, inflammation and allergic reactions can generate tissue kinins.
<img src="assets/images/image-20251214-892980dd.jpeg" alt="img-8.jpeg"></p>
<p>Both kallidin and bradykinin are referred to as 'plasma kinins' and have essentially identical pharmacological properties. In addition to kallikreins, various other serine proteases like trypsin and certain snake venoms are capable of generating kinins. Preformed kinins exist in the venoms of wasps and hornets.</p>
<p>Physiological role: The kinins are potent vasodilators. They may also modulate migration of leucocytes and tissue cells that take part in the inflammatory process. They are also most potent activators of PG-release, including <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> from vessels.</p>
<p>Bradykinin acts on two receptors: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>B</mi><mn>2</mn></msub><mi mathvariant="normal">.</mi><msub><mi>B</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">B_{2} . B_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">.</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05017em;">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0502em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are absent from the normal tissues and are induced by inflammation. In the absence of inflammation, most of the actions of the kinin are mediated through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which are constitutive.</p>
<p>Kinins have been incriminated in the processes of inflammatory and allergic reactions (asthma), shock, disseminated intravascular coagulation and inflammatory bowel disease. Pharmacological actions:</p>
<ul>
<li>Vessels and heart: The kinins have about 10 times the vasodilator activity as histamine. They produce mainly arteriolar dilatation in the skeletal muscle, heart, kidneys, intestines and liver, via the local release of nitric oxide and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. The kinins also have direct positive chronotropic and inotropic actions on the myocardium and in moderate doses, release adrenaline from the adrenal medulla.</li>
<li>Smooth muscle contraction: The kinins stimulate smooth muscles including those of the uterus, the bronchi and the GI tract. The term bradykinin was coined initially to signify the slow contraction of the GI smooth muscle by the nonapeptide. They promote epithelial ion transport and fluid secretion in the airways and GI tract, leading to cough/angioedema in the former and diarrhoea in the latter.</li>
<li>Genesis of pain: The kinins evoke pain (algesia) and itching on application to the base of a blister via the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">B</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{B}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">B</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. NSAID can antagonise this pain producing property.</li>
<li>Vascular permeability: They are more potent than histamine in increasing vascular permeability and inducing edema.</li>
<li>Release of PGs and PAF: Kinins can cause the release of biologically active lipids such as platelet activating factor (PAF) and prostaglandins (PGs) from a variety of cells; some of the actions of kinins may be indirect via the release of such mediators of inflammation. The kinins are rapidly inactivated by the plasma and erythrocyte aminopeptidases and carboxypeptidases. They have very short plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 15 seconds. The enzyme (ACE) that converts angiotensin I to angiotensin II also metabolises bradykinin.</li>
</ul>
<p>A high molecular weight polypeptide aprotinin, extracted from the parotid glands and lymph nodes of cattle, also present in mast cells, inhibits and inactivates kallikrein, trypsin and other proteolytic enzymes. It has been used in the treatment of acute pancreatitis, to prevent blood loss during open heart surgery, and in the treatment of hemorrhage due to hyperplasminemia (Chapter 33).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="leukotrienes-lts">Leukotrienes (LTs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leukotrienes-lts" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leukotrienes along with PGs, thromboxanes and lipoxins, are the major constituents of a group of eicosanoids. All the leukotrienes are derived from a common precursor, leukotriene <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>4</mn></msub><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">A</mi></mrow><mn>4</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{A}_{4}\left(\mathrm{LTA}_{4}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">LTA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>; they are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">B</mi></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">C</mi></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTB}_{4}, \mathrm{LTC}_{4}, \mathrm{LTD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTB</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTC</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">E</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTE}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>; the last three are also collectively known as slow reacting substance of anaphylaxis (SRS-A). They are produced locally and act as "local hormones". Their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is very short.</p>
<p>The sites at which the LTs are synthesised are determined by the cellular distribution of the enzymes controlling the biosynthetic pathways. The enzymes involved are phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and 5 -lipooxygenase (Fig. 25.4) The distribution of 5-lipooxygenase is limited to specific number of cells types: neutrophils, eosinophils, monocytes, macrophages, mast cells, basophils and B-lymphocytes. LTs exert their biological actions through specific ligand-receptor interactions.
<img src="assets/images/image-20251214-f10630c3.jpeg" alt="img-9.jpeg"></p>
<p>Pharmacological/biological actions: LTs have several potent actions. Thus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">B</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTB}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTB</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> :
(1) Is the most potent neutrophil chemotactic agent and plays an important role in the induction of neutrophil-endothelial-cell adhesion.
(2) Causes the release of substantial quantities of glucuronidase and lysozyme from the neutrophils.
(3) Stimulates myelopoiesis and proliferation of T lymphocytes; and
(4) Is an important mediator of infiammatory pain.</p>
<p>LTC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>4</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">D</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">_{4}, \mathrm{LTD}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi><mi mathvariant="normal">E</mi></mrow><mn>4</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LTE}_{4}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LTE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">4</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (SRS) are also called sulfidopeptides or cysteinyl LTs. They play an important role in the inflammatory process. They cause:</p>
<ul>
<li>Vigorous and sustained contraction of smooth muscle. They are the most potent bronchoconstrictors known and are involved in the pathogenesis of asthma.</li>
<li>Vasodilatation and modulation of vascular (venular endothelial) permeability, leading to</li>
</ul>
<p>the development of edema. They constrict the cutaneous and small coronary blood vessels.</p>
<ul>
<li>Increased mucus secretion in the airway; and</li>
<li>Immune modulation.</li>
</ul>
<p>Clinical implications of cysteinyl leukotrienes: LT release has been implicated in the pathogenesis of anaphylactic shock, asthma and various inflammatory diseases such as cystic fibrosis, glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease and adult respiratory distress syndrome. Various LT synthesis inhibitors and antagonists are available for use in asthma (Chapter 27).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prostaglandins-pgs">Prostaglandins (PGs)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prostaglandins-pgs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In 1930, Kurzrok and Lieb demonstrated the activity of human semen on isolated strips of human uterine muscle. This was confirmed by von Euler (1935) who demonstrated a substance present in the extracts of human seminal fluid, which caused contraction of the isolated intestinal and uterine muscle, and vasodilatation. This substance was named as prostaglandin because of its probable origin from the prostate. Bergstrom (Nobel prize, 1982) and associates showed that the various PGs are closely related derivatives of the lipid soluble prostanoic acid (Fig. 25.2). Although human seminal fluid is the richest known source, PGs are also present in extracts of other tissues such as iris, lung, human menstrual fluid, brain, thymus, pancreas and kidneys.
<img src="assets/images/image-20251214-1de23c73.jpeg" alt="img-10.jpeg"></p>
<p>Prostaglandin of the human semen is a mixture of six closely related substances belonging to the groups E, F, A and B. The other human tissues contain mostly groups E and F prostaglandins, though <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">D</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">G</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">H</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGD}_{2}, \mathrm{PGG}_{2}, \mathrm{PGH}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGD</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGG</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Prostacyclin) have also been described. The corals, native to the Caribbean sea, contain large quantities of PGA as a natural constituent.</p>
<p>Chemistry and biosynthesis: Fatty acids (FA) occurring in natural fats are mostly straight chain aliphatic compounds, with even number of carbon atoms connected by C-C bonds, carboxy <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">H</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(\mathrm{COOH})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord"><span class="mord mathrm">COOH</span></span><span class="mclose">)</span></span></span></span></span> group at one end and methyl <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">H</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{CH}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">CH</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> group at the other. The FA may be saturated (SFA, no double bond); or unsaturated (UFA, with double bonds). The UFAs may be mono-unsaturated (MUFA with a single double bond) or; polyunsaturated (PUFA with two or more double bonds). The names of the SFAs end in -anoic e.g. prostanoic acid (Fig. 25.2) and of the UFAs in-enoic e.g. eicosapentaenoic acid.</p>
<p>Fatty acids serve many functions: energy production; electrical insulation; transport of plasma lipids; maintenance of cell membrane integrity; proper development of the CNS; participation in cell communication and oxygen transport; and regulation of inflammation. Animals can synthesise SFA from carbohydrates and some amino acids. However, unlike plants, they cannot synthesise the two PUFAs, linoleic acid (LA) and alpha linolenic acid (alpha-LNA), which are, therefore essential in animals. Using these two, animals</p>
<p>synthesise all other UFAs they need e.g. arachidonic acid, an important constituent of the cell membrane.</p>
<p>Eicosanoids are oxygenation products derived from 20 (eicosa) carbon UFAs: dihomo-gamma-linolenic acid (DGLA), arachidonic acid (AA) and eicosapentaenoic acid (EPA). They are ubiquitous both in animals and (together with the precursor oil) in various plants. AA is the major source of prostanoids (eicosanoids) in mammals.</p>
<p>The three respective series of eicosanoids viz, PG-1, PG-2 and PG-3 are defined by the number of double bonds in their side chains.</p>
<p>The PG-1 and PG-2 series are synthesised from LA (an omega-6 PUFA) and its derivative GLA via DGLA (G1 series), and from AA (G2 series), respectively. The PG-3 series is derived from alpha-LNA via EPA, an omega-3 fatty acid, and docosa-hexaeonic acid (DHA).</p>
<p>Almost all the tissues are capable of synthesising these lipid derived autocoids. Their biosynthesis is trigerred by trauma, infection and inflammation. During their synthesis AA is first released from the cell membrane phospholipids by lipases. It is then oxygenated by four separate routes including cyclo-oxygenase (COX) and lipo-oxygenase (LOX) (Fig. 25.4). Various factors determine the type of eicosanoid synthesised. Besides the cell type, an important factor is the nature of the precursor PUFA that is present in the respective membrane phospholipid. Nature of the substituents in the side chain determines the type (A, B, C, D, E, F) of the eicosanoid. The term omega is used to denote the position of the carbon atom ( 3,6 or 9 from the methyl end) after which the first double bond occurs in an FA. Prostanoids of PG-2 series carry the subscript 2 e.g. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.</p>
<p>The dietary sources of LA are polyunsaturated vegetable oils such as safflower, sunflower and corn oils, lean meats and eggs. Hydrogenation and heating of vegetable oils for production of margarine converts the cis FA present in the oil into trans FA; the latter behave like saturated FA metabolically and are considered atherogenic (Chapter 40).</p>
<p>Coconut oil and animal fats contain SFAs. They are atherogenic. Olive oil and canola oil contain the omega-9 MUFA; almonds, groundnut oil, til oil and mustard oil are the alternative sources. MUFAs are believed to protect from atherogenesis.</p>
<p>Arachidonic acid, a PG-2 series FA, is a constituent of the phospholipids normally present in the human cell membrane. It gives rise to derivatives, PGs of PG-2 series and LT (Fig 25.4), with marked pro-inflammatory activity. They have been incriminated in the pathogenesis of chronic inflammatory disorders such as psoriasis and RA.</p>
<p>Eicosapentaenoic acid and docosahexaenoic acid (both omega-3 PUFA), present in fatty sea-fish, when ingested regularly, can partially replace AA (of PG-2 series) with the less pro-inflammatory eicosanoids of the PG-3 series <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>3</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{TXA}_{3}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> in the tissues, which may benefit patients with chronic, inflammatory diseases such as RA and psoriasis; it may also help to protect from atherosclerosis. The other dietary sources of omega-3 FA are flax seeds, nuts (particularly walnuts and hazelnuts), dark green leafy vegetables and soyabeans. The fatty fish contain EPA and DHA, and are a better source of omega-3 fatty acids than the vegetable sources which contain LNA but not EPA or DHA. It has been suggested that certain constituents of onions, apples and spices such as turmeric and red peppers (red chilly) may enhance the anti-inflammatory effect of omega-3 fatty acids.</p>
<p>Physiologically, tissue cells synthesise PGs at the site of action from the essential fatty acids LA and LNA (Fig. 25.3). The two principal mammalian PGs are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. PGs are very active even in very low concentrations and are degraded rapidly.</p>
<p><img src="assets/images/image-20251214-d7d95885.jpeg" alt="img-11.jpeg"></p>
<p>FIG. 25.3 Biosynthesis of eicosanoids from linoleic and alpha linolenic acids. PGs = Prostaglandins, leukotrienes etc. of Series 1, 2, 3. Those of PGs 1 and 3 are less inflammatory than those of PGs2 (see text).</p>
<p>The PGs A, B and C are artifacts that arise during extraction procedures.
Under stimulation by mechanical, thermal, chemical and bacterial insults, PGs are released in large amounts into the body Both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Fig. 25.4) are potent vasodilators and hyperalgesic agents. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is also a potent pyrogenic substance. In association with other mediators, PGs play an important role in the development of the inflammatory response.</p>
<p>Because of their instability, short duration of action and lack of tissue specificity, the natural PGs have limited clinical applications. Various synthetic derivatives available, however, overcome some of these limitations.</p>
<p>Pharmacological actions: PGs produce their effects by acting on PG receptors.</p>
<ul>
<li>Smooth muscles: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub><mo separator="true">,</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}, \mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stimulate the human myometrium and increase the intestinal motility. PGE inhibits the tone of tracheal and bronchial muscles and thus has a bronchodilator action.</li>
<li>Gastrointestinal system: Prostaglandins are distributed throughout the gut though their concentration varies in different parts,
(a) <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesised by COX-1 inhibit the gastric acid secretion, enhance the mucosal blood flow, and thus have a cytoprotective effect on gastric and duodenal mucosa.
(b) Both PGE and PGF cause contraction of the longitudinal muscle of the gut.
(c) Further, PGs stimulate intestinal fluid secretion and cause diarrhoea when given orally or parenterally. This suggests their possible role in certain diarrhoeas.</li>
<li>Cardiovascular system: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are potent peripheral vasodilators. They mainly dilate the arterioles, and postcapillary venules. The blood flow to most organs increases. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is a potent vasoconstrictor. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">F</mi></mrow><mrow><mn>2</mn><mi>α</mi></mrow></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGF}_{2 \alpha}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span><span class="mord mathnormal mtight" style="margin-right: 0.0037em;">α</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, however, is neutral in this respect in humans. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Alprostadil) is a potent relaxant of the smooth muscle of the ductus arteriosus and preserves the ductal patency in the newborn.</li>
<li>Kidney: The kidney cells that synthesise PGs contain mostly COX-1 (Chapter 11). Although PGs are not involved in maintaining the normal renal blood flow, their local production is important in maintaining blood flow in compromised kidneys. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> cause diuresis, natriuresis and kaliuresis by direct action on the renal tubules. PGE inhibits water reabsorption induced by ADH ; it also inhibits chloride reabsorption.</li>
<li>Reproductive system: Apart from their stimulant action on the uterine smooth muscle, PGs exert other actions on the reproductive system. In animal experiments, PGs cause</li>
</ul>
<p>regression of the corpus luteum (luteolysis) and reduction in secretion of progesterone. This can prevent the implantation of ovum. Both COX-1 and COX-2 are expressed in the uterine epithelium at different times in early pregnancy. COX-2 may play a role in the birth process and its excessive activity may be responsible for premature labour (Chapter 44). Functions of PGs present in the semen are not clear.</p>
<ul>
<li>CNS: The role of PGs as neurotransmitters has been suggested. COX-1 is distributed in neurons throughout the brain, being most prevalent in the forebrain. COX-2 is also expressed constitutively in a few areas. PGs are probably involved in the central mechanisms that cause hyperalgesia. Further, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> is implicated in the causation of fever (Chapter 11).</li>
<li>Platelet aggregation: In the platelets, the only isoform detectable is COX-1. PG endoperoxide and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}\left(\mathrm{TXA}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>, cause platelet aggregation and vasoconstriction, while <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (Prostacyclin) which is found in the vascular endothelium is a potent inhibitor of platelet aggregation and causes vasodilatation. When the platelets are damaged they release PG endoperoxides which cause aggregation of platelets. However, the vascular endothelial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> has anti-aggregatory effect. Damage to the endothelium reduces <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis and increases the tendency to thrombosis because of the unopposed action of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. Aspirin blocks formation of both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> but COX-1 in the vascular endothelial cells regenerates so that <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis is reestablished. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> synthesis however, is irreversibly inhibited for the lifetime (8-10 days) of the platelets in circulation (Chapter 33).</li>
<li>Role in inflammation: Presence of PGE and kinins in the inflammatory exudates suggests their role in the genesis of inflammation. COX-2 is clearly associated with inflammation. Selective COX-2 inhibitors may control inflammation without affecting the beneficial effects of PGE on the stomach (Chapter 11).</li>
<li>Miscellaneous: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> block the lipolytic effect of adrenaline, ACTH and glucagon. They also produce pain when applied to an exposed blister base. Some PGs are potent bone resorbing agents which act by stimulating osteoclasts. Experimentally, bone destruction induced by implanted metastasising tumours in rats and rabbits, can be reduced by PG inhibition by aspirin or indomethacin. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> also stimulates the adrenal steroid production and insulin release.
Therapeutic uses of prostaglandins:
(1) As abortifacients and cervical ripeners (Chapter 44).
(2) As gastric cytoprotectives: Misoprostol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGE}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> (Chapter 43).
(3) In erectile dysfunction: Alprostadil is injected intracavernosally (Chapter 69).
(4) For maintenance of patency of ductus arteriosus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> analogue, Alprostadil IV) (Chapter 11).
(5) In the treatment of primary pulmonary hypertension, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> (epoprostenol) by IV infusion, is effective.
(6) In the treatment of glaucoma (Latanoprost) (Chapter 72).
(7) For treatment of peripheral vascular disease (Epoprostenol).
(8) Post AMI to reduce infarct size (Iloprost).</li>
</ul>
<p>Endocannabinoids, derived from AA in the brain, are the endogenous ligands for the</p>
<p>cannabinoid receptors, and mimic some of the pharmacological actions of D9-tetrahydrocannabinol, dronabinol (Chapters 14 and 41).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cytokines">Cytokines<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Inflammation is an integral part of the body's defence mechanisms against foreign insults, and natural as well as acquired (specific) immunity play an important role in human defence. Several polypeptides are known to act as mediators of the inflammatory process.</p>
<p>The effector phases of both natural and acquired immunity are in large part mediated by protein hormones called cytokines, which are released from a variety of cell types in response to a number of stimuli (induced secretion). These cytokines activate, modulate and control various aspects of body defence and repair. In case of natural immunity, effector cytokines are mainly derived from the mononuclear phagocytes and the natural killer (NK) cells. Most cytokines in acquired immunity are released from activated T lymphocytes. T cells produce several cytokines that serve primarily to regulate the growth, differentiation and activation of various lymphocyte populations (constitutive secretion). They activate and regulate inflammatory cells such as monocytes, neutrophils and eosinophils.</p>
<p>Both lymphocytes and mononuclear phagocytes also produce other cytokines such as colony stimulating factors (CSF) which stimulate the growth and differentiation of immature lymphocytes in the bone marrow.</p>
<p>Like other polypeptide hormones, the cytokines act by binding to specific receptors on the surface of target cells. Such target cells may be (1) the same cells that secrete the cytokine (autocrine action); (2) nearby cells (paracrine action); or (3) distant cells as in the case of classical hormones (endocrine action).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="general-properties-of-cytokines">General properties of cytokines:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#general-properties-of-cytokines" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Cytokines are low molecular weight proteins secreted mainly by white blood cells and other cells, and are responsible for cell to cell communication. Many individual cytokines are produced by multiple types of cells.</li>
<li>They are produced during the effector phase of natural and acquired immunity and play an important role in mediating and regulating intensity and duration of immune and inflammatory responses, including the termination of the inflammatory response, angiogenesis, healing and repair.</li>
<li>They are not stored as preformed molecules. Their constitutive secretion is brief and self-limited. Failure of termination of their induced secretion can lead to chronic inflammatory disorders.</li>
<li>A given cytokine has different biological effects on different cell types (pleotropism).</li>
<li>Cytokines influence the synthesis of other cytokines, which may affect the other cells in turn. Thus, even if small number of cells are involved in the beginning, this cascade induction leads to amplification of the biological effects and involves a larger cellular network. It is also possible that cytokines may enhance or suppress the production of other cytokines.</li>
<li>Two or more cytokines may interact with each other to produce additive, synergistic or antagonistic effects.</li>
<li>For many target cells, cytokines act as regulators of cell division (growth factors). Classification of cytokines:
I Hematopoietin family (e.g. GM-CSF, erythropoietin, IL-2, IL-4);
II Interferon family (e.g. alpha, beta and gamma, IL-10);
III Chemokine family (e.g. IL-8, monocyte chemotactic protein, neutrophil activating</li>
</ul>
<p>protein, platelet factor 4); and
IV Tumor necrosis factor (TNF) family.
Cytokines can also be classified into four groups according to their functions (Table 25.2). IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> have many similarities in regard to physical and biochemical properties, synthesis and release, and they possess overlapping biological properties and functions.</p>
<p>Table 25.2
Cytokine groups according to functions</p>
<table><thead><tr><th style="text-align: center;">Group</th><th style="text-align: center;">Members</th><th style="text-align: center;">Major sources</th></tr></thead><tbody><tr><td style="text-align: center;">Mediators of natural immunity</td><td style="text-align: center;">Interferon <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">Macrophages, fibroblasts</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span></td><td style="text-align: center;">Macrophages</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-1</td><td style="text-align: center;">MNP, endothelial and epithelial cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-6</td><td style="text-align: center;">Macrophages, endothelial cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-8</td><td style="text-align: center;">Macrophages, epithelial cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-12</td><td style="text-align: center;">Macrophages, dendritic cells</td></tr><tr><td style="text-align: center;">Regulators of lymphocyte activation, growth, and differentiation</td><td style="text-align: center;">IL-2</td><td style="text-align: center;">T cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-4</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells; mast cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">TGF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span></td><td style="text-align: center;">T cells; macrophages; others</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Interferong</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> cells, NK cells</td></tr><tr><td style="text-align: center;">Regulators of immune mediated inflammation and repair</td><td style="text-align: center;">Interferong</td><td style="text-align: center;">T cells; NK cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-5</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-10, IL-17</td><td style="text-align: center;">T cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-12 IL-18</td><td style="text-align: center;">Macrophages and dendritic cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Lymphotoxin</td><td style="text-align: center;">Macrophages</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">MIF</td><td style="text-align: center;">T cells T cells</td></tr><tr><td style="text-align: center;">Stimulators of immature leucocytes, growth and differentiation</td><td style="text-align: center;">IL-3, IL-9</td><td style="text-align: center;">T cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">IL-7</td><td style="text-align: center;">Fibroblasts, bone marrow stromal cells</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">GM CSF</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">M CSF</td><td style="text-align: center;">MNP; endothelial cells; fibroblasts</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">G CSF</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Stimulation of erythropoiesis</td><td style="text-align: center;">Erythropoietin</td><td style="text-align: center;">Kidney</td></tr><tr><td style="text-align: center;">Stimulation of platelet production</td><td style="text-align: center;">Thrombopoietin, IL-11</td><td style="text-align: center;">Liver, Bone marrow</td></tr></tbody></table>
<p>TNF - Tumor Necrosis Factor
TGF - Transforming Growth Factor
MIF - Migration Inhibition Factor
CSF-Colony Stimulating Factor
GM - Granulocyte Macrophage
MNP - Mononuclear phagocytes
M - Macrophage
G - Granulocyte
IL - Interleukin</p>
<p>Functions of cytokines: The target cell responses that require cytokines fall broadly into the:
(i) Defence role of alerting the body to invasion and dealing with it, and
(ii) Repair role of cleaning up the debris and replacing lost matrix and tissue
(iii) Controlling cellular proliferation and differentiation. IL-1 also produces metabolic responses; thereby, the necessary energy resources and rebuilding materials are mobilised, and
(iv) Hematopoiesis.</p>
<ul>
<li>Role in body defence and regulation of inflammatory responses: IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> are mediators of biological responses to endotoxins and promote inflammation. IL-1 causes erythema, edema, chemo-attraction, and adherence as well as migration of defence cells into the sites of inflammation. IL-1 is responsible for the immune component of inflammatory diseases. Both can induce the burst in neutrophils and monocytes and the associated production of free radicals, myeloperoxide and hydrogen peroxide, that play an important role in killing the invading organisms. The cytokines activate the cells leading to release of hydrolytic enzymes and to increase in PG production. Inhibition and killing of stray tumour cells is yet another property of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and to a lesser extent of IL-1. These cytokines inhibit the replication of certain RNA and DNA viruses and induce viral resistance in a variety of cell types; this is not due to induction of interferons. Thus, many of the events associated with the acute inflammatory reaction and defence against infections of various kinds are mediated by IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>.
TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and IL-2 are potent upregulators of several cell types including fibroblasts and T cells.
The cytokines secreted from subpopulation of helper T cells ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> ) are important determinants of the immune response generated to eliminate the pathogens. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> cells secretes interferon gamma and IgG which help in defence mechanisms. Cytokines from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>1</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">1</span></span></span></span></span> cells prepare body to respond to viral and intracellular pathogens. On the other hand, IL-4 and IL-5 secreted from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">T</mi><mi mathvariant="normal">H</mi></msub><mn>2</mn></mrow><annotation encoding="application/x-tex">\mathrm{T}_{\mathrm{H}} 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">T</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">H</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord">2</span></span></span></span></span> cells induce production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">IgE</mi><mo>⁡</mo></mrow><annotation encoding="application/x-tex">\operatorname{IgE}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mop"><span class="mord mathrm">IgE</span></span></span></span></span></span>. IL-5 is also responsible for eosinophil differentiation and activation; these defense mechanisms help to tackle helminth infections.</li>
<li>Role in body repair: Both IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> appear to have considerable influence on the earlier repair events of debridement, mitogenesis and differentiation. Release of enzymes including proteoglycanase, collagenase, and gelatinase can be induced from fibroblasts, synoviocytes and chondrocytes by IL-1, and the same is true for TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span>. Enzyme release is accompanied by release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, which may also contribute to the degradation process.
Biological actions of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> : They are related to the quantity released. Thus:</li>
<li>At low concentrations: TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> acts as a paracrine and autocrine regulator of leucocytes and endothelial cells. These actions are useful in generating the inflammatory responses which help to counter the microbial infections. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> is also an endogenous pyrogen, and acts on cells in the hypothalamus to produce fever, a property which it shares with IL-1.</li>
<li>Moderate amounts of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> : enter the blood stream and may cause systemic effects, including an increase in the acute phase proteins (APP); further. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> may be the</li>
</ul>
<p>mediator of matrix destruction in rheumatoid arthritis.</p>
<ul>
<li>Very high concentrations of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> : on the other hand, cause depressed myocardial contractility, relaxation of vascular smooth muscle and intravascular thrombosis, leading to fall of BP, decreased tissue perfusion and metabolic acidosis; thus, TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> contributes in a major way to death in septic shock. It also causes depletion of hepatic and muscle glycogen. TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and IL-1 both can induce bone resorption.
Overall, IL-1 and TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> possess the potential for mediating many of the events crucial to defence of the host, and subsequent repair; but by the same token they may also mediate much of the tissue destruction which characterises the connective tissue diseases.</li>
<li>Metabolic role: It is likely that the body wasting and cachexia seen with severe disease states is due to the catabolic properties of TNF.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, like cytokines, causes a rise in APP by different mechanisms. The severity and outcome of connective tissue diseases such as RA, and number of ischemic heart events during atherosclerosis correlate with APP levels.</li>
</ul>
<p>Other cytokines like IL-10 decrease cytokine and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">E</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGE}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGE</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formation by monocytes. TGF beta which also serves as immunosuppresant, reduces inflammation and increases extracellular matrix formation required for repair. This activity of TGF beta is kept under control by interferon gamma which inhibits collagen production and also has myelosuppressive activity.</p>
<p>Although over 200 cytokines have been detected and shown to be involved in physiological functions, only a few have been shown to be clinically relevant.</p>
<p>Human recombinant IL-2 (Aldesleukin) though structurally different from native IL-2, enhances lymphocyte proliferation, cytotoxic and killer cell activity and IFN gamma activity, all of which contribute to activation of cellular immunity. It is presently used in therapy of melanoma and metastatic renal cell carcinoma.</p>
<p>For uses of gamma interferon, see Chapter 59; of growth factors, GCSF and GM- CSF, Chapter 35; and of TNF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> antagonists, Chapter 75.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="platelet-activating-factor-paf-acether">Platelet activating factor (PAF-acether):<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#platelet-activating-factor-paf-acether" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This ether-linked phospholipid possess a wide range of activities. It is released during mast cell degranulation and is implicated in pathophysiological states including allergic inflammation, anaphylactic shock and bronchial asthma. It is also formed by eosinophils, macrophages, neutrophils, vascular endothelium and the renal medullary cells. Like the eicosanoids, PAF is not stored in the cells but is synthesised and released in response to stimuli.</p>
<p>PAF is a potent vasodilator. It activates most inflammatory cells and is believed to be responsible for mobilisation of eosinophils, neutrophils and/or platelets in lungs after exposure to the allergen. Intradermal injection of PAF in man causes a biphasic inflammatory response in the skin, with acute and late onset components similar to the response to moderate doses of allergens in sensitised individuals. Given by aerosol inhalation, it causes dose dependent broncho-constriction and inflammation of airways. Increased microvascular permeability causes edema of the airways. Further, it also induces non-specific bronchial hyper-responsiveness in non- asthmatic subjects. It promotes platelet aggregation and release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, acts as a chemotactic agent and is a gastric ulcerogen.</p>
<p>A substance called Ginkgolides isolated from the extract of the tree Ginkgo biloba has been used in China for the treatment of asthma and other disorders. It has been claimed to exert specific PAF receptor antagonistic activity. It causes inhibition of PAF induced platelet aggregation, of degranulation of isolated, human neutrophils, and of oxygen free radical production by the human neutrophils. Its possible use in the treatment of bronchial asthma and other allergic disorders is under investigation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-vi-br-drugs-used-in-respiratory-disorders">SECTION VI &lt;br&gt; Drugs Used in Respiratory Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-vi-br-drugs-used-in-respiratory-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 26: Pharmacotherapy of Cough
Chapter 27: Pharmacotherapy of Bronchial Asthma, COPD and Rhinitis</p>
<p>26</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-cough">Pharmacotherapy of Cough<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-cough" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cough, a protective reflex, helps to expel irritant matter from the respiratory tract. This is necessary for preventing mechanical obstruction to breathing. Stimulation of the mucosal Rapidly Adapting Receptors (RAR) and C fibre receptors ending in the respiratory tract at sites such as pharynx, larynx, trachea or bronchi generate tussal impulses. These are carried by afferent fibres in the vagus and sympathetic nerves to the brain stem nucleus solitarius which is connected to the respiration-related neurons in the central cough generator (cough centre), which initiates the act of coughing. C fibre receptors are chemoreceptors, highly sensitive to bradykinin, capsaicin and H ions ( pH ).</p>
<p>The respiratory mucosa contains cells bearing cilia which transport the locally produced mucus towards the throat, from where it can be either coughed out or swallowed to keep the respiratory tract clean (mucociliary clearance). This mucociliary clearance can be defective or even absent in persons with immotile, dysfunctional or congenitally absent cilia. This leads to retention of secretions in the respiratory tract and recurrent respiratory infections including sinusitis and bronchiectasis. In turn, respiratory infection impairs the mucociliary clearance further, with worsening of the infection. Chronic cough is an important symptom in these patients.</p>
<p>The act of coughing involves an initial deep inspiration followed by forced expiration against a temporarily closed glottis. Closure of the glottis causes an increase in intrathoracic pressure. When the glottis opens suddenly, the pulmonary air is forced through the trachea almost at the speed of sound, throwing out the respiratory tract secretions as expectoration. The cough reflex has a tremendous reserve capacity and most coughs are greatly in excess of that required to expel particulate material. Furthermore, the strong expiration leads to a stronger succeeding inspiration and thus produces a vicious cycle in the form of a fit of coughing. Cough may be:</p>
<ul>
<li>Productive, associated with a large amount of sputum; or</li>
<li>Non-productive, dry and usually useless.</li>
</ul>
<p>Environmental pollutants may cause cough by irritating the lungs, trachea or bronchi. Smoking cigarettes is a well known cause of chronic persistent cough. Cough due to the inhalation of allergens such as dust, chemicals and pollen is commonly observed in asthmatics. The commonest cause of transient cough is common cold, and is due to postnasal drip that stimulates receptors in the upper respiratory tract. A similar mechanism probably operates in case of chronic persistent cough observed in persons with allergic rhinitis, chronic sinusitis and obstruction due to enlarged adenoids. Enlarged, infected tonsils, an abnormally elongated uvula or nasal polyps can also cause chronic persistent cough.</p>
<p>Other important causes of cough are:</p>
<ul>
<li>
<p>Upper respiratory tract infections, which may be self-limiting or persistent.</p>
</li>
<li>
<p>Acute lung infections and pleural diseases where therapy of the underlying cause will relieve cough.</p>
</li>
<li>
<p>Chronic pulmonary diseases like asthma, chronic bronchitis, bronchiectasis, tuberculosis and lung cancer where symptomatic treatment for cough is essential along with the specific therapy.</p>
</li>
<li>
<p>Secondary to acute LVF, which calls for immediate attention to the cardiac condition.</p>
</li>
<li>
<p>Gastroesophageal reflux disease (GERD): (Chapter 43).</p>
</li>
<li>
<p>Drug-induced cough: see Table 26.1.</p>
</li>
</ul>
<p>Table 26.1
Some drugs which induce cough</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- ACE inhibitors such as captopril
</span>- Betablockers
- Inhaled corticosteroids and disodium chromoglycate
- Nebulised acetylcysteine
- Amiodarone
- Iodides
- Inhaled ether</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- ACE inhibitors such as captopril
- Betablockers
- Inhaled corticosteroids and disodium chromoglycate
- Nebulised acetylcysteine
- Amiodarone
- Iodides
- Inhaled ether" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Outside the respiratory tract, disorders of the external auditory canal and ear drum, pericardium and even of stomach can give rise to chronic non-productive cough. Thus, wax impacted in the ear, inflammation or eczema or even irritation of the drum by hair can cause dry cough. The entity called 'psychogenic cough' induced voluntarily, is well known; it is non-productive and not present during sleep, usually becoming worse with emotional stress.</p>
<p>Definitive treatment of cough depends upon its cause which should be treated. Stoppage of smoking would correct chronic cough in smokers. Mild acute cough generally does not need drugs. Only when cough serves no useful purpose and causes insomnia, or interferes with daily work, symptomatic treatment is indicated.</p>
<p>In case of productive cough, the patient should be encouraged to cough voluntarily in appropriate posture from time to time. In cases of bronchiectasis or lung abscess, postural drainage aided by percussion of the chest is useful. Since inflamed trachea or bronchi are irritated by cold or dry air, a warm room with humid atmosphere is beneficial. Many patients with cough feel comfortable after a cup of warm tea or even warm water; and simple steam inhalation with or without tincture benzoin, menthol or eucalyptus oil effectively liquifies tenacious respiratory tract secretions (Hydroponic therapy).</p>
<p>Cough can be:
(1) Acute self limiting (less than 3 weeks);
(2) Subacute (3-8 weeks) or
(3) Chronic (more than 8 weeks).</p>
<p>Acute cough such as during and after common cold is usually due to upper respiratory viral infection. Non-viral causes include environmental pollution, asthma, cough-variant asthma and occupational exposure. From therapeutic point of view, chronic cough with normal chest X-ray can be either:
(a) Glucocorticoid responsive, due to eosinophilic disorders as in asthma, eosinophilic bronchitis and allergic rhinitis; or
(b) Inhaled glucocorticoid resistant e.g. postnasal drip, GERD, post-respiratory infection and drug induced.</p>
<p>Barking cough, stridor and chest wall withdrawal are characteristic of croup, common in children. Cough becomes worse at night. Nebulised budesonide or oral/IM dexamethasone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.2</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">(0.2-0.6 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>, single dose) gives dramatic relief. As dexamethasone effect lasts for 2-4 days, second dose is rarely required. Nebulised adrenaline gives immediate but short lived</p>
<p>relief.
Drugs used in the symptomatic treatment of cough classification:
I Pharyngeal demulcents and local sialogogues, e.g., Syrups and Linctuses.
II Expectorants which increase the respiratory tract fluid, e.g., Ammonium salt.
III Central cough suppressants,</p>
<ul>
<li>Opioids and related drugs e.g. Codeine, Dextromethorphan, Pholcodeine, Levopropoxyphene, Noscapine.</li>
<li>Non-opioids e.g., Caramiphene, Pipezethate.</li>
<li>Antihistaminics e.g. Diphenhydramine, Chlorcyclizine.</li>
</ul>
<p>IV Peripherally acting compounds:</p>
<ul>
<li>Local anaesthetics e.g. Benzonatate, Levodropropizine and Nebulised lignocaine.</li>
<li>Mucolytics that help by liquefying thick secretions e.g. Acetylcysteine; and</li>
<li>Anticholinergics e.g. Ipratropium bromide by metered dose inhalation (Chapter 27).</li>
</ul>
<p>Antitussives (tussis: Latin for 'cough') or cough suppressants are used for immediate symptomatic relief of dry cough and are not substitutes for the specific therapy of the underlying cause. They act either centrally or peripherally.</p>
<p>A mucoactive drug is defined as an agent with the capability of modifying mucus production, secretion, its nature and composition, or its interactions with the mucociliary epithelium. Mucoactive drugs include:
(i) Expectorants: which induce cough or increase the volume of secretions.
(ii) Mucolytics: which reduce the viscosity of mucus.
(iii) Mucokinetic drugs: which increase the mobility and transportability of mucus, and (iv) Mucoregulators: which control the process of hypersecretion.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharyngeal-demulcents">Pharyngeal Demulcents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharyngeal-demulcents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Demulcents are useful in cough due to irritation of the pharyngeal mucosa above the larynx. They are administered in the form of lozenges, troches, cough drops or linctuses. They act by increasing the flow of saliva, the best natural demulcent which produces a protective and soothing effect. The 'syrup' part of most cough syrups serves the same function. Salivary secretion can be increased by such simple methods as using a few lemon drops, candy sugar, glycerrhiza or drops of lemon juice in a syrupy base. Costly preparations like lozenges and troches containing multiple ingredients such as menthol and antiseptics are usually unnecessary and wasteful.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="expectorants">Expectorants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#expectorants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The Latin word 'expectorare' means 'to drive from the chest'. Expectorants are the drugs which increase the production of demulcent respiratory tract fluid that covers and protects the irritated mucosa. These drugs are useful in the treatment of useless cough due to irritation of the respiratory mucosa below the larynx and respiratory conditions in which the secretion is thick and viscid, needing liquefaction.</p>
<p>Expectorants can stimulate the output of respiratory tract fluid either directly or reflexly (reflex expectorants).</p>
<p>Direct stimulants: Volatile oils like oil of eucalyptus, anise and lemon, administered orally or inhaled with steam, increase the respiratory secretions probably by a direct action. Alcohol and cedar wood oil (active ingredient terpene hydrochloride), added to steam inhalation, have a similar effect. Large doses of creosote and guaiacol have also been shown to possess this action in animals; and glyceryl guaiacolate forms an important ingredient of many commercial cough mixtures. Guaifenesin, in addition, inhibits coughreflex sensitivity in URTI. However, usefulness of these compounds is limited.</p>
<p>Reflex expectorants: These drugs act by stimulating the gastric reflex which helps to increase the respiratory secretions. Obviously, they produce mild irritation of the gastric mucosa and may produce nausea. Thus, emetic drugs in subemetic doses increase bronchial secretion producing a less tenacious sputum, easier to expectorate. Certain salts which produce such an action are called as saline expectorants.</p>
<p>Ipecacuanha containing an alkaloid emetine is sometimes used as an expectorant. Tincture ipecacuanha 1 ml may increase the respiratory tract fluid and lower the viscosity of the sputum. However, it often produces anorexia and nausea.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="saline-expectorants">Saline expectorants:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#saline-expectorants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Ammonium carbonate, once, used as a saline expectorant, causes anorexia and nausea. It is no more recommended.</p>
<p>POTASSIUM SALTS: Potassium iodide used commonly for this purpose, probably acts both directly and reflexly. It increases the respiratory secretion, and has a reputation for liquefying the thick, viscid fluid. It is generally advocated in productive cough associated with chronic bronchitis, asthma and emphysema. It is administered orally in a dose of 300 mg thrice daily in mixture form. The mixture has a slightly bitter saline taste.</p>
<p>Potassium iodide can cause symptoms of iodism, characterised by nasal catarrh, conjunctival swelling, edema of eyelids, lacrimation, edema of the larynx, headache and various types of skin rashes. Chronic administration occasionally gives rise to goitre and may rarely cause hypothyroidism. It should be avoided in children and pregnant women.</p>
<p>Potassium citrate, though less effective than potassium iodide, is less unpleasant.
The active alkaloid, vasicine, and its derivative vasicinone, from the leaves of Adhatoda vasaca, possess weak bronchodilator, expectorant and mucolytic properties. The aqueous extract of leaves of this plant in syrupy base appears to be safe and effective and has been used as a home remedy in India for ages.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="central-cough-suppressants">Central Cough Suppressants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#central-cough-suppressants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs inhibit the cough reflex by directly suppressing the cough centre in the medulla and are useful in the symptomatic relief of dry irritant cough. They are only partially successful in suppressing cough due to carinal irritation. They are invaluable in the treatment of cough due to pleural diseases. Cough suppressants are particularly useful when complications of severe cough, such as rib fracture or cough syncope, produce discomfort. They should not generally be used in patients with productive cough, especially if they are elderly, not fully alert, or neurologically impaired. In general, cough suppressants do not impair voluntary coughing to clear secretions. Cough suppressants are not recommended in young children particularly those below the age of two years. They are:</p>
<p>CODEINE: This alkaloid of opium resembles morphine in its actions. Like morphine, it depresses the cough centre but is less constipating. Tolerance is not common and drug dependence is rare. A commonly employed preparation is linctus codeine which contains 15 mg of codeine phosphate in 5 ml . Dose: 5 ml by mouth. It can also be used as an analgesic. It is a relatively safe drug and its only bothersome adverse effect is constipation. Codeine preparations are not recommended in children.</p>
<p>Codeine is unlikely to be effective in the distressful cough of terminal lung cancer. In that condition, diamorphine linctus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">3 \mathrm{mg} / 5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> every 4 hours or methadone linctus ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / 5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> every 4 hours is likely to be effective.</p>
<p>With several opioids, the dose required to suppress cough is lower than the analgesic dose.
DEXTROMETHORPHAN HYDROBROMIDE: It is the d-isomer of codeine analogue methorphan. However, it does not act through the opioid receptors and has no analgesic or sedative property. This has led to the belief that distinct receptors (other than the usual opioid receptors) mediate the antitussive action of opioids. It acts centrally to elevate the threshold for coughing. It is as effective as codeine and is much safer; hence, it is commonly used in pediatric practice. It does not depress respiration in the usual doses. It can sometimes cause excitement, irritability and confusion. Adult dose: 10-20 mg every 6-8 hours (maximum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">120 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day). It is a drug of abuse.</p>
<p>Levopropoxyphene mesylate: This levo-isomer of dextropropoxyphene, in the dose of 50100 mg , appears to be as effective as an antitussive as 30 mg of dextropropoxyphene. It has no analgesic activity.</p>
<p>Pholcodeine, though related to opioids, has no opioid-like action. It is as effective as codeine as a cough suppressant, with a longer duration of action. It is non-sedating and non-addicting. It is a common constituent of OTC cough mixtures.</p>
<p>NOSCAPINE: This opium alkaloid, belonging to benzylisoquinoline group, is a smooth muscle relaxant like papaverine. Its antitussive action is approximately equal to that of codeine. It does not produce constipation or drowsiness. Addiction does not occur. Sometimes it causes nausea. The antitussive dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day. Large doses can cause bronchospasm and hypotension due to histamine release.</p>
<p>The other synthetic compounds used include oxeladine, pipezethate and piperidone. There is no convincing evidence about their superiority over codeine. All cough suppressants are dangerous in the presence of excessive secretions as failure to expel them may produce mechanical obstruction and atelectasis of the lung. They are also contraindicated in the presence of respiratory failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="peripherally-acting-agents">Peripherally Acting Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#peripherally-acting-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Benzonatate, chemically related to procaine, probably acts on the stretch and cough receptors in the lungs. It also possesses some central action and can cause sedation and headache. It is not recommended below the age of 10 years. The dose is 100 mg tid.</p>
<p>Levodropropizine and moguisteine are other non-opioid antitussives. The mechanism of action and uses of the former are similar to those of benzonatate; mechanism of action of moguisteine remains to be elucidated.</p>
<p>Lignocaine in nebulised form is used for suppressing cough during pharyngeal examination, bronchoscopy and persistent cough in bronchial carcinoma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-antitussives">Other Antitussives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-antitussives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cough may be the only symptom of bronchial hyper-responsiveness, including asthma. Bronchodilators are useful in these cases, as bronchospasm aggravates and may even initiate cough. The drugs commonly used are: salbutamol and orciprenaline, usually given by inhalation (Chapter 27).</p>
<p>An inhaled glucocorticoid (Chapter 26) may be prescribed for a short period (2-3 weeks) for symptomatic treatment of persistent cough following a viral respiratory infection.</p>
<p>Therapeutic usefulness of antihistaminics as antitussives is limited to the cases where cough is due to conditions associated with post-nasal drip. They are of little value in allergic bronchospasm and may even have a deleterious effect because of their drying effect on the bronchial secretion. Antihistaminics with a sedative action (eg. diphenhyramine) may be useful in children who do not sleep because of cough, provided no contraindication to their use (such as bronchial pathology) exists. However, they may occasionally cause paradoxical excitement. Antibiotics are useful in controlling cough due to respiratory infections.</p>
<p>Sympathomimetic decongestants present in some cough mixtures can cause nervousness, insomnia, hallucinations, hypertension and dystonic reactions especially in children.</p>
<p>Some commercially available preparations promoted for cough and cold contain phenylpropanolamine (PPA). However the use of PPA in cough mixtures has been banned as it may cause hemorrhagic stroke. The safety of other oral decongestants such as pseudoephedrine and phenylephrine is unclear.</p>
<p>The commonest cause of cough is common cold, a viral infection which usually clears within 7 days. Most of the proprietary preparations available as "cough remedies" generally contain a central cough suppressant, an expectorant, an antihistaminic, a bronchodilator and a decongestant in pleasantly flavoured syrupy base. Such remedies may dry up the secretions, prevent natural drainage, cause drowsiness and suppress cough, a protective reflex that helps to get rid of infective material. Multiplicity of such preparations itself indicates that there is no ideal remedy for 'cough'.</p>
<p>Chronic cough hypersensitivity syndrome is characterized by refractory cough not responding to conventional antitussives. It is believed to be due to cough hypersensitivity, abnormal laryngeal and pharyngeal sensations, allotussia and urge to cough. Gabapentin which inhibits central sensitization has been claimed to help patients with chronic cough syndrome.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="mucolytic-agents">Mucolytic Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mucolytic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs are used to make the sputum thin and less viscid, so that it can be easily expectorated. Many patients with chest disease become dehydrated and adequate hydration along with steam inhalation or aerosolised water inhalation can help to liquify viscid sputum. Finally, oxygen should never be administered without adequate humidification as dry oxygen causes drying of the respiratory mucosa (Chapter 77).</p>
<p>ACETYLCYSTEINE: This derivative of a naturally occurring amino acid, 1-cys-teine, reduces viscosity of sputum in vitro. The drug is rapidly metabolised in the body. Clinically, 2 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution is nebulised into a face mask every 8 hours for 5-10 days to liquefy viscous tracheobronchial secretions. It can also be administered by direct instillation into the tracheobronchial tree through a tracheostomy, a bronchoscope or a percutaneous intratracheal catheter, or as an aerosol.</p>
<p>Adverse reactions include bronchospasm, fever, nausea, vomiting, stomatitis, rhinorrhoea and haemoptysis. It reacts with most metals and with rubber.</p>
<p>Carbocysteine and methylcysteine have similar properties as acetylcysteine. They can be given orally or by inhalation.</p>
<p>BROMHEXINE: This is a synthetic benzylamine derivative of alkaloid vasicine obtained from the plant Adhatoda vasaca. It is given orally, parenterally and by inhalation. Experimentally, the drug reduces the viscosity of sputum by dissolving mucopolysaccharide fibres. It is usually administered in doses of 8-16 mg thrice daily. Adverse reactions are minor and infrequent. It can be combined with bronchodilators.</p>
<p>AMBROXOL: This, active metabolite of bromhexine, is used orally ( 15 mg tid) as an alternative to bromhexine.</p>
<p>Dornase alpha: This phosphorylated, glycosylated, recombinant, human deoxyribonuclease, given by nebulisation, can decrease the viscosity of purulent sputum by cleaving long strands of denatured DNA that are released by degenerating neutrophils. It acts extracellularly and does not affect living material. It improves lung function and is well tolerated. It is moderately effective in patients with cystic fibrosis.</p>
<p>It must be remembered that cough serves the useful purpose of clearing the respiratory tract. It should not be severely obtunded in patients with productive cough. Use of antitussives in sedated or debilitated patients may prove dangerous. They should be used cautiously in the acute phase of pertussis and bronchial asthma, as inspissation of mucus plugs may contribute to fatal outcome. The possible anti-tussive effect of pain relieving drugs such as morphine must be kept in mind while prescribing them in post-operative patients. Finally, cough suppressants, especially in syrupy base, should be kept out of the reach of small children, as poisoning with them has been reported.</p>
<p>27</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-bronchial-asthma-copd-and-rhinitis">Pharmacotherapy of Bronchial Asthma, COPD and Rhinitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-bronchial-asthma-copd-and-rhinitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Bronchial asthma is a heterogenous group of conditions, which affects people worldwide, from infancy to old age. It is a clinical syndrome characterised by recurrent cough/paroxysmal dyspnea, chest tightness and wheeze due to increased resistance to air flow through the narrowed bronchi. This narrowing is brought about by:</p>
<ul>
<li>Bronchial hyperreactivity and bronchospasm.</li>
<li>Cellular infiltration and edema of the bronchial mucosa; and</li>
<li>Blockage of the bronchial lumen by inspissated mucus.</li>
</ul>
<p>Patients with asthma have increased susceptibility of developing chest symptoms when infected (rhinovirus)</p>
<p>The diagnosis of asthma is made in a patient with reversible obstructive airway disease by objective evidence of variability in ventilatory function over time or improvement following bronchodilator treatment.</p>
<p>Pathophysiology: The etiology of bronchial asthma is multifactorial: genetic, developmental, environmental, inflammatory and immunological. Its pathogenesis is complex and involves:
(a) Inflammation due to infiltration of eosinophils, mast cells, CD4 lymphocytes,
(b) Mucus cell hyperplasia, and
(c) Re-modelling of the airways with fibrosis</p>
<p>The major role of Th2 (T-helper type 2) cells in pathogenesis of asthma is now recognized.</p>
<p>Many patients have had well defined allergen exposures which are partly or substantially responsible for the asthmatic inflammation. These patients (even the asymptomatic ones, with normal lung function and no recent acute asthmatic episode) have inflamed airways and infiltration with mast cells, eosinophils, basophils, macrophages and activated helper T lymphocytes. Lymphocyte-directed eosinophilic bronchitis is the hallmark of asthma. Mediators released from the cells, damage the bronchial epithelium. Such subacute mucosal inflammation and disruption of the protective epithelial barrier on the mucosal surface contribute to bronchial hyper-responsiveness, an exaggerated response to a variety of stimuli (asthmatic diathesis). This inflammation is clinically silent with no apparent bronchoconstriction during the basal state of the disease.</p>
<p>Exposure to an antigen causes cross-linking of IgE bound to the surface of mast cells (Fig 27.1). A clinical acute attack is produced when the concerned antigen binds to the mast cell which gets activated and degranulated, with the release of histamine and various cytokines. This causes immediate bronchial reactions (Early Reaction) leading to bronchospasm, local vasodilatation, increased capillary permeability, edema, and chemotaxis, with consequent influx of more inflammatory cells into the walls of the bronchi. The newly arrived cells release inflammatory mediators such as PG, LT etc. which aggravate the airway inflammation and cause more sustained bronchoconstriction (Late Phase Reaction). The final common pathway for a clinical attack of asthma is the release of many mediators (Table 27.1) from a variety of inflammatory cells.</p>
<p>Table 27.1
Some important mediators released by mast cells and leucocytes
<img src="assets/images/image-20251214-aa8c5436.jpeg" alt="img-12.jpeg"></p>
<p>FIG. 27.1 Mast cell dependent immediate and late phase reactions
An attack may also be triggered by factors like viral infection, irritants like dust and other air pollutants, cold air, exercise, drugs, chemicals and histamine. The airway hyperresponsiveness may persist for weeks after the acute insult has abated.</p>
<p>Majority of asthmatics ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> ) are atopic, forming IgE antibody on exposure to common environmental allergens, house-dust, mites, cockroaches, pets, pollen and so on. In such atopic subjects, challenge of the airways with allergens to which they are specifically sensitive triggers early and late phases of bronchoconstriction. Mast cells are important in the acute airway response to an allergen and also contribute to their remodelling in chronic asthma.</p>
<p>The early reaction is rapid in onset, reaching maximum in 15-30 min. after challenge and recovering over next 24 hours.</p>
<p>Late-phase bronchoconstriction response begins 4-6 hours after challenge and lasts for up to 24 hours. During this late phase reaction, the airways become non-specifically hyperresponsive to stimuli such as histamine, which may last up to two weeks after a single allergen exposure. During this late (but not early) reaction, there occurs influx of neutrophils, eosinophils and macrophages into the airways which suggests their role in the pathogenesis of this reaction. The acute inflammatory response usually resolves with the repair process restoring normal lung structure and function.</p>
<p>In chronic asthma, the recovery is incomplete due to ineffective repair. This leads to remodelling of the airway structure. Persistent epithelial damage and the loss of its protective function expose the deeper airway structures to further insults, and promote persistent inflammation and cellular infiltration. Various mediators released cause angiogenesis, smooth muscle proliferation, fibrosis and airways thickening, causing persistent obstruction to airflow.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="asthma-is-considered-as">Asthma is considered as:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#asthma-is-considered-as" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Extrinsic when it is associated with history of atopy in patient's childhood, a family history of allergies, illnesses like hay fever, positive skin tests, and raised serum IgE level. This is the commonest form and it starts in childhood or at an early age and usually manifests clinically in 'episodic form;' and</li>
<li>Intrinsic when it occurs in middle aged subjects with no family history of allergies, and clinically assumes a 'chronic form'; there is a lack of identifiable allergen; plasma IgE is not raised.
This classification would appear to imply that there is an allergic factor in extrinsic asthma but none in intrinsic asthma. This is not strictly true and an allergic factor may be involved in many cases of intrinsic asthma as well.</li>
</ul>
<p>Currently, based on molecular phenotyping asthma can also be classified as:
I Th2 high phenotype
II Th2 low phenotype.
Patients expressing high Th2 can be further subdivided into:</p>
<ul>
<li>Early onset allergic asthma which is associated with high levels of Th2 cytokines and IgE and respond to corticosteroids and Th2 targeted therapies; and</li>
<li>Late onset eosinophilic asthma, that occurs with increased severity and high levels of IL5 and eosinophilia. These patients respond poorly to corticosteroids but respond to leukotriene modifiers and IL-5 antibody.
Patients expressing low Th2 can be further subdivided into:
(a) Obesity related, seen frequently in adolescent and adult women, is characterized by absence of Th2 cytokine and respond to antioxidants, weight loss programs and possibly hormonal therapy; and
(b) Neutrophilic adult onset asthma, which is associated with neutrophilia, high levels of Th17 and IL-8 and respond to macrolide antibiotics.</li>
</ul>
<p>Irrespective of type of asthma, persistent bronchial narrowing causes hyperinflation of the alveoli and disruption of alveolar walls with loss of elastic tissue (emphysema-like picture). It promotes infection distal to the obstruction and leads to hypoxemia (reduction in arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension) and hypercapnia (increase in arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension). Prolonged</p>
<p>hypoxemia may cause pulmonary hypertension and right ventricular failure. Hypercapnia causes cerebral vasodilatation, rise in intracranial tension, mental confusion, twitching, drowsiness and finally coma. In severely ill patients, unregulated treatment with oxygen aggravates hypercapnia and the respiratory failure.</p>
<p>Prolonged asthmatic attacks produce dehydration as the patient cannot eat or drink.
Clinically, bronchial asthma presents as:
I Mild intermittent asthma: The patient gets discrete, infrequent, acute attacks, which are relieved by bronchodilators, with no disability between the attacks. There is often a recognisable precipitating factor such as allergy, an upper respiratory tract infection or psychological trauma.
II Chronic persistent asthma: This is generally due to the presence of chronic inflammation and thickening of mucosa of the bronchioles with resultant excessive secretion of mucus, decreased elastic recoil of the lung tissue and finally hyperreactivity of the bronchi with bronchospasm. Symptoms are persistent and relief of bronchospasm with drugs is incomplete.</p>
<p>Chronic form can be subdivided into mild, moderate and severe grades, depending on the interference with daily activities and with sleep, and the degree of incapacity. Clinically, there is more or less persistent dyspnoea and wheeze, with superadded acute attacks. In some patients, chronic asthma co-exists with COPD.</p>
<p>III Severe acute asthma (Status asthmaticus): This is a condition where an acute attack is severe, persistent and does not respond to standard treatment. It is accompanied by evidence of respiratory insufficiency or failure.
IV Exercise-induced bronchospasm in which the attack is precipitated by exercise or by inhalation of cold air.</p>
<p>Principles of therapy: Control of asthma involves:
(1) Environmental control
(2) Pharmacological therapy; and
(3) Treatment of co-morbidities</p>
<p>Environmental control involves avoidance of triggers (respiratory irritants like infection and smoking and environmental/ocupational pollutants) and allergens (dust, mite, pollen, etc.), if known. However, only <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>3</mn><mtext>rd&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">1 / 3^{\text {rd }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0991em; vertical-align: -0.25em;"></span><span class="mord">1/</span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">rd&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> of the patients show symptomatic recovery after avoidance of such exposure.</p>
<p>Aims of Pharmacological therapy are:
(1) Relieving bronchospasm
(2) Reducing bronchial inflammation; and
(3) Prevention of repeated attacks. Bronchodilators and anti-inflammatory drugs are the mainstay of the therapy.</p>
<p>Treatment of co-morbidities include treatment of infection, correction of dehydration and acidosis in severe acute attack, controlled administration of oxygen, when needed.</p>
<p>In addition, a programme of graded exercise training is advised to improve the sense of well being and exercise tolerance. As physial excercise tends to precipitate acute attacks in some patients, an exercise which does not precipitate such attacks (e.g., swimming) is preferred in these patients. Psychological treatment by itself, is rarely of much help, except in functional cases. However, a sympathetic discussion of the patient's problems and patient education about his disease are very helpful.</p>
<p>All these measures, when successful, enable the subject to live as normal a life as possible, including normal exercise tolerance, without experiencing severe adverse drug reactions.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiasthmatics-classification">Antiasthmatics - classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiasthmatics-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="i-bronchodilators">I Bronchodilators:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#i-bronchodilators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Selective beta-2 adrenergic receptor agonists:
(a) Short acting e.g. Salbutamol, Isoetharine, Bitolterol, (a prodrug), Fenoterol and Rimeterol; (b) Long acting Salmeterol, Formoterol, Arformoterol, Indacaterol</li>
<li>Non-selective beta adrenergic agonists e.g. Orciprenaline, Adrenaline and Ephedrine.</li>
<li>Phosphodiesterase inhibitors: Theophylline derivatives - Aminophylline.</li>
<li>Anticholinergics such as Ipratropium bromide, Tiotropium, Aclidinium</li>
</ul>
<p>II Anti-inflammatory drugs:</p>
<ul>
<li>Glucocorticoids.</li>
<li>Leukotriene (LT) modifiers:
(a) LT receptor antagonists: Montelukast; Zafirlukast.
(b) LT synthesis inhibitors: Zileuton;</li>
<li>Mast cell stabilisers: Sodium cromoglycate; Nedocromil.</li>
<li>PAF antagonists: Ketotifen.</li>
</ul>
<p>III Anti-IgE antibody: Omalizumab.
As the pathophysiology of asthma is restricted to the airways, direct, local delivery of drugs to the airways is the preferred method of administration. This route is convenient, promptly effective and reduces the systemic toxicity. It is carried out by using:
(1) Pressurised, metered dose (aerosol) inhalers (MDI) which deliver small doses of the drugs.
(2) Nebulisers which deliver much larger doses with minimal efforts from patients, and
(3) Dry powder inhalers (DPI): The disadvantages of this method are the irritation of the airways; less stability during storage; and the difficulty that the children, the old and the very ill may have in generating the high inspiratory air flow needed to operate the system.</p>
<p>Nonadherence to regular inhaled therapy and faulty inhalation technique are important causes of treatment failure. Patients who find the inhalation route inconvenient or difficult to follow are given oral drug therapy which invariably causes more systemic adverse effects.</p>
<p>With all the methods of local administration, only about 10-30% of the administered drug reaches the desired site, the distal bronchial tree. The rest is swallowed but undergoes first pass metabolism, thus minimising the systemic adverse effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-during-an-acute-attack">Drug Therapy During an Acute Attack<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-during-an-acute-attack" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs used to produce quick relief from acute attack are called rescue drugs. Selective short acting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor agonists (SABA) are the rescue drugs par excellence as both airway smooth muscle and mast cells have <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptors. They:</p>
<ul>
<li>Relax the smooth muscle of all airways from trachea to the terminal bronchi, irrespective of the spasmogen involved. Therefore, they serve as physiological antagonists.</li>
<li>Enhance mucociliary clearance from the respiratory tract.</li>
<li>Suppress microvascular leakage in the airway.</li>
<li>Inhibit mediator release from the mast cells and the basophils, and cytokine release from the inflammatory cells in the airway; and</li>
<li>May inhibit release of acetylcholine from the postganglionic cholinergic nerves in the respiratory tract.
These drugs, however, do not inhibit either the late response to allergens or the subsequent bronchial hyper-responsiveness.
There is no evidence that one <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stimulant is superior to others, except with regard to the duration of action. The choice depends upon the convenience and the cost. Salbutamol is usually preferred and is the prototype of this class.</li>
</ul>
<p>SALBUTAMOL (Albuterol): It is a selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi><mn>2</mn></mrow><annotation encoding="application/x-tex">\beta 2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="mord">2</span></span></span></span></span> adrenergic agonist related chemically to isoprenaline. (Chapter 18)</p>
<ul>
<li>It has a prominent bronchodilator action of rapid onset (1-5 minutes after inhalation).</li>
<li>It has poor cardiac (beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor) action. Hence, it causes less palpitation or a rise of blood pressure; and</li>
<li>It is resistant to inactivation by COMT and, therefore, has a longer duration of action.</li>
</ul>
<p>The effect of a single inhalation or a single oral dose lasts for about 4-6 hours.
Methods of Administration: It is more rapidly effective by pressurised metered dose inhalation (MDI) (dose 100 micrograms/puff) than orally (dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) as it reaches smaller bronchi. Each inhalation may improve the effectiveness of subsequent inhalations. The dose must be prescribed clearly as "so many puffs at a time and the maximum number of puffs per day". It may also be given SC or IM in the dose of 0.5 mg every 4 hours and IV slowly, in the dose of 0.25 mg at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> per minute. It is generally well tolerated. Larger doses can cause dose dependent ADR such as tachycardia, tremor and anxiety.</p>
<p>When a patient is prescribed an inhaler, he must be taught to synchronise the actuation of the inhaler with inspiration, so as to maximise the delivery of the drug to the lungs (Table 27.2).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-27-2">Table 27.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-27-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Technique of using a pressurised inhaler when a spacer is not available</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-2" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<p>Children, old people and those who are breathless find such synchronisation difficult. Further, the velocity of the aerosol causes the latter to impinge on the oropharynx, leading to the decreased delivery of the drug to airways. Spacers are available (Fig. 27.2) which reduce the velocity of the aerosol and allow more of the drug to reach the airways. The coordination between actuation of the aerosol and inspiration is less critical when a spacer is used.
<img src="assets/images/image-20251214-293678b7.jpeg" alt="img-13.jpeg"></p>
<p>Salbutamol may also be administered by a nebuliser wherein synchronisation with breathing is not required. The dose administered <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>2</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(2-5 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span> is much larger than that by a puff of the inhaler ( 100 mcg ). The drug can also be administered by a dry-powder inhaler.</p>
<p>Salbutamol is used in mild intermittent asthma on 'as needed' basis and may be the only treatment needed. In an acute attack, it must be administered in adequate doses such as 10-12 puffs in one hour. Inadequate dosage is the cause of apparent 'resistance'.</p>
<p>Levosalbutamol (Levolin): Salbutamol is a racemate. The active compound levosalbutamol is available in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> puff MDI. It is not clinically superior to salbutamol either in efficacy or ADR.</p>
<p>Terbutaline, fenoterol, bitolterol, pirbuterol, tolubuterol and rimiterol are other selective SABA with similar properties as salbutamol. However, the use of more potent <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist than salbutamol, such as fenoterol has been associated with greater cardiac toxicity in patients with acute asthma.</p>
<p>SABA are very effective for:
(1) Treating acute attacks and
(2) Prevention of exercise-induced asthma.</p>
<p>They are less useful when taken regularly, and hence should be used only as needed. They are safe during pregnancy.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists are also useful in treating wheezing following upper respiratory tract viral infection in infants and children under 5 years and are used orally in syrup form or by a nebuliser.</p>
<p>They may be less effective in some patients who use a beta blocker concurrently. In such a patient, aminophylline is preferred.</p>
<p>Excessive use of beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists has been associated with asthma deaths.
It must be kept in mind that all beta-adrenergic agonists may cause hypokalemia which can be aggravated by concurrent use of theophylline and its derivatives, diuretics and glucocorticoids, and</p>
<p>by hypoxemia.
ORCIPRENALINE (Metaproterenol): This derivative of isoprenaline stimulates both <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors. Thus it is less selective than salbutamol. It is given orally ( 20 mg qid); or IM/SC <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, and by inhalation.</p>
<p>Adrenaline hydrochloride: This is a potent bronchodilator. It also relieves pulmonary congestion by constricting the pulmonary arterioles. When administered SC in the dose of 0.2 to 0.5 ml of a 1 in 1000 aqueous solution ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">1 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ), it is effective within a few minutes. It must be injected slowly and no further injection is given if the attack subsides. The relief of an acute attack by adrenaline is generally dramatic. Once used extensively, adrenaline is now no more recommended because of the inconvenience of administration and its CVS toxicity.</p>
<p>Ephedrine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ), if taken early, orally may abort an acute attack. It is a cheap, convenient and relatively safe medication for treating mild acute attacks of asthma, but it lacks selectivity (Chapter 18).</p>
<p>AMINOPHYLLINE: This is a stable mixture of theophylline and ethylene diamine; the latter makes theophylline more water soluble (Chapter 12). It can be given orally or slowly IV. It:</p>
<ul>
<li>Causes bronchodilatation by its weak and non-selective inhibition of pulmonary enzyme PDE-4.</li>
<li>Inhibits adenosine receptors in the airways.</li>
<li>Inhibits the late response to allergens but does not inhibit the release of mediators.</li>
<li>Acts synergistically with beta adrenergic agonists.</li>
</ul>
<p>It is less effective orally because though it is absorbed, it undergoes first pass metabolism. Given rapidly IV, it may cause nausea, vomiting, cardiac arrhythmias and collapse. Deaths have been reported following rapid IV aminophylline, particularly in the presence of cardiac damage. Rapid IV administration can also cause twitching of the facial muscles, severe hyperventilation and seizures. The repeated use of theophylline in children may cause learning difficulties and sleep disturbances. Hepatic enzyme inhibitors eg. ciprofloxacin, erythromycin and OC (pills) can increase the plasma concentration of theophylline.</p>
<p>It is safer than adrenaline in hypoxic subjects in status asthmaticus, and in patients with concomitant cardiac disease. It is especially helpful when one cannot decide whether a given attack is one of bronchial or cardiac asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Acute attack of asthma: If treatment with inhaled selective SABA in adequate doses fails to relieve an acute attack in about half to one hour, aminophylline is administered by IV infusion in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose in a dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">15-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span> minutes, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> per hour for several hours. The infusion rate should be lowered in patients with cirrhosis, pneumonia, acute viral infection and congestive heart failure and in patients receiving drugs which interfere with its metabolic degradation. Smokers may need a larger dose.</li>
<li>Chronic persistent asthma: Slow release oral preparations may be useful in patients with persistent bronchospasm between acute attacks and in preventing nocturnal attacks. However, these preparations may also prolong the toxic effects as peak plasma level is reached 12-24 hours after the ingestion.</li>
</ul>
<p>If an acute asthmatic attack is not terminated within 2 hours by the above measures, the patient should be treated as a case of severe acute asthma (status asthmaticus).</p>
<p>Selective and potent PDE-4 inhibitors with anti-inflammatory action, cilomilast and roflumilast are being evaluated in asthma and COPD.</p>
<p>Anticholinergics: As the airways have parasympathetic innervation, atropine-like drugs can induce bronchodilatation and have been used as a remedy for bronchial asthma:</p>
<p>IPRATROPIUM BROMIDE is a congener of methylatropine. Administered by inhalation in the dose of 1-2 puffs ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> ) tid, it is as effective as 200 mcg of salbutamol in relieving bronchospasm in patients with chronic bronchitis, and in prolonged bronchial hyperresponsiveness following viral respiratory infections. It is the preferred drug in patients with COPD.</p>
<p>It has a slow onset of action ( 30 min .) and lower efficacy than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists in the management of acute attacks. Hence, it is not recommended for acute attacks. It is particularly useful in patients with concomitant heart disease and those intolerant to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> agonists. A combination of ipratropium and a beta adrenergic agonist by inhalation produces additive effects because ipratropium acts on large and medium sized bronchi whereas <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist act on the smaller bronchi. It is also useful in asthmatic attack induced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-blockers.</p>
<p>Oxitropium bromide and tiotropium bromide are other analogues with similar properties; tiotropium has a longer duration of action.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="prevention-of-acute-attacks">Prevention of Acute Attacks<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#prevention-of-acute-attacks" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Currently, there is no definite strategy for primary prevention of asthma or preventing the development of airflow limitation in patients. It is interesting to note that children raised on farms and in rural areas were consistently found to have low incidence of asthma as against those raised in affluent and urban areas. This could be associated with microbial deversity seen in urban and rural areas, particularly innocuous microorganisms triggering protective immunological responses in the rural children.</p>
<p>Avoidance of the causal factors, such as an allergen, may eliminate acute attacks. This is not easy, and if the allergen is not easily detected, extensive skin testing and desensitisation are unlikely to yield much success. Patients in whom acute attacks are precipitated by a psychologically unpleasant situation are likely to benefit from some readjustment in their family and social life; in case of children, a discussion with the parents is helpful in identifying the problem.</p>
<p>The drugs used in the prevention of acute attacks (maintenance therapy) are:
(1) Inhaled long acting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-agonists (LABA) e.g. salmeterol, formoterol.
(2) Inhaled glucocorticoids
(3) Oral theophylline and
(4) Oral leukotriene modifiers</p>
<p>As the beta-adrenergic agonists and theophylline act by different mechanisms, their concurrent use has an additive effect.</p>
<p>GLUCOCORTICOIDS: When attacks are frequent (more than 3 per week), are not easily relieved by the inhaled bronchodilators and interfere with daily activities and with sleep, the current practice is to start prophylactic inhaled glucocorticoids, on a regular basis. The glucocorticoids beclomethasone, budesonide and fluticasone have the advantages that they are potent, lipid soluble and effective promptly in small doses. Because of their low bioavailability due to high first pass metabolism, their systemic toxicity is low, although almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the drug is swallowed during inhalation. Intake of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of the prescribed ICS dose is necessary to achieve satisfactory control of exacerbation. In case of failure to achieve 'good asthma' control, by inhaled corticosteriod alone, inhaled LABA may be added. The use of micronised MDI may also improve the asthma control.</p>
<p>SALMETEROL is a long acting <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> partial adrenergic agonist, weaker than salbutamol. It is used as the drug of choice in the prevention of nocturnal asthmatic attacks and those induced by exercise. Its onset of action is slow (10-15 min) and the duration of action long (12 hours). It is not useful in relieving acute attacks. It is available in pressurised MDI delivering 25 mcg per puff. The dose is 1-2 puffs every 12 hours. It should not be used more than twice a day.</p>
<p>Formoterol, an analogue, has quicker onset (3-5 min.) than and similar duration of action as salmeterol.</p>
<p>These drugs are usually well tolerated. However, tolerance may develop during long term therapy. They are always used in combination with an inhaled glucocorticoid to reduce incidence of fatal asthmatic attacks seen in patients receiving LABA alone.</p>
<p>EPHEDRINE HYDROCHLORIDE: This sympathomimetic drug, given orally in the dose of 30 mg at bed time, was considered useful in preventing nocturnal asthmatic</p>
<p>attacks. Patients who get daytime attacks need 60 mg on waking and 30 mg at mid-day. Taken later in the day, it may cause insomnia. Sometimes, it causes palpitation and difficulty in passing urine, particularly in the elderly. Repeated at frequent interval, it may cause tachyphylaxis. It also raises the BP in hypertensive patients. Tolerance to ephedrine develops after several weeks of continuous therapy but it is reversible (Chapter 18).</p>
<p>THEOPHYLLINE and AMINOPHYLLINE may not be tolerated orally in therapeutically effective doses ( 1 g daily in divided doses) because of nausea. However, given in the form of tablets, they are cost effective for general use. Their major drawback is the variability in bioavailability. Slow release preparations of theophylline given in the evening may be useful as adjuncts in preventing nocturnal attacks.</p>
<p>Cromolyn sodium: See later.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="leukotriene-modifiers">Leukotriene Modifiers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#leukotriene-modifiers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Leukotrienes liberated during inflammation are more potent and longer acting bronchoconstrictors than histamine (Chapter 25). They increase bronchial secretion, decrease mucociliary clearance, and increase vascular permeability. Drugs can modify the leukotriene system by:</p>
<ul>
<li>Acting as competitive antagonist on type-1 cysteinyl LT receptors eg. Montelukast; or</li>
<li>Blocking the leukotriene synthesis e.g. Zileuton.</li>
</ul>
<p>MONTELUKAST: This is a competitive and selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">L</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{LT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">LT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor antagonist. Its oral bioavailability is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours. It is highly protein bound and metabolised by the liver. It is moderately effective in asthma with once to twice daily administration.</p>
<p>Adverse reactions: These are mild, self-limited and include dyspepsia, headache, eosinophilia and raised liver enzymes. The drug may rarely cause systemic vasculitis.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Aspirin-induced bronchospasm.</li>
<li>Cold-air-induced airway obstruction.</li>
<li>Exercise-induced bronchospasm; and</li>
<li>Mild to moderate chronic persistent asthma.</li>
<li>Allergic rhinitis.</li>
</ul>
<p>Pranlukast and Zafirlukast are the analogues of montelukast. The latter can cause severe hepatitis, and can interact with warfarin to enhance its effect.</p>
<p>Zileuton, a 5 lipoxygenase inhibitor, is as effective as montelukast. It is available only as extended release formulation.</p>
<p>Leukotriene modifiers have no bronchodilator action and cannot be used as rescue drugs. For prophylaxis they are less potent than low dose inhaled glucocorticoids. Combined use of glucocorticoids and leukotriene modifiers may permit a reduction in steroid dose (steroid sparing role). They can be used as an alternative to low dose inhaled glucocorticoid therapy in mild asthma, and in children. Their main advantage is that they are effective orally and hence can be used as substitute for cromolyn. Their use mandates periodic monitoring of hepatic function. Their superiority over the older drugs is not established and they are expensive. They should be used only in selected cases.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-chronic-persistent-asthma">Treatment of Chronic Persistent Asthma<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-chronic-persistent-asthma" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Over and above the treatment during acute attack, patients with persistent asthma need some form of maintenance therapy.</p>
<p>Inhaled <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-agonists: Salmeterol and formoterol are the beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists of choice for this purpose. However, they lack anti-inflammatory action and their efficacy diminishes with continued use owing to development of tolerance. They are best used concurrently with an inhaled glucocorticoid.</p>
<p>Salbutamol should be used additionally (preferably by inhalation) to treat acute attacks when they occur. Inappropriate administration of repeated doses of potent sympathomimetics can induce lethal cardiac arrhythmias.</p>
<p>Inhalational Glucocorticoids: They are the first-line therapy for chronic persistent asthma since chronic inflammation is important in its pathogenesis. Glucocorticoids suppress the inflammatory response and improve lung function at multiple levels. They do not cure the asthmatic inflammation. They:</p>
<ul>
<li>Inhibit phospholipase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="bold">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathbf{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8361em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathbf">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and thereby reduce the cellular histamine and SRS-A content.</li>
<li>They also reduce the microvascular leakage due to the mediators, thereby decreasing mucosal edema</li>
<li>Inhibit the influx of inflammatory cells into the lungs after exposure to an allergen.</li>
<li>Stabilise the cellular lysosomal membranes.</li>
<li>Inhibit the release of mediators from the macrophages and the eosinophils in the lungs. Therefore, they are useful in blocking the late response and the consequent bronchial hyperresponsiveness.</li>
<li>Reduce bronchial hyperactivity by blocking expression of COX-2 and cytokines.</li>
<li>Prevent and reverse the downregulation of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic receptors, and thus maintain/restore the responsiveness of the airway smooth muscle to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists.</li>
<li>Long term administration also reduces the immediate response to allergens, and prevents exercise-induced asthma.
Clinically, they reduce the frequency of acute attacks as well as interval symptoms; and thus improve the quality of life. During long term steroid therapy, the reduction in bronchial hyper-responsiveness is gradual, and may take several months. Effective, long term suppression of airway inflammation reduces the need for bronchodilators, and may reduce the morbidity and perhaps mortality in bronchial asthma. Concurrent use of glucocorticoids and a LABA is beneficial.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="limitations-of-inhaled-glucocorticoids">Limitations of inhaled glucocorticoids:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#limitations-of-inhaled-glucocorticoids" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Locally, they may cause sore throat, coughing, hoarseness and rarely candidiasis.
(2) Higher doses produce limited additional benefits; and
(3) Long term use of high doses may cause systemic adverse effects such as skin bruising, osteoporosis, cataract, glaucoma, HPA axis suppression and growth retardation in children.</p>
<p>Hence, once good control is obtained attempt should be made to taper down the dose.
The macrolide antibiotics (erythromycin, trioleandomycin, clarithromycin) increase the half life of glucocorticoids and theophylline in the body.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beclomethasone-dipropionate">BECLOMETHASONE DIPROPIONATE:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beclomethasone-dipropionate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>This halogenated glucocorticoid ester is used in an MDI which delivers 50 micrograms of the drug per puff.</p>
<p>The usual dose recommended is 2 puffs ( 200 mcg ) 3-4 times a day. Modest but significant decrease in bone mineral density (BMD) occurs in women receiving doses as low as 500 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day. Doses up to 1.5 mg daily in adults do not cause significant suppression of the hypothalamo- pituitary axis, and this is its major advantage.</p>
<p>BUDESONIDE: This drug has a higher ratio of topical to systemic activity and is more potent than beclomethasone. Its uses and limitations are similar to those of beclomethasone. Its major advantage is that it is effective in the dose of 1-2 puffs bid; this improves patient compliance.</p>
<p>Fluticasone has properties similar to those of budesonide. It is expensive.
The adverse reactions to budesonide and fluticasone are similar to those to beclomethasone.</p>
<p>Mometasone furoate is another glucocorticoid used as a powder for inhalation.
Table 27.3 lists the doses of inhaled steroids.
Table 27.3
Doses of inhaled steroids</p>
<table><thead><tr><th style="text-align: left;">Drug (formulation)</th><th style="text-align: left;">mcg/puff</th><th style="text-align: center;">Low dose, mcg</th><th style="text-align: center;">High dose, mcg/day, in divided doses</th></tr></thead><tbody><tr><td style="text-align: left;">Beclomethasone (MDI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo separator="true">,</mo><mn>200</mn><mo separator="true">,</mo><mn>250</mn></mrow><annotation encoding="application/x-tex">100,200,250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">200</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">250</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">100-400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">&gt;1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Budesonide (DPI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo separator="true">,</mo><mn>200</mn><mo separator="true">,</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">100,200,400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">200</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">400</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">100-300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">&gt;1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Fluticasone (MDI, DPI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo separator="true">,</mo><mn>125</mn><mo separator="true">,</mo><mn>250</mn></mrow><annotation encoding="application/x-tex">50,125,250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">125</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">250</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>125</mn></mrow><annotation encoding="application/x-tex">50-125</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">125</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>500</mn></mrow><annotation encoding="application/x-tex">&gt;500</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">500</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Ciclesonide (MDI)</td><td style="text-align: left;">80,160</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>160</mn></mrow><annotation encoding="application/x-tex">80-160</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">160</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">&gt;400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Mometasone furoate (DPI)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo separator="true">,</mo><mn>60</mn><mo separator="true">,</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">30,60,120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">60</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn></mrow><annotation encoding="application/x-tex">100-200</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">200</span></span></span></span></span> bid</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>400</mn></mrow><annotation encoding="application/x-tex">&gt;400</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">400</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Flunisolide</td><td style="text-align: left;">250</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mo>−</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">500-1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">500</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2000</mn></mrow><annotation encoding="application/x-tex">&gt;2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2000</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Triamcinolone</td><td style="text-align: left;">100</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>1000</mn></mrow><annotation encoding="application/x-tex">400-1000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1000</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>2000</mn></mrow><annotation encoding="application/x-tex">&gt;2000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2000</span></span></span></span></span></td></tr></tbody></table>
<p>'Solution for nebulisation is also available
Clinically, all the inhaled steroids are equally effective. They can cause localised infection with Candida albicans in the throat. This can be prevented by rinsing the mouth after every dose. It may interfere with the growth of lungs and other organs in young children; hence should be avoided in mild asthma. A flare up of allergic rhinitis and nasal polyps has been reported on stopping treatment. Steroid inhalation is of no value in treating acute attacks.</p>
<p>DISODIUM CHROMOGLYCATE: This is the sodium salt of 1,3-bis- (2-carboxychromon-5-yloxy)-2 hydroxy propane (Fig 27.3). It is useful in preventing attacks of bronchial asthma in selected cases.
<img src="assets/images/image-20251214-48ae3439.jpeg" alt="img-14.jpeg"></p>
<p>Pharmacological actions: The drug prevents mast cell and eosinophil activation. by</p>
<p>altering the function of the delayed chloride channels in the cell membrane. Thus, (a) It inhibits release of spasmogenic autocoids after combination of the antigen and antibody. In this respect, like glucocorticoids, it acts as an anti-inflammatory agent. (b) It also prevents the early response to allergens and exercise, and the subsequent bronchial hyper-responsiveness.</p>
<p>The drug relieves coughing due to asthma. It has few other significant pharmacological actions.</p>
<p>Absorption, fate and excretion: It is absorbed poorly after oral administration ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span> ) but is absorbed better after inhalation (5%). The absorbed portion is rapidly eliminated unchanged in urine and bile.</p>
<p>Adverse reactions: Except some local irritation, no serious toxicity has been observed.
Preparation and dosage: Disodium chromoglycate is administered in 20 mg capsules, given by inhalation, 3-4 times daily. It is inhaled by using a spinhaler. Its effect is enhanced when the patient's ventilation is improved by prior (but not simultaneous) inhalation of a beta stimulant. It is available as powder for nasal insufflation and as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">2 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">2%</span></span></span></span></span> aqueous eye drops and ointment.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic bronchial asthma: When inhaled during a symptom-free interval, it protects against an attack for several hours in most patients with extrinsic asthma. It is, however, ineffective when used after the beginning of an attack. The results in patients with intrinsic asthma are less satisfactory.
It is more beneficial in patients with clear evidence of allergic factors and in those with exercise-induced bronchospasm. A single dose taken 15-30 minutes before exercise may prevent an acute attack for 1-2 hours. It helps to reduce the requirement of glucocorticoids and bronchodilators. Some patients have to take the drug for 3-4 weeks before they notice its beneficial effects. Cromolyn is probably the antiinflammatory drug of first choice in children.</li>
<li>Other respiratory allergies: It has been used in allergic alveolitis and in allergic rhinitis.</li>
<li>Miscellaneous: It may also be useful in the treatment of allergic conjunctivitis, aphthous stomatitis, ulcerative colitis, food allergy and systemic mastocytosis with variable results.
Nedocromil sodium has properties similar to those of cromolyn but is effective orally. It also inhibits PAF. Nedocromil and its analogues have now been largely superceded by low dose inhaled glucocorticoids.
KETOTIFEN, a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocker, is claimed to be useful in asthma. It is believed to inhibit airway inflammation induced by platelet activating factor (PAF) in primates. It can cause drowsiness. Its usefulness in asthma is equivocal.
OMALIZUMAB: This is a recombinant, humanised anti-IgE monoclonal antibody. It binds to IgE and prevents it from binding to IgE receptors on mast cells and basophils. It thus prevents the allergic reaction at a very early step. Plasma level of IgE diminishes markedly. It is administered as a single SC injection once in 2-4 weeks. The IgE-Ab complex is degraded by the RE system in the liver; the elimination <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 26 days. It is not a bronchodilator. In adults with allergic, moderate-to-severe persistent asthma, it reduces the dependance on glucocorticoids and decreases the frequency of asthma exacerbations. It may also be useful in seasonal allergic rhinitis and food allergy. It is</li>
</ul>
<p>generally well tolerated, but may cause local reactions and, rarely, anaphylaxis. Its use is not recommended in children below the age of 12 years. It is very expensive.</p>
<ul>
<li>Patients with late onset eosinophilic asthma with high levels of IL-5 have been reported to respond to Mepolizumab, an humanized monoclonal antibody against IL-5.
Other concurrent medications: Most chronic asthmatic patients have associated chronic bronchitis and lung damage. Such cases should receive antimicrobial therapy whenever the sputum turns yellow or other signs of infection develop. Those prone to get repeated infections, may need regular antimicrobial prophylaxis during winter or monsoon seasons.</li>
</ul>
<p>Antihistaminics are not so useful in the treatment of asthma except in the presence of definite allergy, where they may prevent the onset of an attack. They may, however, produce drowsiness and dry the respiratory secretions.</p>
<p>Although most of the cases of asthma can now be controlled by a stepwise approach (Table 27.4) using a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic agonist, glucocorticoids and theophylline, a few cases may still be difficult to manage. These may be benefited by oral glucocorticoid therapy in larger doses. In such cases, careful monitoring for adverse effects is necessary (Chapter 66).</p>
<p>Table 27.4
Stepwise management of asthma</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Mild, short-lived intermittent asthma:
</span>Inhaled, short acting beta, agonist as needed
Mild chronic persistent asthma: daily use of
- Low dose inhaled glucocorticoid (LIGS)
(If not controlled, select one of the following)
- LIGS + inhaled long acting beta, agonist
- LIGS + leucotriene antagonists
- ICS + sustained release theophylline
- Inhaled medium-high dose glucocorticoids
Moderate chronic persistent asthma: Daily use
(Select one or more of the following)
- Inhaled medium-high dose glucocorticoids plus inhaled LABA
- Leukotriene modifier
- Aminophylline
- Sustained release theophylline
Severe chronic persistent asthma:
(As above plus one of the following)
- Oral glucocorticoids (prednisolone 30 mg/day for 5-7 days);
- Anti-IgE, Anti-IL-5 monoclonal antibodies in refractory cases
Acute attack (in any of the above categories):
(Additional treatment)
- Inhaled SABA
- Aminophylline IV Prophylaxis: Disodiumchromoglycate Status asthmaticus: See text.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Mild, short-lived intermittent asthma:
Inhaled, short acting beta, agonist as needed
Mild chronic persistent asthma: daily use of
- Low dose inhaled glucocorticoid (LIGS)
(If not controlled, select one of the following)
- LIGS + inhaled long acting beta, agonist
- LIGS + leucotriene antagonists
- ICS + sustained release theophylline
- Inhaled medium-high dose glucocorticoids
Moderate chronic persistent asthma: Daily use
(Select one or more of the following)
- Inhaled medium-high dose glucocorticoids plus inhaled LABA
- Leukotriene modifier
- Aminophylline
- Sustained release theophylline
Severe chronic persistent asthma:
(As above plus one of the following)
- Oral glucocorticoids (prednisolone 30 mg/day for 5-7 days);
- Anti-IgE, Anti-IL-5 monoclonal antibodies in refractory cases
Acute attack (in any of the above categories):
(Additional treatment)
- Inhaled SABA
- Aminophylline IV Prophylaxis: Disodiumchromoglycate Status asthmaticus: See text." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Table 27.5 lists the drugs which cause bronchospasm and may precipitate asthma. They are to be avoided in patients with asthma. Beta blockers used commonly to treat hypertension, angina, glaucoma are contraindicated in patients with asthma. Even a use of eyedrops can cause fatal attacks.</p>
<p>Table 27.5
Some drugs known to cause bronchospasm</p>
<ul>
<li>Aspirin and other NSAID</li>
<li>Beta adrenergic blockers</li>
<li>Cholinergic drugs</li>
<li>Quinine</li>
<li>Morphine and other histamine liberators</li>
<li>Sedatives</li>
<li>Antihistaminics</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="severe-acute-asthma-status-asthmaticus-treatment">Severe Acute Asthma (Status Asthmaticus) Treatment<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#severe-acute-asthma-status-asthmaticus-treatment" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Severe acute asthma (Status asthmaticus) is a serious medical emergency, requiring urgent hospitalisation and vigorous therapy. It is often precipitated by:</p>
<ul>
<li>An acute respiratory infection.</li>
<li>Abrupt cessation of glucocorticoid therapy.</li>
<li>Drugs (aspirin or NSAID) or inhaled allergens; or</li>
<li>Acute emotional stress.</li>
</ul>
<p>A patient in status is markedly dyspnoeic, exhausted, cyanosed and dehydrated. He has tachycardia, may have pulsus paradoxus and may become drowsy if respiratory failure supervenes. Signs of right ventricular failure including a gallop may occur as a further complication. Pulsus paradoxus, prominence of the sternomastoid muscles and high pitched wheezing with absent breath sounds are indicative of the severity of status asthmaticus. Silent chest, feeble respiratory efforts, cyanosis, bradycardia, hypotension, exhaustion, confusion and coma are life-threatening features in status asthmaticus.</p>
<p>Relief of tachycardia and dyspnoea and evidence of better oxygenation, including a clearer mental state, are evidence of favourable response to therapy if repeated measurements of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{FEV}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">FEV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> are not available. The intensity of wheezing can be misleading; it may decrease with worsening obstruction.</p>
<p>Table 27.6 outlines the principles of management of a severe acute asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-27-6">Table 27.6<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-27-6" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Management of severe acute asthma</p>
<table><thead><tr><th style="text-align: left;">Initial treatment</th></tr></thead><tbody><tr><td style="text-align: left;">- Correct dehydration</td></tr><tr><td style="text-align: left;">- Humidified oxygen ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> ) by mask.</td></tr><tr><td style="text-align: left;">- Nebulised salbutamol and ipratropium.</td></tr><tr><td style="text-align: left;">- Oral prednisolone or IV hydrocortisone.</td></tr><tr><td style="text-align: left;">If poor response to above in 1 hour</td></tr><tr><td style="text-align: left;">- Hospitalise.</td></tr><tr><td style="text-align: left;">- Correct dehydration and acidosis.</td></tr><tr><td style="text-align: left;">- Repeat nebulised salbutamol every 30 minutes.</td></tr><tr><td style="text-align: left;">- Repeat nebulised ipratropium ( 0.5 mg 6 hif)</td></tr><tr><td style="text-align: left;">- IV hydrocortisone.</td></tr><tr><td style="text-align: left;">- IV infusion of aminophylline or salbutamol.</td></tr><tr><td style="text-align: left;">- Monitor serum IC, arterial oxygen saturation.</td></tr><tr><td style="text-align: left;">- Antibiotics for chest infection.</td></tr><tr><td style="text-align: left;">- Exclude pneumothorax (X-ray chest).</td></tr><tr><td style="text-align: left;">If still poor response after 1 hour</td></tr><tr><td style="text-align: left;">- Shift to intensive care unit.</td></tr></tbody></table>
<p>Glucocorticoids in large doses are the mainstay of therapy. Hydrocortisone is administered IV in the dose of 200-300 mg every 4-6 hours. Equivalent doses of another glucocorticoid, e.g., methylprednisolone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> by slow IV infusion may be used. Prednisolone 30-60 mg orally every 6-8 hours is equally effective. The bronchodilator therapy should be continued in full dose, using nebulised salbutamol <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> ipratropium, as glucocorticoids need at least 6 hours to produce a beneficial effect. In resistant cases, aminophylline or salbutamol may be administered by slow IV infusion.</p>
<p>Once the patient shows improvement, he should be switched to oral glucocorticoids; 50-</p>
<p>60 mg of prednisolone should be given as a single morning dose. If the patient continues to improve, the dose should be reduced by 5 mg every 3-4 days. If it is not possible to discontinue the glucocorticoid altogether, it should be continued in the minimum effective dose. An attempt should be made to change the treatment to inhaled glucocorticoid. Alternate day glucocorticoid therapy has not been successful in the management of asthma, as the patient deteriorates on the 'steroid-off' day.</p>
<p>Rehydration of the patient either orally (using liquids to which glucose and salt have been added) or by parenteral administration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose-saline (with appropriate quantities of potassium) is essential. It not only corrects dehydration but also makes the bronchial secretions less tenacious. Correction of acidosis by means of IV sodium bicarbonate is likely to restore the patient's sensitivity to the bronchodilators. Some cases would need treatment for acute respiratory failure.</p>
<p>Sedatives, tranquillizers and antihistaminics should be avoided in status asthmaticus. They make the patient drowsy, diminish the voluntary ventilatory drive and thus aggravate the hypoxemia.</p>
<p>Steroid resistant asthma: Rarely, inspite of adequate doses, glucocorticoids may not be effective. Glucocorticoids act by binding to nuclear receptors and attach to DNA sites that code for cytokine production. Corticosteroids resistance has been related to defective DNA binding, a decrease in number of glucocorticoid receptors and decreased ligand receptor affinity. Interestingly, glucocorticoid resistance in these cases is confined to T-cells. In such cases increase in dosage will cause toxicity without any relief from asthma.</p>
<p>Table 27.7 enumerates the important points to remember in the management of asthma.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-27-7">Table 27.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-27-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Points to remember in asthma</p>
<ul>
<li>Asthma is a heterogenous symptom complex.</li>
<li>Inhaled glucocorticoids is the mainstay therapy of persistent chronic asthma.</li>
<li>Where symptoms of asthma persist in spite of low dose inhaled glucocorticoids, add inhaled LABA instead of increasing the dose of inhaled glucocorticoids.</li>
<li>High dose inhaled glucocorticoids (more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1500 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> day) increase the risk of its long term toxicity.</li>
<li>LABA are highly effective as prephylactics in exercise-induced and nocturnal asthma.</li>
<li>Inhaled LABA should not be used as monotherapy but combined with inhaled glucocorticoids for long term treatment.</li>
<li>Oral aminophylline is much less effective than inhaled glucocorticoids.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="copd-management">COPD - Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#copd-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Chronic Obstructive Pulmonary Disease (COPD) is characterized by "air flow resistance that is not reversible". It includes:
(1) Emphysema an anatomically defined entity associated with enlarged and distorted lung alveoli, and
(2) Chronic bronchitis, a clinical entity associated with disease of small brochioles with chronic airflow obstruction, chronic cough and marked expectoration.</p>
<p>Chronic bronchitis without airflow obstruction is not COPD.
COPD is a complex syndrome which results in slow albeit progressive loss of lung function due to chronic inflammation of small airways and lung parenchymatous tissue. The risk factors are smoking, indoor air pollution, biomass fuel and occupational exposure. It is a major cause of mortality and morbidity all over the world. Often asthma coexist with COPD.</p>
<p>COPD is a heterogeneous disorder, and responds differently according to its phenotype. The main physiological abnormality in COPD is an accelerated rate of decrease in the Forced Expiratory Volume <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">F</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">V</mi></mrow><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{FEV}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">FEV</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> compared to normals. There is hyperinflation which is present at rest and worsens on exercise, increasing the work of breathing. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> diffusing capacity decreases with resultant hypoxemia. The situation becomes worse with comorbidities such as cardio-vascular diseases.</p>
<p>The current therapy of COPD includes:</p>
<ul>
<li>Inhaled bronchodilators</li>
<li>Inhaled glucocorticoids</li>
<li>Oxygen inhalation</li>
<li>Prophylactic antibiotics</li>
<li>Preventation of dehydration; and</li>
<li>Physiotherapy, pulmonary rehabilitation and education.</li>
</ul>
<p>Inhaled bronchodilators are the mainstay of therapy, and any one of the regimens given in Table 27.8 may be used. However, long term use of combination therapy with an inhaled glucocorticoid (fluticasone, budesonide) and a LABA (salmeterol) gives better benefits with acceptable side effects. Indocaterol, another LABA, administered OD can be used as maintenance therapy in COPD. Unlike asthma, COPD has preponderance of CD8 lymphocytes and neutrophils in the airways. Inhaled glucocorticoids probably help to reduce the number of exacerbations; but they alone do not substantially modify airway obstruction. They are better avoided in elderly because of possible ADR. Addition of theophylline may be beneficial in some subjects.</p>
<p>Table 27.8
Bronchodilator regimens in COPD</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Duration of action (hr)</th><th style="text-align: center;">Dose</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Short acting</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Salbutamol sulfate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></td><td style="text-align: center;">2 puffs every 4 hours (MDI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> puff)</td></tr><tr><td style="text-align: center;">Ipratropium bromide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span></td><td style="text-align: center;">2 puffs every 4 hours (MDI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">20 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> puff)</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Long acting</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Formoterol fumarate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">One inhalation twice a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">12 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Salmeterol xinafoate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">One inhalation twice a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">50 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Arformoterol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: center;">One nebulisation, 15 mcg Twice a day</td></tr><tr><td style="text-align: center;">Indacaterol</td><td style="text-align: center;">24</td><td style="text-align: center;">One inhalation once a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Tiotropium bromide</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>24</mn></mrow><annotation encoding="application/x-tex">&gt;24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">24</span></span></span></span></span></td><td style="text-align: center;">One inhalation once a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>18</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">18 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">18</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Aclidinium</td><td style="text-align: center;">12</td><td style="text-align: center;">One inhalation twice a day (DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">400 \mathrm{mcg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span></span></span></span></span> inhalation)</td></tr><tr><td style="text-align: center;">Roflumilast</td><td style="text-align: center;">24 &lt;br&gt; Long acting combinations</td><td style="text-align: center;">1 tablet per day ( 500 mcg ) orally</td></tr><tr><td style="text-align: center;">Budesonide + formoterol</td><td style="text-align: center;">12</td><td style="text-align: center;">Two inhalations twice a day (HFA MDI 160 mcg budesonide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mn>4.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">+4.5 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">+</span><span class="mord">4.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> formoterol/inhalation)</td></tr><tr><td style="text-align: center;">Fluticasone + Salmeterol</td><td style="text-align: center;">12</td><td style="text-align: center;">Two inhalations twice a day (HFA MDI 45,115,230 mcg fluticasone +21 mcg salmeterol/inhalation)</td></tr><tr><td style="text-align: center;">Mometasone + Formoterol</td><td style="text-align: center;">12</td><td style="text-align: center;">Two inhalations twice a day (HFA MDI 100, 200 mcg mometasone +5 mcg formoterol/inhalation)</td></tr><tr><td style="text-align: center;">Fluticasone + Vilanterol</td><td style="text-align: center;">24</td><td style="text-align: center;">One inhalation once a day (DPI 100 mcg fluticasone +25 mcg vilanterol)</td></tr><tr><td style="text-align: center;">Umeclidinium + Vilanterol</td><td style="text-align: center;">24</td><td style="text-align: center;">One inhalation once a day (DPI 62.5 mcg umeclidinum +25 mcg vilanterol)</td></tr></tbody></table>
<p>MDI = Metered dose inhaler.
DPI <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Dry powder inhaler
Intermittently inhaled oxygen improves long term survival in COPD and home oxygen therapy (HOT) should be used along with pulmonary rehabilitation. Severe cases may need oral glucocorticoid therapy.</p>
<p>Antibacterial proplylaxis: An exacerbation of COPD can be defined as "an event in the natural course of the chronic disease, characterised by increase in the baseline dyspnea, cough and mucopurulent sputum beyond the normal variation". It is usually triggered by bacteria, viruses and pollutants. The most common viruses are rhinovirus, coronavirus and influenza virus. In COPD lungs have lower-airway bacterial colonisation mainly by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>H</mi></mrow><annotation encoding="application/x-tex">H</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.08125em;">H</span></span></span></span></span>. influenzae, Moraxella catarrhalis, S. pneumoniae and Ps. pyogenes. Purulent sputum is a reliable marker for bacterial infection, and should be treated promptly with antibiotics. Prophylactic use of fluoroquinolones (Moxifloxacin) for 5 days every 8 weeks or erythromycin/azithromycin has been reported to be useful in preventing exacerbation in subjects with mucopurulent sputum. Acute exacerbation must be treated with antibiotics and oral glucocorticoids administered after giving optimum combination inhaled therapy.</p>
<p>Mucolytic agent, carbocysteine given in the dose of 500 mg tid has been claimed to be useful in reducing the rate of exacerbations when used for long term management of COPD.</p>
<p>Giving up smoking provides definite benefit. Treatment of comorbid CVS conditions with statins, ACEI/ARB and selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers may reduce overall mortality. Respiratory irritants such as smoke, chemicals and dust must be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-acute-respiratory-failure">Treatment of Acute Respiratory Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-acute-respiratory-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Respiratory insufficiency indicates impaired ability of the lungs to eliminate carbon dioxide or to take up oxygen. It may become apparent at rest or only on exercise. Respiratory failure is said to exist when a serious abnormality of blood gases (arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{CO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">CO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension of over 50 mm Hg or arterial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> tension of 60 mm Hg or less) is present at rest. Respiratory failure may be:</p>
<ul>
<li>Ventilatory failure; or</li>
<li>Oxygenation failure</li>
</ul>
<p>In the commoner variety of acute ventilatory failure, prolonged bronchial obstruction in patients with already badly damaged lungs as in COPD leads to an inadequate uptake of oxygen and inefficient elimination of carbon dioxide. Hence, the immediate need is to correct the reduced oxygen tension of the blood. Since oxygen lack stimulates the respiration reflexly, its correction leads to a reduction of ventilatory drive, with the result that carbon dioxide accumulates further. The patient becomes drowsy or even comatose. To avoid this, oxygen is given continuously, preferably in a concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25-30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> (Chapter 77), just enough to correct hypoxaemia without causing hypercapnea and respiratory acidosis.</p>
<p>The patient should be made to cough vigorously while his chest wall is being percussed. Coughing out mucus plugs may result in significant improvement and this is further helped by humidification.</p>
<p>Respiratory stimulants (analeptics) may be used to increase ventilation in patients in whom oxygen therapy is followed by a reduction in ventilation. They may also help by stimulating coughing and thus helping the patient to expel secretions. They are usually given IV and have to be repeated frequently. Satisfactory response is characterised by a return of deeper breathing and consciousness, and a reduction in carbon dioxide tension in the blood. Later, this may be maintained by orally administered drugs. There is no drug which selectively, safely and in a controlled manner stimulates the respiratory centre. Generally used is doxapram is used as an IV infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mo>−</mo><mn>4.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1.5-4.0 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, adjusted according to the response. It may be useful as a short term measure along with assisted ventilation, but is not useful in the long term management of respiratory insufficiency.</p>
<p>Almiprine bismethylate a piperaizne derivative selectively stimulates peripheral chemoreceptors. It has no central actions. It is claimed to stimulate ventilation in patients with hypoxia. Its long term use may cause peripheral neuropathy. It is under evaluation.</p>
<p>Other supportive measures in acute ventilatory failure in COPD include bronchodilators, antibiotics, large doses of glucocorticoids, a diuretic (furosemide) to treat heart failure and correction of acid-base imbalance. If these conservative measures do not help sufficiently, secretions from the respiratory passages may be aspirated through a bronchoscope or a cuffed endotracheal tube.</p>
<p>In acute ventilatory failure due to disorders of the CNS (narcotic poisoning, stroke, head injuries), peripheral nervous system and respiratory muscles, intensive nursing care, assisted mechanical ventilation, and other life supporting measures are the mainstay of treatment. In some cases e.g. morphine poisoning, specific antidote therapy is helpful.</p>
<p>In the syndrome of oxygenation failure, which occurs in patients with diffuse interstitial fibrosis, there is no tendency to retention of carbon dioxide, and oxygen can be administered without any reservation and safely. The response is, however, disappointing.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="surfactants-and-the-respiratory-distress-syndrome">Surfactants and the Respiratory Distress Syndrome<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#surfactants-and-the-respiratory-distress-syndrome" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Surfactant is secreted by the type II pneumocytes within the alveolar epithelium of the lungs, into the alveolar lumen. It is a complex mixture of phospholipids, proteins and carbohydrates. By its local action, it:</p>
<ul>
<li>Reduces surface tension within the alveoli and facilitates their aeration at lower ventilatory pressures; this increases the lung compliance and reduces the work of breathing.</li>
<li>Aids in keeping the alveoli dry (antiedema action).</li>
<li>Enhances oxygenation of blood at lower intra-alveolar, partial oxygen pressure; and</li>
<li>May play a role in the immune defence system of the lungs.</li>
</ul>
<p>The secretion of the surfactant is stimulated by cortisol, adrenergic agonists, cholinergic agonists and prostaglandins. Deficiency of surfactant action may be due to:</p>
<ul>
<li>Diminished production as in full term infants delivered by caesarian section, where stimulation of the adrenocortical production of cortisol occurring during vaginal delivery is absent and in prematurely born infants with immature secretory mechanisms. This is the cause of atelectasis and Neonatal Respiratory Distress Syndrome (Neonatal RDS).</li>
<li>More rapid degradation of the surfactant by the macrophages; and</li>
<li>Abnormal composition of the surfactant. The last two factors probably are at work in Adult Respiratory Distress Syndrome (ARDS).
Adverse reactions include bradycardia, hypotension and endotracheal tube blockage. Allergic reactions are rare.</li>
</ul>
<p>The preparations available are bovine-lung derived Calfactant and Beractant; porcinelung derived poractant alpha; and the recombinant calfasceril.</p>
<p>Therapeutic uses: Instillation of surfactant into the trachea of the newborns at risk of developing or already having RDS reduces the morbidity and mortality. The results in adult ARDS are less encouraging. Neonates born by caeserian section can be protected from RDS by administration of dexamethasone to the mother 24 hours prior to the surgery.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-therapy-of-rhinitis">Drug Therapy of Rhinitis<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-therapy-of-rhinitis" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Rhinitis, an inflammation of the nasal mucosa can be:</p>
<ul>
<li>Noninfectious e.g., allergic and nonallergic rhinitis, which is frequently caused by seasonal allergy (e.g., hay fever, pollinosis) and leads to sneezing, nasal stuffiness, ocular pruritus, lacrimation and a postnasal drip.</li>
<li>Infectious e.g., viral common cold and bacterial infection.</li>
</ul>
<p>Chronic or nonseasonal rhinitis, often referred to as perennial rhinitis, results in daily episodes of rhinorrhoea, nasal congestion and sneezing that are present for several weeks during most months of the year. It is caused by various allergic and nonallergic nasal disorders. It includes:
(1) Vasomotor Rhinitis (VMR), a no allergic, noninfectious rhinitis in which eosinophils are generally absent on nasal smear; and
(2) Nonallergic, Non-infectious Rhinitis with eosinophilia (NARES).</p>
<p>Chronic rhinitis can also be induced by drugs such as adrenergic blockers, cholinesterase inhibitors, estrogen preparations (including oral contraceptives), and by the presence of a foreign body, nasal polyps, tumours and nasociliary disorders.</p>
<p>Non-Drug therapy for all types of rhinitis is similar. Exposure to cigarette smoke, pollutants, allergens and other irritants should be avoided. In patients with pharyngitis, saline gargles, steam inhalation and warm mist therapy is helpful. Local instillation of hyperheated, humidified air directly into the nasal passages significantly relieves symptoms of allergic rhinitis. When nasal congestion is severe, nasal irrigation with warm saline solution, prepared by dissolving one tablespoonful each of table salt and baking soda in a pint of warm <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mn>37</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(37^{\circ} \mathrm{C}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord">3</span><span class="mord"><span class="mord">7</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> tap water, may relieve the congestion. The patient should drink plenty of fluids.</p>
<p>Drug Therapy: No drug is likely to abolish the symptoms completely. In general, (i) drugs are more effective in allergic rhinitis than in nonallergic forms and (ii) Acute rhinitis responds more favourably than the chronic form.</p>
<p>The treatment is directed at preventing the release of inflammatory mediators such as histamine and leucotrienes, or blocking their effects. The drugs used are:</p>
<ul>
<li>Antihistaminics</li>
<li>Nasal decongestants</li>
<li>Antiallergic drugs</li>
<li>Anticholinergic drugs; and</li>
<li>Local corticosteroids</li>
</ul>
<p>The selection of drugs in individual patients requires that the noninfectious, allergic forms be distinguished from the infectious forms (common cold). The agents useful in the former, antihistaminics, cromolyn sodium and intranasal corticosteroids, have little value in the latter. Nasal decongestants are beneficial in both. However, antibiotics should be reserved only for patients with bacterial infections.</p>
<p>Antihistaminics and antiallergic drugs: In allergic rhinitis, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">H</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{H}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antihistaminics help to relieve rhinorrhoea, sneezing, nasal pruritus and conjunctivitis but do not affect nasal congestion. They are usually effective in seasonal allergic rhinitis when sneezing and rhinorrhoea predominate and edema and congestion are minimal. They can be used prophylactically in smaller doses by susceptible patients during the allergen exposure</p>
<p>period even when symptoms are absent. A single daily dose of an antihistaminic with a long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> taken at bedtime, may relieve symptoms the following day. The non-sedating antihistaminics such as cetirizine and loratadine, are preferred (Chapter 23) when sedation needs to be avoided.</p>
<p>Antiallergic drugs like glucocorticoids and cromolyn sodium prevent the release of inflammatory mediators. The nasal spray of cromolyn sodium is as effective as an oral antihistaminic in preventing the symptoms of allergic rhinitis. They are reasonably safe.</p>
<p>Nasal decongestants: These drugs are synthetic alpha-adrenergic agonists (Chapter 18). When used locally by spray or as drops, they constrict the dilated blood vessels in the mucosa of swollen turbinates and help to reduce edema. The drugs commonly used are:</p>
<ul>
<li>Ephedrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.5%</span></span></span></span></span>.</li>
<li>Phenylephrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.25%</span></span></span></span></span>.</li>
<li>Naphazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span></li>
<li>Oxymetazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span> and</li>
<li>Xylometazoline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.05 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.05%</span></span></span></span></span>.</li>
</ul>
<p>They provide temporary symptomatic relief in allergic rhinitis, common cold, and acute rhinitis associated with other respiratory infections. NARES, sinusitis, and in acute otitis media with eustachian tube blockage. Oral decongestants such as pseudophedrine may be preferred when sinuses are involved. They are not useful in VMR.</p>
<p>The most common adverse effects of the orally administered nasal decongestants (phenylephrine, pseudoephedrine) are insomnia and irritability. Topical decongestants sometimes cause local discomfort, stinging, burning, dryness of the mucosa, rebound congestion and rhinitis medicamentosa.</p>
<p>Nasal decongestants are only palliative. Only a few drugs in very dilute solution are safe. Ephedrine hydrochloride in isotonic saline, used as nasal drops, is as effective as any other drug, and cost effective. In infants and children, imidazole drugs such as naphazoline and tetrahydrozoline are known to cause disturbance of body temperature, CNS depression and even coma. Hence, decongestants should be stored beyond the reach of children.</p>
<p>Anticholinergic drugs: Rhinorrhoea is primarily the result of glandular hypersecretion, mediated by the cholinergic innervation of the nasal mucosa. Some patients with severe rhinorrhoea and congestion obtain more relief from topical antimuscarinic, ipratropium bromide, than from nasal decongestants.</p>
<p>Topical glucocorticoids exert a marked anti-inflammatory effect on the nasal mucosa by inhibiting the release of inflammatory mediators from the mast cells and basophils, and by blocking the inflammatory effect of leucocytes in the nose. Intranasal glucocorticoids are safe, and are the most effective agents available for the prophylaxis and treatment of seasonal and nonseasonal allergic rhinitis and for weaning the patients with rhinitis medicamentosa from topical decongestants. NARES also responds to local glucocorticoids, but their effectiveness in VMR is limited. Topical glucocorticoids occasionally shrink nasal polyps and reduce nasal obstruction significantly. Small polyps may even disappear.</p>
<p>The efficacy of nasal spray preparation of beclomethasone dipropionate, flunisolide, budesonide, fluocortil butyl and fluticasone is similar. However, local use of dexamethasone formulations is contraindicated as the drug is rapidly absorbed and can cause systemic adverse effects. Sneezing, headache, drying and nasal bleeding can occur after the use of these drugs. In patients with infection, topical steroids, if required, should be used along with</p>
<p>appropriate systemic antibiotics. They should be used with caution in patients with ocular herpes zoster.</p>
<p>Injudicious use of commercially promoted combinations of decongestants with antihistaminics, glucocorticoids and antibiotics may be hazardous and not recommended.</p>
<p>Hyposensitisation: This comprises carrying out skin tests with several antigens individually, followed by serial injections of desensitising vaccines prepared from the 'offending' allergens. The use of such vaccines may benefit (i) patients with allergy to pollens (causing seasonal hay fever); and (ii) those with allergy to wasp and bee venom. It is currently felt that:
(a) Most atopic (allergic) patients are allergic to multiple allergens and are not likely to benefit from vaccines prepared from single allergen.
(b) Diagnostic tests are unreliable, if used by themselves.
(c) The allergen extract desensitising vaccines can precipitate either severe asthma or anaphylaxis and
(d) Vaccines prepared from house dust, house dust mite, animal danders and foods have not been shown to be effective.</p>
<p>All such vaccines should be avoided in asthmatics, pregnant women, children under 5 years and those taking beta-blockers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-vii-br-cardiovascular-drugs">SECTION VII &lt;br&gt; Cardiovascular Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-vii-br-cardiovascular-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 28: Pharmacotherapy of Cardiac Arrhythmias
Chapter 29: Pharmacotherapy of Angina Pectoris, Acute MI and Peripheral Vascular Diseases
Chapter 30: Pharmacotherapy of Hypertension, Pulmonary Hypertension and Orthostatic Hypotension
Chapter 31: Pharmacotherapy of Heart Failure
Chapter 32: Pharmacotherapy of Shock</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-cardiac-arrhythmias">Pharmacotherapy of Cardiac Arrhythmias<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-cardiac-arrhythmias" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Cardiac arrhythmia is defined as disturbance of initiation or conduction of cardiac impulse. Most of us have occasional disturbances (ripple) of cardiac rhythm which are transient and go unnoticed. Normal healthy heart, not genetically predisposed to arrhythmia, is resistant to such minor disturbances by triggers. However, sometimes arrhythmias can be symptomatic and certain arrhythmias are fatal, e.g. those following acute MI.</p>
<p>Anti-arrhythmic drugs are the drugs used to prevent or correct cardiac arrhythmias. The antifibrillatory drugs are compounds which prevent the development of atrial and/or ventricular fibrillation. The antifibrillatory drugs must be differentiated from the defibrillatory drugs i.e. drugs capable of restoring normal sinus rhythm of the heart under atrial and/or ventricular fibrillation. Although many drugs are able to arrest rapid atrial and ventricular arrhythmias, no drug is available that can consistently restore normal rhythm to a fibrillating ventricle.</p>
<p>Electrophysiology of cardiac tissue: The cardiac cell is bounded by a lipoprotein membrane which has receptor channels crossing it. These are ion-selective membranespanning proteins which permit passive movement of ions <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup><mo separator="true">,</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\left(\mathrm{Na}^{+}, \mathrm{K}^{+}, \mathrm{Ca}^{++}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left.\mathrm{Cl}^{-}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2057em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen nulldelimiter"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;"><span class="delimsizing size1">)</span></span></span></span></span></span></span>down their electrochemical gradients during the open but not during the closed state of the channels. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels, known as 'fast' channels, are present in the myocytes of the atria, ventricles and the His-Purkinje tissue; they are absent from the SA node and the AV node. The other ion channels are present in all the cardiac tissues. The rapid depolarisation (Phase 0) is due to the influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the cell, with the late addition of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>, through the 'fast' channels. However, the SA and AV nodes depend upon the inward movement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> through the 'slow' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels. The outward movement of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is responsible for the repolarisation (Phases 1 to 3) of all cardiac tissues (Fig. 28.1).</p>
<p><img src="assets/images/image-20251214-05ff7d4c.jpeg" alt="img-15.jpeg"></p>
<p>FIG. 28.1 Relationship between transmembrane cationic fluxes, ECG recording and transmembrane action potential recorded from mammalian (A) sinus node and (B) His-Purkinje fibre (ventricular)
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi><mi>P</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">R P=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">RP</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Resting potential. TP = Threshold potential
(O) = Phase of depolarisation
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1</mn><mo separator="true">,</mo><mn>2</mn><mo separator="true">,</mo><mn>3</mn><mo separator="true">,</mo><mo stretchy="false">)</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">(1,2,3,)=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">2</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">3</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mclose">)</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Phases of repolarisation
(4)= Resting period</p>
<p>In addition to the above mentioned 'channels', there are two, energy requiring exchange pumps in the cardiac myocyte cell membrane:
(1) The adenosine triphosphate (ATP) energised <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump which pumps <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> out of the cell and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the interior of the cell (see below); and
(2) The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump, which mainly extrudes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the cell to the exterior. Such extrusion is dependent on the activity of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>pump, and diminishes when the latter is made inoperative by digoxin (Chapter 31).</p>
<p>Normally, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions are concentrated extracellularly and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions intracellularly. Ordinarily, this would lead to diffusion of these ions across the cell membrane along their concentration gradients and to equalisation of concentrations on its two sides. Such diffusion is, however, opposed by the membrane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>pump which actively pushes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> ions out of the cell and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions into the cell. For every three <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions pushed out of the cell,</p>
<p>the pump pushes two <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions into the cell, and the pump is thus electrogenic. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> pump operates continuously and does not switch on and off during the action potential of the cardiac cells. During the diastole, more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions leave the cell than the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions that enter it, because of the differences in the membrane permeability. Thus, there is a net loss of positive charges from the cell during the diastole. The anions <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span>and proteins do not leave the cell along with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>because the cell membrane is impermeable to them, and contribute to the intracellular negativity. Thus, the inside of the resting myocardial cell remains (about 90 millivolts) negative to its outside; the cell membrane is said to be polarised.</p>
<p>During the excitation of the cell, larger quantities of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ions cross the cell membrane. These ion fluxes though too small to be measured directly, are, in fact, responsible for the phenomenon of the continuously varying potential difference (transmembrane electrical potential) across the cell membrane. These variations can be recorded as an action potential by inserting a microelectrode into the myocardiac cells. Figure 28.1 shows the action potentials as recorded from the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>driven tissues - SA and AV nodes wherein the resting potential is 30 to 40 mv (Fig 28.1 A) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>driven tissues (others) of the heart (Fig 28.1 B).</p>
<p>In the normal heart, only the SA node and the AV node are capable of spontaneous depolarisation i.e. generating an action potential without external stimulation. As the frequency of spontaneous discharge at the SA node ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">70 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">70/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ) is faster than at the AV node <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>45</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(45 / \mathrm{min})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">45/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mclose">)</span></span></span></span></span>, the former acts as the pace-maker. The other cardiac tissues merely respond by depolarisation to an action potential generated by the SA node. The diseased heart may contain other sites capable of spontaneous depolarisation, giving rise to arrhythmias.</p>
<p>When an atrial or a ventricular cell receives an action potential, it starts depolarising and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>starts entering it; the intracellular negativity starts diminishing. When such depolarisation reaches a threshold potential (TP in Fig. 28.1), the sodium channels open abruptly and a large amount of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>enters the cell (potential becomes positive). Phase ' 0 ' of the action potential (Fig. 28.1) indicates rapid depolarisation of the cardiac cell membrane associated with fast selective inflow of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. During the latter part of Phase 0 , <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>also enters the cell via the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels. The entry of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>continues through Phases 1 and 2 via the slow <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channels. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>which enters the cell causes release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> stored in the sarcoplasmic reticulum of the cardiac myocytes, raising the concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>within these cells. The intracellular free calcium interacts with the troponin-actinmyosin system and causes contraction of the heart. The P wave, the P-R interval and the QRS complex of the ECG are inscribed during Phases 0 and 1 of the action potential propagation in the atria, the AV nodal tissue and the ventricles, respectively.</p>
<p>After depolarisation, the repolarisation occurs in several phases (Fig. 28.1):</p>
<ul>
<li>Phase ' 1 ' - A short rapid repolarisation due to beginning of outflow of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and entry of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">l</mi></mrow><mo lspace="0em" rspace="0em">−</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Cl}^{-}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8557em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Cl</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8557em;"><span style="top: -3.1473em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">−</span></span></span></span></span></span></span></span></span></span></span></span></span> ions into the cells.</li>
<li>Phase ' 2 ' - A prolonged plateau phase (delay in repolarisation) at the neutral level due to a balance between the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>entering the cell (through slow calcium channel) and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> leaving the cell. The ST segment of the ECG coincides with this phase of the action potential.</li>
<li>Phase ' 3 ' - The rapid repolarisation upto the resting potential caused mainly by continued extrusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>; it corresponds to the T wave.
During Phase 3, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>is removed from the cytoplasm by reaccumulation into the</li>
</ul>
<p>sarcoplasmic reticulum sacs and by extrusion from the cell. The lowering of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> concentration in the cytoplasm allows the cardiac muscle fibre to relax; and</p>
<ul>
<li>Phase ' 4 '- In this resting phase, the final ionic reconstitution of the cell is achieved by the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump which actively pushes <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>out of the cell and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>into the cell. The cycle is then repeated. In the atria and the ventricles, the membrane potential is steady throughout the diastole; in contrast, the SA node, the AV node and the HisPurkinje tissue depolarise spontaneously because the cell membrane is leaky to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>.
During the greater part of the action potential, the cardiac muscle is resistant to further stimulation (refractoriness, Fig. 28.2). The earliest transient depolarisation that can be produced (without propagation) marks the end of the absolute refractory period (ARP, Phases 1 and 2). The part of the action potential during which a stimulus can evoke only a local, non-propagated response is called effective refractory period (ERP). Relative refractory period extends from the end of ERP to the time that the cardiac tissue has recovered fully; during this period, a stimulus of greater than threshold strength is needed to evoke response that is propagated, though slowly.
<img src="assets/images/image-20251214-a0ce3f6d.jpeg" alt="img-16.jpeg"></li>
</ul>
<p>FIG. 28.2 The normal pattern (dotted line) of transmembrane action potential of a pacemaker cardiac cell and mechanisms of action of antiarrhythmic drugs: (1) Delaying the spontaneous diastolic depolarisation from the resting potential (RP), thus decreasing the rate (all drugs); (2) Increasing excitation threshold potential (TP) e.g. quinidine, procainamide, propranolol; (3) Prolonging the resting period in part by increasing maximum diastolic intracellular negativity e.g. phenytoin and (4) Increasing the effective refractory period (ERP) e.g. quinidine, procainamide.</p>
<p>The above concepts are important for understanding the mechanisms of action of antiarrhythmics in terms of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-channel blocking, Ca-channel blocking and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>-channel blocking.</p>
<p>Certain terms appear repeatedly during a discussion of cardioactive drugs; they are:</p>
<ul>
<li>
<p>Automaticity is the capacity of a cell to undergo spontaneous diastolic depolarisation. In the normal heart, it is maximum in the SA node (pacemaker). In the diseased heart, other areas of the myocardium may develop automaticity and act as ectopic foci.</p>
</li>
<li>
<p>Excitability is the ability of a cell to respond to an external stimulus by depolarisation. It depends upon the level of the resting (diastolic) intracellular negativity; if the negativity decreases (say from -90 to -70 mv ), the excitability of the cell increases.</p>
</li>
<li>
<p>Threshold potential (TP) is the level of intracellular negativity at which abrupt and complete depolarisation occurs. If the TP is raised (i.e. changed from -70 to -60 mv ), the automaticity of the tissue is suppressed.</p>
</li>
<li>
<p>The conduction velocity of an impulse is determined primarily by the slope of action potential and amplitude of Phase 0 (Fig. 28.1) in that tissue; any reduction in the slope leads to depression of conduction.
Propagation of an impulse in the cardiac tissue depends upon (a) the ERP of the tissue and (b) its conduction velocity.</p>
</li>
<li>
<p>Inotropic action is the action of a drug on the contractility of the myocardium.</p>
</li>
<li>
<p>Chronotropic action is the action of a drug on the heart rate.</p>
</li>
<li>
<p>Lusitropic action is the action on relaxation (diastolic function) of the heart.</p>
</li>
</ul>
<p>The autonomic nervous system modulates the inotropic state of the myocardium by regulating the transmembrane ion movements, e.g., beta adrenergic stimulation allows entry of larger amounts of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>through the slow channels and exerts a positive inotropic effect. Beta adrenergic blockers counter this adrenergic influence and exert a negative inotropic effect.</p>
<p>Cardiac arrhythmias, mechanisms: According to the present concept a triggering beat/s interact with a predisposed cardiac tissue (substrate) to initiate and perpetuate cardiac arrhythmia. They could be due to:
(a) Disorders of impulse formation and/or
(b) Disorders of impulse conduction</p>
<ul>
<li>Tachyarrhythmias due to disturbed impulse formation are associated with spontaneous, irregular and rhythmic discharge from ectopic pacemaker activity from areas other than the SA node. Production of such ectopic impulse involves an abnormality of the spontaneous diastolic depolarisation (Phases 3 and 4), leading to ectopic areas of automaticity.
The differences among various atrial arrhythmias could be explained on the basis of the rate of discharge of the ectopic focus. Thus, an ectopic pacemaker with a rate 160180/min. causes atrial tachycardia. If the ectopic rate becomes more rapid, 220-300/min., it produces atrial flutter, while very rapid rates over 350/min results in atrial fibrillation (AF).</li>
<li>Disorders of impulse conduction, commonly referred to as re-entry disturbances, are the commoner of the two mechanisms of arrhythmias. According to this theory, the affected myocardium has areas of depressed function with prolonged refractory period. Due to that, an impulse approaching such an area would be diverted to adjacent excitable tissue. It is possible that the same impulse, after taking a circuitous route through normal tissue, will again reach the depressed area which by then becomes excitable. Upon traversing it, the excitatory process is free to re-enter normal regions and restimulate the chamber or entire heart. Repetition of this cycle would produce an ectopic tachycardia. The presence of a single re-entry mechanism within the ventricle may account for ventricular premature systoles, ventricular tachycardia (VT) and ventricular fibrillations (VF). The presence of a similar mechanism within the atria could cause atrial flutter. Atrial and ventricular fibrillation are caused by the fragmentation of single re-entrant path into multiple smaller cycles. In arrhythmias of the re-entrant type, conduction velocity and duration of RP are the two most critical electrophysiological properties which could be altered by drugs.
Clinically, it is usually not possible to determine whether an arrhythmia represents a disorder of impulse formation or impulse conduction. Identical arrhythmias on the ECG</li>
</ul>
<p>may result from disparate mechanisms in different patients, or even in the same individual at different times. Hence, except in a few cases, an antiarrhythmic drug cannot be selected simply on the basis of its effect on electrophysiological properties.</p>
<p>Not all arrhythmias need the same aggressive drug therapy. If an arrhythmia is precipitated by hypotension, restitution of BP by vasopressor agents like DA or NA may reestablish normal sinus rhythm. Further, sinus tachycardia and sinus bradycardia generally need no treatment other than that of the underlying cause. Only those which are lethal (VF), herald more dangerous rhythm (ventricular premature beats in acute MI) or seriously compromise cardiac output (AF with fast ventricular rate) require rapid and effective therapy.</p>
<p>Apart from common risk factors such as smoking, hypertension, metabolic diseases (diabetes), genetic predisposition seems to be important. The presence of long QT syndrome phenotype has been associated with sudden death. Blacks have higher prevalence of high BP and metabolic disease but lower incidence of atrial fibrillation compared to white population. Familial occurrence of atrial fibrillation is well known. Every patient with an arrhythmia should be evaluated for a possible underlying cause such as : a cardiovascular disorder; pulmonary disease; autonomic disorders; electrolyte disturbances; systemic disease; and drug induced toxicity. Correction of an identifiable factor, when possible should precede the administration of an anti-arrhythmic drug. In many situations, arrhythmias tend to be benign. Their treatment should be expectant, and potentially toxic drugs should be avoided.</p>
<p>The basic electrophysiological actions of antiarrhythmic drugs (Fig. 28.2) are:</p>
<ul>
<li>Decreasing the slope of Phase 4 (diastolic depolarisation) of the action potential in the excitable cardiac tissues. This action is possessed by all antiarrhythmic drugs and suppresses the enhanced automaticity of ectopic foci.</li>
<li>Shifting the threshold potential towards zero (i.e., making it less negative). This again suppresses the automaticity of ectopic foci. Quinidine, Procainamide, Propranolol and Potassium possess this action.</li>
<li>Shifting the resting potential away from zero (i.e. making it more negative), which also slows the rate of diastolic depolarisation and suppressing automaticity. Lignocaine and Phenytoin possess this action.</li>
<li>Increase in the duration of the action potential, thus increasing the effective refractory period (ERP) and blocking re-entrant impulses. Quinidine, Procainamide, Propranolol and Potassium possess this action.</li>
<li>Shortening of the duration of action potential by Lignocaine and Phenytoin, on the other hand, reduces the refractoriness of the AV junctional tissue.</li>
<li>Decreasing the slope of Phase 0 of the action potential and slowing the conduction velocity of a propagated impulse. This blocks the re-entrant impulses responsible for an arrhythmia. Quinidine, Procainamide, Disopyramide, Lignocaine (in large doses) and Verapamil possess this action.
Antiarrhythmic drugs, classification: They are generally classified according to their mechanism of action as:</li>
</ul>
<p>Class I: Fast sodium channel blockers: Which predominantly block open and/or inactivated sodium channels rather than resting sodium channels. In higher concentrations, they also block nerve conduction. With the usual doses, most drugs, other</p>
<p>than group IC, have little effect on the normal conduction system. They impede the initial rapid depolarisation and slow the phase 0 depolarisation rate, without altering the resting potential and are sometimes called membrane stabilisers (Chapter 16). They are further subdivided into 3 groups:
(IA) Those which cause moderate phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi></mrow><annotation encoding="application/x-tex">O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span> depression. and hence, moderately suppress conduction. They prolong repolarisation (refractoriness, phase 3) and prolong the action potential duration, in addition to suppression of automaticity e.g. Quinidine, Procainamide, Disopyramide;
(IB) Those which are weak phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi></mrow><annotation encoding="application/x-tex">O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span> depressants and have little influence on conduction velocity. They shorten repolarisation (refractoriness, phase 3) and action potential duration. They suppress automaticity e.g. Lignocaine, Phenytoin, Mexiletine, Tocainide, and
(IC) Those which cause marked phase <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>O</mi></mrow><annotation encoding="application/x-tex">O</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.02778em;">O</span></span></span></span></span> depression; they markedly slow conduction. They have no effect on action potential duration and repolarisation. e.g., Flecainide, Propafenone.</p>
<p>Class II: Beta adrenergic blockers which block the beta-1 cardiac receptors and mainly suppress automatic discharge (phase 4 depolarisation). They do not prolong repolarisation (phase 3).</p>
<p>Class III: Potassium channel blockers: They markedly prolong repolarisation (phase 3) and increase action potential duration without affecting the conduction velocity. They increase RP e.g. Amiodarone, Sotalol, Ibutilide, Vernakalant, Sotalol is a noncardioselective beta blocker with additional class II activity.</p>
<p>Class IV: Calcium channel blockers (CCB: Verapamil but not Nifedipine) which shorten the action potential duration and depress the slow inward <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>current (phase 2). Their action is mostly limited to SA and AV node where they suppress automaticity in pacemaker cells and slow conduction and increase ERP.</p>
<p>Mechanism of action of some drugs does not fall in any of the four classes.
Class V: Miscellaneous:
(a) Those which do not cause prolongation of repolarisation, e.g. Adenosine.
(b) Digitalis (Chapter 31); Potassium; Magnesium.</p>
<p>Most of the antiarrhythmic drugs have multiple actions. Further, the metabolites of some of these drugs contribute to or even are primarily responsible for the action.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="clinical-classification">Clinical classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#clinical-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Those used for supraventricular arrhythmias, viz. Adenosine, CCB such as Verapamil and Diltiazem.
II Those used for both supraventricular and ventricular arrhythmias, viz. Amiodarone, Beta blockers, Quinidine and Procainamide; and
III Those used for ventricular arrhythmias, viz. Lignocaine.
The choice of anti-arrhythmic agent in a given arrhythmia depends on :</p>
<ul>
<li>Correct diagnosis.</li>
<li>Urgency for treatment.</li>
<li>Route of administration.</li>
<li>Extent of cardiac damage; and</li>
<li>The risk-benefit ratio of the drug concerned.</li>
</ul>
<p>All the antiarrhythmic drugs have both cardiac and noncardiac adverse effects.</p>
<p>Table 28.1 lists the major risks with Group I antiarrhythmics. All drugs that block the sodium channels have the capacity to reduce ventricular function. This propensity is highest with flecainide (IC). Class III agents are also proarrhythmic but to a smaller extent. Further, flecainide is known to cause</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-28-1">Table 28.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-28-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="cardiovascular-risks-with-group-i-antiarrhythmic-agents">Cardiovascular risks with Group I antiarrhythmic agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-risks-with-group-i-antiarrhythmic-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Torsade de pointes</li>
<li>Increased frequency of ventricular tachycardia.</li>
<li>Increased mortality during long term treatment.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><mo>−</mo><mo>&gt;</mo></mrow><annotation encoding="application/x-tex">--&gt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">−</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&gt;</span></span></span></span></span>
<img src="assets/images/image-20251214-bb097c42.jpeg" alt="img-17.jpeg">
(a) incessant, sustained ventricular tachycardia;
(b) ventricular fibrillation, particularly in patients with poor ventricular function, and
(c) unexplained, sudden deaths. Therefore, although the presence of ventricular premature beats and non-sustained ventricular tachycardia increase the risk in patients with recent MI, asymptomatic and mildly symptomatic patients with such arrhythmias may not benefit from atiarrhythmic drugs other than beta adrenergic blockers.</li>
</ul>
<p>QUINIDINE: This first antiarrhythmic agent used to treat both atrial and ventricular arrhythmias, is an isomer of the antimalarial drug quinine, one of the alkaloids occurring in the cinchona bark. The beneficial effect of quinine on AF was first noted by a Dutch colonial with atrial fibrillation, when he took quinine for malaria. Later, Wenckebach, an Austrian cardiologist confirmed this observation and introduced quinine as an antiarrhythmic drug.</p>
<p>Pharmacological actions: These are:
I Cardiac actions and
II Extracardiac actions
The cardiac actions are due to its direct myocardiac depressant properties, and to a smaller extent due to its vagolytic (antimuscarinic) action. It blocks the sodium channels. It also inhibits potassium channels in the cardiac cells.</p>
<ul>
<li>
<p>Automaticity: Quinidine depresses diastolic depolarisation and hence, automaticity in all tissues, especially the ectopic pacemaker. This action helps to suppress the arrhythmias due to enhanced impulse formation. Quinidine does not suppress the automaticity of the normal SA node.</p>
</li>
<li>
<p>Excitability: Quinidine depresses the excitability of the cardiac tissue and hence a weak ectopic impulse becomes ineffective.</p>
</li>
<li>
<p>Conduction velocity: Quinidine slows the conduction velocity in all the cardiac tissues. This property, along with the increased RP and decreased excitability, contributes to a decreased cardiac rate in arrhythmias due to the presence of an ectopic focus.</p>
</li>
<li>
<p>Refractory period: Quinidine blocks delayed rectifier potassium current, thus depressing the potassium efflux during repolarisation. Thus, it prolongs (by a direct action) repolarisation and hence, the RP. However, its vagolytic action (indirect action) increases the atrial RP, shortens that of the AV node while leaving that of the ventricles unaltered. The overall action of quinidine is:
(a) To prolong the RP markedly in the atria,
(b) To increase RP in the ventricles to a smaller extent and
(c) To decrease RP in the AV node.</p>
</li>
</ul>
<p>Simple prolongation of RP prevents the heart from responding to premature or rapid stimulation. Re-entrant impulse finds the originally depolarised tissue still inexcitable. Quinidine thus abolishes the arrhythmias due to re-entrant circuits.</p>
<ul>
<li>AV conduction: Quinidine depresses conduction predominantly within the atria and the His-Purkinje system. However, its vagolytic effect permits or even enhances conduction in the AV node, causing tachycardia.</li>
<li>Contractility: Quinidine exerts a negative inotropic action on the heart. This obviously is a disadvantage. Hyperkalemia enhances the depressant effects of quinidine.</li>
<li>Effects on ECG: Early changes comprise increase in Q-T interval. Decrease in amplitude or inversion of T wave and depression of S-T segment may also occur. Later changes include widening and frequent notching of the P wave, and prolonged P-R interval.
Widening of the QRS complex signifies reduction of conduction velocity, and if accompanied by a considerable increase in the RP of the ventricle, might lead to the development of VT and eventually to VF. When, the QRS complex is widened by 25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> or above 0.12 to 0.14 second, quinidine should be withheld.</li>
</ul>
<p>Quinidine is known to cause unpredictable abnormalities of rhythm in digitalised heart. Extracardiac actions:</p>
<ul>
<li>Blood pressure: Quinidine lowers BP in most patients. In patients with low cardiac output, quinidine may shift it towards normal. This is accomplished by a reduction in BP which reduces the left ventricular load, permitting a more complete emptying of the ventricle.</li>
<li>Miscellaneous actions: Quinidine depresses the skeletal muscle and like quinine, shows antimalarial, antipyretic and weak oxytocic activities.
Absorption, fate and excretion: Quinidine is almost completely absorbed from the gut. Following a single oral dose, the peak effects are reached within 2 to 3 hours and persist for 6 to 8 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> is bound to plasma albumin. It is primarily metabolised ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> ) in the liver with half life of 4-8 hours. One metabolite 3-hydroxyquinidine is as potent as quinidine. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of the drug is excreted in the urine unchanged. With the same quinidine regimen, there are wide differences in the serum quinidine levels in different persons. Electrophysiological and toxic effects correlate better with serum levels than with dosage. Hence, frequent clinical and ECG monitoring is mandatory. Adverse reactions: Quinidine given IV could be very toxic.</li>
<li>Cardiac toxicity: The drug causes bradycardia, conduction defects and heart failure, particularly in patients with marked cardiac damage. Further, there may be increased frequency of ventricular premature beats. In addition, two distinct, drug-induced ventricular arrhythmias may occur:
(a) Torsade de pointes; and</li>
</ul>
<p>(b) Incessant ventricular tachycardia.</p>
<p>All antiarrhythmics that prolong QT interval markedly can precipitate a polymorphic ventricular tachycardia known as torsade de pointes, which may result in syncope and sudden death. Presence of bradycardia and hypokalemia increases this risk. It is generally dose related and women and elderly are more susceptible. Drugs that cause similar prolongation of QTc (corrected QT) are listed in Table 28.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-28-2">Table 28.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-28-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="some-drugs-causing-prolongation-of-qtc">Some drugs causing prolongation of QTc<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#some-drugs-causing-prolongation-of-qtc" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Antiarrhythmics (Class IA): Disopyramide, Procainamide, Quinidine</li>
<li>Antiarrhythmics (Class III): Amiodarone, Dofetilide, Ibutilide, Dronedarone, Sotalol</li>
<li>Antipsychotics: Chlorpromazine, Haloperidol, Thioridazine, Pimozide, Ziprasidone, Quetiapine</li>
<li>Antibiotics: Erythromycin, Clarithromycin, Moxifloxacin</li>
<li>Miscellaneous: Cisapride, Quinine, Methadone, Pentamidine</li>
<li>Hypotension: Hypotension has been observed more commonly in older patients.</li>
<li>Embolic phenomena: Sudden restoration of sinus rhythm by quinidine in a patient with chronic AF may dislodge the mural thrombi attached to auricular appendages. This might rarely precipitate embolic occlusion of the vessels of the vital organs.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="miscellaneous-toxicity">- Miscellaneous toxicity:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-toxicity" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Allergic Reactions: The manifestations of intolerance include skin rashes, fever and thrombocytopenic purpura.
(b) Gastrointestinal: Nausea, vomiting and diarrhoea are common.
(c) CNS: Headache, dizziness and convulsions may result from a direct action of quinidine on the CNS.
(d) Cinchonism: It results from cumulative overdosage and includes impairment of hearing, ringing in ears, vertigo, blurred vision, light headedness, giddiness and tremor.
Drug interactions: Quinidine is metabolised by hepatic cytochrome P450 enzymes and hence, induction or inhibition of these enzymes affects plasma concentration of quinidine (Chapter 3). Quinidine increases the plasma digoxin level needing adjustment of digoxin dose.</p>
<p>Preparations and dosage: Quinidine sulfate, 200 mg Dose 200-400 mg. every 6 hours.
Therapeutic uses: Quinidine, because of its toxicity, is now rarely used to treat arrhythmias.</p>
<ul>
<li>Atrial fibrillation and atrial flutter: See later.</li>
<li>Paroxysmal atrial, nodal and ventricular tachycardia: Adenosine is usually preferred. Vasopressor agents and parasympathomimetic drugs may also help. Although carotid sinus massage may be effective, it is a potentially hazardous procedure and should be applied only by those with experience in treating its possible complications. Other treatment includes ventricular rate controllers (CCB and beta blockers) or rhythm controller (amiodarone). Quinidine may be used if the above measures prove ineffective.</li>
<li>Atrial, nodal and ventricular premature beats: Most supraventricular premature beats are benign, and patient should be reassured about their harmless nature. Smoking and consumption of tea and coffee should be stopped or at least minimised. If these</li>
</ul>
<p>therapies are ineffective, a beta blocker or amiodarone may be used. Ventricular premature beats, especially if they are frequent (more than 100 beats per 24 hours), need to be investigated to rule out an underlying cardiac lesion. The development of ventricular premature beats during acute MI may herald onset of ventricular tachycardia. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers and amiodarone are effective in many patients; quinidine may be used as the last resort. Contraindications to quinidine therapy:</p>
<ul>
<li>QT prolongation</li>
<li>Chronic heart failure</li>
<li>History of quinidine intolerance.</li>
<li>Ventricular tachycardia associated with complete A-V block.</li>
<li>Hypotension.</li>
<li>Stokes-Adams syndrome.</li>
<li>Myasthenia gravis</li>
</ul>
<p>Quinidine must not be used to treat digitalis-induced arrhythmias.
PROCAINAMIDE: Procainamide, a derivative of procaine, a local anaesthetic (Chapter 16) is effective orally, IM and IV; it is not destroyed by esterase. The cardiac and hemodynamic effects of procainamide are similar to those of quinidine. It is free from CNS toxicity.</p>
<p>Absorption, fate and excretion: Procainamide is rapidly and almost completely absorbed from the gut. Given orally, peak plasma level is reached within 1 hour and declines by 4 hours. It is minimally bound to plasma proteins and about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> is excreted unchanged in urine. Impairment of renal function can produce cumulative toxicity.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic reactions which include chills, fever, itching, skin rash and angioedema.</li>
<li>Cardiotoxicity is similar to that of quinidine. Hypotension (or a shock-like state) occurs most often with the IV use.</li>
<li>Gastrointestinal ADR such as anorexia, nausea and vomiting.</li>
<li>Blood: Agranulocytosis and SLE are rare but serious manifestations.</li>
</ul>
<p>Preparations and dosage:
(i) Procainamide hydrochloride tablet 250 mg .
(ii) Procainamide hydrochloride injection, 100 mg per ml .</p>
<p>It is administered orally in the dose of 0.25 to 0.5 g every 4 to 6 hours. In serious cases, 0.5 to 1 g may be given every 2 to 4 hours. The maintenance dose is 0.25 to 0.5 g 6 hourly.</p>
<p>Therapeutic uses: Procainamide may be used as a substitute for quinidine. It is not recommended for more than 6 months treatment because of the risk of SLE.</p>
<p>DISOPYRAMIDE PHOSPHATE: This drug has membrane depressant (quinidine like) and anticholinergic properties. Its therapeutic effects and toxicity are similar to those of quinidine but it is better tolerated. Given orally, it is completely absorbed and has a plasma half life of 6 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> of the drug is excreted in urine and the rest in the bile.</p>
<p>It is now rarely used.
LIGNOCAINE (Lidocaine): This drug belonging to Class IB is a local anaesthetic (Chapter 16). Given IV, it:</p>
<ul>
<li>
<p>Selectively acts on diseased or ischemic myocardium and depresses diastolic depolarisation and automaticity in ventricular tissue.</p>
</li>
<li>
<p>Has a rapid onset and short duration of action.</p>
</li>
<li>
<p>Shortens the ventricular action potential.</p>
</li>
<li>
<p>Has little influence on conduction velocity.</p>
</li>
<li>
<p>Does not significantly affect the electro physiological function of the atria, SA node and AV node, and causes hardly any change in the surface ECG.</p>
</li>
<li>
<p>Has no hemodynamic adverse effects; and</p>
</li>
<li>
<p>Toxicity, if it occurs, is of short duration.</p>
</li>
</ul>
<p>Since the electrophysiological effects of lignocaine are primarily limited to ventricular myocardium, it is most useful in abolishing ventricular arrhythmias. Its lack of action on AV nodal conduction velocity, makes it a suitable drug in the treatment of digitalis induced ventricular arrhythmia.</p>
<p>The drug is usually given IV, although it can also be used IM. The IV preparation must not contain a preservative nor a sympathomimetic or other vasoconstrictor. The common local anaesthetic preparation should not be used intravenously. It is not effective orally because of extensive hepatic first pass metabolism. Its plasma-protein-binding is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>30</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">15-30 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">30</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span> after a single injection.</p>
<p>Adverse reactions: In recommended dosage, lignocaine is a relatively safe drug. Adverse reactions include drowsiness, disorientation, muscle twitching, blurred vision and rarely convulsions. An IV preparation of a barbiturate or diazepam should be at hand while using IV lignocaine. It diminishes the cardiac output and may cause hypotension, bradycardia and apnea. It should be avoided in the presence of liver damage.</p>
<p>Therapeutic uses: It is the drug of choice for:
(1) Severe ventricular arrhythmias.
(2) Emergency termination of ventricular tachycardia following recent MI and that occurring during cardiac surgery and cardiac catheterisation; and
(3) Digitalis-induced ventricular arrythmias. Because of its immediate effect and short duration of action ( 10 min ), lignocaine is given as a single large initial IV bolus, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 30 sec , followed by a continuous IV infusion at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-4 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> to maintain the effect. Smaller doses ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ) are used in patients with congestive heart failure, shock, hepatic dysfunction and in those over 70 years.</p>
<p>MEXILETINE: This drug resembles lignocaine, chemically as well as in its pharmacological actions. It is, however, effective orally. Adverse reactions are common and are dose related. They include vomiting, tremor, ataxia, blurred vision and hypotension. The dose is 400 mg followed by 200 mg tid.</p>
<p>PHENYTOIN SODIUM (Diphenyl-hydantoin): The hypothesis that the excitatory processes or substances initiating the discharge of impulses in cardiac arrhythmias may be similar to those responsible for epilepsy, led to the use of phenytoin in the treatment of cardiac arrhythmias (Chapter 9).</p>
<p>Phenytoin, a sodium channel inhibitor, depresses the ventricular automaticity; but like lignocaine it does not decrease the conduction velocity between the ventricular fibres. It has less action on the A-V conduction. Similar to lignocaine, it reduces the duration of the action potential. Phenytoin has little effect on the surface electrocardiogram although it may shorten the QT interval.</p>
<p>It is administered orally in the dosage of 100-200 mg 4 times daily for the suppression of ectopic beats and for prophylaxis against recurrent paroxysmal tachycardia. Because of its long half life, the therapeutic effect can be maintained by oral administration of 1.0 g on</p>
<p>the first day, 0.6 g on the second and third days and 0.4 g per day thereafter.
Therapeutic uses: The main use of IV phenytoin is to terminate digitalis induced cardiac arrhythmias where it was preferred as it does not aggravate the A-V block and is relatively safe. However, lignocaine is more effective.</p>
<p>It is given by slow IV injection. A constant IV infusion is liable to cause phlebitis because of the high pH , and should be avoided.</p>
<p>TOCAINIDE: This is an amine analogue of lignocaine and can be given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. every 8 hours. It can cause serious dose related neurological adverse effects.</p>
<p>FLECAINIDE: This fluorinated analogue of procainamide belongs to class 1C. It is well absorbed on oral administration ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>14</mn><mo>−</mo><mn>20</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 14-20</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9713em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">14</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">20</span></span></span></span></span> hours). It can also be given IV slowly. It is highly effective in AV nodal tachycardia and tachycardia associated with WPW syndrome. It, however, causes prolongation of PR, QRS and QT intervals, and is liable to cause arrythmias and sudden death. It has negative inotropic effect. It is contraindicated in cases with heart failure and sick sinus syndrome. Less common toxicities include nausea, tremors and blurred vision.</p>
<p>ENCAINIDE: It has properties similar to flecainide and is effective orally.Although encainide and flecainide readily suppress ventricular premature beats after MI, they can promote incessant ventricular tachycardia (proarrhythmic effect) which is difficult to terminate.</p>
<p>PROPAFENONE: This class 1C antiarrhythmic drug also has mild beta blocker and calcium channel blocker activities. It is relatively safe for suppression of supraventricular arrythmia including WPW syndrome and recurrent AF. It is also used for treating life threatening ventricular arrythmia provided there is no associated structural heart disease. At the onset of paroxysm, 600 mg is administered orally, followed by 300 mg 8 hourly.</p>
<p>The adverse effects are dose related and include prolongation of PR and QRS complex, conduction blocks, inhibition of sinus node and precipitation of CHF, dyspepsia and taste disturbances.</p>
<p>Moricizine: This phenothiazine derivative belongs to class IC and is used to treat supraventricular arrhythmias. It is given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid. Its active metabolites contribute to its long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span>. Mood change, nausea and tremors may occur.</p>
<p>Adrenergic Blocking Agents: Alpha-adrenergic blocking drugs like phenoxybenzamine, administered prophylactically, can prevent the cardiac arrhythmias during surgery of pheochromocytoma (Chapter 18).</p>
<p>Myocardial ß-receptor stimulation increases automaticity, enhances A-V conduction velocity and shortens the refractory period especially in supraventricular tissues.</p>
<p>Beta-adrenergic blocking agents are useful because they:</p>
<ul>
<li>Antagonise the effects of beta-adrenoreceptor activation on SA node and some ectopic foci.</li>
<li>Prolong the refractoriness of AV node and slow down the ventricular rate.</li>
<li>Have a membrane stabilising property (propranolol, oxprenolol and acebutolol).</li>
<li>Reduce myocardial oxygen demand, particularly in the presence of IHD.</li>
<li>Are mainly useful in supraventricular tachyarrhythmias, particularly those precipitated by exercise, emotions, thyrotoxicosis; and</li>
<li>Are generally well tolerated and are much safer than class I group of drugs.</li>
</ul>
<p>See Chapter 18 for the detailed pharmacology of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>-adrenergic receptor blocking drugs.</p>
<p>PROPRANOLOL This beta blocker is well absorbed on oral administration and it is used in the dose of 10-40 mg every 6 to 8 hours. Its plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 2-3 hours following IV administration and 4 to 6 hours after oral use. The drug is given slowly IV at the rate of 1 mg . over 1 minute, repeated at 2 minutes interval upto a total dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>. Other beta blockers may such as atenolol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">25-100 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) can also be used. Severe propranolol toxicity may result in progressive bradycardia and cardiac asystole.</p>
<p>Beta blockers prolong PR interval, shorten <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">Q</mi><mi mathvariant="normal">T</mi></mrow><mi mathvariant="normal">C</mi></msub></mrow><annotation encoding="application/x-tex">\mathrm{QT}_{\mathrm{C}}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9275em; vertical-align: -0.2441em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">QT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.2342em;"><span style="top: -2.4559em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">C</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.2441em;"><span></span></span></span></span></span></span></span></span></span></span> and may potentiate the negative inotropic action of antiarrhythmic drugs, particularly verapamil, which can result in marked bradycardia and even asystole.</p>
<p>They are useful for rate control in SVT.
They exhibit synergistic effect when combined with other antiarrhythmic drugs from class I and III. Broad spectrum of antiarrhythmic activity and established safety record make beta blockers agents of choice for general use as antiarrhythmic agents (see Chapter 31).</p>
<p>Esmolol is a rapidly acting cardioselective beta blocker with a short duration of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>9</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 9</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">9</span></span></span></span></span> minutes). It is given IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">500 \mu \mathrm{~g} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over one minute, followed by a 4 min infusion of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi>μ</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">50 \mu \mathrm{~g} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">50</span><span class="mord mathnormal">μ</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.</p>
<p>SOTALOL: This Class III drug is a non-cardioselective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blocker with potency similar to that of propranolol. However, it has no membrane stabilising action. It:
(a) Prolongs the duration of action potentials in the atria and the ventricles in a concentration-dependent fashion.
(b) Prolongs the ERP of all cardiac tissues, including the AV node and His-Purkinje system.</p>
<p>These actions are unrelated to its beta blocking action.
(c) Has no negative inotropic effect and clinically it does not reduce the left ventricular ejection fraction in the majority of cases.
(d) Increases the ventricular fibrillation threshold in normal and ischemic myocardium, when given experimentally IV.</p>
<p>The surface ECG shows prolongation of PR and QT intervals.
Absorption, fate and excretion: Given orally, it is absorbed completely and does not undergo first pass metabolism in the liver. It is excreted unchanged ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> ) in the urine. Its apparent plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 7 to 18 hours.</p>
<p>Adverse reactions: These are due to its beta blocking properties viz. sinus bradycardia, conduction blocks and hypotension; and due to its property of prolonging the QT interval viz. torsade de pointes (similar to quinidine).</p>
<p>Preparations and dosage: Sotalol hydrochloride tablets ( 40,80 and 200 mg ) and a solution <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(10 \mathrm{mg} / \mathrm{ml})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mclose">)</span></span></span></span></span> for IV injection. The oral dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>160</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">80-160 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">160</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per day in divided doses (maximum oral dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>640</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">640 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">640</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day). It is important to avoid hypokalemia during its use.</p>
<p>Therapeutic uses: Although sotalol is relatively safe in patients who have arrhythmias after MI, it is not recommended routinely as a substitute for other beta blockers. It has been found to be specifically useful in:</p>
<ul>
<li>Unsustained ventricular arrhythmias such as ventricular ectopic beats, even in patients with reduced left ventricular function.</li>
<li>Sustained ventricular tachycardia.</li>
<li>WPW syndrome or recurrent atrioventricular nodal tachycardia; and</li>
<li>Prevention of inducible ventricular tachycardia and fibrillation.</li>
</ul>
<p>The main advantage of sotalol is that its use is associated with low incidence of adverse</p>
<p>effects as compared to the Class I anti-arrhythmic agents. It is very expensive.
AMIODARONE: This Class III drug, structurally related to thyroxine, exerts Class I, as well as Class II (non competitive beta blockade) and Class IV actions. It:</p>
<ul>
<li>Depresses automaticity of sinus, atria and AV node.</li>
<li>Prolongs the ERP of myocardial cells, AV node and abnormal pathway; and</li>
<li>Slows the conduction in AV node and specialised conducting tissues.</li>
</ul>
<p>Thus, it reduces cardiac rate, increases cardiac output and causes a fall in peripheral and coronary vascular resistance due to direct effect on vascular smooth muscles, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>channel blockade and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> adrenergic blockade.</p>
<p>It is used orally as well as IV. It has a large apparent volume of distribution and is stored in fat and tissues. Its half life is 18-60 days. It is metabolised in the liver and excreted through bile. In an emergency, it is given by IV infusion.</p>
<p>Adverse reactions: It causes various dose-dependent adverse effects. Photosensitivity is common. Other ADR include anorexia, nausea, abdominalpain, tremor, hallucinations, peripheral neuropathy, hepatic damage, hypotension and A-V block. Rarely, it can cause hypersensitivity, pneumonitis, pulmonary fibrosis and asymptomatic corneal microdeposits. It contains iodine and can cause disorders of thyroid function and interferes with thyroid function tests (Chapter 64). The drug is embryotoxic.</p>
<p>It is also responsible for drug interactions. It inhibits warfarin metabolism. It enhances bradycardia and A-V block caused by beta blockers and Ca channel blockers.</p>
<p>Therapeutic uses: Amiodarone is a potent antiarrhythmic drug, useful in preventing and treating both supraventricular and ventricular tachyarrhythmias even in those with poor LV function. Though its toxicity profile is wide, in the doses recommended, it appears to be well tolerated.</p>
<p>It is particularly useful in patients with sustained ventricular tachycardia. It is now increasingly used to treat AF wherein it not only reduces ventricular rate but can also restore sinus rhythm (chemical cardioversion). Its beneficial effects are seen after 5 to 10 days and full improvement may not occur for 4 to 6 weeks of therapy.</p>
<p>Dronedarone: It is a structural analog of amiodarone. It, however, does not cause thyroid dysfunction or pulmonary fibrosis, probably because of absence of iodine moieties in its structure. Its common ADR include bradycardia and prolongation of QT-interval, nausea, diarrhoea, rash, severe hepatic damage and creatinine elevation.</p>
<p>The drug is less effective than amiodarone in the treatment of non-permanent AF and probably dangerous in patients with permanent AF.</p>
<p>Aprinidine, like amiodarone, is useful in controlling refractory ventricular (and, to a smaller extent, supraventricular) tachyarrhythmias. Its electrophysiological effects resemble those of quinidine.</p>
<p>IBUTILIDE: This Class III agent is used for chemical cardioversion of atrial flutter and fibrillation. It prolongs the atrial and ventricular RP with minimal effect on conduction, probably through its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channel inhibiting action. It also activates the inward <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>current. Given IV, it acts within 1 to 2 hours.</p>
<p>Dofetilide has similar properties as ibutilide but can be given orally. It blocks the delayed rectifier current in dose-dependent manner; the effects are more in hypokalemia. Given orally, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> undergoes renal excretion unchanged.</p>
<p>VERNAKALANT: This new drug acts as antiarrhythmic by blocking the ultra-rapid</p>
<p>delayed rectifier potassium current, mainly expressed in the atria. It also blocks the sodium channel and muscarinic receptor-operated potassium channel. It is administered IV and has been used for rapid conversion of AF of recent origin. It is contraindicated in patients with hypotension, bradycardia and severe heart disease.</p>
<p>VERAPAMIL: This CCB (Chapter 29) is the drug of choice for rapid conversion to sinus rhythm in cases of paroxysmal supraventricular tachycardia. It is given IV in the dose of 510 mg injected over a period 2 to 3 minutes; and can be repeated, if necessary, after 30 minutes. It can also be given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>120</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-120 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">120</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. three times a day. It can also be used to reduce the ventricular rate in patients with AF and atrial flutter. Verapamil IV is absolutely contraindicated in patients on beta blockers, quinidine or disopyramide (Chapter 29).</p>
<p>DILTIAZEM has similar uses as Verapamil in supra-ventricular arrythmias. In fact, it may be the preferred drug because of its less marked negative inotropic effect. Like verapamil, it may be used orally or IV. The IV dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>0.35</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-0.35 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.35</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> over 10 minutes, followed by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> hour. CCB are not likely to be useful in the prevention or suppression of most clinically important ventricular arrhythmias.</p>
<p>ADENOSINE: This is a naturally occurring purine nucleoside which is released during myocardial ischemia. It has antiarrhythmic and potent vasodilator properties. It stimulates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors on cardiac cells and activates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>current leading to increase in resting membrane potential. It suppresses automaticity and shortens APD, thereby slowing sinus rate. Further, it slows A-V conduction. It dilates the coronaries and peripheral arteries.</p>
<p>It is rapidly metabolised by circulating adenosine deaminase and has a very short plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mo stretchy="false">(</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}(4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.138em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mopen">(</span><span class="mord">4</span></span></span></span></span> to 8 sec<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mclose">)</span></span></span></span></span>. Given IV, as a rapid bolus, it can rapidly terminate paroxysmal, supraventricular tachycardia and is safer than verapamil as it lacks negative inotropic action. It is not effective in converting AF or VT into sinus rhythm. Unlike verapamil, adenosine may be used after a beta blocker. It is contraindicated in the presence of asthma, sick sinus syndrome or A-V block.</p>
<p>Adverse effects are not serious and usually short lasting. They include flushing, nausea, dyspnoea, bronchospasm, cough, headache, ventricular ectopy (proarrhythmic), bradycardia and A-V block.</p>
<p>Digoxin, because of its positive inotropric action, is an important antiarrhythmic agent useful in slowing A-V conduction in AF with increased ventricular rate. (Chapter 31).</p>
<p>POTASSIUM: The basic cardiac effects of potassium administration without causing hyperkalemia are:</p>
<ul>
<li>Diminution in the automaticity</li>
<li>Reduction in conduction velocity and</li>
<li>Prolongation of the refractory period</li>
</ul>
<p>These effects are most marked in the Purkinje fibres. In toxic doses, it is more likely to cause intraventricular conduction defects than A-V block. Hypokalemia predisposes to digitalis toxicity (Chapter 31). Slight, induced hyperkalemia can protect against arrhythmias arising after cardiac surgery (Chapter 37). Correction of hypokalemia, hypoxia and acid-base disturbances often restores sinus rhythm without the use of antiarrhythmic drugs.</p>
<p>The administration of antiarrhythmic agents in the presence of hyperkalemia can be disastrous.
Magnesium, as magnesium sulfate 2-4 g by slow IV injection over 10-15 minutes, repeated once if necessary, is useful in the emergency treatment of ventricular tachycardia, including digoxin-induced and polymorphic ventricular tachycardia (especially torsades de</p>
<p>pointes). It is especially indicated in the presence of hypokalemia where hypomagnesemia may also be present.</p>
<p>Cholinergic and anticholinergic drugs: Similar to vagal action, acetylcholine decreases the automaticity and slows conduction through the AV node, increases its refractory period and may cause A-V block. Edrophonium, a short acting cholinesterase inhibitor, is sometimes useful in the treatment of supraventricular arrhythmia (Chapter 20).</p>
<p>Atropine, blocks the effects of vagal stimulation. It is useful for the diagnosis of sinus bradycardia, where it increases the heart rate, and in the treatment of heart block, (see below). Its indiscriminate use, however, to treat sinus bradycardia after MI may precipitate ventricular arrhythmias because the sympathetic activity is no longer moderated by vagal influences.</p>
<p>Table 28.3 illustrates electrophysiological, hemodynamic and ADR features of antiarrythmic agents from Group IA, IB, II and IV. Table 28.4 summarises the drug therapy of cardiac arrhythmias.</p>
<p>Table 28.3
Principal effects of some antiarrhythmic drugs on the heart</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: left;">Group IA (Quinidine, Procainamide, &lt;br&gt; Disopyramide)</th><th style="text-align: left;">Group IB (Lignocaine, &lt;br&gt; Phenytoin)</th><th style="text-align: left;">Group II (Propranolol)</th><th style="text-align: left;">Group IV (Verapamil)</th></tr></thead><tbody><tr><td style="text-align: left;">Electrophysiological</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Automaticity</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Excitability</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Conduction velocity</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">ERP</td><td style="text-align: left;">Increase</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Increase</td><td style="text-align: left;">Increase</td></tr><tr><td style="text-align: left;">Electrocardiogram</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">PR duration</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">No change or increase</td></tr><tr><td style="text-align: left;">QRS duration</td><td style="text-align: left;">Increase</td><td style="text-align: left;">No change</td><td style="text-align: left;">No change</td><td style="text-align: left;">No change</td></tr><tr><td style="text-align: left;">Q-T duration</td><td style="text-align: left;">Increase</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change</td></tr><tr><td style="text-align: left;">Hemodynamic</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Blood pressure</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">No change or decrease</td></tr><tr><td style="text-align: left;">Cardiac output</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Contractility</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">No change or decrease</td><td style="text-align: left;">Decrease</td><td style="text-align: left;">Decrease</td></tr><tr><td style="text-align: left;">Left ventricular end diastolic &lt;br&gt; pressure</td><td style="text-align: left;">May increase</td><td style="text-align: left;">No change or increase</td><td style="text-align: left;">May increase</td><td style="text-align: left;">May increase</td></tr><tr><td style="text-align: left;">Adverse effects</td><td style="text-align: left;">Proarrhythmic;</td><td style="text-align: left;">Negative inotropic effect</td><td style="text-align: left;">Sinus bradycardia;</td><td style="text-align: left;">Conduction block;</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Negative inotropic effect;</td><td style="text-align: left;"></td><td style="text-align: left;">Conduction block;</td><td style="text-align: left;">Negative inotropic &lt;br&gt; effect</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">Conduction block</td><td style="text-align: left;"></td><td style="text-align: left;">Negative inotropic &lt;br&gt; effect</td><td style="text-align: left;"></td></tr></tbody></table>
<p>Table 28.4
Drug treatment of cardiac arrhythmias</p>
<table><thead><tr><th style="text-align: center;">Arrhythmia</th><th style="text-align: center;">Emergency Treatment*</th><th style="text-align: center;"></th><th style="text-align: center;">Chronic treatment prophylaxis</th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Preferred treatment</td><td style="text-align: center;">Other treatment</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">SA Node:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sinus arrhythmia</td><td style="text-align: center;">Needs no treatment</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Sinus tachycardia</td><td style="text-align: center;">Sedative, Propranolol</td><td style="text-align: center;">Treat the cause</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Sinus bradycardia</td><td style="text-align: center;">Atropine or temporary or transvenous pacing</td><td style="text-align: center;">Treat the cause</td><td style="text-align: center;">Permanent pacemaker</td></tr><tr><td style="text-align: center;">Atria:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Premature beats</td><td style="text-align: center;">Reassurance, Propranolol</td><td style="text-align: center;">-</td><td style="text-align: center;">Radiofrequency ablation</td></tr><tr><td style="text-align: center;">Paroxysmal supraventricular tachycardia (PSVT)</td><td style="text-align: center;">DCC/Vagal maneuvers, Adenosine</td><td style="text-align: center;">Propranolol Verapamil/diltiazem If LVEF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> : Digoxin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span> /Amiodaron</td><td style="text-align: center;">Radiofrequency ablation, Propranolol</td></tr><tr><td style="text-align: center;">Atrial fibrillation and Atrial flutter</td><td style="text-align: center;">DCC &lt;br&gt; To control ventricular rate: Verapamil, Diltiazem, Beta blockers If LVEF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> Digoxin</td><td style="text-align: center;">To terminate AF: &lt;br&gt; a) Elective DCC &lt;br&gt; b) Amiodarone/Ibutilid/Dofetilide &lt;br&gt; c) Procainamide</td><td style="text-align: center;">Rate controllers: &lt;br&gt; Diltiazem, Beta blockers &lt;br&gt; Rhythm controllers: &lt;br&gt; Amiodarone or &lt;br&gt; Dofetilide &lt;br&gt; Stroke prevention: &lt;br&gt; Warfarin</td></tr><tr><td style="text-align: center;">Ventricles:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Premature beats</td><td style="text-align: center;">If symptomatic:</td><td style="text-align: center;">-</td><td style="text-align: center;">Propranolol**</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">Beta blockers</td><td style="text-align: center;"></td><td style="text-align: center;">Digoxin</td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;">If LVF <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> Digoxin</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Paroxysmal ventricular tachycardia (PVT)</td><td style="text-align: center;">Amiodarone DCC</td><td style="text-align: center;">Procainamide Lignocaine</td><td style="text-align: center;">Implantation of cardioverterdefibrillator (ICD)z Amiodarone/Beta blockers</td></tr><tr><td style="text-align: center;">Ventricular fibrillation</td><td style="text-align: center;">Defibrillation &lt;br&gt; Epinephrine/Vasopressin (if needed)</td><td style="text-align: center;">Amiodarone Lignocaine</td><td style="text-align: center;">Implantation of cardioverterdefibrillator (ICD)z Amiodarone/Beta blockers</td></tr><tr><td style="text-align: center;">Digitalis induced tachyarrhythmias</td><td style="text-align: center;">Lignocaine</td><td style="text-align: center;">Phenytoin</td><td style="text-align: center;">Procainamide</td></tr><tr><td style="text-align: center;">Tornados de Pointes</td><td style="text-align: center;">DCC, Magnesium Temporary pacing</td><td style="text-align: center;">Lignocaine, Phenytoin Isoprenaline</td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Second/Third degree A-V Block</td><td style="text-align: center;">Atropine &lt;br&gt; Temporary pacing</td><td style="text-align: center;">Isoprenaline</td><td style="text-align: center;">Permanent pacemaker</td></tr></tbody></table>
<p>When using digoxin, verapamil or a beta blocker IV, drugs such as atropine and isoprenaline and cardiac pacemaker equipment should be at hand in the event of complete A-V block; for verapamil-induced complete A-V block, calcium gluconate 1 g IV is also effective.
*DCC= Direct Current cardioversion (if hemodynamic unstability);
*= If related to congestive cardiac failure;
**= Useful when ventricular tachyarrhythmias are associated with increased sympathetic tone or circulating catecholamines.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="atrial-fibrillation-management">Atrial fibrillation: Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#atrial-fibrillation-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The management of AF, perhaps the most common sustained cardiac rhythm disorder, has undergone considerable changes during the last decade. Many patients of AF are asymptomatic; often they present themselves with complication such as stroke as first manifestation.</p>
<p>The predisposing risk factors for AF include cardiovascular (hypertension, CHF, diabetes mellitus etc.) and non- cardiovascular (smoking, chest diseases, infections etc). AF often coexists with other comorbid conditions such as hypertension and heart diseases.</p>
<p>The patient with established AF should be evaluated for:
(a) The risk of thromboembolism and the need for anticoagulation
(b) The need for either cardiac rate control or rhythm control; and
(c) Any underlying condition.</p>
<p>The medical management of AF involves:
(a) Treatment of predisposing factors
(b) Control of heart rate
(c) Control of cardiac rhythm (conversion)
(d) Thromboprophylaxis</p>
<p>Paroxysmal AF is self terminating usually within 48 hrs while in persistent AF, the attack lasts for more than 7 days. When the arrhythmia persists in spite of therapy, it is diagnosed as permanent. The treatment of AF should be carried out under supervision of the specialist.
(a) Treatment during an episode: If the patient is severely symptomatic or hemodynamically unstable, and in urgent need of lowering of ventricular rate, he is best treated by DC cardioversion. For patients with the first episode of AF or rare recurrences of AF, particularly those that terminate spontaneously, no specific therapy to control rhythm may be indicated.
(b) Rate control: The immediate goal is to control symptoms due to increased cardiac rate and or underlying structural cardiac disease. The drugs used are given in Table 28.5. For most patients, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> blockers or on dihydropyridine CCB are to be preferred for the initial treatment of ventricular rate control. In patients with decompensated CHF, digoxin is to be preferred</p>
<p>Table 28.5
Drugs for rate control and cardioversion in AF</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Dose</th></tr></thead><tbody><tr><td style="text-align: center;">For rate control</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Beta blockers</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Propranolol</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>3</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo separator="true">,</mo><mo>&lt;</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-3 \mathrm{mg},&lt;1 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>240</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">80-240 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">240</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid</td></tr><tr><td style="text-align: center;">Metoprolol</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bolus every 5 min upto 15 mg . &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-200 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> od</td></tr><tr><td style="text-align: center;">Esmolol</td><td style="text-align: center;">IV infusion loading dose: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> Maintenance: dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.05</mn><mo>−</mo><mn>0.12</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.05-0.12 \mathrm{mg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.05</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.12</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>.</td></tr><tr><td style="text-align: center;">- Calcium channel blockers</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Verapamil</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bolus; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid</td></tr><tr><td style="text-align: center;">Diltiazem</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.25 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> bolus, then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg} / \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span> &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid</td></tr><tr><td style="text-align: center;">- Amiodarone</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 1st hr, then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>200</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100-200 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">200</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day</td></tr><tr><td style="text-align: center;">For rhythm control</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">- Propafenone</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>450</mn><mo>−</mo><mn>600</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">450-600 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">450</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">600</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">- Amiodarone</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> in 1 hr , then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.5-1 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> per min.</td></tr><tr><td style="text-align: center;">- Ibutilide</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">- Flecainide</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>; &lt;br&gt; Oral <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">200-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr><tr><td style="text-align: center;">- Vemakalant</td><td style="text-align: center;">IV <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td></tr></tbody></table>
<p>*Can also be used for AF more than a week. All others are used for AF less than a week.
(Ref : Lip GYH, Tsc HF, Lane DA. Lancet 2012; 379: 648-61).
so as to avoid any deterioration of hemodynamic status. Amiodarone IV is usually reserved for critically ill patients with severe heart failure or hypotension who do not respond to other agents.
(c) Rhythm control: Drugs used for control of rhythm are given in Table 28.5. For uncomplicated AF of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">&lt;7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span> days duration, oral or IV administration of Class IC or III antiarrhythmic agents can be used. Propafenone is a safe and effective therapy for conversion to sinus rhythm.</p>
<p>Nearly 15-40% of the patients with AF &gt; 7 days duration (persistent AF), convert back to sinus rhythm with pharmacology cardioversion. For those who do not, electrical cardioversion can be considered. In patients with structural heart disease such as IHD and impaired left ventricular ejection fraction, Class I antiarrhythmic such as flecainide, propafenone are contraindicated as they are proarrhythmic and may precipitate VF.
(d) Thromboprophylaxis: Warfarin used prophylactically reduces the incidence of ischaemic stroke but not that of haemorrhagic stroke. Aspirin-clopidogrel combination is less active than aspirin + warfarin for stroke prevention. Aspirin is much less effective in patients older than 75 years. New anticoagulant drugs like dabigatran (100-150 mg bid), a direct thrombin inhibitor and apixaban, fraction Xa inhibitor are reported to be equally effective as warfarin (See Chapter 33).
(e) Maintenance Therapy: Patients with recurrent AF and minimal symptoms and those</p>
<p>with persistent or permanent AF can be managed by long term rate-control strategy. If acute episodes continues, an antiarrhythmic drug may have to be used. The commonly used drug for this purpose is oral amiodarone. The dose should be adjusted to achieve and maintain the ventricular rate at 60 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">80 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> at rest, and 90 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>115</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">115 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">115/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> with moderate exercise. Procainamide may be used in patients intolerant to amiodarone. Flecainide, though effective, is proarrhythmic and is generally not preferred.</p>
<p>Resistant cases may need catheter ablation of the AV junction with insertion of a cardiac pacemaker. Anticoagulation, if started during an attack, has to be continued mostly lifelong.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-the-treatment-of-heart-block">Drugs Used in the Treatment of Heart-Block<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-the-treatment-of-heart-block" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ISOPRENALINE (Isoproterenol): The effects of isoprenaline in enhancing the rhythmicity of sinus as well as subsidiary nodal and ventricular pacemakers have proved invaluable in the treatment of advanced second degree and high grade A-V block. In emergency, the drug is administered IV slowly in the dose of 2 mg in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose under ECG control. In less urgent situations, it is generally given sublingually in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every 4 to 6 hours. Isoprenaline is also effective in abolishing ventricular tachycardia in the presence of advanced AV block. It acts by:</p>
<ul>
<li>Accelerating the basic sinoauricular pacemaker resulting in the suppression of ectopic ventricular activity,</li>
<li>Enhancing A-V conduction, and</li>
<li>Increasing the cardiac output as a result of increased heart rate. This tends to augment the coronary flow.
A-V conduction can also be improved during an emergency by atropine 0.6 mg IV.
Other drugs used are adrenaline, dopamine, aminophylline and glucagon but they are less effective than isoprenaline.</li>
</ul>
<p>Glucocorticoids are helpful when the heart block is due to an inflammatory disorder such as rheumatic fever.</p>
<p>No drug, however, is useful in the treatment of advanced heart block and implantation of permanent pacemaker is essential.</p>
<p>Electrical depolarisation of the heart: Electroversion has been used successfully in supraventricular tachycardias (AF, flutter and paroxysmal atrial tachycardia). It is a lifesaving procedure in case of VT and VF. However, electrical cardioversion does not obviate the need for antiarrhythmic drugs which are used to prevent the recurrence.</p>
<p>It is contraindicated in digitalis-induced arrhythmias. When it is used for treating other types of arrhythmias, digitalis is generally omitted for 24 hours before electroversion. It may induce VF if employed in patients with advanced A-V block.</p>
<p>DC shock is used under IV diazepam cover.
Medical treatment of arrhythmia is complex and is better left for the specialists. No drug is safe. Selective surgical or radiofrequency (RF) ablation of arrhythmic focus using devices and sophisticated catheters guided by computerized mapping system has produced spectacular results (cure) in certain cardiac arrhythmias.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-angina-pectoris-acute-mi-and-peripheral-vascular-diseases">Pharmacotherapy of Angina Pectoris, Acute MI and Peripheral Vascular Diseases<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-angina-pectoris-acute-mi-and-peripheral-vascular-diseases" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Ischemic heart disease (IHD) develops due to myocardial ischemia produced in a variety of ways, of which Angina pectoris is a symptom complex. It is a result of an imbalance between the oxygen supply and the oxygen demand of the myocardium. The manifestations of IHD are:
(1) Silent (asymptomatic) ischemia.
(2) Angina of effort and variant angina of Prinzmetal.
(3) Acute coronary syndrome (ACS)
(a) Unstable angina (UA)
(b) Acute myocardial infarction (AMI)
(i) Non-ST-Segment Elevation MI (NSTEMI)
(ii) ST-Segment Elevation MI (STEMI)
(4) Congestive heart failure (CHF) and
(5) Sudden cardiac death (SCD)</p>
<p>These clinical modalities are related to:</p>
<ul>
<li>The physiology of the coronary circulation.</li>
<li>The factors governing myocardial metabolism; and</li>
<li>The mechanism regulating the genesis and appreciation of pain.</li>
</ul>
<p>The design of the coronary circulation has three bad features:</p>
<ul>
<li>The coronary arteries are functionally end arteries. In health, there is little communication between the larger branches of coronary arteries although collateral circulation does develop in patients who have had MI.</li>
<li>Unlike the skeletal muscle, the cardiac muscle shows almost maximum oxygen extraction at rest, as shown by the comparative values of oxygen saturation of coronary sinus blood ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> ) and skeletal muscle venous blood ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> ). Hence, during exercise the tissue demand for increased oxygen supply is met, at least partly, by increased oxygen extraction in the case of skeletal muscle, but in the case of cardiac muscle it can only be met by increasing the coronary blood flow. Such increase can be severely limited by coronary artery disease. Moreover, unlike the skeletal muscle the cardiac muscle has extremely limited capacity for anaerobic metabolism and, therefore, cannot incur 'oxygen debt'.</li>
<li>The coronary blood flow is influenced by the inflow (aortic) pressure and the resistance of the coronary vascular bed. The latter depends on: (a) the state of dilatation of the coronary arterioles, determined largely by local metabolites, and (b) the pressure exerted upon the coronary vessels from the exterior by the contracting myocardium during systole. Thus, in contrast to other areas where the arterial blood flow is continuous, coronary blood flow to the left ventricle is intermittent and mainly diastolic; whereas in the absence of pulmonary hypertension it is both systolic and diastolic in case of the right ventricle.
In spite of these limiting features, the coronary circulation has a very large reserve and the coronary flow can increase upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>500</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">500 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">500%</span></span></span></span></span> of the resting value in exercising healthy dogs.</li>
</ul>
<p>Physiologically, vascular endothelial cells control the vascular tone by producing (a) vasodilators such as prostacyclin (Chapter 25) and NO/EDRF; and (b) vasoconstrictors such as endothelin (Chapter 30). Thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> produced by platelets also constricts vessels.</p>
<p>NITRIC OXIDE (Endothelium Derived Relaxing Factor - EDRF): Robert Furchgott (1980) first demonstrated that the endothelial cells release a labile factor that causes vascular relaxation. He designated it as EDRF, which later was identified as NO. Nitric oxide (NO), a simple diatomic molecule, is biosynthesised through the action of a class of enzymes nitric oxide synthases (NOS). These enzymes utilise the amino acid l-arginine as the endogenous substrate for NO generation. Organic nitrates are reduced by reductases to organic nitrites, which are then converted to NO which acts as a direct vasodilator. (Fig. 29.2) Thus, nitrates serve as exogenous sources of NO without involving endothelial cells and NOS and are termed as NO donors. Three NOS isoforms have been identified:
<img src="assets/images/image-20251214-eb412717.jpeg" alt="img-18.jpeg"></p>
<p>FIG. 29.2 NO-Cyclic GMP pathway and mechanism of action of nitrates and dipyridamole as vasodilators.
GTP: Guanosine triphosphate. Cyclic GMP: Cyclic guanosine monophosphate.
(1) nNOS (NOS-1), is found in high concentrations in central and peripheral neurons and some non-neural tissues such as endometrium and skeletal muscle.
(2) iNOS (NOS-2), is found in macrophages, Kupffer cells, fibroblasts, vascular smooth muscle cells, neutrophils and endothelial cells; and
(3) eNOS (NOS-3), first identified as the enzyme that produces EDRF and found in the vascular endothelium, brain and heart.</p>
<p>Types 1 and 3 are constitutive NOS and their activities are regulated by intracellular</p>
<p>calcium. These isoenzymes produce on demand short bursts of NO in small amounts. Type 2, on the other hand, is the inducible NOS and is not expressed in resting cells. When macrophages and other cells are activated, this enzyme triggers the production of large amounts of NO.</p>
<p>NO causes both:
(a) Direct effects, partly mediated by NO molecule itself and mainly by the interaction of NO with soluble guanylyl cyclase (which acts as the receptor for NO), resulting in the production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>3</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup><msup><mn>5</mn><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">3^{\prime} 5^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7519em;"></span><span class="mord"><span class="mord">3</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mord">5</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span>-cyclic guanosine monophosphate (cGMP); and
(b) Indirect effects mediated by the interaction of reactive nitrogen species (intermediates in NO synthesis) with oxygen and superoxide radicals, to yield cytotoxic peroxynitrite anion.</p>
<p>NO is a highly diffusible second messenger that can produce effects far from its site of production. The source of NO and its concentration determine its biological effects. At low concentrations, the direct (physiological) effects of NO predominate. Induced, high concentrations of NO cause indirect and often toxic effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="functions-of-no">Functions of NO:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#functions-of-no" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>NO as a vasodilator: NO causes vascular smooth muscle relaxation and vasodilatation that helps to regulate blood flow and BP. NO release from the endothelial cells is primarily the result of an influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>into the endothelial cells. Thus, any agent or stimulus capable of eliciting an influx of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>into these cells such as acetylcholine, bradykinin or shear force, can activate NO biosynthesis. The NO then acts through cyclic GMP and causes vascular muscle relaxation by lowering <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>influx (Fig 29.2).
Endothelial dysfunction (impaired NO production), is implicated in hypertension, cerebral and coronary vasospasm, atherosclerosis, ischemic reperfusion injury and diabetes mellitus.</li>
<li>NO and RBCs: NO appears to be a critical factor in the prevention of sickling of RBCs. Its precursor l-arginine is used to treat pulmonary hypertension in sickle cell disease.</li>
<li>NO as a platelets inhibitor: NO causes inhibition of platelet aggregation and adhesion. It diffuses from the vascular endothelial cells to function primarily as an inhibitor of platelet adhesion to the vascular endothelium.</li>
<li>NO and the CNS: Non-adrenergic, non-cholinergic (NANC) neurons innervate a variety of smooth muscles, such as those of the GI tract, the corpora cavernosa and the esophagus. The exclusive neurotransmitter in the NANC is NO. Thus NO is the physiological mediator of penile erection (Chapter 69) and gastric emptying.</li>
<li>NO and immune system: When the macrophages are exposed to infective agents, there is a dramatic local increase in NO production. NO synthesis induced by activated macrophages represents an immune response to infection. NO appears to be utilised by the immune system as a cytotoxic agent.
Adverse effects of NO: It is an important mediator of inflammation and neurodegenerative disorders. Exposure to bacterial endotoxins can lead to overproduction of NO, which can cause severe hypotension and/or endotoxic shock. Excessive NO can be toxic to the host cells, including pancreatic islet cells.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="methods-of-assessing-coronary-circulation">Methods of Assessing Coronary Circulation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#methods-of-assessing-coronary-circulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Experimentally, the coronary blood flow can be studied either in animals or isolated hearts. The data obtained from such studies, however, are many times inapplicable to humans. Even in human studies, it has been observed that the responses of atherosclerosed and normal coronary vessels to a given drug differ. Important methods used clinically are:</p>
<ul>
<li>Methods using a radionuclide <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msup><mrow></mrow><mn>201</mn></msup></mrow><annotation encoding="application/x-tex">\left({ }^{201}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;"><span class="delimsizing size1">(</span></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">201</span></span></span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> Thallium) or a radiopharmaceutical ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>99</mn></msup><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">{ }^{99} \mathrm{~m}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">99</span></span></span></span></span></span></span></span></span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">m</span></span></span></span></span></span> Technetium pyrophosphate) to study myocardial ischemia: The former localises in the healthy, well perfused myocardium but not in the ischemic one; the latter localises in the necrosed myocardium. These methods, with or without the use of exercise, permit detection, localisation and quantification of myocardial ischemia; they also permit assessment of LV function in the form of ejection fraction and localised wall motion abnormalities.</li>
<li>Coronary angiography: This is the definitive method of diagnosing CAD and has shown important differences between the response of normal and atherosclerotic arteries to drugs. Coronary angiography can be combined with pharmacological or exercise stress testing to assess the physiological significance of the observed coronary artery stenotic lesions. However, angina can occur even in the presence of normal coronary arteriograms.</li>
<li>Coronary CT/MR angiography: They give information about calcification and patency of coronary arteries but not about condition of the myocardium.</li>
<li>Computerised stress test: This test is used for evaluating anti-anginal drugs. Patients with angina pectoris are subjected to exercise, and the amount of exercise which they can tolerate without the development of pain with concomitant ECG changes is noted. The procedure is then repeated after the drug. An increase in the exercise tolerance, as shown by a delay in the development of precordial pain and ECG changes, is a measure of anti-anginal activity of the drug.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angina-pectoris">Angina Pectoris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angina-pectoris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Occurrence of angina pectoris depends upon two factors (a) Coronary blood flow; and (b) Oxygen consumption by the myocardium. The former may be compromised by either obstructive (atherosclerotic) or vasospastic disease of the coronary arteries.</p>
<p>Cardiac <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> consumption increases with increase in:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="heart-size">- Heart size<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heart-size" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="heart-rate">- Heart rate<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heart-rate" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Systemic blood pressure; and</li>
<li>Myocardial contractility, which is the rate at which the cardiac muscle fibre shortens.</li>
</ul>
<p>The last three are increased by heightened sympathetic activity. The myocardial oxygen consumption increases significantly during exercise and other states (emotional excitement, exposure to cold) with increased sympathetic activity. If, for any reason, the increase in coronary blood flow is unable to match this increased oxygen demand, angina develops. It is generally described by the patient as retrosternal pain, heaviness or discomfort which may radiate to the neck, shoulder, back or the arm. In each patient, there exists at a given time a threshold (angina index <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> heart rate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>x</mi></mrow><annotation encoding="application/x-tex">x</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">x</span></span></span></span></span> systolic BP) at which angina occurs. The angina index is a measure of the myocardial oxygen consumption. Spasm of the coronary arteries is also important in the production of angina.</p>
<p>Clinically angina can be:</p>
<ul>
<li>Stable, exertional angina: This commonest form is usually provoked by physical exertion or emotional stress and is relieved by rest and nitrates. It is diagnosed when the chest pain has remained unchanged in severity, frequency and duration over several weeks. The main pathophysiological factor appears to be increased myocardial oxygen demand, induced by tachycardia and rise of BP, in a person with fixed, atherosclerotic narrowing of epicardial, coronary arteries. The ECG shows ST depression during the attack.</li>
<li>Cardiac syndrome X: More common in women, this condition comprises of (1) Angina or angina-like chest pain on exercise; (2) ST segment depression on treadmill exercise testing; and (3) Normal coronary angiography. Endothelial or microvascular dysfunction is responsible for ischaemia and hence it is also termed as microvascular angina. Some patients having chest discomfort without ischaemia may have abnormal pain perception or sensitivity. Therapeutic response to physical training and to beta blockers is better than to nitrates and CCB.</li>
<li>Variant angina of Prinzmetal (Vasospastic angina): It is characterised by chest pain at rest rather than during exertion or stress, and ST elevation rather than depression. Spasm of large epicardial coronary arteries is responsible for this entity. It is relatively uncommon.
Unstable angina (UA) includes a variety of clinical syndromes such as new onset angina, angina occurring at rest or with minimal exertion, progressive angina with prolonged or more frequent attacks superimposed on chronic stable angina (Crescendo angina); it can progress to MI and sudden death (pre-infarction angina). The diagnosis is made by the ECG showing ST depression, and a negative troponin test.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-angina-pectoris">Drugs Used in Angina Pectoris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-angina-pectoris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The drugs effective in the treatment of angina pectoris act by:
(a) Dilating the coronary arteries and/or
(b) Reducing the cardiac workload by reducing pre- and after-load (Fig. 29.1). The agents currently used are:
<img src="assets/images/image-20251214-1d199df7.jpeg" alt="img-19.jpeg"></p>
<p>I Organic nitrates.
II Beta-adrenergic blocking agents.
III Calcium channel blockers (CCB); and
IV Potassium channel activators.
Additional beneficial effects can be obtained by using adjuncts such as:</p>
<ul>
<li>Antiplatelet drugs</li>
<li>Treatment of hyperlipidemia; and</li>
<li>Cytoprotectives</li>
</ul>
<p>ORGANIC NITRATES: Organic nitrates which are polyol esters of nitric acid are potent vasodilators. Usefulness of nitroglycerine was discovered by William Murrell, a physician, in 1879 .</p>
<p>Mechanism of action: All the effects of nitrates, except those produced by toxic doses, are mediated through the direct relaxant action on vascular smooth muscles. Organic nitrates are reduced by reductase to organic nitrites, which are then converted to NO which acts as a direct vasodilator. (Fig. 29.2) Thus, nitrates serve as exogenous sources of NO, and termed as NO donors.</p>
<p>Pharmacological actions
I Cardiovascular system:</p>
<ul>
<li>Hemodynamic actions: Nitrates cause a relaxation of the systemic venous and arteriolar bed. Venodilatation causes peripheral pooling of blood and a reduction in venous return and in cardiac output. On the arterial side, relaxation is maximum in the large arteries (resulting in bounding pulse), followed by the arterioles (resulting in lowered impedence). The BP falls, the systolic more than the diastolic accompanied by reflex tachycardia. Syncope may occur if the patient is standing.
These actions on the systemic venous (capacitance) and arteriolar (impedence) vascular beds reduce respectively the preload (end-diastolic left ventricular pressure) and the afterload (resistance to left ventricular ejection) on the heart. The left ventricular work load and energy expenditure thus decrease. The improvement in the left ventricular function as a result of this generally outlasts the measured pharmacological actions of individual doses of nitrates; this is of great importance in the therapy of angina pectoris.
Sublingual nitroglycerine (NTG) in clinically used doses is predominantly a venodilator causing reduction of ventricular preload. By contrast, inhalation of amyl nitrite, which acts very rapidly, has preferential systemic arteriolar dilator action which primarily reduces the afterload. Rapid arteriolar dilatation causes distinct fall in BP. Compensatory rise in sympathetic activity causes tachycardia and increased myocardial oxygen requirement. This is a disadvantage.</li>
<li>Coronary circulation: A transient decrease in the coronary resistance and an increase in the total coronary flow occur in a normal subject. In patients with angina nitrates:
(a) Dilate the large epicardial coronary arteries without affecting the resistance of the arterioles.
(b) Dilate collateral vessels, and
(c) Cause redistribution of the coronary blood flow along collaterals and from epicardial to endocardial region with improved perfusion of ischemic subendocardial areas.
Chronic administration promotes the development of inter-arterial anastomoses within the myocardium.</li>
<li>Effects in angina pectoris: Nitrates help most patients with angina by increasing their exercise tolerance but without increasing their 'angina index'. They achieve this by reducing the oxygen consumption of the heart at submaximal exercise levels and thus extending the duration of exercise. In such patients, they prevent the ECG changes of cardiac ischemia during exercise. However, they do not increase the maximum aerobic capacity of the heart.</li>
<li>Other vascular beds: Nitrates cause dilatation of other vascular beds as well, viz. (a) the skin, giving rise to flushing, (b) the meningeal vessels, resulting in throbbing headache, (c) pulmonary vessels, with fall in pulmonary arterial pressure, and (d) kidneys, with a reduction in renal flow.
II Other smooth muscles: Nitrates relax the smooth muscles of the gall bladder, the biliary ducts, the sphincter of Oddi, the bronchi, the GI tract and the ureteral and uterine smooth muscle.</li>
</ul>
<p>Absorption, fate and excretion: Organic nitrates are readily absorbed from the sublingual mucosa, and cause more rapid and more predictable effects. This is because after sublingual administration, they bypass the liver where normally they are rapidly metabolised by denitration. With relatively small sublingual doses, the various organic</p>
<p>nitrates have similar duration of action, 10-45 minutes.
Small oral doses ( 0.6 mg of NTG or 5 mg of isosorbide dinitrate) are of doubtful value as antianginal agents due to the first pass effect. Large oral doses ( 6.5 mg of NTG, 30 mg of isosorbide dinitrate or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of pentaerythritol tetranitrate, every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours) which exceed the metabolising capacity of the liver, however, produce beneficial hemodynamic effects and are useful in prophylaxis. NTG skin ointment and transdermal patches have similar prolonged effect. NTG lingual aerosol has onset and duration of action similar to those of the sublingual tablet.</p>
<p>Preparations and dosage: See Table 29.1. For IV use, NTG is diluted in 5% dextrose or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> saline. It is administered in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5 \mathrm{mcg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, increasing the rate every 3-5 minutes upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">80-100 \mathrm{mcg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. It is useful in the treatment of refractory chest pain of myocardial ischemia or MI, and refractory, variant angina.</p>
<p>Table 29.1
Nitrate and nitrite preparations for clinical use</p>
<table><thead><tr><th style="text-align: center;">Drug Preparations</th><th style="text-align: center;">Dose</th><th style="text-align: center;">Onset</th><th style="text-align: center;">Duration</th><th style="text-align: center;">Schedule</th><th style="text-align: center;"></th><th style="text-align: center;">Remark</th></tr></thead><tbody><tr><td style="text-align: center;">Glyceryl trinitrate &lt;br&gt; (Nitroglycerine)</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab 0.3, 0.4 and &lt;br&gt; 0.6 mg .</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">.</mi><msup><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">L</mi></mrow><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">0.3-0.6 \mathrm{mg} . \mathrm{SL}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.0196em; vertical-align: -0.1944em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">.</span><span class="mord"><span class="mord"><span class="mord mathrm">SL</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8251em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 1-2 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">2</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">15-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span> min</td><td style="text-align: center;">SOS</td><td style="text-align: center;"></td><td style="text-align: center;">Volatile. Unstable in plastic containers. Store tablets in tightly closed amber coloured glass bottles, without cotton plugs, preferably in a fridge. &lt;br&gt; Once a bottle is opened, it should be discarded after 8 weeks and fresh supply obtained. Sublingual tablets give immediate relief. Capsules, oral tablets and ointment for prophylaxis.</td></tr><tr><td style="text-align: center;">Sustained release &lt;br&gt; cap. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">(2.5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>. P 0</td><td style="text-align: center;">60 min</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">8-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sublingual spray</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.4 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> metered dose</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 1-2 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">2</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>15</mn><mo>−</mo><mn>40</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mtext>&nbsp;for&nbsp;</mtext><mn>3</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;doses&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 15-40 \mathrm{~min} \\ \text { for } 3 \\ \text { doses } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 4.5em; vertical-align: -2em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">40</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span><span style="top: -3.16em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;for&nbsp;</span></span><span class="mord">3</span></span></span><span style="top: -1.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;doses&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">every 5 &lt;br&gt; min.</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">2% skin ointment &lt;br&gt; ( 15 mg . per &lt;br&gt; inch)</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1 / 2-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1/2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span>-inch applied without rubbing</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>20</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 20-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrly</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Transdermal &lt;br&gt; patches</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 30-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">12 hrs</td><td style="text-align: center;">once &lt;br&gt; daily</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Isosorbide dinitrate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi>S</mi><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">L</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{mg} S \mathrm{~L}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">L</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>10</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 10-30 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">1-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> hrly</td><td style="text-align: center;"></td><td style="text-align: center;">Hepatic metabolism to isosorbide mononitrate. Useful in immediate relief and in prophylaxis</td></tr><tr><td style="text-align: center;">Tab. 5, 10 mg</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Buccal spray</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> actuation</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>2</mn><mo>−</mo><mn>5</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 2-5 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">5</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. Oral 10, 20, &lt;br&gt; 40 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 30-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">4 hrs</td><td style="text-align: center;">6 hrly</td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. sustained release</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO</td><td style="text-align: center;">60 min</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Isosorbide mononitrate</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. 10, 20 mg</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> PO</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 30-60 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">60</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">6-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">No first pass metabolism. &lt;br&gt; Used in prophylaxis.</td></tr><tr><td style="text-align: center;">Pentaerythritol tetranitrate</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Tab. 30 mg</td><td style="text-align: center;">30 mg PO</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>15</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 15-30 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>8</mn><mo>−</mo><mn>12</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;hrly&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 8-12 \\ &amp; \text { hrly } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">8</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">12</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;hrly&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"></td><td style="text-align: center;">Used in prophylaxis.</td></tr></tbody></table>
<p>'When the tablet, placed under the tongue, fails to produce local burning, flushing of the face and pounding in the head, it should be considered inert. Tab. = tablets. Cap. = capsules; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">S</mi><mi mathvariant="normal">L</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{SL}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">SL</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> sublingually; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">O</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{PO}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">PO</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> orally.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Headache: Though common, it usually decreases gradually on repeated administration</li>
</ul>
<p>and can be controlled by aspirin.</p>
<ul>
<li>Hypotension and syncope: Transient episodes of giddiness, weakness and other signs of cerebral ischemia associated with postural hypotension may develop. These are seen especially when the patient stands immobile. Hypoxemia may stimulate the central vagal nuclei and cold sweats, nausea, vomiting, involuntary passage of urine and faeces may accompany postural hypotension. Head-low position to augment the venous return quickly corrects the nitrite syncope. Marked hypotension may occur when nitrates are used along with potent anti-hypertensive drugs especially vasodilators; it is also seen following the ingestion of alcoholic beverages or sildenafil (Chapter 69).</li>
<li>Tolerance to nitrates can develop after repeated administration. Cross tolerance is common. Tolerance to the anti-anginal action develops commonly when the patient is exposed to nitrate for all the 24 hours of the day. Hence, it is more common with long acting nitrate preparations such as SR tablets and transdermal preparations. It can be avoided by omitting the night-time dose of long acting preparations. However, during such nitratefree periods, the patient needs to be protected by another anti-anginal drug, especially if he has severe angina. Tolerance is rare with sublingual nitrate because of the intermittent exposure.</li>
<li>Withdrawal symptoms: Sudden stoppage of nitrates during chronic administration may precipitate severe angina.</li>
<li>Miscellaneous: Drug rash may occasionally be observed, most commonly with pentaerythritol tetranitrate.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses-of-nitrates">Therapeutic uses of nitrates:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses-of-nitrates" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>All varieties of angina pectoris: Discussed later.</li>
<li>At the onset of pain of acute MI (See later) except in those with inferior wall infarct (with right ventricular involvement).</li>
<li>Paroxysmal nocturnal dyspnoea due to LVF: NTG may give dramatic relief.</li>
<li>Acute LVF: Nitroglycerine by IV infusion is useful in this condition.</li>
<li>Chronic heart failure: Organic nitrates are sometimes used in the long term management of chronic heart failure due to ischemic heart disease (Chapter 31).</li>
<li>Achalasia cardia</li>
<li>Acute anal fissure: Chapter 42.</li>
<li>Cyanide poisoning: Amyl nitrite inhalation and IV sodium nitrite are used to treat cyanide poisoning. Nitrites convert hemoglobin to methemoglobin, which competes with cytochrome oxidase for the cyanide ion and forms cyanmethemoglobin, a relatively non-toxic product (Chapter 77).
BETA-ADRENERGIC BLOCKING AGENTS: These drugs are a cornerstone of the therapy of all stages of IHD, except Prinzmetal's, vasospastic, variant angina. Only their actions relevant to angina are discussed below (also see Chapter 18).</li>
</ul>
<p>Pharmacological actions: Increased sympathetic activity following exercise and emotional excitement increases heart rate, BP, myocardial contractility and oxidative metabolism and can precipitate an attack of angina in predisposed subjects. Beta blockers by blocking beta adrenergic activity prevent the angina attack. Moreover, they help to control BP in hypertensive patients. Like nitrates, beta-blockers:</p>
<ul>
<li>
<p>Increase the exercise tolerance without increasing the angina index;</p>
</li>
<li>
<p>Prevent both subjective and ECG manifestations of cardiac ischemia.</p>
</li>
<li>
<p>Prevent arrhythmias precipitated by exercise, emotion and conditions involving excessive sympathetic activity.</p>
</li>
<li>
<p>Decrease the NTG requirement. In most patients, the net effect is a beneficial reduction in cardiac work load and myocardial oxygen consumption. However, they are not useful in acute attacks.
Long term studies indicate their prophylactic value as they decrease the incidence of MI in such patients. For chronic prophylaxis, they are usually combined with nitrates. Patients with an cardiac decompensation should be stabilised before starting a beta-blocker.</p>
</li>
</ul>
<p>For use of beta blockers immediately after acute MI, see later. Long term use of beta blockers after MI has been shown to reduce the rate of re-infarction and sudden death.</p>
<p>Clinically, all beta blockers are probably equally effective. Generally, the more selective beta-blockers such as atenolol, metoprolol and bisoprolol are preferred.</p>
<p>Beta blockers are not useful in the therapy of Prinzmetal's, vasospastic, variant angina.
Absorption, fate and excretion: Chapter 18.
Adverse reactions: The adverse reactions of relevance to antianginal therapy are:
(a) Precipitation or aggravation of CHF. Patients receiving both digoxin and a beta-blocker should be watched for the development of heart block.
(b) Development of severe syncope on using NTG in patients on a beta-blocker.
(c) Bradycardia and bronchospasm may.</p>
<p>Abrupt withdrawal of beta-blockers, especially when large doses are being used, can cause aggravation of angina and even precipitation of MI (Chapter 18).</p>
<p>CALCIUM CHANNEL BLOCKERS (CCB): Calcium is necessary for the excitationcontraction coupling in the skeletal, cardiac and smooth muscle. However, in contrast to the contractile activity of the skeletal muscle, the contractility of the cardiac and vascular muscle is highly dependent on the extracellular calcium.</p>
<p>Calcium transport in myocardial and vascular smooth muscle involves:</p>
<ul>
<li>Voltage dependent channel which is controlled by a gate that opens and closes in response to a voltage gradient. There are 2 types of calcium channels in heart: the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>L</mi></mrow><annotation encoding="application/x-tex">L</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">L</span></span></span></span></span> and T :
(i) L-channels make the calcium ions available in the cytoplasm, that are required for initiation of contraction. These ions in turn induce calcium release from the sarcoplasmic reticulum.
(ii) T-channels open at more negative potentials than the L-channels and play a role in the initial depolarisation of sinus and AV nodal tissue.</li>
<li>Receptor operated channel, normally activated by an alpha adrenergic agonist, such as NA, or angiotensin interacting with the alpha adrenergic receptors. They increase degree of contraction of arterioles. Similarly, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonists increase calcium influx in cardiac muscles and enhance contraction, frequency and conduction velocity of heart.</li>
<li>Sodium-calcium exchange which is an electrogenic mechanism. It operates bidirectionally to mediate the movement of calcium ions across the sarcolemma.</li>
<li>Calcium ATPase which extrudes calcium from the cell in an energy dependent way. Sarcoplasmic calcium is also regulated by uptake and release of calcium by sarcoplasmic reticulum, mitochondria and by buffering of calcium by various intracellular proteins such as calmodulin and troponin C.</li>
</ul>
<p>Mechanism of action: CCB bind to alpha-1 subunit of L-channel, and inhibits the entry</p>
<p>of calcium into the myocardial and vascular smooth muscles, thus decreasing availability of the intra-cellular calcium. They are potent vasodilators.</p>
<p>CCB belong to 3 chemically distinct classes:
I Phenylalkylamines e.g., Verapamil
II Dihydropyridines (DHP) e.g., Nifedipine and Amlodipine.
III Benzothiazepines e.g., Diltiazem.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiovascular-actions">Cardiovascular actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Antianginal action of these drugs is due to:
(1) Improvement in the coronary blood flow; and
(2) Decrease in the oxygen demand of the heart due to reduction in systemic vascular resistance (vasodilatation) and BP (afterload). Verapamil, in addition, reduces the heart rate. As a group, these drugs can be used in anginal patients with COPD in whom beta-blockers are contraindicated.</li>
<li>Coronary artery dilatation: These drugs are more potent than NTG as coronary artery dilators. Nitroglycerine dilates the large epicardial branches of coronary arteries but not the smaller intramyocardial coronary arterioles; CCB dilate both, even in the presence of coronary artery spasm. Further, they can prevent the spasm even in diseased, atherosclerotic coronary arteries. This effect accounts for their efficacy in Prinzmetal angina.</li>
<li>Effect on peripheral blood vessels: CCB relax the vascular smooth muscle in systemic as well as pulmonary arterial circulations. They thus decrease the vascular resistance and the BP in both territories, and are useful in the treatment of systemic and pulmonary hypertension. Further, reduction in the afterload contributes to their efficacy in angina of effort. The reduction in BP is accompanied by reflex tachycardia in the case of nifedipine but not in the case of verapamil which depresses the SA node. They have little effect on the venous capacitance (cardiac preload).</li>
<li>Negative inotropic effect: CCB depress myocardial contractility, and decrease the cardiac workload and oxygen consumption. This effect is beneficial in the treatment of angina of effort. Verapamil and diltiazem have negative inotropic actions and hence should not be combined generally with beta-blockers in the treatment of angina of effort; however, nifedipine can be used together with beta blockers (but see later).</li>
<li>Antiarrhythmic effect: CCB:
(a) Decrease the rate of discharge of the SA node.
(b) Suppress ectopic pacemaker activity.
(c) Increase the refractoriness of the AV node and;
(d) Slow the conduction (Chapter 28).</li>
</ul>
<p>The slowing of the conduction prevents re-entrant excitation. This effect plus the improvement of cardiac ischemia accounts for the potent (though selective) antiarrhythmic action. Verapamil and diltiazem are particularly potent in this respect. Verapamil and diltiazem (but not nifedipine), however, can aggravate A-V block.</p>
<p>Properties of commonly used CCB are summerized in Table 29.2.</p>
<p>Table 29.2
Properties of some calcium channel blockers</p>
<table><thead><tr><th style="text-align: center;"></th><th style="text-align: center;">Verapamil</th><th style="text-align: center;">Diltiazem</th><th style="text-align: center;">Nifedipine</th><th style="text-align: center;">Amiodipine</th></tr></thead><tbody><tr><td style="text-align: center;">Chemical class</td><td style="text-align: center;">Diphenylalky lamine</td><td style="text-align: center;">Benzothiazepine</td><td style="text-align: center;">Dihydropyridine</td><td style="text-align: center;">Dihydropyridine</td></tr><tr><td style="text-align: center;">Bioavailability</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20-35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Plasma half-life</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">3-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> hr</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn></mrow><annotation encoding="application/x-tex">2-5</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">5</span></span></span></span></span> hr</td><td style="text-align: center;">35 hr</td></tr><tr><td style="text-align: center;">Blocks A-V conduction</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td></tr><tr><td style="text-align: center;">Antiarrthymic effect</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td></tr><tr><td style="text-align: center;">Negative inotropic effect</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Vasodilatation</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">+++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Heart rate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;">Nor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↓</mo></mrow><annotation encoding="application/x-tex">\downarrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↓</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>↑</mo></mrow><annotation encoding="application/x-tex">\uparrow</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mrel">↑</span></span></span></span></span></td><td style="text-align: center;">N</td></tr><tr><td style="text-align: center;">Blocks reflex sympathetic effects</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">0</td><td style="text-align: center;">0</td></tr><tr><td style="text-align: center;">Dose (mg/day) in hypertension</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>240</mn></mrow><annotation encoding="application/x-tex">120-240</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">240</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">60-120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">30-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">2.5-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dose (mg/day) in angina</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>240</mn><mo>−</mo><mn>480</mn></mrow><annotation encoding="application/x-tex">240-480</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">240</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">480</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>360</mn></mrow><annotation encoding="application/x-tex">120-360</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">360</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mo>−</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">15-60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">2.5-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dosage schedule</td><td style="text-align: center;">8 hourly</td><td style="text-align: center;">8 hourly</td><td style="text-align: center;">6-8 hourly</td><td style="text-align: center;">O.D.</td></tr><tr><td style="text-align: center;">Adverse effects</td><td style="text-align: center;">A-V block, constipation, nausea, possibly LVF</td><td style="text-align: center;">A-V block, hy potension, Rarely LVF</td><td style="text-align: center;">Palpitation, hy potension, nausea, edema</td><td style="text-align: center;">Palpitation, hy potension, nausea, edema</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">+=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Mild effect;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mo>=</mo></mrow><annotation encoding="application/x-tex">++=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Moderate effect;
+++ = Potent effect;
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">N</mi><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{N}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm">N</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Normal
VERAPAMIL: This drug is a synthetic papaverine derivative. It causes:</p>
<ul>
<li>Suppression of SA and AV nodes which are <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>dependent.</li>
<li>Coronary and peripheral vasodilatation.</li>
<li>Potent antiarrhythmic effect; and</li>
<li>Potent negative inotropic effect and may cause A-V block.</li>
</ul>
<p>It does not cause reflex sympathetic overactivity and tachycardia.
Given orally, it is absorbed completely but is substantially metabolised by first pass hepatic metabolism. It is highly protein bound. Adverse effects include constipation, vertigo, bradycardia, heart block, CHF, hypotension and rarely cardiac asystole.</p>
<p>It is available as 40 mg tablets and as sustained release tablets. It is used in the treatment of angina in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">40-80 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day. Its use in paroxysmal supraventricular tachycardia is described in Chapter 28.</p>
<p>DILTIAZEM: This drug has properties intermediate between those of verapamil and nifedipine (see Table 29.2). It has less negative inotropic effect than verapamil and less vasodilating effect than nifedipine and verapamil. It can be combined with nitrates.</p>
<p>NIFEDIPINE: The pharmacological properties of this dihydropyridine derivative (Fig 29.3) are shown in Table 29.2.</p>
<p><img src="assets/images/image-20251214-49fa29f8.jpeg" alt="img-20.jpeg"></p>
<p>Compared to verapamil, it:</p>
<ul>
<li>Has negligible negative inotropic effect</li>
<li>Is a more potent coronary and peripheral vasodilator,</li>
<li>Causes tachycardia.</li>
<li>Is a potent inhibitor of platelet aggregation.</li>
</ul>
<p>It also relaxes bronchial, ureteric and uterine smooth muscle. It is used either orally or (for a rapid effect) sublingually. However, for long term use a sustained release formulation in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>90</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-90 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> OD is preferred.</p>
<p>Adverse reactions: These include headache, tachycardia, dizziness, fatigue, orthostatic hypotension, leg cramps, skin rashes and gingival hyperplasia. Occasionally, CHF may be precipitated.</p>
<p>Angina may worsen with nifedipine because of decrease in coronary perfusion pressure resulting from rapid fall in BP, increase in oxygen demand due to reflex sympathetic activation, (tachycardia) and coronary steal phenomenon. In IHD, the narrowed coronary arteries are always maximally dilated to compensate for the decreased blood supply. Nifedipine induced arteriolar dilatation in the non-ischaemic zone (there is no further dilatation of arterioles of the ischaemic zone) shunts oxygenated blood away from ischaemic zone to highly perfused non-ischemic zones of the heart. This stealing of coronary blood away from ischaemic zone may precipitate angina. The slower-onset, longeracting calcium blockers such as amlodipine are less likely to cause this phenomenon.</p>
<p>Therapeutic uses: Its main use is in the treatment of:
(i) Variant angina refractory to nitrate therapy.
(ii) Hypertension and
(iii) Raynaud's syndrome (Chapter 30).</p>
<p>Nicardipine and isradipine are other dihydropyridine compounds with pharmacological properties and uses similar to those of nifedipine.</p>
<p>Amlodipine and felodipine, with long <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>t</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">t \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord mathnormal">t</span><span class="mord">%</span></span></span></span></span> are the second generation dihydropyridine CCBs. They are potent coronary and peripheral vasodilators; bradycardia and AV block are less liable to occur with their use (Table 29.2).</p>
<p>Nisoldipine: This dihydropyridine is available as SR tablets for prophylactic therapy for chronic stable angina and hypertension.</p>
<p>Nimodipine is related to nifedipine but is claimed to have a preferential vasodilating action on the cerebral arteries in animal studies. Its use is confined to the prevention of vascular spasm and subsequent ischaemic neurological damage following subarachnoid</p>
<p>hemorrhage; its usefulness for this purpose is, however, uncertain. It is given in the dose of 60 mg every four hours for the first few days.</p>
<p>Clevidipine is a novel dihydropyridine compound available for IV administration. It has rapid action with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 2 min . It is metabolised by esterases in the blood. It is preferentially an arteriolar dilator and is used to control BP in hypertensive emergencies.</p>
<p>Non-cardiac uses of CCB: See Chapters 24, 39 and 44 for their use in migraine, mountain sickness and as tocolytics, respectively.</p>
<p>Contraindications to CCB are:</p>
<ul>
<li>Tight aortic stenosis.</li>
<li>Severe myocardial depression, bradycardia and heart block.</li>
<li>Clinical heart failure.</li>
<li>Unstable angina; and</li>
<li>Preexisting hypotension It is unwise to use them in patients on digoxin or a beta blocker, as they may exacerbate A-V block or heart failure. They should be used in pregnancy only if absolutely necessary.
Abrupt withdrawal of CCB during long term therapy can precipitate angina and MI.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-channel-activators">Potassium Channel Activators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-channel-activators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These are discussed in Chapter 30.
NICORANDIL: It acts as ATP dependent myocyte potassium channel nad produces vasodilatation. In addition, it aslo act as a NO donor. Though it preferentially acts on the venous side and reduces the preload, it also acts on the arteriolar side and reduces the afterload. Given orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid, it is equivalent to standard dose of a beta-blocker or a CCB in angina of effort. Adverse effects are mostly due to vasodilator action and include headache, dizziness and dose dependent hypotension.</p>
<p>Nicorandil is perhaps useful but expensive background therapy for patients with angina pectoris. It is particularly useful as an alternative to nitrates when tolerance is a problem. It can be used in the presence of asthma or cardiac failure.</p>
<p>Pinacidil is similar to nicorandil in its properties, adverse reactions and uses. Its duration of action is about 6 hours; the controlled release preparation ( 37.5 mg capsule) acts for about 12 hours.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiplatelet-drugs">Antiplatelet Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiplatelet-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ASPIRIN: Prophylactic aspirin reduces the incidence of MI in patients with chronic stable and unstable angina (Chapter 33).</p>
<p>Dipyridamole: This drug is a coronary dilator; but unlike nitrates which dilate conductance vessels it is claimed to dilate coronary resistance vessels (Fig. 29.2). It is a weak platelet inhibitor. It is used as an antithrombotic drug (Chapter 33).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cytoprotectives">Cytoprotectives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cytoprotectives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Trimetazidine: This drug is a Partial inhibitor of Fatty acid Oxidation (PFOX) pathway in the myocardium, thereby improving its metabolism in the presence of ischemia. It is claimed to maintain normal LV function without exerting any hemodynamic effect. It has been used to treat stable angina of effort. However, its superiority over standard treatment is doubtful.</p>
<p>Ranolazine: This drug is chemically related to trimetazidine. Calcium abnormalities following cardiac ischemia are associated with disregulation of ion homeostasis, leading to increased intracellular sodium and calcium. Ranolazine is claimed to act by selective inhibition of late sodium influx and thus, prevents calcium overload via the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> exchanger. Clinically, it produces modest improvement in exercise tolerance. Its side effects are dizziness, nausea, asthenia and constipation. It is contraindicated in hepatic impairment and in patients with preexisting Q-T prolongation.</p>
<p>Ivabradine is a pure heart rate lowering agent which acts by selectively inhibiting the sinoatrial node. It has no other hemodynamic actions. It may be useful to treat high resting heart rate in patients with Coronary Artery Disease (CAD). It is not useful in chronic stable angina.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-angina-pectoris">Treatment of Angina Pectoris<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-angina-pectoris" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Exertional angina (angina of effort): Table 29.3 outlines the principles of treatment of angina of effort.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-29-3">Table 29.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-29-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-treatment-of-angina-of-effort">Principles of treatment of angina of effort<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-treatment-of-angina-of-effort" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>I General</p>
<ul>
<li>Reassurance</li>
<li>Measures to prevent progression
(a) Treatment of IHD risk factors e.g., hypertension, hyperlipidaemia, diabetes, obesity.
(b) Use of anti-atherogenic agents, e.g. statins (Chapter 40).
(c) Advise about life style modification (control of emotional excitement, alcohol and smoking and weight control).
(d) Supervised, graded, physical exercises.</li>
<li>Treatment of associated conditions which increase oxygen demand, e.g. hyperthyroidism, anaemia, valvular disease, heart failure.</li>
<li>Avoidance of preparations containing sympathomimetic amines (cold remedies, anti-asthmatic and anorectic agents), atropine, aminophylline and antidepressants II Specific</li>
<li>Drugs for acute attack e.g. a Nitrate (See Table 29.1).</li>
<li>Chronic prophylaxis (prevention of MI and improved survival) (See text).
(a) Aspirin
(b) Use of nitrates, beta blockers, CCB</li>
</ul>
<p>III Surgical revascularisation</p>
<p>Relief and prevention of individual attacks: Nitroglycerine (NTG) is the drug of choice in all types of angina. The patient is advised to carry the tablets, and to put one sublingually as soon as premonitory symptoms develop. He should be advised to use NTG while sitting, to avoid possible syncope. If symptoms are not relieved immediately, additional tablets may be used at 5 minute intervals, but not more than three tablets should be used in a 15 minute interval. The remnant of the tablet should be discarded soon after pain relief as excessive absorption of the drug would lead to hypotension. One may use as many tablets per day as needed.</p>
<p>NTG or isosorbide dinitrate, used sublingually 10-15 minutes before a period of increased activity such as walking, climbing or sexual intercourse, can frequently prevent the attack. This is the preferred method of using these drugs for prophylaxis. The acute prophylactic effect of sublingual NTG and isosorbide dinitrate persists for about 30 minutes and 2 hours respectively. Longer prophylactic effect (upto 4 hours) is obtained with NTG cutaneous ointment as NTG is absorbed slowly and bypasses the liver. Generally, isosorbide dinitrate causes less headache than NTG.</p>
<p>Chronic prophylaxis: This comprises of:</p>
<ul>
<li>Nitrates: Large oral doses of organic nitrates decrease the frequency of anginal attacks and increase the exercise tolerance. They, however, increase the risk of hypotension, tachycardia and tolerance. Small oral doses are of doubtful value for this purpose. Nitrates may be combined with beta-blockers or diltiazem but not with nifedipine or verapamil.</li>
<li>Beta blockers: All beta blockers seem to be equally effective and reasonably safe as anti-</li>
</ul>
<p>anginal drugs. They are the drugs of choice for chronic prophylaxis of angina of effort (IHD). They can be combined, if necessary, with nitrates for this purpose. They are particularly preferred for the treatment of asymptomatic (silent) myocardiac ischemia. Generally, propranolol is started in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>3</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">10 \mathrm{mg} 3-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day. The daily dose is gradually increased by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>30</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-30 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once in 3-4 days until the resting pulse rate is lowered to about 60 /minute and the symptoms are relieved without the development of CHF. Weight gain is a useful early indicator of the latter. The average, effective, daily dose of propranolol is about 100-200 mg. But some patients may require larger doses. Alternatively, a selective beta blocker such as metoprolol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> twice a day) or atenolol ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> once a day) can be used.
Beta blockers are the drugs of choice in cardiac syndrome <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>X</mi></mrow><annotation encoding="application/x-tex">X</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">X</span></span></span></span></span> but are not particularly effective against angina at rest or on minimal exercise since their beneficial effect in the absence of sympathetic overactivity is small.</p>
<ul>
<li>Calcium channel blockers: Variant angina is generally relieved rapidly by NTG. CCB are to be preferred for its prophylaxis. In patients with angina of effort, these drugs appear to be as effective as beta-blockers as prophylactics but they are less well tolerated. Further, they do not improve life expectancy after MI. They are mainly used in patients not responding to a combination of beta blockers and nitrates; wherein dihydropyridines can be combined with beta blocker. They can be used in patients with COPD, asthma and AV conduction disturbances. Verapamil can be used instead of a beta blocker to control tachycardia in thyrotoxic patients with asthma.
In patients with stable angina, the dose of nifedipine needs to be titrated very finely. If a patient benefits from 10 mg tid, he is likely to deteriorate on a higher dose. Calcium channel blockers have no beneficial effect, and may even be detrimental, in acute MI.</li>
<li>Combination of a beta blocker and a CCB is additive but not synergistic. Verapamil should not be combined with betablockers. Diltiazem may be combined with betablockers only in patients with normal cardiac function and without conduction defects.
Nifedipine or amlodipine and betablockers have complimentary actions on the coronary blood supply and myocardial oxygen demand. The former dilate the coronaries and decrease the BP whereas the latter slow the heart rate and reduce the myocardial contractility. The second generation dihydropyridines (e.g. amlodipine) are particularly useful in patients with angina associated with hypertension.
Table 29.4 outlines a step-wise approach to the drug treatment of angina.</li>
</ul>
<p>Table 29.4
Stepwise approach to drug therapy of angina</p>
<table><thead><tr><th style="text-align: left;">All patients are prescribed aspirin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day orally and glyceryl trinitrate sublingually, whenever needed.</th><th style="text-align: left;"></th></tr></thead><tbody><tr><td style="text-align: left;">- Control risk factors</td><td style="text-align: left;">Obesity, hyperlipidemia, hypertension, diabetes, smoking. Consider using a statin.</td></tr><tr><td style="text-align: left;">- Treat concomitant diseases</td><td style="text-align: left;">Anemia, thyrotoxicosis, valvular disease, heart failure.</td></tr><tr><td style="text-align: left;">- Mild to moderate symptoms</td><td style="text-align: left;">Beta blockers; if contraindicated, CCB.</td></tr><tr><td style="text-align: left;"></td><td style="text-align: left;">If both are not tolerated, use prophylactic isosorbide dinitrate/mononitrate, or nicorandil.</td></tr><tr><td style="text-align: left;">- If symptoms persist</td><td style="text-align: left;">Combine beta blockers with a CCB</td></tr><tr><td style="text-align: left;">- If severe and not responding</td><td style="text-align: left;">Refer for revascularisation.</td></tr></tbody></table>
<ul>
<li>Advice about the life style: Excitement and emotional upset can precipitate anginal attacks. A patient who suspects that he has 'heart pain' is worried, and reassurance can give much relief. Rest, choice of occupation not involving heavy manual work and mental relaxation are important. In fact, the value of change in 'life style' is more than that of any known drug. A placebo can diminish the severity of the symptoms in many patients; hence, one should be wary of accepting a cleverly advertised anti-anginal drug or manoeuvre which has helped "many" patients.
The patient should be advised to avoid overeating, exercise after eating, and extremes of heat, cold and humidity. He should avoid any type, amount or pace of activity known to precipitate anginal attack; if it is unavoidable the prophylactic use of NTG or isosorbide dinitrate sublingually 10-15 minutes before commencing the activity is recommended. Sexual activity can be permitted in most patients.
Alcohol should be avoided by patients with angina. It is not a coronary vasodilator. By removing the higher inhibitory controls in the CNS, it may induce an individual to ignore the anginal pain, leading to more exertion and an aggravation of the cardiac ischemia. A further disadvantage is the liberation of catecholamines by acetaldehyde, a metabolite of alcohol. Alcohol has a negative inotropic action on the heart damaged by CAD. However, in alcohol addicts, its abrupt withdrawal may precipitate undesirable effects, and small amounts of alcohol may be permitted.</li>
<li>Cessation of smoking: Patients with angina must be advised to give up smoking which increases the heart rate and oxygen consumption of the myocardium. Further, absorption of carbon monoxide from the inhaled smoke increases the concentration of carboxyhemoglobin; this reduces the oxygen carrying capacity of blood.</li>
<li>Treatment of associated diseases: Weight reduction in obese patients and treatment of associated hyperlipidemia, anemia, hypertension or thyrotoxicosis help in prophylaxis of angina. Vasodilator anti-hypertensive drugs can aggravate angina by causing tachycardia; but this can be countered by using a beta-blocker.</li>
<li>Supervised, graded, exercise training improves exercise tolerance in anginal patients probably by increasing oxygen extraction in the peripheral circulation. This allows more physical activity with less increase in heart rate and in cardiac output. Isometric physical activity of any type may, however, be harmful.
Variant angina of Prinzmetal: The treatment of this condition comprises (a) NTG sublingually or nifedipine first chewed and then swallowed, for rapid onset of action in acute attacks; and (b) long acting nitrates or CCB for prophylaxis. Beta-blockers are to be avoided.</li>
</ul>
<p>Unstable angina: It requires aggressive treatment in an ICCU to prevent MI or sudden death. The patient is treated with aspirin ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150-300 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">150</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ); sublingual NTG or IV isosorbide dinitrate/NTG, continued till the patient remains pain-free for 24 hours. A beta blocker is administered to lower the heart rate to 50-60/minute. The combined use of aspirin and clopidogrel is synergistic. Routine anticoagulation with heparin is helpful. A CCB such as diltiazem is substituted in patients in whom beta blockers are contraindicated; but, it does not reduce the risk of MI. Thrombolytic therapy (Chapter 33) is not indicated in these patients as it may worsen the condition.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acute-myocardial-infarction-management">Acute Myocardial Infarction: Management<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acute-myocardial-infarction-management" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute MI is a medical emergency and needs immediate attention. The symptomatology varies from very mild (silent infarct) to severe presentation (with cardiogenic shock).</p>
<p>Rise in creatinine kinase-myocardial band (CK-MB) and troponin indicates degree of myocardial necrosis and are used as biochemical markers. They are always elevated in STEMI. In patients with NSTEMI, they are usually elevated but may be normal. In unstable angina they are not elevated indicating absence of necrosis. STEMI is precipitated when a coranary artery thrombus develops rapidly.</p>
<p>Table 29.5 summarises the treatment of acute myocardial infarction.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-29-5">Table 29.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-29-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-treatment-of-acute-myocardial-infarction">Principles of treatment of acute myocardial infarction<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-treatment-of-acute-myocardial-infarction" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="before-hospitalisation">Before hospitalisation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#before-hospitalisation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>For promptrelief of pain
(a) Sublingual nitroglycerine 0.4 mg every 5 minutes till pain is relieved (max. 3 doses) in mild cases and in the absence of hypotension (systolic BP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;90 \mathrm{~mm}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span></span></span></span></span> ).
(b) IV morphine, 1 mg per minute, titrated to a maximum total dose of 10 mg , together with IV metoclopramide 10 mg (antiemetic).
(c) Oxygen.</li>
<li>Aspirin 75 to 150 mg (antiplatelet action).</li>
</ul>
<p>After hospitalisation</p>
<ul>
<li>Bed rest</li>
<li>Treatment of hypotension</li>
<li>IV betablocker</li>
<li>ACE inhibitor</li>
<li>Thrombolytic therapy and/or anti-coagulants (See text)</li>
<li>Treatment of complications</li>
<li>General measures (sedation, diet, bowel care, activity)</li>
</ul>
<p>Discharge and rehabilitation</p>
<ul>
<li>Coaded increase in physical activity, including exercise therapy</li>
<li>Aspirin</li>
<li>ACE inhibitors</li>
<li>Betablockers</li>
<li>Statin</li>
<li>Modification of cardiac risk factors smoking (including nicotine substitution), alcohol, hypertension, diabetesmellitus, hyperlipidemia, obesity</li>
<li>Relief of pain: In mild cases, sublingual nitroglycerine may suffice. Transdermal or IV nitrate therapy is helpful in relieving persistent pain. In patients with severe pain, the slow IV administration of 10 mg of morphine hydrochloride over 10 minutes ensures rapid relief from pain and thereby minimises the shock. Morphine SC is less useful in such cases because of peripheral circulatory collapse which delays its absorption.
Morphine may be repeated, if necessary, after 30 minutes. Pethidine hydrochloride 25 to 50 mg may be given IV, particularly in the presence of bradycardia. Both, morphine and pethidine can produce hypotension. This can be corrected by elevating the lower limbs. Morphine may cause sinus bradycardia and respiratory depression. Alternatively buprenorphine 0.4 mg SC or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.3</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.3-0.6 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM may be used and repeated if necessary 6-8 hrly.</li>
<li>Oxygen and rest: The patient should be confined to bed and made to breathe 100% oxygen by means of a face mask. Even a slight increase in activity could worsen the condition.</li>
<li>Antiplatelet therapy: Aspirin 150-300 mg is chewed as soon as the diagnosis of MI is made. It is continued once daily throughout convalescence and after recovery and has</li>
</ul>
<p>shown to reduce the mortality significantly.</p>
<ul>
<li>Thrombolytic therapy (Chapter 33). This is most useful in patients with STEMI.</li>
<li>Maintenance of effective blood volume: In presence of cardiogenic shock the effective circulating volume is reduced which can be corrected by:
(i) Elevating the lower limbs and thus increasing the venous return to the heart and,
(ii) Infusing 5% dextrose. Excessive infusion, however, may cause pulmonary edema. This can be averted by a careful monitoring of CVP or PAOP and arterial blood pressure.</li>
<li>Inotropic drugs: Dopamine and dobutamine are the drugs of choice for regulating BP. Dobutamine is less likely to cause arrhythmias and sinus tachycardia. If they are not available, NA may be used (Chapter 18).</li>
<li>Prevention and treatment of arrhythmias: Prophylactic therapy with Class I antiarrhythmic drugs is not recommended in patients without an arrhythmia. It is best not to give drugs empirically for a paroxysmal tachyarrhythmia or rapid irregularity of the pulse until an ECG is recorded. Ventricular ectopic beats at a frequency of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>., herald the possibility of serious ventricular arrhythmia and should be treated with:
(a) Lignocaine, IV infusion given at a rate of 1 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, or
(b) Procainamide, 100 mg IV every 5 minutes, to a total dose of not more than 1 gm , or alternatively
(c) Lignocaine IM in the dose of 400 mg and repeated if necessary.</li>
</ul>
<p>Ventricular tachycardia is a serious complication needing immediate therapy with IV infusion of lignocaine or DC shock. Atrial fibrillation and flutter may need digitalisation or DC shock. Sinus or nodal bradycardia is treated with IV atropine sulfate 0.3 to 2 mg , or isoprenaline 0.05 mg , respectively Digoxin may be given if CHF develops.</p>
<ul>
<li>Beta blockers: Given IV within 4-6 hours of the onset of symptoms, propranolol, atenolol and metoprolol may limit the infarct size and reduce early mortality. They are of maximum benefit in patients with continued pain, evidence of sympathetic overactivity and absence of heart failure. The contraindications to the use of these drugs are: bronchospasm, resting bradycardia (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>55</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">55 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">55/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ), low systolic BP (less than 95 mm Hg ) and heart block. Propranolol IV has been used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.1 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.1</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> divided into three doses at 5-10 minutes, followed by 20-40 mg orally every 6-8 hours. Atenolol has been used in the IV dose of 5-10 mg, followed by 100 mg orally once daily. Metoprolol has been used in the IV dose of 5 mg over 2 minutes, repeated every 5 minutes (total 3 doses), followed by 50-100 mg orally every 12 hours. Currently, it is recommended that a betablocker should be given to all patients who do not have a contraindication (Chapter 18). Intravenous therapy should be commenced as soon as possible after hospitalisation, at least within 24 hours of onset of symptoms; oral therapy should be given in patients who are admitted late. For long term use of beta-blockers has been shown to be beneficial (See below).</li>
<li>ACE inhibitors (ACEI): They should be administered to all patients within 24 hours of the onset of symptoms, if important contra-indications (hypotension, bilateral renal artery stenosis, renal failure or history of intolerance to these drugs) are absent. ACEI reduce LV dysfunction and slow the progression of CHF. They should be used, in the first instance, for 5-6 weeks.</li>
<li>Anticoagulants: Anticoagulants may be given to all patients with STEMI, and NSTEMI. They prevent venous thrombosis, pulmonary embolism, and stroke in patients with</li>
</ul>
<p>severe LV dysfunction after MI. Heparin, especially LMWH, is the preferred drug for this purpose (Chapter 33). The risk of bleeding is higher in patients who receive fibrinolytics.</p>
<ul>
<li>General measures: Sedation with a benzodiazepine is useful in the initial days of illness to allay anxiety. The diet should be liquid on the first day; subsequently, it should be soft, with no added salt and low in calories. Caffeinated beverages and very hot or very cold liquids should be avoided. A stool softener is administered routinely as straining at stool can precipitate cardiac arrhythmias.</li>
<li>Rehabilitation and long term drug therapy: Modification of cardiac risk factors (see Table 29.3) is a must. Every effort must be made to persuade the patient to give up smoking (Chapter 21). Lifelong continuation of low dose aspirin is valuable to reduce the reinfarction rate. For patients with large infarcts and severe left ventricular dysfunction, long term anticoagulant therapy should be considered to reduce the risk of systemic embolisation.
Beta adrenergic blockers (atenolol, 100 mg OD or metoprolol 100 mg bid) have been shown to reduce mortality, sudden deaths and reinfarction after MI. This therapy should be used for at least 2-3 years after acute infarction.</li>
</ul>
<p>ACE inhibitors reduce mortality, incidence of heart failure and re-infarction. They can be stopped after 1-2 years in many patients but must be continued lifelong in patients with left ventricular dysfunction, with or without symptoms.</p>
<p>Glucocorticoids and NSAID (except low dose aspirin) should be avoided in patients with MI as they interfere with infarct healing.</p>
<p>Calcium channel blockers have no place in the treatment of acute MI. Antioxidant and/or vitamin therapy after MI has not been shown to be useful in reducing mortality.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-used-in-the-treatment-of-peripheral-vascular-disorders">Drugs Used in the Treatment of Peripheral Vascular Disorders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-used-in-the-treatment-of-peripheral-vascular-disorders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Peripheral vascular disease may be:
I Obstructive: Atherosclerosis or thrombo-angiitis obliterans (TAO) with large vessel involvement, or diabetes with small vessel involvement); or
II Vasospastic: Raynaud's syndrome.
I Obstructive peripheral vascular disease:
In these patients vasodilator drugs are of little avail as they fail to increase the blood flow to ischemic areas with blocked arteries/arterioles. Further, the associated generalised vasodilatation can produce severe adverse reactions. Such patients may benefit from</p>
<ul>
<li>Correction of remediable underlying factors such as CHF, anemia or diabetes mellitus. - Cessation of smoking.</li>
<li>Daily physical exercise (such as walking) which can increase the walking distance.</li>
<li>Foot care (cleanliness, avoidance of any injury and prompt treatment of infection).</li>
<li>Drugs: Low dose aspirin (antiplatelet action), statins (cholesterol lowering action) and pentoxyphylline (hemorheologic action) have been used with variable success, (Chapter 33).</li>
</ul>
<p>Naftidofuryl oxalate (Praxilene) 100 mg orally 2-3 times a day alleviates symptoms and increases pain-free walking distance in moderate peripheral obstructive vascular disease. It is not a direct vasodilator but may increase the supply of ATP and reduce lactate level in muscles. It activates the enzyme succinate dehydrogenase. It is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">5 \mathrm{HT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord">5</span><span class="mord"><span class="mord"><span class="mord mathrm">HT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonist and it inhibits 5HT induced vasoconstriction and platelet aggregation.
PENTOXIFYLLINE: This analogue of xanthines is claimed to increase the deformability of the RBCs in circulation and thus improve the microcirculation (hemorheological action). It has been claimed to be useful in patients with cerebrovascular disease, especially those getting transient ischemic attacks; in those with intermittent claudication and in subjects with ischemic legs ulcers. The clinical results, however, have been variable and difficult to predict. The drug may reduce plasma fibrinogen level and inhibit platelet aggregation. It causes mild GI upset and CNS adverse effects. It is available as 400 mg sustained release tablets. Dose is one tablet bid after food.
Cilostazol is a PDE3 inhibitor which inhibits platelets and dilates vessels. Given as 100 mg bid ( 30 minutes before or 2 hrs after food), it may be useful in patients without rest pain and no peripheral tissue necrosis.</p>
<ul>
<li>Endarterectomy or peripheral arterial bypass surgery in selected cases may be helpful. It is important to note that intermittent claudication can be of vascular origin (e.g. Burger's disease) or neurological origin. The former is only partially helped by vasodilators while they are not at all useful in the latter group.
II Vasospastic diseases: Drugs useful in these conditions are:</li>
<li>Calcium channel blockers, e.g., Nifedipine and Diltiazem are preferred.</li>
<li>Beta adrenergic stimulants: Nylidrin and Isoxsuprine (Chapter 18).</li>
<li>Alpha adrenergic blockers: Tolazoline and Prazosin (Chapter 18).</li>
<li>Anticoagulants: Heparin and Warfarin, discussed in Chapter 33.</li>
</ul>
<p>In Raynaud's syndrome, prazosin is used in the dose of 0.5 mg bid (first dose at bed time); the maintenance dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid. Nifedipine is used in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid.</p>
<p>Other drugs claimed to be useful are nicotinic acid derivatives, cyclandelate (Cyclospasmol), pentoxifylline, ketanserin (Chapter 24) and prostacyclin.</p>
<p>The drug therapy must always be combined with non-pharmacological measures such as exercise, avoidance of exposure to cold and cessation of smoking.</p>
<p>30</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-hypertension-pulmonary-hypertension-and-orthostatic-hypotension">Pharmacotherapy of Hypertension, Pulmonary Hypertension and Orthostatic Hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-hypertension-pulmonary-hypertension-and-orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypertension, which affects over one billion adults worldwide is a major risk factor for cardiovascular and renal diseases. Clinically it can be divided into two major divisions: I Primary or essential hypertension, where definite cause for the rise in blood pressure (BP) is not known; and
II Secondary hypertension, secondary to renal (e.g. chronic diffuse glomerulonephritis, pyelonephritis, polycystic kidneys), endocrine (e.g. Cushing's syndrome, pheochromocytoma, primary hyperaldosteronism) and vascular (e.g. renal artery disease, coarctation of aorta) lesions.</p>
<p>The syndrome of essential hypertension is characterised by elevation of the diastolic BP, a normal cardiac output (in most cases) and increased peripheral vascular resistance, with documented natural history and with characteristic pathologic changes in the arterioles.</p>
<p>The 'Normal' BP in adults is defined as below 120/80 mm Hg (day time); and 'High Normal' BP (prehypertension) as 130 to 139 mmHg systolic and 80 to 89 mmHg diastolic. BP above 139 mm Hg systolic or above 89 mm Hg diastolic on several occasions qualifies as hypertension, at all ages. Systolic BP above 140 mm Hg plus diastolic BP of below 90 mm Hg in the elderly is termed isolated systolic hypertension.</p>
<p>Hypertension, if untreated, leads to a variety of disabling cardiac, cerebrovascular, and renal complications, with shortened life expectancy, regardless of its etiology. Further, the risk of morbidity and mortality rises with BP and there is no clearly defined cut-off point for increased risk.</p>
<p>Physiologically, the BP is controlled by two main types of systems (Fig. 30.1).</p>
<p><img src="assets/images/image-20251214-fb5d50d6.jpeg" alt="img-21.jpeg"></p>
<p>PGANE <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Postganglionic adrenergic nerve ending
(a) The adrenergic nervous system which operates through the baroreceptors and is mainly responsible for the counteracting acute changes in the BP. Baroreceptor reflexes protect the circulation against stresses that alter arterial pressure acutely. When one stands up from the lying down position, the cardiac output tends to fall due to reduced venous return to the heart. This may lead to a fall in BP and fainting. Normally, it is prevented by a reflex increase in heart rate and in peripheral resistance through the baroreceptor mechanism.
(b) The humoral renin-angiotensin- aldos-teronal system, which has a slow response, is important in long term regulation of BP. It operates through the kidneys and involves various humoral agents (Fig. 30.1).</p>
<p>Renin, a proteolytic enzyme, is produced and stored in the kidneys. It is released in response to:
(a) reduction in renal perfusion pressure,
(b) reduction in sodium delivery to the macula densa,
(c) increase in the sympathetic activity, and
(d) certain humoral factors.</p>
<p>Renin cleaves the serum globulin angiotensinogen to an inactive decapeptide, 'angiotensin I.' The latter, during its passage through the lungs, is converted into an active octapeptide, 'angiotension II' by the action of enzyme Angiotensin Converting Enzyme (ACE). Angiotensin II is the most potent direct vasoconstrictor agent, effective in as small a dose as 0.1 mcg per kg body weight. Angiotensin II also stimulates the synthesis and release of aldosterone from the adrenal cortex and thus regulates the ECF volume. In the circulation, angiotensin II is converted into a heptapeptide Angiotensin III which is as potent as angiotensin II in its action on the adrenal cortex but is weaker in its other actions. "The kidney thus plays an important role in determining the BP level, doing so via renin-angiotensin- aldosterone system (RAAS) activity, which presides over both vasoconstriction and volume, the two major determinants of BP and of tissue flow."</p>
<p>Renin and angiotensin are also produced locally in many tissues including blood vessels,</p>
<p>brain, kidney, heart and adrenal glands. It is likely that these tissue angiotensin-generating systems are involved in the local control of cardiac, renal and vascular function, and cardiovascular damage.</p>
<p>The etiology of primary hypertension is not clear. The factors implicated in its genesis are:</p>
<ul>
<li>In adult populations, the BP rises with age. However, the rise in BP with age in a population is not uniform. This is due to the development of hypertension in a discrete group of individuals with advancement of age. Such individuals are presumed to differ qualitatively from the remainder population in their BP regulation.</li>
<li>There is a strong familial clustering of essential hypertension and the inheritance is polygenic.</li>
<li>The arterial pressure is a function of the cardiac output and the peripheral resistance. Both can be readily affected by various factors. Resistance to the blood flow resides chiefly in the arterioles. Changes in their calibre produce enormous changes in the peripheral resistance.
Arteriolar walls have very reactive smooth muscle. Factors which tend to diminish their radius augment the total peripheral resistance and consequently, the BP.</li>
<li>The renin-angiotensin system is involved in the pathogenesis of some forms of secondary hypertension such as the renovascular hypertension. It is also believed to play a role in the pathogenesis of essential hypertension. In man, procedures that increase sympathetic nervous activity are associated with increased plasma renin activity (PRA). On the basis of renin activity, patients with high BP can be divided into (1) those with high renin activity or (2) those with low renin activity.
The adrenergic blockers, methyldopa, reserpine and propranolol reduce PRA whereas, vasodilator antihypertensives such as hydralazine, diazoxide, sodium nitroprusside and the thiazides increase PRA in hypertensive patients.</li>
<li>There is deficient vascular synthesis and release of nitric oxide (NO) in hypertensives.</li>
<li>There is a positive correlation between total body sodium and BP, and a negative one between total body potassium and BP, in hypertensive patients. Essential hypertension and agerelated increase in BP are virtually absent in populations where less than 50 mmol of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>3.00</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;3.00 \mathrm{~g}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">3.00</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span></span></span></span></span> of salt) is consumed daily. It appears that both excess of body sodium and deficit of body potassium contribute to the development of hypertension. Increase in intracellular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span> stimulates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump, driving <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>into the cell. Increased cytosolic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span> triggers vascular smooth muscle contraction. Further, sodium retention in the cell decreases NO synthesis by endothelial cells whereas high potassium diet causes endothelium-dependent vasodilatation. Clinically, salt restriction reduces BP in many hypertensive patients.</li>
<li>The other endocrine abnormalities that have been demonstrated in some patients with "essential hypertension" are: (a) insulin resistance with resultant hyperinsulinemia; (b) secretion of a structurally abnormal steroid (a hybrid between cortisol and aldosterone) by the adrenal cortex; this heritable condition is called glucocorticoid-remediable aldosteronism (GRA) and (c) an inherited defect in the modulation by salt of the local renin-angiotensin system in the kidney and the adrenals; these subjects have a salt sensitive form of hypertension.
Experimental evaluation of anti-hypertensive drugs: Although many techniques exist</li>
</ul>
<p>for causing a sustained rise in the BP in various species, none has duplicated, in every detail, the picture of human essential hypertension. The important experimental models for evaluating antihypertensive drugs are:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nephrogenic-hypertension">- Nephrogenic hypertension:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nephrogenic-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Dogs can be made hypertensive by partial constriction of one renal artery, accompanied by removal of the other kidney (Goldblatt).
(b) Similar hypertension can be produced in the rat without removing the other kidney.</p>
<ul>
<li>Neurogenic hypertension:
(a) Sectioning of the carotid sinus and the aortic arch nerves produces hypertension in dogs.
(b) Other methods include subjecting rats to intermittent loud noise and injection of kaolin into the cisterna magna of dogs.</li>
<li>Hormonal hypertension: The methods used include:
(a) Prolonged administration of deoxycorticosterone acetate (DOCA) or aldosterone together with sodium chloride in chicks and rats;
(b) Severe hypertension can be produced in uninephrectomised and uniadrenalectomised, salt treated rats during regeneration of the enucleated adrenal cortex.</li>
<li>Spontaneously hypertensive rats (SHR) are available. They would seem to come closest to human essential hypertension.
In many animal models, ingestion of salt is necessary for the development of hypertension. Drugs like methyldopa and beta blockers have little hypotensive effect in animals; but they are effective in hypertensive patients. Hence, the final evaluation has to be done in hypertensive human subjects.
Antihypertensives, classification: The drugs used in the treatment of hypertension act by reducing the
(1) cardiac output and/or
(2) the total peripheral resistance, without correcting the cause. They can be classified according to site of action: (Fig. 30.1).
I Drugs acting centrally:
(a) Alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor stimulants, e.g., Clonidine and Alpha methyldopa.
(b) Selective imidazole receptor (IR) stimulants, e.g., Moxonidine.</li>
</ul>
<p>II Drugs acting on the autonomic ganglia:
Ganglion blocking agents, eg., Trimethaphan.
III Drugs acting on the postganglionic sympathetic nerve endings:
(a) Adrenergic neuron blockers: Guanethidine, Bethanidine, Debrisoquine, Bretylium.
(b) Catecholamine depletors: Reserpine.</p>
<p>IV Drugs acting on adrenergic receptors:
(a) Alpha-adrenergic blocking agents: Phentolamine, Phenoxybenzamine, Prazosin, Indoramin.
(b) Beta-adrenergic blocking agents: Propranolol, Atenolol, Metoprolol.
(c) Both alpha and beta adrenergic blocking drugs: Labetalol.</p>
<p>V Drugs acting directly on the vascular smooth muscle (Vasodilators):
(a) Arteriolar vasodilators: CCB, Hydralazine, Diazoxide, Minoxidil.</p>
<p>(b) Arteriolar-venular vasodilators: Sodium nitroprusside.</p>
<p>VI Potassium channel activators:
Diazoxide, Minoxidil, Pinacidil, Nicorandil.
VII Drugs which block renin-angiotensin-aldosterone axis:
(a) Those which block renin release: Beta-adrenergic blockers.
(b) Those that inhibit PRA e.g. Aliskiren.
(c) Those which block the conversion of angiotensin I to angiotensin II by inhibiting the ACE: Captopril, Enalapril (ACEI).
(d) Those which competitively block angiotensin II vascular receptors (ARB): Losartan.
(e) Those which counter the action of aldosterone (Aldosterone antagonist): Spironolactone.
VIII Oral diuretics: Thiazides.
IX Miscellaneous: Metyrosine.
Various antihypertensive drugs may ultimately reduce BP by more than one mechanism.
Further, the hemodynamic alterations produced by a single parenteral dose of a given drug may differ from those resulting from its prolonged oral use.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-acting-centrally">Drugs Acting Centrally<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-acting-centrally" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>CLONIDINE: This imidazoline derivative (Fig 30.2) has a potent antihypertensive action.
<img src="assets/images/image-20251214-0ade9bc4.jpeg" alt="img-22.jpeg"></p>
<p>Mechanism of action: Clonidine mainly acts centrally as agonist at postsynaptic adrenergic alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors in the vasomotor centre and the hypothalamus. Activation of these receptors suppresses the sympathetic outflow and decreases the release of NA from the neuronal terminals, leading to lowering of BP. Almost all the central effects of clonidine can be blocked by the alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptor blocker yohimbine.</p>
<p>Larger doses stimulates the peripheral inhibitory presynaptic alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenoreceptors (autoreceptors). This reduces the peripheral NA release. Clonidine also reduces the PRA.</p>
<p>Since alpha adrenoreceptors are widely distributed, their interaction with clonidine can produce other effects such as increase in the level of plasma growth hormone. It potentiates the analgesic action of opioids.</p>
<p>Clonidine also binds to CNS non-adreno-receptor sites (imidazoline receptor), which may contribute to its antihypertensive effect.</p>
<p>Pharmacological actions: Given IV it produces a transient hypertensive response followed by a prolonged fall in both systolic and diastolic BP accompanied by bradycardia. Initial hypertensive effect is not seen after its oral administration.</p>
<p>Chronic administration of 0.3 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1.5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day:</p>
<ul>
<li>Reduces both supine and standing BP without affecting the cardiovascular reflexes.</li>
<li>Diminishes heart rate.</li>
<li>Does not cause postural hypotension.</li>
<li>Does not affect the renal blood flow and the GFR; hence, the drug is valuable in patients with compromised renal function.</li>
<li>The hypotensive effect is associated with a reduction in cardiac output, total peripheral resistance, or both. With time, this reduction in cardiac output becomes less apparent.</li>
<li>Its hypotensive effect is enhanced by simultaneous use of a thiazide diuretic.</li>
</ul>
<p>Tolerance to antihypertensive effect develops on prolonged use.
Absorption, fate and excretion: Being highly lipid soluble, it is well absorbed from the gut and has a high volume of distribution. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is about 12 hours. About half of the drug is excreted unchanged in the urine.</p>
<p>Preparations: Clonidine hydrochloride 0.1 mg tablets. A transdermal preparation is also available; its effect lasts for 7 days.</p>
<p>Adverse reactions: It commonly causes drowsiness (central sedative action) and oral dryness due to central inhibition of salivation. Vertigo, constipation, parotid pain, impotence, GI disturbances, allergic reactions and hallucinations may occur. Toxic doses</p>
<p>cause marked bradycardia, miosis and hypotension.
Abrupt cessation of clonidine therapy can cause hyperirritability and a dangerous and sometimes lethal rebound rise of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">B P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">BP</span></span></span></span></span>. The treatment of such rebound hypertension is either reinstitution of clonidine or use of a combined <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span> adrenergic blocking agent e.g. labetalol. Therefore, when clonidine must be withdrawn, gradual tapering is recommended.</p>
<p>Clonidine produces sodium and fluid retention and rapid development of tolerance to its antihypertensive effect. Combination of clonidine and a beta-blocker can cause severe drowsiness. TCA like desipramine may impair the hypotensive action of clonidine.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="therapeutic-uses">Therapeutic Uses:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#therapeutic-uses" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Hypertension: It is now rarely used.</li>
<li>Menopausal hot flushes (Chapter 67).</li>
<li>Opiate, alcohol and nicotine withdrawal, to control adrenergic symptoms.</li>
<li>Miscellaneous: Diagnosis of growth hormone deficiency (Chapter 63) and prophylaxis of migraine.
Guanfacine and Guanabenz are related to clonidine and have actions similar to clonidine. Their duration of action, however, is prolonged.</li>
</ul>
<p>ALPHA METHYLDOPA: This isomer of methyldopa (Fig 30.3) which bears a close similarity to dihydroxy-phenylalanine (DOPA). It is a prodrug.
<img src="assets/images/image-20251214-e5e5bec0.jpeg" alt="img-23.jpeg"></p>
<p>Mechanism of action: It is metabolised in the adrenergic neurons to an active metabolite, alphamethyl-noradrenaline which cannot be metabolised by MAO and, like clonidine, acts centrally by activating the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>-adrenergic receptors in the vasomotor centre. Methyldopa also inhibits renin release by the kidneys.</p>
<p>Pharmacological actions: After oral or IV administration, the hypotensive effect appears after a latent period of 3-6 hours and 1-2 hours, respectively. Its pharmacological effects are similar to that of clonidine (see earlier).</p>
<p>Absorption, fate and excretion: Given orally, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of the drug is absorbed and is carried into the brain via aromatic amino acid transporters. As the drug metabolite gets stored in the neuronal endings the effect lasts longer ( 24 hours), though its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 1.5 hrs . The drug is almost completely excreted in urine in 12 hours. In patients with severely impaired renal function, the drug may accumulate during chronic administration.</p>
<p>Adverse reactions: Commonly, it produces sedation, Other CNS effects are diminished intellectual drive, forgetfulness, nightmares, mental depression and parkinsonism. It causes hyperprolactinemia and gynecomastia. The drug may also cause retention of sodium and water. GI upset, constipation, failure of ejaculation, arthralgia and skin rashes can occur. Tolerance to the antihypertensive effect may occur.</p>
<p>Alpha methyldopa produces fever accompanied by abnormal liver function tests, and</p>
<p>parenchymal/cholestatic jaundice in a few cases. Rarely it causes thrombocytopenia. Methyldopa produces positive direct antibody (Coomb's) test in upto 25% of patients. Rarely it causes SLE and leucopenia.</p>
<p>Preparations: Alpha methyldopa hydrochloride 250 mg tablets; injection 50 mg per ml .
MOXONIDINE: This is claimed to be a selective imidazole receptor ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>I</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">I_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07847em;">I</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0785em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) agonist. Discharge at central sympathetic neurons in the rostroventral medulla maintains arteriolar smooth muscle tone, and hence peripheral vascular resistance. Moxonidine activates <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">R</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{IR}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">IR</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> in the medulla, thereby reducing central sympathetic drive and peripheral vascular resistance. It has similar hypotensive action as clonidine and methyldopa. However, its clinical superiority over clonidine needs confirmation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ganglionic-blocking-agents">Ganglionic Blocking Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ganglionic-blocking-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs competitively block the nicotinic receptors in both sympathetic and parasympathetic ganglia.</p>
<p>Pharmacological actions: Hexamethonium blocks the cholinergic receptors on the postganglionic neurons in the both, sympathetic and parasympathetic ganglia. This blockade reduces the amount of NA released from the postganglionic sympathetic nerve endings leading, to a reduction in the peripheral sympathetic tone and a fall in BP. The normal protective vasomotor reflexes mediated through the baroreceptors and the sympathetic nervous system are blocked, which causes marked postural hypotension.</p>
<p>The ganglion blocking drugs, once used to treat hypertension, are now obsolete because of the high incidence of ADR due to blockade of both sympathetic and parasympathetic ganglia. (Chapter 21).</p>
<p>Trimethaphan camphor sulfonate (Arfonad): Because of its extremely transient action, it is used by IV infusion to produce controlled hypotension for short periods, during surgery and is considered as the drug of choice in the treatment of dissection of the aorta.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenergic-neuron-blockers">Adrenergic Neuron Blockers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenergic-neuron-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Adrenergic neuron blocking agents are the drugs that block release of NA from the postganglionic adrenergic neurons in response to impulses or nerve stimulation. The ganglionic transmission is unaffected and the effector organs are fully responsive to injected NA. Guanethidine is the prototype of this group.</p>
<p>GUANETHIDINE was employed in the treatment of resistant severe hypertension.
Mechanism of action: The drug is selectively taken up by adrenergic neuron, the uptake mechanism being same as uptake of NA (uptake <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ). It is concentrated in the vesicle where it replaces NA and thus causes adrenergic neuron blockade because of:</p>
<ul>
<li>Inhibition of the release of NA at the adrenergic nerve terminals. This is its main action.</li>
<li>Blockade of re-uptake of NA by the adrenergic nerve endings, following higher doses (Fig. 17.4). This effect may account for the transient sympathomimetic overactivity following IV guanethidine in animals.</li>
<li>Depletion of vesicular NA stores at the adrenergic nerve endings and tissues such as the heart and the aorta.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Following oral administration: The antihypertensive action of guanethidine is usually delayed for 48-72 hours. It:</p>
<ul>
<li>Ensures prolonged fall of BP.</li>
<li>Abolishes baroreceptors reflex and thus produces severe postural hypotension.</li>
<li>Impairs cardiovascular responses to exercise and the cold pressor response.</li>
<li>Diminishes the renal blood flow markedly.</li>
<li>Augments the pressor response to exogenous adrenaline and NA and</li>
<li>Usually diminishes the heart rate and pulse pressure.</li>
</ul>
<p>On IV administration in animals, guanethidine exerts a triphasic response: an initial, transient fall in BP due to membrane stabilising action on the heart; followed by a transient rise in BP (sympathomimetic action); and finally a marked and prolonged fall in BP. This is accompanied by an increased heart rate.</p>
<p>Adverse reaction: These are due to marked sympathetic blockade (postural hypotension, failure to ejaculate) and consequent predominance of cholinergic system (diarrhoea, parotid pain). It causes fluid retention. TCA inhibit the entry of guanethidine into the adrenergic neuron and can antagonise its anti-hypertensive action.</p>
<p>It is no more recommended. Other drugs in this group, Bethanidine and Debrisoquine, are now obsolete.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="catecholamine-depletors">Catecholamine Depletors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#catecholamine-depletors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RESERPINE: The root of the plant Rauwolfia serpentina has been in medicinal use in India since ancient times. It was considered useful for such diverse conditions as insomnia, snake bite and insanity. The root contains alkaloids reserpine, rescinnamine, deserpidine and ajmaline. Reserpine (Chapter 13) is by far the most potent of all hypotensive alkaloids whereas ajmaline has quinidine-like properties (Chapter 28).</p>
<p>Mechanism of action: Reserpine depletes the catecholamines, adrenaline, NA and dopamine, from the various storage sites in the body. This is accompanied by depletion of 5-HT as well, particularly from the CNS. The depletion of NA stores in the peripheral sympathetic nerve endings, including those of heart, explains the antihypertensive action of reserpine.</p>
<p>Normally, the NA released at the sympathetic nerve endings is metabolised partly by COMT, but is largely taken up by the adrenergic neuronal endings (Chapter 17) and is stored in the intracellular granules or vesicles. Reserpine binds to storage vesicles in adrenergic neurons. This binding persists for a long time, and causes inhibition of both granular uptake and storage of catecholamines. Thus, the reserpine action leads to depletion of the transmitter and consequently to peripheral sympathetic blockade. The transmitter which 'leaks out' from the storage granules is inactivated by the mitochondrial MAO. It is for this reason that reserpine does not exhibit any sympathomimetic activity; however, if the enzyme MAO is inhibited by an MAO inhibitor, the subsequent reserpine administration produces a rise in BP (reserpine reversal). It also interferes with the granular uptake and storage of adrenaline, DA and 5HT.</p>
<p>The drug also inhibits the release of renin.
Pharmacological actions: These are due to depletion of NA, 5HT and DA.
Cardiovascular system:</p>
<ul>
<li>The hypotensive effect appears 30 minutes after IV administration of a single dose, whereas, the maximum effect develops after 2 to 4 weeks of repeated oral medication. Hypotension is usually accompanied by bradycardia. Hypotensive action of reserpine lasts longer even after missing a daily pill. There is no rebound.</li>
<li>In therapeutic doses, reserpine has less action on the homeostatic reflexes in man and postural hypotension is not a problem.</li>
<li>Renal and muscle blood flow is not much affected.</li>
<li>It acts synergistically with other hypotensive agents, particularly the diuretics.</li>
</ul>
<p>Reserpine pretreatment causes upgradation of post-synaptic receptors and enhances the pressor response to sympathomimetic amines like adrenaline and NA, and this must be kept in mind when the sympathomimetic amines have to be employed in individuals on reserpine therapy.
CNS: Reserpine has sedative and antipsychotic actions due to depletion of 5-HT and DA from the CNS (Chapter 13).
GI system: It causes increased gastric acid secretion and augmentation of peristalsis. The drug has been used to induce experimental peptic ulceration in animals.
Absorption, fate and excretion: On oral or parenteral administration it gets widely distributed in the various parts of the CNS. The metabolic pathway of reserpine is not known. The central and the peripheral effects of oral reserpine are established slowly and maintained for a long time even after complete elimination of the drug (Hit and run drug).</p>
<p>Adverse reactions: These usually develop as an extension of its pharmacological actions and are dose dependent.</p>
<ul>
<li>Parasympathetic predominance due to peripheral sympathetic blockade causes salivation, cutaneous vasodilatation, nasal congestion, increased motility of the gut and increased gastric acidity. Reserpine should be avoided in individuals with history of hyperacidity and/or peptic ulcer. It can prolong A-V conduction time, particularly if administered along with digitalis.</li>
<li>Orthostatic hypotension as a result of sympathetic blockade may occur infrequently.</li>
<li>Mental depression is by far the most serious but uncommon, dose-related adverse effect. It may assume serious proportions resulting in nightmares, insomnia and suicidal tendencies in some cases. Hence, it is contraindicated in the presence of depression. Further, reserpine-induced depression lasts for a long time after stopping the drug and is resistant to treatment with TCA. Reserpine may also exacerbate epilepsy.</li>
<li>Weight gain is due to an increased appetite and retention of sodium and water. Release of ADH by the central action of reserpine probably plays some part in water retention. The use of diuretics with reserpine reduces the danger of salt and water retention.</li>
<li>Parkinsonism can occur due to depletion of DA following large doses of reserpine. This is reversible.</li>
<li>Endocrine disturbances such as gynecomastia and impotence in males and reduction in fertility in females can occur with relatively large doses of reserpine.</li>
<li>Allergic manifestations are rare. These include thrombocytopenia and purpura.</li>
<li>Hypotension and death during induction of anaesthesia have been reported in patients taking reserpine. Surgery should, therefore, be done in such patients with full access to resuscitative procedures.
Not withstanding the above listed ADR, they are uncommon with therapeutic doses (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day). In general, reserpine is well tolerated even in elderly, was used extensively in the past, and is cost-effective. However, its use has declined. It has been suggested that "reserpine is a tragic victim of myth, marketing and fashionable prescribing."</li>
</ul>
<p>Preparations and dosage:
(i) Rauwolfia tablet containing powdered root-bark standardised to contain 4 mg . of total alkaloids. The daily dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.
(ii) Reserpine tablet 0.25 mg . Dose: 0.25 mg or less OD. As little as 0.05 mg per day may be effective when used in combination with a diuretic.
(iii) Reserpine injection, 2 and 10 ml ampoules containing 2.5 mg per ml .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adrenergic-receptor-blockers">Adrenergic Receptor Blockers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adrenergic-receptor-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Alpha adrenergic blocking agents: Peripheral vascular alpha-receptors are of two types (Chapter 18):</p>
<ul>
<li>Postsynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which are stimulatory in nature; their activation causes vasoconstriction and</li>
<li>Presynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors (auto-receptors), which are inhibitory in nature; their activation inhibits NA release.
Blockade of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> causes fall in BP. However, simultaneous blocking of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> results in enhanced output of NA that acts on cardiac beta receptors leading to tachycardia. The nonselective alpha adrenergic blocking agents like phentolamine are of relatively little value in the treatment of essential hypertension because their use leads to preponderance of the beta adrenergic activity, palpitation and tachycardia.</li>
</ul>
<p>PHENTOLAMINE: Phentolamine, a nonselective competitive blocker with a short duration of action. It can be administered IV in the dose of 2.5 to 10 mg to prevent or treat severe hypertension due to release of catecholamines during removal of pheochromocytoma. It may also be used to treat the severe hypertension induced by abrupt clonidine withdrawal (Chapter 18).</p>
<p>PHENOXYBENZAMINE: This long acting non-competitive blocker is used in the preoperative management of pheochromocytoma. Its use controls hypertension and causes an expansion of plasma volume; intraoperative hypertensive episodes are prevented. It is also used for long term management of inoperable cases of pheochromocytoma, where it is combined with a beta-adrenergic blocker.</p>
<p>PRAZOSIN: This quina-zoline derivative is a peripheral vasodilator (Chapter 18). It acts by selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> adrenergic receptor blockade. The drug is relatively ineffective in blocking presynaptic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors which are inhibitory. Prazosin, thus does not cause reflex tachycardia. Though it has a short plasma half life (2.5-4 hours), its effect lasts much longer (10 hours).</p>
<ul>
<li>It controls both supine and standing BP with minimum of postural hypotension.</li>
<li>Tachycardia is minimal or absent.</li>
<li>It does not affect renal function, cardiac output or the RAAS.</li>
<li>It is effective in all grades of severity of hypertension but its main use is for the treatment of moderate to severe hypertension as an adjunct to diuretics and beta-blockers.
Selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> antagonists may decrease total and LDL cholesterol, and TG and increase HDL cholesterol levels.</li>
</ul>
<p>Adverse reactions: These are giddiness, drowsiness, tiredness, nausea, diarrhoea, and fluid retention. The first dose should be 0.5 mg or less and should be taken on retiring to bed at night, as some patients may have adverse reactions such as palpitation, postural hypotension and even collapse following the first dose (First dose effect). In females it may cause urinary incontinence.</p>
<p>The therapy is started with 1-3 mg/day in divided doses. The maintenance dose is 3 to 7.5 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. A sustained release preparation (Minipres XL) is also available.</p>
<p>Other uses: It is also used to treat CHF (Chapter 30), benign prostatic hyperplasia and prostatism with obstructive symptoms (Chapter 69).</p>
<p>Terazosin, doxazosin and alfuzosin are the other analogues of prazosin. Doxazosin has <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">\mathrm{t} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord mathrm">t</span><span class="mord">%</span></span></span></span></span> of eight hours. The initial dose is 1 mg daily, doubled at 1-2 weeks intervals, according to response, upto a maximum of 8 mg daily; the usual maintenance dose is 2-4 mg daily. All these drugs are metabolised in the liver.</p>
<p>INDORAMIN: This selective alpha-1 adrenergic blocker lowers the BP in a manner similar to that of prazosin.</p>
<p>For other uses of alpha blockers, see Chapter 18.
Dihydrogenated ergot alkaloids: A mixture of three alkaloids of ergot, namely ergocornine, ergocristine and ergocryptine (chapter 44), is no more used as an antihypertensive.
II Beta-adrenergic blocking agents: Their detailed pharmacology is discussed in Chapter 18. Only their antihypertensive effects are discussed below.</p>
<p>Mechanism of action: The exact mechanism of antihypertensive action is not clear. However, the antihypertensive effect correlates best with their <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocking action. Peripheral resistance is lowered during chronic administration. Reduction in cardiac output and lowering of plasma renin are variable during long term therapy. They also increase the natriuretic peptide secretion 2-3 fold. The lipid soluble agents (e.g. propranolol) have some central effect on catecholaminergic neurons, and reduce sympathetic outflow.</p>
<p>Beta blockers also reduce the tyrosine hydroxylase and dopamine beta hydroxylase activities in the peripheral sympathetic nervous system. The relative role of these actions in producing the therapeutic effect is not clear.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>All of them seem to be equal in their ability to control hypertension and if one drug fails to control the BP in the maximally tolerated doses, a change to another one generally does not help.</li>
<li>Systolic and diastolic BP are moderately lowered, both in the supine and standing positions.</li>
<li>There is no accompanying tachycardia and in fact tachycardia caused by vasodilators is prevented by a beta-blocker.</li>
<li>They protect against stress-induced hypertension.</li>
<li>They do not block baroreceptor mechanisms and postural hypotension is not a problem. Protective, alpha receptor constrictor mechanisms remain intact.</li>
<li>They are cardioprotective and are especially valuable in patients with concurrent IHD (Chapter 29).</li>
<li>They do not impair the kidney function.</li>
<li>They are generally safe, and cost-effective.</li>
</ul>
<p>Absorption, fate and excretion: See Chapter 18 for details. The clinical hypotensive effect of a single dose lasts longer than the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> (2-5 hours) would suggest and hence, most of these drugs can be used on a twice a day basis. Longer acting drugs such as atenolol can be used on a once a day basis. The onset of anti-hypertensive effect is dose-related but generally takes takes 5-7 days to become manifest. Highly lipid soluble agents such as propranolol, metaprolol and oxprenolol are metabolised in the liver while highly water soluble atenolol and nadolol are excreted by kidney.</p>
<p>Adverse reactions: Generally, these drugs are well tolerated and cause minimal ADR. Commonly they cause bradycardia. Because beta receptor density increases during chronic</p>
<p>administration, their abrupt withdrawal can result in potentially dangerous tachycardia, rebound rise in BP and angina pectoris. Cardiac enlargement is a relative contraindication to their use. In a patient with pheochromocytoma, their use alone can cause a dangerous rise of BP unless it is combined with an alpha-blocker. Deterioration of renal function in some patients with established renal disease may occur.</p>
<p>Most NSAIDs reduce the antipypertensive effect of beta blocker, and cause sodium retention probably because of inhibition of formation of renal prostacyclin. Highly lipid soluble beta blockers such as propranolol are likely to cause CNS adverse effects.</p>
<p>Preparations and Dose: See Chapter 18.
Therapeutic uses: Beta blockers are used to treat all grades of hypertension. Relatively selective <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers (e.g. Atenolol) are preferred.
III Alpha <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi>α</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\alpha_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\left(\beta_{1}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) adrenergic blockers:
LABETALOL: For details see Chapter 18. It is given orally in the dose of 100 mg twice daily an increased gradually upto <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">400-800 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">800</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily. The evidence that labetalol has an important advantage over other beta blockers is lacking. However, it can be given IV to treat hypertensive emergencies (see later).</p>
<p>Carvedilol ( 6.25 mg bid) has similar actions as labetalol. It is also used in CHF (Chapter 31).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="vasodilator-drugs">Vasodilator Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasodilator-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HYDRALAZINE: Hydralazine (Fig 30.4) was first synthesised and tested for antihistaminic activity. However, subsequent investigations demonstrated its hypotensive action instead of antihistaminic activity.
<img src="assets/images/image-20251214-1b2fadcf.jpeg" alt="img-24.jpeg"></p>
<p>Pharmacological actions:</p>
<ul>
<li>Hydralazine lowers the BP by causing a direct relaxation of the arteriolar wall.</li>
<li>The effect is slow in onset but prolonged. Even on its IV administration, the BP falls only after 15-20 minutes.</li>
<li>The fall in BP is accompanied by a decrease in the total peripheral resistance, and by a compensatory tachycardia, increase in stroke volume and in cardiac output. Orthostatic hypotension is rare.</li>
<li>The splanchnic, coronary, cerebral and renal blood flow may increase.</li>
<li>It causes increase in plasma renin activity and fluid retention.</li>
</ul>
<p>Absorption, fate and excretion: It is well absorbed after oral and parenteral administration. Maximal blood levels are reached within 3 to 4 hours after oral administration. The drug is acetylated in the liver and there may be 'fast acetylators' and 'slow acetylators'. Elimination of the drug is almost complete within 24 hours. Less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> of an oral dose is excreted unchanged in urine. Hence, it can be used even in the presence of renal damage.</p>
<p>Adverse reactions: The high incidence of ADR is the main drawback of hydralazine therapy. The manifestations are:</p>
<ul>
<li>Gastrointestinal irritation producing nausea, vomiting, gastric hypersecretion, anorexia and diarrhoea.</li>
<li>Cardiac effects: These include palpitation, tachycardia and anginal attacks.</li>
<li>Others like headache, nasal congestion, flushing, tremors and dizziness. It causes secondary salt and water retention.</li>
<li>Intolerance: The manifestations are fever, skin rash and polyneuritis. GI haemorrhage and pancytopenia are serious manifestations.</li>
<li>Acute rheumatoid arthritis or SLE like syndrome may develop with large doses (over 600 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) given for prolonged periods.
Preparations and dosage:
(i) Hydralazine hydrochloride tablets 10, 25, and 50 mg . Maximum dose 100 mg daily.
(ii) Dihydralazine sulphate 25 mg tablet.
(iii) Injection 20 mg for IM/IV use.</li>
</ul>
<p>SODIUM NITROPRUSSIDE: This drug, known since 1850, has been used as a colour indicator for acetone and aldehydes. It was regarded as a poison because of its cyanide</p>
<p>group.
Given by IV infusion, it is metabolised to active compound NO which causes relaxation of arterioles and veins.</p>
<ul>
<li>This results in the reduction in peripheral resistance and venous tone, lowering the after load and the preload, respectively.</li>
<li>The myocardial oxygen consumption is reduced with improvement in myocardial function in low output states.</li>
<li>Heart rate and the regional blood flow are little affected.</li>
<li>It increases plasma renin activity.</li>
<li>It is rapidly metabolised to thiocyanate.</li>
<li>The action is of rapid onset but of very short duration.</li>
</ul>
<p>Sodium nitroprusside is supplied as 50 mg powder to be dissolved in 500 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose in water, just prior to administration. When it is exposed to light, it is converted to cyanide; hence a brown or black paper bag over the IV fluid container is necessary. Translucent plastic tubing may need taping. Only freshly prepared solution should be used.</p>
<p>Adverse reactions: Hepatic dysfunction may result in excessive accumulation of toxic cyanide which may cause metabolic acidosis, arrhythmia, hypotension and death.</p>
<p>Prolonged administration of sodium nitroprusside either in high doses or in the presence of renal insufficiency may precipitate thiocyanate toxicity. This results in fatigue, anorexia, nausea, vomiting, sweating, disorientation, psychotic behavior and muscle twitching. Larger doses may cause ataxia, rigidity, convulsions and metabolic acidosis.</p>
<p>Therapeutic Uses: It is mainly used in hypertensive emergencies. It has also been used to produce controlled hypotension during surgery and to improve left ventricular function in acute MI and low output states. It is infused IV slowly in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-5 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. In the treatment of severe hypertension, if the BP is not adequately controlled after 10 minutes of infusion at the maximal rate, the drug should be stopped immediately for fear of toxicity. On the other hand, nitroprusside must not be stopped abruptly during treatment of heart failure because of the danger of rebound hypertension.</p>
<p>CALCIUM CHANNEL BLOCKERS (CCB): Their properties and uses are discussed in detail in Chapter 29.</p>
<ul>
<li>They are used in the long term treatment of hypertension. Nifedipine has also been used in the management of hypertensive emergencies.</li>
<li>CCB are particularly preferred in patients with impaired renal function or asthma, and in acute hypertension during pregnancy.</li>
<li>They are often used as a monotherapy particularly in moderately hypertensive patients with diabetes mellitus.</li>
<li>CCB have no significant CNS effects. Edema of feet may be observed.</li>
<li>As these drugs are metabolised by liver, dose adjustment in patients with renal disease is less critical.
There is some concern about the long term safety of the short acting dihydropyridines. Hence, the standard formulations (used for immediate relief) of nifedipine and other short half-life dihydropyridines are not recommended for long term treatment of hypertension. Diltiazem and amlodipine are as effective as diuretics, beta-blockers or their combination, in the long term treatment of essential hypertension.</li>
</ul>
<p>Nitrates have a synergistic effect with the vasodilator drugs and, therefore, the use of</p>
<p>nitroglycerine by a patient receiving a peripheral vasodilator drug e.g. a CCB can lead to sudden fall of BP and collapse.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="potassium-channel-activators">Potassium Channel Activators<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#potassium-channel-activators" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The group includes: diazoxide and minoxidil (Fig 30.5) used in hypertension; and nicorandil and pinacidil used in angina (Chapter 29).
<img src="assets/images/image-20251214-6b9b6e1c.jpeg" alt="img-25.jpeg"></p>
<p>Mechanism of action: Potassium channels play an important role in the regulation of membrane potential and excitability of cells. Potassium channel activators combine with ATP modulated potassium channels; opening these channels causes potassium ions to leak out from the cell. This action hyperpolarises and stabilises the cell membrane of the vascular smooth muscle. This reduces <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>entry and prevents vasoconstriction, leading to relaxation. Thus, they act as arterial vasodilators. Nicorandil, in addition, also activates cGMP to produce NO.</p>
<p>The drugs reduce the excitability of the myocytes. They may have a role in the management of IHD because the ATP modulated potassium channels are believed to be crucial in myocardial adaptation to ischemic injury via 'preconditioning'.</p>
<p>DIAZOXIDE: It is a compound structurally related to the diuretic chlorothiazide but has no diuretic activity. It is a potent, direct arteriolar vasodilator with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 36 hour. As with hydralazine, compensatory reactions include tachycardia, increased cardiac contractility and sodium retention. It is highly protein bound. When injected by IV bolus, it lowers the BP within 3-5 minutes. It also raises blood sugar levels and is used to treat hypoglycemia due to insulinoma (Chapter 65).</p>
<p>MINOXIDIL a prodrug, is used orally as a peripheral vasodilator. Its active metabolite minoxidil N-O sulfate acts similar to hydralazine, but is more potent and more toxic. It causes compensatory tachycardia, increased cardiac contractility, palpitation, angina and sodium retention. It can also cause pulmonary hypertension, hypertrichosis and headache. Pericardial effusion and cardiac tamponade have been reported. Its effective dose range is wide, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-40 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. Because of its toxicity, the drug is reserved for resistant cases.</p>
<p>See Chapter 71 for its use in alopecia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="renin-inhibitors">Renin Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#renin-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Aliskiren: Renin cleaves angoitensinogen from the liver to form angiotensin I, which is then converted to angiotensin II (Fig. 30.1). Oral, nonpeptide, renin inhibitor, aliskiren, causes dose-dependent, direct inhibition of the plasma renin activity and thereby reduces both angiotensin I and II levels, and produces fall in BP. Reduction in angiotensin II due to aliskiren lead to increase in plasma renin levels. In contrast to ACEI and ARB, which increase both plasma renin levels and PRA (estimated by angiotensin I levels), aliskiren increases only renin levels. The drug needs further evalvation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-converting-enzyme-inhibitors-acei">Angiotensin Converting Enzyme Inhibitors (ACEI)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-converting-enzyme-inhibitors-acei" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Introduction of this new class of drugs distinctly improved the management of hypertension. Several ACEI are now available (Table 30.1) Captopril was the first ACEI introduced in 1981.</p>
<p>Table 30.1
ACE inhibitors in current use</p>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 2^{\circ}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span></span></span></span></span> (hrs)</th><th style="text-align: left;">Usual dosage (mg) in hypertension</th></tr></thead><tbody><tr><td style="text-align: left;">Captopril</td><td style="text-align: left;">1.9</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>50</mn></mrow><annotation encoding="application/x-tex">12.5-50</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">50</span></span></span></span></span> bid</td></tr><tr><td style="text-align: left;">Lisinopril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">11-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">5-40 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Enalapril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">11-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">5-20 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Ramipril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>13</mn><mo>−</mo><mn>17</mn></mrow><annotation encoding="application/x-tex">13-17</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">13</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">17</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-20 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Benazepril</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>11</mn></mrow><annotation encoding="application/x-tex">10-11</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">11</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Fosinopril</td><td style="text-align: left;">12</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Quinapril</td><td style="text-align: left;">3</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">o</mi><mi mathvariant="normal">d</mi></mrow></mrow><annotation encoding="application/x-tex">10-80 \mathrm{od}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm">od</span></span></span></span></span></span></td></tr></tbody></table>
<p>Drugs other than Captopril and lisinopril are prodrugs.
*Of active drug/metabolite
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>3</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span></span></span></span></span></span></span></span></span> Smaller doses in patients on diuretics, in CHF and with renal insufficiency.
Mechanism of action: ACEI competitively inhibit ACE and thus blocks the conversion of angiotensin I to angiotensin II (Fig 30.1). Thus it prevents:
(a) The pressor effect of angiotensin II; and
(b) Stimulation of aldosterone synthesis and release. As a consequence, the plasma levels of renin and angiotensin I show a marked compensatory rise.
(c) As ACE also metabolises bradykinin (See Chapter 25), its inhibition of ACE raises the levels of bradykinin, a potent vasodilator, which may also contribute to its antihypertensive and cardioprotective effects. Blockade of angiotensin II synthesis in the tissues (vascular, cardiac and renal) by ACEI may be responsible for their other beneficial effects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions">Pharmacological actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>In healthy, sodium replete humans, a single oral dose of ACEI lowers the systemic BP only slightly; the effect is more marked on repeated administration. By contrast, a single dose of ACEI causes substantial lowering of BP in salt depleted subjects.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="in-hypertensive-subjects">In hypertensive subjects:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#in-hypertensive-subjects" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>ACEI cause vasodilation, lower systemic arterial resistance, as well as both systolic and diastolic BP.</li>
<li>There is no reflex tachycardia.</li>
<li>The antihypertensive effect is seen in all varieties of hypertension except that due to primary aldosteronism; it is most marked in patients with renovascular hypertension. Concurrent use of a diuretic potentiates its action.</li>
<li>Renal, cerebral and coronary blood flow is increased.</li>
<li>Baroreceptor function is reset, cardiovascular reflexes are not compromised and responses to posture and exercise are not impaired. Postural hypotension is not a problem.</li>
<li>Secretion of aldosterone is reduced but adequate levels are maintained by other secretogogues, ACTH and potassium. As these secretogogues need a permissive level of angiotensin II for their action, the inhibition of ACE is not complete.</li>
</ul>
<p>In patients with chronic CHF: ACEI produce several beneficial effects:</p>
<ul>
<li>They reduce the afterload and preload. The cardiac output increases and the heart rate diminishes. BP is not much affected.</li>
<li>They cause natriuresis (diuretic sparing) following hemodynamic changes and reduction in aldosterone secretion. The venous return to the heart diminishes, decreasing the preload.</li>
<li>Pulmonary arterial pressure, pulmonary capillary wedge pressure and of left atrial and left ventricular filling pressure (preload) are reduced.</li>
<li>Exercise tolerance increases.</li>
<li>They prolong survival in these patients.</li>
</ul>
<p>In diabetic patients, ACEI improve kidney function and reduce microalbuminuria. (renoprotection).</p>
<p>In patients with acute MI (See Chapter 29).
Absorption, fate and excretion: Various ACEI differ in their pharmacokinetic properties (Table 30.1). Captopril (Fig. 30.6) is rapidly absorbed from the gut with a bioavailability of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">65%</span></span></span></span></span>. Its absorption is reduced by food and so it is given 1 hour before a meal. It is cleared rapidly from the body by renal excretion ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>95</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">95 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">95%</span></span></span></span></span> ); about half is excreted as captopril and the other half as metabolites.
<img src="assets/images/image-20251214-1b918ee3.jpeg" alt="img-26.jpeg"></p>
<p>Adverse reactions: ACEI are generally well tolerated. Most adverse effects are the result of the specific inhibition of ACE. Relatively common adverse effect is persistent dry cough. It is believed to be due to raised bradykinin. A steep fall in BP may occur after the first dose in subjects with severe hypertension who are on multidrug regimes including a diuretic, and generally in all salt depleted patients. In such cases, ACEI should be started in very small doses, preferably after stopping the diuretic.</p>
<p>Aldosterone synthesis inhibition by ACEI causes hyperkalemia, particularly in patients with renal insufficiency and in those taking a potassium sparing diuretic. It should be used with caution in patients on an NSAID or a beta blocker.</p>
<p>The other adverse effects are skin rashes, disturbances of the sense of taste, vitiligo, headache, GI disturbances, muscle cramps and rarely leucopenia. Proteinuria ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>1</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">&gt;1 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day) has been described. Rarely it causes serious angioedema. The drug causes foetal toxicity in animals and should be avoided in pregnancy.</p>
<p>Preparation and dosage: See Table 30.1. Because of reduced clearance, smaller doses are indicated in patients with impaired renal function.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Hypertension: These are useful in hypertension of all grades, including malignant hypertension. Combined with a thiazide they can reduce thiazide-induced hypokalemia, hypercholesterolemia, hyperglycemia and hyperuricemia. They can be used safely in asthmatics and diabetics. There is no rebound hypertension on stopping the drugs abruptly. They can be combined with an antihypertensive from any other class and are generally well tolerated by the elderly. Sexual function is not affected.</li>
<li>Chronic congestive heart failure: ACEI are indicated in all clinical manifestations of heart failure and in individuals with asymptomatic LV dysfunction (Chapter 31). Addition of ACEI to conventional treatment in patients with severe CHF can reduce mortality and improve symptoms.</li>
<li>Diabetic nephropathy: ACEI protect kidneys and decrease microalbuminuria in patients with insulin dependent diabetes mellitus and nephropathy.</li>
<li>Acute MI: They reduce LV dysfunction and mortality (Chapter 29).</li>
</ul>
<p>ENALAPRIL: This congener of captopril is without an SH group.
It differs from captopril in that:</p>
<ul>
<li>It is a prodrug and is converted in the body to the active metabolite enalaprilat.</li>
<li>Food does not interfere with its absorption.</li>
<li>It is more potent.</li>
<li>Its action is slower but lasts longer.</li>
<li>It is less liable to cause taste disturbances, leucopenia and glomerulopathy.</li>
</ul>
<p>In patients with CHF, the starting dose should be <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2.5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in subjects over 60 years of age and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day in subjects younger than 60 . It is given once daily. Usual maintenance dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per day.</p>
<p>Contraindication for ACEI:
(1) Severe bilateral renal artery stenosis as they reduce GFR and may cause renal failure,
(2) Aortic stenosis,
(3) Coarctation of the aorta; and
(4) Pregnancy.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="angiotensin-receptor-blockers-arb">Angiotensin Receptor Blockers (ARB)<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-receptor-blockers-arb" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>ACEI inhibit ACE which is not a specific enzyme, and has other substrates (bradykinin, substance <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>P</mi></mrow><annotation encoding="application/x-tex">P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">P</span></span></span></span></span> and neurokinins); inhibition of which may cause ADR such as cough and angioedema. Hence specific angiotensin receptor blockers have been developed (Table 30.2).</p>
<p>Table 30.2</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="angiotensin-receptor-blockers">Angiotensin receptor blockers<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#angiotensin-receptor-blockers" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Drug</th><th style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mi mathvariant="normal">t</mi><mi mathvariant="normal">/</mi><msup><mi mathvariant="normal">s</mi><mo mathvariant="normal" lspace="0em" rspace="0em">′</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{t} \mathrm{t} / \mathrm{s}^{\prime}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.0019em; vertical-align: -0.25em;"></span><span class="mord mathrm">tt</span><span class="mord">/</span><span class="mord"><span class="mord mathrm">s</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7519em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">′</span></span></span></span></span></span></span></span></span></span></span></span></span> (hrs)</th><th style="text-align: left;">Dosage (mg/day) in hypertension</th></tr></thead><tbody><tr><td style="text-align: left;">Losartan</td><td style="text-align: left;">2</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>100</mn></mrow><annotation encoding="application/x-tex">25-100</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">100</span></span></span></span></span> od or bid</td></tr><tr><td style="text-align: left;">Valsartan</td><td style="text-align: left;">6</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>320</mn></mrow><annotation encoding="application/x-tex">40-320</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">320</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Candesartan</td><td style="text-align: left;">9</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>32</mn></mrow><annotation encoding="application/x-tex">4-32</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">32</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Irbesartan</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mo>−</mo><mn>15</mn></mrow><annotation encoding="application/x-tex">11-15</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">11</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">15</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">75-300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Eprosartan</td><td style="text-align: left;">5</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>400</mn><mo>−</mo><mn>800</mn></mrow><annotation encoding="application/x-tex">400-800</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">400</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">800</span></span></span></span></span> od or bid</td></tr><tr><td style="text-align: left;">Telmisartan</td><td style="text-align: left;">24</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>80</mn></mrow><annotation encoding="application/x-tex">20-80</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">80</span></span></span></span></span> od</td></tr><tr><td style="text-align: left;">Olmesartan</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>14</mn><mo>−</mo><mn>16</mn></mrow><annotation encoding="application/x-tex">14-16</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">14</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">16</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn></mrow><annotation encoding="application/x-tex">10-40</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">40</span></span></span></span></span> od</td></tr></tbody></table>
<p>SARALASIN: This synthetic analogue of angiotensin II is a competitive inhibitor of angiotensin II; however, it has significant partial agonist properties. Infused IV, it lowers the BP in patients with angiotensin dependent hypertension. It was used as a diagnostic agent.</p>
<p>LOSARTAN: This phenyl tetrazole substituted imidazole compound acts as a selective, competitive blocker of angiotensin II receptor type <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mo fence="true">(</mo><msub><mi>A</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">1\left(A_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathnormal">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and decreases peripheral vascular resistance. However, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockade can activate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">T</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{AT}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">AT</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and may increase bradykinin. Clinically this effect is short lasting. It has some uricosuric action.</p>
<p>Given orally, it is well absorbed and undergoes hepatic first pass metabolism, being partly converted to a more active metabolite. Its effect on the cardio-vascular hemodynamics are similar to those of ACEI.</p>
<p>Adverse reactions: Like the ACEI it can cause fetotoxicity and should not be used during pregnancy. It can precipitate renal failure in patients with bilateral renal artery stenosis and in those with low, fixed renal blood flow. It can cause skin rashes and neuropsychiatric disturbances such as insomnia, confusion, nightmares, agitation and depression. Even cough and angioedema can occur rarely.</p>
<p>Valsartan, Irbesartan, Eprosartan, Telmisartan, Candesartan, Olmesartan and Azilsartan are the other analogues of losartan.</p>
<p>Therapeutically ACEI and ARB are equally effective for treatment of hypertension. The choice between them depends upon familiarity and cost. Whether ARBs offer the same degree of cardioprotection as ACEI is not known. ARB have similar contraindications as ACEI.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aldosterone-antagonist">Aldosterone Antagonist<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aldosterone-antagonist" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>SPIRONOLACTONE: This aldosterone antagonist is discussed in Chapter 39. By itself it is not an antihypertensive agent. As an add-on drug, it may be particularly useful in hypertensive patients with significant hyperuricemia, hypokalemia, or glucose intolerance. It is the drug of choice in primary hyperaldosteronism. It is now also recommended in small doses as an add-on drug in congestive heart failure (Chapter 31).</p>
<p>Eplerenone: See Chapter 39.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="thiazides-as-antihypertensives">Thiazides as Antihypertensives<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#thiazides-as-antihypertensives" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The thiazide group and related compound chlorthalidone (Chapter 39) have proved extremely valuable in the treatment of mild to moderate hyper-tension. In addition, they enhance the effect of other antihypertensive agents.</p>
<p>Mechanism of action: The thiazides probably reduce the BP by several mechanisms. The sodium depletion and consequent reduction in plasma volume and cardiac output produced by them are important in the initial days of treatment of essential hypertension. Severe dietary restriction of sodium can produce a similar fall in BP.</p>
<p>After a few weeks of thiazide therapy, the plasma volume and the cardiac output, return to the pre-treatment level. From then on, decreased systemic vascular resistance, probably due to changes in the ionic composition of the vascular wall, is important in maintaining the antihypertensive effect. Diuretics may produce cellular sodium loss and increased entry of potassium into the vascular cells, thereby reducing their responsiveness to endogenous vasoconstrictors, mainly NA. Activation of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>channels may also contribute to thiazide-induced vasodilatation.</p>
<p>When GFR is reduced by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> or more, thiazides lose most of their diuretic and antihypertensive effects. Thiazides also increase the PRA which may contribute to the development of tolerance.</p>
<p>Pharmacological actions: The anti-hypertensive effect develops slowly. There is a reduction in both, the systolic and the diastolic BP. The hypotensive action is moderate. The maximum effect is obtained with 50 mg of hydrochlorothiazide or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> of chlorthalidone once a day. Increase in the dose does not enhance the hypotensive effect and there appears little difference in their antihypertensive action with equivalent doses of thiazides. Differences do exist, however, in their duration of action. (Chapter 39). The very potent diuretic furosemide is not recommended for the long term management of hypertension because of its short duration of action and the serious electrolyte disturbances. However, it can be valuable in patients with chronic kidney disease who do not respond to thiazides.</p>
<p>However, tolerance may develop after prolonged use. Thiazides are not useful in patients with markedly decreased GFR. Further, they are less effective than ACEI in reducing left ventricular hypertrophy.</p>
<p>Adverse reactions: These include hypokalemia, hyperuricemia and hyperglycemia (Chapter 39). With the recommended low doses, hypokalemia and other metabolic changes are generally not a problem. Data indicate that:
(a) In the absence of digitalis and possibly overt heart disease, hypokalemia is not associated with increased occurrence of ventricular arrhythmias; and
(b) Although serum LDL cholesterol levels do rise modestly after thiazide the levels usually revert to the pre-treatment levels during long term use.</p>
<p>Routine potassium supplementation during thiazides use is not necessary. Those at high risk of developing hypokalemia (patients with IHD, arrhythmias, diabetes, severe hepatic disease as well as those on digitalis or glucocorticoids) should receive prophylactic potassium supplements or potassium sparing diuretics.</p>
<p>Thiazides and chlorthalidone used in small doses have several advantages:</p>
<ul>
<li>
<p>Their efficacy in mild to moderate hypertension is similar to other antihypertensive agents (see text).</p>
</li>
<li>
<p>Postural hypotension is rare.</p>
</li>
<li>
<p>Blood flow to vital organs such as kidney and brain is not compromised.</p>
</li>
<li>
<p>They do not cause reflex tachycardia or reduce the cardiac output.</p>
</li>
<li>
<p>Unlike vasodilators, they do not cause compensatory volume overload and edema.</p>
</li>
<li>
<p>They have substantial residual effects and BP rises slowly after discontinuation. Hence, missing a dose occasionally carries no risk of sudden rebound rise.</p>
</li>
<li>
<p>With doses recommended, they are well tolerated, with minimal acceptable side effects. They have been in use for several years and their long term toxicity profile is well known. They reduce calcium excretion and these may prevent hip fractures and osteoporosis in postmenopausal women.</p>
</li>
<li>
<p>Clinically relevant drug interactions are few.</p>
</li>
<li>
<p>They can be combined with several other antihypertensives with synergistic effect.</p>
</li>
<li>
<p>They are convenient to take, remain effective for long time.</p>
</li>
</ul>
<p>In general, the oral thiazides still remain the most valuable, safe and highly cost-effective antihypertensive drugs.</p>
<p>As large proportion of hypertensive patients eventually need more than one drug to achieve satisfactory BP control, the discussion regarding their use to start with or later as "an add on" drug is academic. That their use has been declining is not because they lack virtues, but is due to "absence of corporate promotion" and "aggressive marketing" of newer but more expensive agents.</p>
<p>INDAPAMIDE: This compound, an indole derivative of chlorosulphonamide, is chemically related to chlorthalidone. Like the latter drug, it has a long duration of action with a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of about 18 hours. Given orally in the dose of 2.5 mg once daily, it reduces the BP in mild and moderate hypertension. Larger doses cause diuresis. It has similar therapeutic activity as chlorthalidone and is available as 2.5 mg tablets. A sustained release (SR) preparation is available.</p>
<p>XIPAMIDE: This is 4-chloro-5-sulfamoyl-2'- 6' salicyloxlidide. The drug has diuretic and hypotensive effects as well as adverse effects similar to thiazides. It also resembles furosemide in that it is an effective diuretic in patients with renal failure. It is administered in a single daily dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="miscellaneous-drugs">Miscellaneous Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#miscellaneous-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>METYROSINE (Alpha methyl tyrosine): This drug blocks the synthesis of catecholamines by inhibiting tyrosine hydroxylase. It is useful in the treatment of patients with pheochromocytoma, The ADR include sedation, GI symptoms, extrapyramidal effects, crystalluria, nasal congestion, gynecomastia, galactorrhoea and peripheral edema. It is not indicated in essential hypertension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypertension-therapy">Hypertension - Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertension-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Effective treatment of hypertension is an important part of any programme to reduce the toll of cardiovascular disease, viz end-organ damage and mortality, in the society. This is so because any elevation of BP significantly increases morbidity and mortality which are directly related to the level of the BP.</p>
<p>The drug treatment of essential hypertension is still 'empiric', as these drugs reduce the BP without correcting the cause. However, the reduction of BP (even suboptimally) prevents or postpones renal, cardiac and cerebral complications and prolongs life. The control of hypertension in diabetics also helps to delay the onset of retinal and renal damage. Complications arising from associated atherosclerosis are now the chief cause of death. Therefore, control of the other modifiable cardiovascular risk factors such as smoking and obesity is an essential part of the treatment of hypertension.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pretreatment-evaluation-includes">Pretreatment evaluation includes:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pretreatment-evaluation-includes" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Multiple BP readings in supine and standing positions after sufficient rest.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="assessment-for-target-organ-damage">- Assessment for target organ damage<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#assessment-for-target-organ-damage" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) Detailed history and physical examination: Dyspnoea; polyuria; nocturia; edema; cardiomegaly.
(b) Kidneys: Urine examination; serum creatinine; serum electrolytes.
(c) Heart: ECG, X-ray chest, 2 D-Echo.
(d) Fundoscopy: The condition of the retinal vessels reflects that of the cerebral vessels.</p>
<ul>
<li>Assessment for other cardiovascular risk factors: Salt intake; alcohol consumption; smoking; obesity; diabetes; hyperlipidemia; premature CV death in close relatives.</li>
<li>Special investigations to identify the cause of hypertensions: USG of the urinary tract/renal blood vessels; renal angiography; tests for pheochromocytoma, aldosteronoma, etc. These are done if indications exist; or if the hypertension is drug-resistant. It should be noted that:
(a) Every patient who knows that his/her BP is elevated requires treatment, though not necessarily with antihypertensive drugs.
(b) Systolic hypertension is as damaging as diastolic hypertension.
(c) Treatment with antihypertensives, once started, will generally have to be continued for life.
(d) Success of the treatment depends upon the care and the time spent by the doctor upon educating and counseling the patient; and the patient's compliance.</li>
</ul>
<p>Reassurance by a physician and lifestyle modifications (Table 30.3) are necessary in all hypertensive patients, including the prehypertensives. In addition, they are essential for normotensives with diabetes, those with history of CVS disease or with coronary risk factors. In fact, they may suffice in those with uncomplicated, mild hypertension and should be given a trial for 6-10 weeks.</p>
<p>Table 30.3
Lifestyle modification in hypertensives</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>• Weight reduction in obese persons.
</span>    • Restriction of salt consumption to 4-6 g, (about 2-3 g, of sodium) a day
    • Increase in dietary potassium (fruits and vegetables) consumption.
    • Restriction of fat consumption (Chapter 40).
    • Physical exercise such as brisk walking; and mental relaxation.
    • Reduction in alcohol and caffeine consumption.
    • Cessation of smoking.
    • Better adjustment at work and in family life.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="• Weight reduction in obese persons.
    • Restriction of salt consumption to 4-6 g, (about 2-3 g, of sodium) a day
    • Increase in dietary potassium (fruits and vegetables) consumption.
    • Restriction of fat consumption (Chapter 40).
    • Physical exercise such as brisk walking; and mental relaxation.
    • Reduction in alcohol and caffeine consumption.
    • Cessation of smoking.
    • Better adjustment at work and in family life." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>'Increased salt intake is a necessary but not sufficient cause for hypertension. Reduction in salt intake reduces BP in hypertensives as well as those with high normal BP. It may also prevent a recurrence in those who were previously normotensive on drugs. Salt restriction needs to be at least moderate (a reduction of salt intake to 4 g or less/day), sustained, and may take several weeks to be effective. Salt restriction also minimises the age-related rise in BP. Chloride is as important as sodium in elevating BP, and their effect is additive; other salts such as sodium citrate are less liable to elevate the BP. Liability for BP to be elevated by salt (salt sensitivity) is partly genetic. It is also seen in insulin resistance, hyperlipidemia and microalbuminuria. It is alleviated by increased postassium intake. Extreme salt restriction has been reported to be harmful.</p>
<p>Clinically, hypertension can be divided into mild, moderate, severe and very severe grades (Table 30.4).</p>
<p>Table 30.4
Classification of hypertension</p>
<table><thead><tr><th style="text-align: left;">Category</th><th style="text-align: left;">Systolic BP (mm Hg)</th><th style="text-align: left;"></th><th style="text-align: left;">Diastolic BP (mm Hg)</th><th style="text-align: left;">Recommendation</th></tr></thead><tbody><tr><td style="text-align: left;">Normal</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">&lt;120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: left;">and</td><td style="text-align: left;"></td><td style="text-align: left;">Recheck in 2 years</td></tr><tr><td style="text-align: left;">High Normal (prehypertension)</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>139</mn></mrow><annotation encoding="application/x-tex">120-139</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">139</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>80</mn><mo>−</mo><mn>89</mn></mrow><annotation encoding="application/x-tex">80-89</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">80</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">89</span></span></span></span></span></td><td style="text-align: left;">Recheck in 6 months.</td></tr><tr><td style="text-align: left;">Hypertension</td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td><td style="text-align: left;"></td></tr><tr><td style="text-align: left;">Mild</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mo>−</mo><mn>159</mn></mrow><annotation encoding="application/x-tex">140-159</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">140</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">159</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>99</mn></mrow><annotation encoding="application/x-tex">90-99</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">99</span></span></span></span></span></td><td style="text-align: left;">Confirm and treat within 2 months.</td></tr><tr><td style="text-align: left;">Moderate</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>160</mn><mo>−</mo><mn>179</mn></mrow><annotation encoding="application/x-tex">160-179</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">160</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">179</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>109</mn></mrow><annotation encoding="application/x-tex">100-109</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">109</span></span></span></span></span></td><td style="text-align: left;">Treat within 1 month.</td></tr><tr><td style="text-align: left;">Severe</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>180</mn><mo>−</mo><mn>209</mn></mrow><annotation encoding="application/x-tex">180-209</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">180</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">209</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>110</mn><mo>−</mo><mn>119</mn></mrow><annotation encoding="application/x-tex">110-119</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">110</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">119</span></span></span></span></span></td><td style="text-align: left;">Treat within 1 week.</td></tr><tr><td style="text-align: left;">Very severe</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>210</mn></mrow><annotation encoding="application/x-tex">\geq 210</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">210</span></span></span></span></span></td><td style="text-align: left;">or</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>120</mn></mrow><annotation encoding="application/x-tex">\geq 120</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7719em; vertical-align: -0.136em;"></span><span class="mrel">≥</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">120</span></span></span></span></span></td><td style="text-align: left;">Treat immediately.</td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{*}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Stage 1.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∼</mo></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{\sim}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6198em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6198em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mrel mtight">∼</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Stage 2 .</p>
<ul>
<li>Patients with very severe hypertension are at grave risk of developing 'hypertensive complications' such as cerebral hemorrhage, hypertensive encephalopathy, acute LVF, renal failure or dissection of the aorta. These patients and those with papilloedema (malignant hypertension) need urgent and aggressive treatment.</li>
<li>Patients with severe hypertension are also at risk of developing the same 'hypertensive complications', especially if they are old or have long-standing high BP. Although the risk of a fatal complication is less in young patients, they are more liable to suddenly develop malignant hypertension. Prompt treatment of such patients can ward off a 'hypertensive complication' but unfortunately does not slow down the accelerated rate of atherosclerosis.</li>
<li>Patients with moderate hypertension are also at risk if they have a bad family history (a near relative has had a 'hypertensive complication'), or if they have cardiomegaly, fundus changes or ECG abnormalities. They too require energetic treatment.</li>
<li>If the hypertension is mild, the need for drug treatment is determined by the patient's</li>
</ul>
<p>age. Studies by the Veterans' Administration have shown that young patients in this group definitely benefit from aggressive treatment of their hypertension. Aggressive reduction of BP is, however, likely to prove dangerous in elderly, arteriosclerotic individuals with elevated systolic but normal diastolic BP.
In mild hypertension along with nonpharmacological treatment drug therapy is also indicated.</p>
<ul>
<li>In patients with hypertension and renal failure, there may be an initial deterioration of renal function following aggressive therapy. In the long run, however, control of BP halts the progress of renal failure and prolongs life. In CKD the target BP to be achieved is SBP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>140</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&lt;140 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">140</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">D</mi><mi mathvariant="normal">B</mi><mi mathvariant="normal">P</mi></mrow><mo>&lt;</mo><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{DBP}&lt;90 \mathrm{~mmHg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">DBP</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">mmHg</span></span></span></span></span></span>.</li>
<li>In patients with diabetes mellitus, the target BP should be the same as in CKD.</li>
</ul>
<p>Antihypertensive drugs should be used cautiously in patients who have had a recent MI or a stroke, as a rapid lowering of BP can worsen their condition.</p>
<p>The duration of drug treatment is lifelong in most patients. An occasional patient may be able to give up the treatment and remain normotensive thereafter. How often this happens is not known; but it is rare.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="principles-of-drug-therapy">Principles of Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The aims of treatment of hypertension are:
(a) Maintaining the BP, including the early morning BP, as near normal as possible (less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> ) without undue side effects
(b) Maintaining/improving the quality of life, including the intellectual and sexual functions.
(c) Reduction in left ventricular mass.
(d) Prevention of cardiac arrhythmias, heart failure and other complications.
(e) Control of other CHD risk factors; and
(f) Doing all this in a cost-effective manner.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-drug-therapy">Principles of drug therapy:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>In the long run, one aims at keeping the BP in the erect posture as near normal as possible- a systolic BP of less than 140 mm Hg and a diastolic BP of less than 90 mm Hg . However, a higher level of BP may have to be accepted in elderly patients, in patients with impaired renal function and in those with IHD or cerebrovascular disease. This is done in order to avoid the unpleasant symptoms and the possible complications (including myocardial and cerebral ischemia) of postural hypotension.</li>
<li>Antihypertensive drugs are started in small doses, increased gradually (start low, go slow) and only infrequently (every 3-4 weeks) as the maximum effect of a drug or drug combination at a given dose level may take some days or weeks.
However, in severe and very severe hypertension, one generally initiates the treatment with full doses of drugs, often using more than one drug from the start.</li>
<li>Having found a regimen that controls BP in the best possible manner, it is wrong to change the schedule unless there is a good reason to do so. However, in hot weather the patient may be asked to reduce the doses of antihypertensive drugs slightly in order to avoid postural hypotension. The fall in standing pressure may be exaggerated by exercise, or salt deficiency and sudden change of position. The patient should be warned of the possibility of fainting.</li>
<li>With drugs such as thiazide, ACEI, ARB and CCB, which do not cause significant postural hypotension, it is possible to maintain both standing and supine BP normal or near normal in many patients. If this can be done safely and continuously, then this is almost ideal antihypertensive therapy.</li>
<li>In patients with severe and very severe hypertension (see Table 30.3), the diastolic BP should be lowered to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>110</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-110 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">110</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> in the first 24 hours; further lowering to target levels should be carried out over the next 2-3 days.</li>
<li>During chronic therapy, adjustments occur in homeostatic mechanisms including the reflex cardiovascular responses and in the end organ receptor concentration; for example, the number of beta adrenergic receptors increases (up-regulation) during chronic beta-blocker therapy. The reaction of the patient to the abrupt cessation of drug therapy depends upon the dose and its duration of action, and the readjustment time for the homeostatic mechanisms activated during drug therapy. If the former is much shorter than the latter (as is the case with propranolol and clonidine) rebound rise in BP is likely to occur, with serious consequences such as cerebral hemorrhage. If, on the other hand, the duration of action is prolonged (as is the case of reserpine) no such</li>
</ul>
<p>rebound occurs.</p>
<ul>
<li>In practice, it is difficult to be familiar with more than a few preparations and hence, it is wise to continue using the one or two preparations which one knows best, and change them only if they are ineffective or adverse effects are troublesome.</li>
<li>Patients should be educated about the drugs they are receiving and their possible adverse effects. Impress upon the patient the hazards of uncontrolled or intermittently controlled hypertension and the rewards of keeping the BP under check continuously and lifelong.</li>
<li>The patient must be given a card bearing the names and doses of the drugs he is receiving.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="choice-of-drug-therapy">Choice of Drug Therapy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#choice-of-drug-therapy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>With the availability of many effective and reasonably safe antihypertensives, greater flexibility can be exerted in choosing the initial drug. What is most important is to reduce BP to the goal level. How that is done is less important.</p>
<p>Long term studies indicate that there are no important differences as regards efficacy, adverse effects or quality of life among patients who receive thiazides, calcium channel antagonists, ACEI or ARB. Although the responses to different groups of drugs are known to be similar in heterogeneous population, individual responses vary strikingly, even to same drug. Hence, the drug therapy has to be "tailor-made" for each patient. Currently, drugs used for the initial therapy of hypertension belong to any one of the 4 groupsACEI, ARB, CCB and Thiazide like diuretics.</p>
<p>Generally thiazides/CCB are preferable for elderly people ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>60</mn></mrow><annotation encoding="application/x-tex">&gt;60</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">60</span></span></span></span></span> years) and those of black ethnic origin at any age including those with DM, while younger patients who have more responsive RAAS than older subjects may be more benefited by ACEI or ARB. The latter should be preferred for patients aged 18yr or mor having CKD <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> DM for their beneficial effects on kidney function. In all CKD patients they also remain the first choice regardless of age, race or diabetes.</p>
<p>Analysis of many clinical trials reconfirms that the low-dose thiazide/thiazide-type diuretics alone or in combination (depending upon the severity) remain the first line therapy in majority of the patients. The 'diabetogenic' and 'hyperlipidemic' effects of the thiazides are often overstressed. An ACEI or CCB is considered a reasonable, but more expensive, alternative first choice. Patients with special problems (Table 30.5) benefit from a non-diuretic as a first line drug eg. ACEI in patients with LV dysfunction or diabetes mellitus; or a beta-blocker/CCB in patient with stable angina pectoris. Half the patients, however, in long term, would need a minimum of two drugs for controlling their BP.</p>
<p>Table 30.5
Symptom profiling of antihypertensive drugs</p>
<table><thead><tr><th style="text-align: center;">Associated Problem</th><th style="text-align: center;">Recommended</th><th style="text-align: center;">Not Recommended</th></tr></thead><tbody><tr><td style="text-align: center;">Migraine</td><td style="text-align: center;">BB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Depression</td><td style="text-align: center;">Diuretics &lt;br&gt; ACE inhibitors &lt;br&gt; CCB &lt;br&gt; Vasodilators <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers</td><td style="text-align: center;">Reserpine &lt;br&gt; Clonidine &lt;br&gt; Methyldopa &lt;br&gt; BB</td></tr><tr><td style="text-align: center;">Bronchospasm</td><td style="text-align: center;">CCB &lt;br&gt; Vasodilators</td><td style="text-align: center;">BB esp. propranolol</td></tr><tr><td style="text-align: center;">Palpitation</td><td style="text-align: center;">BB &lt;br&gt; Diltiazem</td><td style="text-align: center;">Vasodilators</td></tr><tr><td style="text-align: center;">Angina pectoris</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \mathrm{BB} \\ &amp; \mathrm{CCB} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">BB</span></span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">CCB</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Vasodilators like hydralazine</td></tr><tr><td style="text-align: center;">Old MI</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">C</mi><mi mathvariant="normal">E</mi><mi mathvariant="normal">I</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">R</mi><mi mathvariant="normal">B</mi></mrow></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mrow><mi mathvariant="normal">A</mi><mi mathvariant="normal">A</mi></mrow></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; \mathrm{BB} \\ &amp; \mathrm{ACEI} / \mathrm{ARB} \\ &amp; \mathrm{AA} \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 4.5em; vertical-align: -2em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.5em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -3em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -1.5em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 2.5em;"><span style="top: -4.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">BB</span></span></span></span><span style="top: -3.16em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">ACEI</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ARB</span></span></span></span><span style="top: -1.66em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord"><span class="mord mathrm">AA</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 2em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">CCB</td></tr><tr><td style="text-align: center;">Congestive heart failure</td><td style="text-align: center;">ACEI/ARB &lt;br&gt; Diuretics, AA &lt;br&gt; Vasodilators</td><td style="text-align: center;">CCB</td></tr><tr><td style="text-align: center;">Bradycardia</td><td style="text-align: center;"></td><td style="text-align: center;">BB, Verapamil Diltiazem</td></tr><tr><td style="text-align: center;">Mitral valve prolapse syndrome</td><td style="text-align: center;">BB</td><td style="text-align: center;">Drugs causing tachycardia or orthostatic hypotension</td></tr><tr><td style="text-align: center;">Left ventricular hypertrophy</td><td style="text-align: center;">ACE inhibitors</td><td style="text-align: center;">Direct acting vasodilators</td></tr><tr><td style="text-align: center;">Raynaud's phenomenon</td><td style="text-align: center;">CCB <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers</td><td style="text-align: center;">BB</td></tr><tr><td style="text-align: center;">Fluid retention</td><td style="text-align: center;">Diuretics</td><td style="text-align: center;">Vasodilators Clonidine BB</td></tr><tr><td style="text-align: center;">Thyrotoxicosis</td><td style="text-align: center;">BB</td><td style="text-align: center;">Drugs causing tachycardia</td></tr><tr><td style="text-align: center;">Recurrent</td><td style="text-align: center;">ACEI/ARB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">TIA</td><td style="text-align: center;">Diuretics &lt;br&gt; CCB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hyperlipidemia</td><td style="text-align: center;">Low dose thiazides, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers, ACEI</td><td style="text-align: center;">High dose thiazides BB</td></tr><tr><td style="text-align: center;">Essential tremor</td><td style="text-align: center;">Propranolol</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Open angle glaucoma</td><td style="text-align: center;">BB</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Diabetes mellitus</td><td style="text-align: center;">ACEI, ARB CCB</td><td style="text-align: center;">Potassium sparing diuretics</td></tr><tr><td style="text-align: center;">Azotemia</td><td style="text-align: center;">Loop diuretics &lt;br&gt; Direct acting vasodilators &lt;br&gt; CCB, BB &lt;br&gt; Alpha methyl dopa <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers</td><td style="text-align: center;">ACEI &lt;br&gt; Potassium sparing diuretics</td></tr><tr><td style="text-align: center;">History of sexual dysfunction</td><td style="text-align: center;">Gradual reduction of blood pressure (CCB, ACEI, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers are preferred)</td><td style="text-align: center;">Rapid reduction of blood pressure</td></tr><tr><td style="text-align: center;">Benign prostatic hyperplasia</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blockers (relieve prostatism)</td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Osteoporosis</td><td style="text-align: center;">Thiazides</td><td style="text-align: center;">Loop diuretics</td></tr><tr><td style="text-align: center;">Renal calculi</td><td style="text-align: center;">Thiazides</td><td style="text-align: center;">Loop diuretics</td></tr><tr><td style="text-align: center;">Chronic renal disease</td><td style="text-align: center;">Loop diuretics &lt;br&gt; ACEI/ARB+ &lt;br&gt; CCB</td><td style="text-align: center;">BB</td></tr></tbody></table>
<p>BB - Beta blockers;
CCB - Calcium channel blockers;
AA-Aldosterone antagonist.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="use-of-drug-combinations">Use of Drug Combinations<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#use-of-drug-combinations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>An appropriate combination of anti-hypertensive drugs can produce beneficial effects on:</p>
<ul>
<li>Blood pressure</li>
<li>Adverse reactions; and</li>
<li>Hemodynamic effects</li>
</ul>
<p>Combinations not only help to achieve better BP control but also reduce the incidence of ADR from individual drugs because of reduction in their doses as well as by pharmacological means. Fixed-dose combinations ensure better compliance. They however, should be chosen by the physician with the full knowledge of the clinical pharmacology of the drugs.</p>
<p>It is rational to combine antihypertensive drugs with different pharmacodynamic actions or with different anatomical sites of action, e.g., a diuretic can be combined with a beta-blocker, a vasodilator, methyldopa or ACEI. Drugs with similar adverse effects should not be combined. e.g. methyldopa and clonidine. Extra care should be taken in patients who are at risk for postural hypotension.</p>
<p>The drugs which interfere with the adrenergic system tend to produce fluid retention with consequent diminution in their therapeutic effect (pseudotolerance). Addition of a thiazide effectively counteracts fluid retention, enhances the therapeutic effect and permits the use of smaller doses of other drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-with-drugs">Management with Drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-with-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major factors in hypertension are:</p>
<ul>
<li>Peripheral vasoconstriction</li>
<li>Expansion of plasma volume; and</li>
<li>Hyperdynamic heart action, particularly in the young.</li>
</ul>
<p>Since the majority of hypertensive subjects will have BP reduction no matter what drug is used, the initial choice of the drug should depend upon such factors as safety, cost, likely patient compliance and associated medical problems. Such symptom drug profiling (Table 30.5) is very useful in practice.</p>
<p>Generally, a stepped-care approach is recommended.
(1) Start the therapy with low dose of an agent (monotherapy), appropriate for a given patient, depending upon the age, race, and the co-morbid conditions such as diabetes mellitus, angina, pregnancy and so on (Table 30.5). If the BP is not controlled within a month of treatment, the dose should be increased in small increments (start low, go slow), till the desired BP level is achieved without undue ADR or the maximum recommended dose is reached.
(2) If the BP is still not controlled, another drug from a different class may be added which is likely to be well tolerated, as the compliance and the long term efficacy of drugs depend upon their long term tolerability. The second drug can be added without achieving maximum recommended dose of the initial drug.
(3) When two agents are used, one of them should be a diuretic, preferably a low dose of a thiazide e.g. hydrochlorthiazide 25 mg or less/day, or its equivalent, in nearly all cases.
(4) Use low dose combination therapy, if indicated, as initial therapy e.g. A thiazide (hydrochlorthiazide) with
(a) long acting CCB (amlodipine) or
(b) an ACEI or
(c) an ARB.</p>
<p>CCB can be combined with ACEI/ARB but never ACEI with ARB.
(5) A two drug combination will control BP in almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> of patients. If this is not achieved, the primary agent should be increased to the full dose e.g. enalapril 20 mg , atenolol 50 mg or diltiazem 360 mg . This may be combined with reduction in salt intake to less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">4 \mathrm{gm} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">/</span></span></span></span></span> day and increased intake of potassium in the form of fresh vegetables and fruits, (the latter not in combination with ACEI or ARB).
(6) In resistant cases, the primary agent other than thiazide should be replaced by a drug from another class. Triple drug therapy with a thiazide + an ACEI/ARB + CCB may also be effective. In still resistant cases, the patient should be investigated in detail for a possible cause of secondary hypertension.
(7) Once the BP is controlled and maintained consistently, an attempt should be made to reduce the dose step-wise and possibly omit one of the drugs, to determine the minimal therapeutic regimen that will maintain the BP less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> or less, without any inconvenient, adverse effects.</p>
<p>Mild hypertension: The basic drug is a thiazide such as hydrochlorothiazide ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) or chlorthalidone ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ) once daily unless a specific contraindication exists. Increasing the dose of hydrochlorothiazide beyond 50 mg OD usually does not produce any further</p>
<p>therapeutic benefit. The antihypertensive effect is usually established within 2 to 3 weeks. Subsequently, smaller doses ( 12.5 mg OD) can be administered for maintenance therapy. If the BP is not adequately controlled by thiazides, the therapy can be intensified with the addition of a CCB or ACEI/ARB.</p>
<p>If the patient is younger than 50 years of age and has evidence of tachycardia and hyperdynamic cardiac action, a beta-blocker may be initial drug of choice, especially if there is no evidence of peripheral vascular disease. Beta-blockers are also preferred in hypertensive patients with IHD. Atenolol 12.5-50 mg per day is usually preferred. In patients with diabetes mellitus, ACEI would be the first drug of choice.</p>
<p>Alpha blockers should not be used as first line therapy.
In patients with repeated BP readings of more than 160/100 mm Hg it is justifiable to start the therapy with two drugs, one of which preferably should be a thiazide diuretic.</p>
<p>Moderate hypertension: In moderate hypertension, thiazide or chlorthalidone with a beta-blocker may not be able to control the BP effectively. In such patients, a long acting CCB or an ACEI/ARB is substituted for (mono therapy) or added to the thiazide.</p>
<p>CCB such as diltiazem or amlodipine are effective anti-hypertensive agents. Diltiazem is contraindicated if congestive heart failure or AV block is present and in patients on digitalis or a beta blocker. Short acting nifedipine formulations are considered not suitable for long term use.</p>
<p>An ACEI such as enalapril may be a good drug to add to thiazide, especially if the patient is also in congestive heart failure. ACEI is the preferred drug in hypertensive patients with diabetic nephropathy for several reasons:</p>
<ul>
<li>It does not alter or may even improve glucose tolerance.</li>
<li>It does not mask the symptoms and signs of, nor interfere with recovery from hypoglycemia.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="ace-inhibitors-protect-the-kidney-in-the-long-term">- ACE inhibitors protect the kidney in the long term.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#ace-inhibitors-protect-the-kidney-in-the-long-term" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Severe and very severe hypertension: These patients usually have damaged target organs such as kidneys and heart. A sudden reduction in BP may produce azotemia or coronary insufficiency. If, however, the diastolic BP is above 120 mm Hg and there is no evidence of target organ damage, vigorous therapy is advocated.</p>
<p>Treatment of severe hypertension may need combination with additional drugs such as an alpha adrenergic blocker (prazosin), a centrally acting drug (alpha methyl dopa) or a direct acting peripheral vasodilator such as hydralazine.</p>
<p>An <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> blocker e.g. prazosin is especially useful in patients having concurrent symptomatic benign prostatic hyperplasia.</p>
<p>Alpha methyldopa may be used along with a thiazide. Initial dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>2</mn><mo>−</mo><mn>4</mn></mrow><annotation encoding="application/x-tex">250 \mathrm{mg} 2-4</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">250</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span></span></span></span></span> times a day and it is increased by 250 mg at intervals of 2 to 7 days to a maintenance level. Doses of methyldopa larger than 1.5 g daily should be avoided as it can cause mental apathy.</p>
<p>Hydralazine is usually started in a small dose, 10 mg bid, which is then gradually increased to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid. The upper limit of 400 mg should not be exceeded for fear of toxicity. Hydralazine is particularly useful in the presence of kidney damage as it dilates the renal vessels. It is contraindicated in patients with arteriosclerotic hypertension, angina, MI or peptic ulcer.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypertension-in-the-elderly">Hypertension in the Elderly<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertension-in-the-elderly" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Both diastolic and isolated systolic high BP are cardiovascular risk factors in the elderly. The beta adrenergic responses of vascular smooth muscle and plasma renin levels decline with age. The most consistent cardiovascular physiologic change in elderly patients is increased peripheral resistance.</p>
<p>Not all hypertensive old people need drug treatment; this is especially so in patients over 60 years of age. Treatment should be considered for those elderly patients whose BP exceeds 150/90 mm Hg. Rapid lowering of BP and postural hypotension can be dangerous. The low dose thiazides/CCB would appear to be relatively safe in these patients. ACEI/ARB are also well tolerated. Doses of diuretic larger than the equivalent of 25 mg of hydrochlorothiazide per day should be avoided and even mild hypokalemia treated.</p>
<p>As per ALLHAT trial in elderly high risk patients over 55 years, chlorthalidone 12.5-25 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">\mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day alone or in combination was found as effective as ACEI or CCB in preventing the CVS events. Chlorthalidone is twice as potent as hydrochlorothiazide and has a longer duration of action. Hence, low dose thiazides or chlorthalidone <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span> atenolol (12.5-25 mg) appears to be suitable first line therapy in the vast majority of elderly hypertensive subjects. Amlodipine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ), a CCB, can be substitued for atenolol.</p>
<p>Complex, multiple-drug regimes are best avoided in the elderly as they may be confusing. Hypertension which persists after cardiac failure is corrected, needs treatment with an antihypertensive drug whereas a patient with an established stroke in old age does not benefit from such therapy. In fact, some patients of the latter group may show an intellectual deterioration on lowering of the BP.</p>
<p>The aim of therapy in the elderly should be to lower the BP as much below 180/100 mm Hg as the patient can tolerate comfortably, preferably to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>150</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">150 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">150/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> or less. No attempt should be made to make the BP 'normal' (&lt;J40mm Hg).</p>
<p>However, in case an elderly attains <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">B</mi><mi mathvariant="normal">P</mi></mrow><mo>&lt;</mo><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{BP}&lt;140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">BP</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> and tolerates drug/s well with no adverse effects on health and quality of life, no adjustment should be made in doses or drugs.</p>
<p>Isolated systolic hypertension (defined as systolic BP over 140 mm Hg and diastolic BP less than 90 mm Hg ) is often resistant to treatment; attempts to treat it aggressively lowers the diastolic BP to such an extent as to compromise blood flow to vital organs such as brain. It may be treated with a low dose thiazide or a beta blocker, (or both), or with low of dose amlodipine alone.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="hypertension-in-pregnancy">Hypertension in Pregnancy<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertension-in-pregnancy" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Hypertension in pregnant women may be diagnosed when the systolic BP is 135 mm Hg or more and the diastolic BP is 85 mm Hg or more. Hypertension during pregnancy may be:</p>
<ul>
<li>Chronic hypertension, either essential or secondary, dating from before the pregnancy.</li>
<li>Transient hypertension developing after midpregnancy; this is usually mild and the BP returns to normal postpartum. Such women are liable to develop hypertension subsequently; or</li>
<li>Pre-eclampsia with moderate to severe hypertension, edema, proteinuria and disturbances of liver function and coagulation. It can lead to eclampsia with generalised convulsions and fetal death.
Chronic hypertension dating from before pregnancy, especially when secondary, long standing and associated with organ damage, predisposes to pre-eclampsia. However, more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>85</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">85 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">85%</span></span></span></span></span> of women with mild pre-existing chronic, essential hypertension have uncomplicated pregnancies. Hypertension during pregnancy needs treatment in order to possibly prevent preeclampsia; however, no treatment guaranteedly prevents pre-eclampsia.</li>
</ul>
<p>Women with secondary hypertension and those with diastolic BP of 95 mm Hg or higher need aggressive treatment. Women with risk factors such as renal disease or end organ damage should be treated even at lower levels of diastolic BP. Methyldopa is effective, and is considered safe for the mother and the baby; it is the preferred drug in pregnant women. The alternative is beta blockers (like atenolol); they are safe in the third trimester of pregnancy but may cause intrauterine growth retardation when prescribed earlier. However, by causing fetal bradycardia, beta blockers mask an important index of fetal distress, viz. fetal bradycardia. In acute episodes of hypertension during pregnancy, nifedipine may be used safely.</p>
<p>Labetalol may be hepatotoxic whereas the use of ACE inhibitors is associated with oligohydramnios and neonatal renal failure. ACE inhibitors and ARBs are absolutely contraindicated during pregnancy. Diuretics should not be used as first-line agents to treat hypertension in pregnancy as they can deplete maternal intravascular volume, and may rarely cause neonatal thrombocytopenia. However, they may be useful in patients with edema. Clonidine and hydralazine are not considered desirable in pregnant women.</p>
<p>Severe hypertension may develop near term or during labour. When such is the case or when preeclampsia is suspected at any time during the pregnancy, the patient should be hospitalised and put to complete bed rest. The urgent need is to lower the diastolic BP to between 90 and 100 mm Hg . For this purpose, IV labetalol or sublingual/oral nifedipine (see later) given every 30 min as needed is the treatment of choice. Magnesium sulfate IV is the drug of choice for prevention and treatment of eclamptic convulsions. However, its anti-hypertensive action is slight and unpredictable. Simultaneous use of magnesium sulfate and nifedipine can cause precipitous fall of BP. Sodium nitroprusside is used only if other agents fail. If the patient's condition deteriorates or if eclampsia supervenes, the pregnancy is terminated regardless of its duration.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="supportive-treatment-of-hypertension">Supportive Treatment of Hypertension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#supportive-treatment-of-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>General treatment: Adequate rest, relaxation and sleep are desirable. Ambitions may have to be curbed or sacrificed for reasons of health. Reassurance and a benzodiazepine could benefit the patient. The patient should be explained in detail what 'moderation in all things' actually means. Yoga, meditation and relaxation exercises are helpful. Very strict restrictions are, however, often unnecessary, as Page has aptly remarked, "I firmly believe that those who follow directions minutely do better than the careless. But there are important areas of living in which we physicians know no more than others. Often when we don't know what to do, we proscribe instead of prescribing - we forbid this or that of the things people often most enjoy. I suppose this characteristic is a hangover from the days when anything that was pleasurable was sinful. Whether we forbid smoking, alcohol and such, may make a good deal of difference as to whether people will think life worth living. I should therefore remind you that smoke and alcohol were the oldest known preservatives and that Winston Churchill was 100 proof of this observation."</p>
<p>Weight reduction by diet control in obese patients is beneficial. Although sodium restriction is known to help the reduction in BP, with the present day diuretic drug treatment rigid restriction of salt intake is rarely necessary.</p>
<p>Prevention of cardiovascular disease: Aspirin in daily dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> can reduce major cardiovascular events in hypertensive patients. Hence, for primary prevention it is recommended in patients aged 50 years or over, only after BP is controlled.</p>
<p>In patients under the age of 70 years, who have total serum cholesterol of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>180</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mi mathvariant="normal">d</mi><mn>1</mn></mrow><annotation encoding="application/x-tex">&gt;180 \mathrm{mg} / \mathrm{d} 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">180</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord mathrm">d</span><span class="mord">1</span></span></span></span></span>, a statin may be used on long term basis (Chapter 40). Use of aspirin and statin should be considered in all high risk patients irrespective of age.</p>
<p>Resistant hypertension may be defined as BP persistently higher than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>140</mn><mi mathvariant="normal">/</mi><mn>90</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">140 / 90 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">140/90</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> in most hypertensive patients, and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>130</mn><mi mathvariant="normal">/</mi><mn>80</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">130 / 80 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">130/80</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> or more in diabetics and subjects with renal disease, despite prescription of three drugs including a diuretic. The common causes of inadequate response to antihypertensive treatment (resistant hypertension) are listed in Table 30.6. The commonest cause is noncompliance, probably present in 50-70% of patients. Apparent resistance is commonly due to faulty BP apparatus and/or faulty technique employed for measurement.</p>
<p>Table 30.6
Common causes of inadequate response to antihypertensive treatment</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-3" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-hypertensive-crises">Treatment of Hypertensive Crises<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-hypertensive-crises" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>High DBP ( 120 mm Hg or higher DBP) may sometimes be found in completely asymptomatic patients. Long term treatment with gradual reduction of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">B P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">BP</span></span></span></span></span> is sufficient in such cases to prevent severe organ damage.</p>
<p>On the other hand, in many situations <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>B</mi><mi>P</mi></mrow><annotation encoding="application/x-tex">B P</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">BP</span></span></span></span></span> must be reduced in several hours or even within one hour to prevent death or severe damage to vital organ functions; they constitute hypertensive crises (Table 30.7). It usually occurs in patients with known hypertension, but may occur in previously normotensive persons. It is characterised by some or all of the following:</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-30-7">Table 30.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-30-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="hypertensive-crises">Hypertensive crises<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#hypertensive-crises" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(A) Hypertensive urgencies: These may be defined as sudden or severe elevation of BP, usually with DBP of 120 mm Hg or higher with an impending complication. Such patients need immediate treatment, preferably in an ICU. The DBP needs to be reduced to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mo>−</mo><mn>110</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">100-110 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">100</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">110</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> within <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>48</mn></mrow><annotation encoding="application/x-tex">24-48</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">48</span></span></span></span></span> hours without the use a loading dose. The BP may then be reduced further, gradually, over the next several days. Urgencies include:</p>
<ul>
<li>Severe epistaxis</li>
<li>Severe perioperative hypertension</li>
<li>Unstable angina pectoris</li>
<li>Diabetic retinopathy</li>
<li>Pre-eclampsia</li>
<li>Tyramine ingestion during MAOI therapy</li>
<li>Amphetamine or cocaine intoxication</li>
<li>Hypertension with papilledema
(B) Hypertensive emergencies: These may be defined as severe elevation of BP to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>210</mn><mi mathvariant="normal">/</mi><mn>120</mn><mo>−</mo><mn>130</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">210 / 120-130 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">210/120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">130</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span>, with evidence of target organ damage or dysfunction. Such patients also require admission into an ICU and rapid, but not too rapid, lowering of BP to 150-160/100-110 within thour; the BP should be maintained at that level for a few days, before lowering it, slowly, still further. Examples of emergencies are:</li>
<li>Hypertensive encephalopathy</li>
<li>Intracranial hemorrhage</li>
<li>Acute myocardial infarction</li>
<li>Acute LVF with pulmonary edema</li>
<li>Eclampsia</li>
</ul>
<p>Most bypertensive emergencies are characterised by vasoconstriction and normal or reduced plasma volume. Therefore, drugs which do not cause reduction in renal blood flow (CCBs, fenoldopam and sodium nitroprusside) are preferred.</p>
<ul>
<li>Sudden or sustained rise of DBP to 120 mm Hg or higher and/or SBP <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>180</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">&gt;180 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">180</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span>.</li>
<li>Papilledema (not always present)</li>
<li>Decrease in renal function</li>
<li>Epistaxis</li>
<li>Neurological dysfunction (encephalopathy, intracranial haemorrhage); and</li>
<li>Acute LVF, Unstable angina or MI.</li>
</ul>
<p>The severity of a hypertensive crisis depends not only upon the absolute BP but also on the rapidity of its rise to the present level.</p>
<p>Hypertensive crises should be treated in a hospital ICU with facilities for invasive BP monitoring. In its absence, IV antihypertensives should be avoided. Drugs which reduce the perfusion of vital organs minimally are preferred. Patients should be treated in a strictly supine position to avoid orthostatic complications. If renal function is greatly impaired, even a small reduction in GFR may worsen it.</p>
<p>Drastic lowering of BP in a few minutes is hazardous. Such an immediate fall of BP to below the autoregulatory range of cerebral blood flow (which in hypertensives can be as high as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>120</mn><mo>−</mo><mn>160</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">120-160 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">120</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">160</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> systolic) can cause cerebral ischaemia and severe brain damage and may precipitate MI, blindness and stroke. The initial reduction in DBP should be about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span>; further reduction of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> every two to four hours till the diastolic pressure</p>
<p>reaches <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">90-100 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> is desirable. Drugs with long plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> may cause extended hypotension with its attendant complications. Close monitoring by frequent BP measurements is, therefore, mandatory.</p>
<p>The drugs used to reduce BP in hypertension crisis are given in Table 30.8:
Table 30.8
Some parenteral/oral drugs in hypertensive emergencies</p>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Dose</th><th style="text-align: center;">Onset</th><th style="text-align: center;">Duration</th><th style="text-align: center;">Remarks</th></tr></thead><tbody><tr><td style="text-align: center;">Arteriolar and venous dilator:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Sodium nitroprusside</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.25</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.25-10 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>, IV infusion</td><td style="text-align: center;">Immediate</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;">Thiocyanate toxicity</td></tr><tr><td style="text-align: center;">Nitroglycerine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow></mrow><annotation encoding="application/x-tex">5-100 \mathrm{mcg} / \mathrm{min}, \mathrm{IV}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span></span></span></span></span> infusion</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>5</mn><mo>−</mo><mn>10</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 5-10 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Preferred in patients with IHD</td></tr><tr><td style="text-align: center;">Arteriolar dilator:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Hydralazine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV bolus every 30 min or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IM</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>10</mn><mo>−</mo><mn>20</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mi>min</mi><mo>⁡</mo></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 10-20 \\ \min \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mop">min</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>4</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">2-4 \mathrm{hrs}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">hrs</span></span></span></span></span></span></td><td style="text-align: center;">May ppt. angina, MI, Used in pregnancy</td></tr><tr><td style="text-align: center;">D, receptor agonist:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Fenoldopam</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.1</mn><mo>−</mo><mn>0.6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.1-0.6 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.6</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> IV infusion</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>10</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 10-30 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">Maintains renal perfusion</td></tr><tr><td style="text-align: center;">Alpha and beta adrenergic blocker:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Labetalol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>80</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-80 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">80</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, IV bolus every 10 min to max. total dose of 300 mg or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mrow><mi mathvariant="normal">I</mi><mi mathvariant="normal">V</mi></mrow></mrow><annotation encoding="application/x-tex">2 \mathrm{mg} / \mathrm{min}, \mathrm{IV}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">IV</span></span></span></span></span></span> infusion</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">5-10 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;">Avoid in pts with cardiogenic shock or marked bradycardia</td></tr><tr><td style="text-align: center;">Nonselective alpha blocker:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Phentolamine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">5-15 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">2</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="right left" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mn>3</mn><mo>−</mo><mn>10</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow></mrow></mstyle></mtd><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mrow></mrow><mtext>&nbsp;min&nbsp;</mtext></mrow></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{aligned} &amp; 3-10 \\ &amp; \text { min } \end{aligned}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-r"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.75em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span><span style="top: -2.25em;"><span class="pstrut" style="height: 2.84em;"></span><span class="mord"></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span><span class="col-align-l"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">10</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord"></span><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">For pheochromocytoma and MAOI interactions</td></tr><tr><td style="text-align: center;">Beta adrenergic blocker:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Esmolol</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> for 1 min ; then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>300</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-300 \mathrm{mcg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">300</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span></span></span></span></span> for 1 min ; then <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>300</mn></mrow><annotation encoding="application/x-tex">50-300</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">300</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">c</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mcg} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mcg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">4-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">3-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>10</mn><mo>−</mo><mn>20</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mtext>&nbsp;min&nbsp;</mtext></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 10-20 \\ \text { min } \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">20</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord text"><span class="mord">&nbsp;min&nbsp;</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">For post-operative hypertension</td></tr><tr><td style="text-align: center;">CCB:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Nifedipine</td><td style="text-align: center;">SL 10 mg , then 10 mg PO 6 hry.</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn></mrow><annotation encoding="application/x-tex">2-3</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">3</span></span></span></span></span> hrs</td><td style="text-align: center;">May cause fluctuation in BP</td></tr><tr><td style="text-align: center;">Nicardipine</td><td style="text-align: center;">5 mg IV bolus, repeated every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>15</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">10-15 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">15</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span>, max <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{mg} / \mathrm{hr}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">hr</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>5</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">1-5 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6679em;"></span><span class="mord">5</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hrs</td><td style="text-align: center;">Can cause reflex tachycardia</td></tr><tr><td style="text-align: center;">ACE blockers:</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr><tr><td style="text-align: center;">Enalaprilat</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1.25</mn><mo>−</mo><mn>5</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1.25-5 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">5</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> IV bolus 6 hrly</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mtable rowspacing="0.25em" columnalign="center" columnspacing="0em"><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mrow><mn>15</mn><mo>−</mo><mn>30</mn></mrow></mstyle></mtd></mtr><mtr><mtd><mstyle scriptlevel="0" displaystyle="true"><mi>min</mi><mo>⁡</mo></mstyle></mtd></mtr></mtable><annotation encoding="application/x-tex">\begin{gathered} 15-30 \\ \min \end{gathered}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 3em; vertical-align: -1.25em;"></span><span class="mord"><span class="mtable"><span class="col-align-c"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 1.75em;"><span style="top: -3.91em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mord">15</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mord">30</span></span></span><span style="top: -2.41em;"><span class="pstrut" style="height: 3em;"></span><span class="mord"><span class="mop">min</span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 1.25em;"><span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">6 hrs</td><td style="text-align: center;"></td></tr></tbody></table>
<p>Sodium nitroprusside: It has almost instantaneous onset of action and is most consistently effective. Since it can cause a precipitous fall in BP, the infusion should be titrated very carefully. It is the drug of choice in the presence of MI or pulmonary edema.</p>
<p>Nitroglycerine (NTG): It reduces BP in a few minutes. It is the preferred agent in advanced renal or hepatic insufficiency where nitroprusside is contraindicated. Since it reduces the preload more than the afterload, it should be avoided in patients with inferior wall MI with RV involvement. It can also be administered sublingually.</p>
<p>Fenoldopam: This drug is a peripheral, dopamine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">D</mi><mn>1</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{D}_{1}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">D</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> receptor agonist with a short action. It causes peripheral and renal vasodilatation, and natriuresis. It is as effective as sodium nitroprusside. It can cause headache, flushing and raised intra-ocular pressure.</p>
<p>Labetalol, IV, reduces BP in a dose-dependent manner. It affects the heart rate and cardiac output minimally. Since its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>8</mn></mrow><annotation encoding="application/x-tex">5-8</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">8</span></span></span></span></span> hours, the IV infusion should be discontinued before starting oral therapy with 200 mg ; oral labetalol is continued as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>200</mn><mo>−</mo><mn>400</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">200-400 \mathrm{mg} 6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">200</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">400</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span></p>
<p>hourly. Labetalol IV (infusion or bolus doses) is preferred in hypertensive crisis in pregnancy.</p>
<p>Esmolol: This beta-1 selective blocker gets rapidly metabolised by blood esterases and has a very short <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 9 minutes. Given by IV infusion, the effects begin almost immediately and last for 30 minutes. The therapy may be stopped abruptly, if necessary.</p>
<p>Nifedipine: Sublingual nifedipine is effective in lowering the BP rapidly. Given in the dose of 10 mg , it acts within 2-3 minutes and the action lasts for 2-3 hours. In less urgent cases, it is given orally in the dose of 10 mg 6 hourly. If a sublingual preparation is not available, the patient can chew a 10 mg tablet for immediate local absorption and should swallow a second 10 mg tablet at the same time. Nifedipine is the drug least liable to aggravate regional blood flow imbalances and to cause ischemia of the brain, eyes or kidney; but it can cause undesirable fluctuations in BP. Although not an ideal drug, given under supervision, it is the preferred drug when intensive care facilities are not available. Nifedipine should be avoided in patients with CAD or with ECG evidence of LVH.</p>
<p>Enalaprilat: This active metabolite of enalapril has a rapid onset and long duration of action. Peak effect may not be seen for 4 hours. It is contraindicated in renal artery stenosis.</p>
<p>Diuretics should be used only to treat salt retention or acute LVF with pulmonary edema.
Although parenteral drugs are administered with precaution and care, an occasional patient may develop excessive hypotension. Hence, noradrenaline should be kept ready to treat drug induced hypotension. Similarly, if diuretics are used, attention must be given for maintaining adequate hydration to avoid oligemia.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-induced-hypertension">Drug Induced Hypertension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-induced-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Some drugs used in therapeutics may cause a rise in BP as their adverse effect (Table 30.9).</p>
<p>Table 30.9
Some drugs causing hypertension</p>
<ul>
<li>Hormones: Glucocorticoids, fludrocortisone, testosterone, ethinyl estradiol.</li>
<li>Vasoconstrictors: Adrenergic agents, ergot alkaloids, anorexiants, decongestants.</li>
<li>MAO inhibitors.</li>
<li>Salt retaining drugs: NSAID, liquorice.</li>
<li>Miscellaneous: Bromocriptine, Alcohol, Caffeine in excess, Epoeitin alpha, Cyclosporine.</li>
</ul>
<p>Further, some dietary supplements such as bitter orange have been reported to increase BP. It is imperative, therefore, to enquire whether the patient is taking any such drug or herbal remedies while evaluating a hypertensive subject.</p>
<p>Many proprietary 'cold cures' and 'cough mixtures' contain adrenergic drugs e.g. ephedrine, phenylephrine, phenteramine or phenylpropanolamine. Hence, it is best to warn the patients on antihypertensives to avoid such preparations as they may cause a sudden rise of BP. Their enquiry should form a part of history taking.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pulmonary-hypertension">Pulmonary Hypertension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pulmonary-hypertension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Pulmonary hypertension (PH) is an abnormal increase of BP in the lung vasculature arising from diverse etiology- cardiac, pulmonary or intrinsic vascular disease. It is associated with shortness of breath, dizziness, edema and markedly decreased exercise tolerance. It results in heart failure.</p>
<p>Increase in PH with normal pulmonary capillary wedge pressure is termed as pulmonary arterial hypertension (PAH), which is a progressive disease. PAH is associated with abnormalities of pulmonary vascular endothelium and smooth muscle cells, resulting in smooth muscle proliferation and remodeling leading to obliteration of vascular lumen and increase pulmonary vascular resistance. This results in right ventricular failure and death. PAH is also common in advanced cases of idiopathic pulmonary fibrosis. Pulmonary perfusion is regulated by local production of NO and prostacycline, which are vasodilators and endothelin, a vasoconstrictor in the lung and their impaired release is reported in PAH. Though, there is no cure, drugs are now available which can prolong life and improve its quality.</p>
<p>ENDOTHELIN (ET): This 21 residue polypeptide, originally isolated from cultured vascular endothelium, is present in several tissues (brain, kidney, intestine, adrenal glands). It is a potent endogenous vasoconstrictor that also has proliferative, pro-fibrotic and pro-inflammatory effects. It also stimulates secretion of many hormones.</p>
<p>Three types of ETs have been identified so far: ET-1, ET-2 and ET-3. Of these ET-1 is the most potent, long acting vasoconstrictor which is continuously formed in the cells of resistance vessels and contributes to peripheral vascular resistance. It controls the uteroplacental blood flow and is involved in the development of cardiorespiratory system. Patients with PAH have raised plasma and lung levels of ET-1. It is also present in thyroid follicles and is involved in thyroglobulin synthesis.</p>
<p>Role of ET-2 and ET-3 remains to be elucidated.
There are two types of ET receptors: ETA and ETB. ETA is expressed on vascular smooth muscles, heart, lung and kidney. ET-1 preferentially activates ETA which, results in vasoconstriction, bronchoconstriction, aldosterone release and smooth muscle proliferation.</p>
<p>ETB is mainly expressed in brain, but moderate expression is observed in vessels, heart, lungs, kidney and adrenals. In contrast to ETA, ETB is highly expressed on the endothelial cells (ETB1); its activation causes vasodilatation by stimulating NO and PGI2 synthesis. ETB found on smooth muscles (ETB2) is responsible for vasoconstrictor effects.</p>
<p>Endothelin receptor antagonists can be classified as: I. Nonselective - Bosentan and Macitentan II. Selective - Ambrisentan.</p>
<p>BOSENTAN: This substituted pyrimidine derivative acts as a nonselective competitive antagonist of ET1. It binds to both ETA receptors in vascular smooth muscles and ETB receptors in the brain, smooth muscles, and endothelium. In patients with PAH, it reduces the pulmonary vascular resistance and lowers the pulmonary arterial pressure.</p>
<p>The drug is well absorbed orally. It is highly ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>98</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">98 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">98%</span></span></span></span></span> ) protein bound and has a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 3 hours. It is metabolised in the liver, and the metabolites excreted in the bile. Inhibition of hepatic microsomal enzymes by ketoconazole and fl uvastatin can increase its plasma levels. Bosentan can cause decrease in the serum levels of warfarin and oral contraceptives.</p>
<p>Cyclosporin-A increases its plasma concentration.
Adverse reactions: These include nausea, anemia and liver damage. It is teratogenic and carcinogenic in mice and rats, and is contraindicated during pregnancy.</p>
<p>Therapeutic uses: It has been used to treat severe PAH, in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>62.5</mn><mo>−</mo><mn>125</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">62.5-125 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">62.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">125</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> bid.
Macitentan, a derivative of bosentan has similar properties but risk of liver toxicity may be lesser.</p>
<p>Ambrisentan, is a selective, newer analogue of bosentan and used for similar purpose.
Other drugs used in PAH are:
(i) Prostacyclin analogues e.g. epoprostenol, iloprost, treprostinil by IV infusion (Chapter 25);
(ii) Nitric oxide inhalation;
(iii) PDE5 inhibitors (which) such as sildenafil or tadalafil orally (Chapter 69), which maintain cGMP and thereby NO levels;
(iv) Furosemide; and
(v) Warfarin to counter the tendency to thrombosis (Chapter 33).</p>
<p>Pirfenidone, a pyridine immunosuppressant, has been recently introduced as antifibrotic drug for therapy of advanced pulmonary fibrosis. It reduces production of fibrosis associated proteins and cytokines response to growth factors such as TGF-beta and platelet-derived growth factor (PDGF). It has shown some marginal benefits. ADR include mild GI symptoms, dizziness, photosensitivity and rash.</p>
<p>Riociguat is recently approved as an oral soluble guanylate cyclase (sGC) stimulator for PAH. sGC binds to NO, forming an enzyme that promotes the synthesis of cGMP. In PAH, there is an impaired synthesis of NO and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat acts directly by stimulating sGC and also indirectly by increasing sensitivity of sGC to NO.</p>
<p>The adverse effects include headache, gastritis, dizziness, hypotension, diarrhea, vomiting anemia and rarely fatal hemorrhage. Riociguat is contraindicated for use with nitrates and PDE inhibitors.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="orthostatic-hypotension">Orthostatic hypotension<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#orthostatic-hypotension" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Orthostatic hypotension is defined as a reduction in systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of standing from a supine or sitting position. It is often most troublesome on rising in the morning and after meals, especially breakfast. Severe orthostatic hypotension can be disabling and its management is unsatisfactory.</p>
<p>The first step is to establish that the condition is persistent and find out whether there is a remediable cause. Drug therapy (diuretics, nitrates, phenothiazines, antiparkinsonian drugs, tricyclic antidepressants and antihypertensives) is by far the commonest correctable cause. Often, chronic orthostatic hypotension is due to autonomic failure secondary to diseases such as diabetes mellitus. It is important to treat the symptomatic orthostatic hypotension and not just the blood pressure reading alone. Patients with starting systolic BP as low as 70 mm Hg may be completely symptom-free. It should be remembered that treatment of orthostatic hypotension may lead to supine hypertension.</p>
<p>In mild cases, non-pharmacological measures should be tried: advice to rise slowly, high salt diet, sleeping with the head of the bed elevated 10 cm and use of 'support tights'. Drug therapy is used for those who remain disabled or have severe faintness, syncopeal episodes or inability to stand. The patient is advised to drink two cups of coffee ( 250 mg of caffeine) before breakfast. Midodrine, an <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>α</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\alpha_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5806em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0037em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> agonist, in a dose of 2.5 mg tid may be helpful. The dose may be increased gradually to the maximum of 10 mg tid if required. The last dose of the day is to be given at least 4 hr before bedtime to reduce potential for supine hypertension. The alternatives are pseudoephedrine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">30-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">30</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid) and phenylephrine ( 10 mg every 4 hourly).</p>
<p>In severe cases, fludrocortisone is the drug of choice despite its shortcomings (Chapter 66). The main problem with this drug is the occurrence of supine hypertension.</p>
<p>31</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-heart-failure">Pharmacotherapy of Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Heart failure is a common and serious condition with high morbidity and mortality. Since the introduction of digitalis (in 1776) the pharmacotherapy of heart failure has made spectacular advances, resulting in better prognosis.</p>
<p>The normal heart is capable of increasing the cardiac output (CO) upto 3-4 times the resting value during exercise and in other states of increased need. Heart failure may be defined as the inability of the heart to maintain the cardiac output adequate to meet the metabolic demands of the body at all times. It manifests as :
(1) Acute heart failure (as after MI); or
(2) Chronic heart failure.</p>
<p>For rational therapy of heart failure, it is necessary to understand the physiology of cardiac contraction and the pathophysiology of failure of the heart as a pump.</p>
<p>Physiology of cardiac contraction: The structural and functional unit of the cardiac muscle (myocyte) is a sarcomere. It is made up of two interdigitating myofilaments: the thicker filament made of the protein myosin and the thinner one made of the protein actin. Myosin has intrinsic enzymatic (ATPase) activity sites. Actin possesses the ability to combine reversibly with myosin in the presence of ATPase and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. Calcium ions activate myosin ATPase, which in turn breaks down ATP, the energy source for excitationcontraction coupling in cardiac muscle.</p>
<p>The principal mediator for the inotropic state of the heart is increased intracytoplasmic <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>. Cardiac contraction and relaxation result from the changing concentration of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>in the myocyte cytosol. During depolarisation, calcium ions enter the myocyte via the calcium channels and trigger the release of more <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>from the sarcoplasmic reticulum, and thereby initiate the cardiac contraction-relaxation cycle (Chapter 28). According to Starling's law, "the force of contraction of the cardiac muscle is a function of the enddiastolic length of the muscle fibre", which in turn closely relates to the ventricular enddiastolic volume. Upto a limit, increase in the muscle fibre length increases the force of contraction, resulting in increased cardiac output.</p>
<p>Among the neurohumoral influences that affect the cardiac contractility, the most important is the adrenergic system which acts via the neurotransmitter noradrenaline that stimulates the cardiac beta <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors.</p>
<p>Cardiac output depends upon rate of cardiac contraction (heart rate) and the stroke volume ejected by the ventricle with each beat. Thus,
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">O</mi></mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">\mathrm{CO}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord mathrm">CO</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> heart rate x stroke volume (SV) Stroke volume is regulated by:
(1) Preload, the length of the ventricular muscle fibre at the onset of contraction, which reflects the ventricular and diastolic pressure. It depends upon the amount of blood received into the left ventricle from the left atrium at the end of ventricular diastole.
(2) Myocardial contractility, the ability of the heart to contract in response to given preload and after load; and
(3) Afterload, defined as the tension or stress developed in the ventricular wall during ejection of blood into the arteriolar system. It is dependent on aortic pressure as well as the volume of the ventricular cavity and the thickness of the ventricular wall. The aortic</p>
<p>pressure in turn is regulated by the peripheral resistance and the condition of the arterial wall.</p>
<p>When myocardial contractility is impaired and the ventricle dilates, the cardiac output diminishes. The resultant neural (ANS) and humoral stimuli following decrease in cardiac output causes peripheral vasoconstriction and increase in the afterload. This reduces the cardiac output further while increasing the myocardiac oxygen requirement, thus establishing a vicious cycle.</p>
<p>Among the techniques used to assess the global cardiac function, the most clinically convenient is the evaluation of left ventricular ejection fraction (LVEF), the ratio of the stroke volume to the end-diastolic volume of the left ventricle (normal value about 65%).</p>
<p>Pathophysiology of heart failure (HF): A failing heart is characterised by inability to provide a cardiac output sufficient for the body's metabolic needs, initially during exercise, but later even at rest. Basically, heart failure is failure of the heart as a pump, the left ventricle more often than and earlier than the right ventricle. This can arise in several ways:
(a) Pressure overload as in hypertension and stenosis of cardiac valves (mitral or aortic).
(b) Volume overload as in congenital heart disease and in regurgitant lesions of the mitral and aortic valves.
(c) Loss of cardiac muscle due to infarction or chronic ischemic damage.
(d) Impaired cardiac contractility due to causes such as myocarditis; and
(e) Restriction of cardiac filling as in constrictive pericarditis (diastolic heart failure).</p>
<p>The syndrome of heart failure is worsened by
(a) factors which increase the need for a higher cardiac output such as, e.g., fever, anemia or thyrotoxicosis; and
(b) hypoxia, acidosis and cardiac arrhythmias which impair contractility.</p>
<p>The diminished cardiac output causes fatigue, diminution in exercise tolerance and a variety of compensatory circulatory changes. LVEF may be as low as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> in patients with severe cardiac failure. The increased venous pressure behind the failing ventricle causes:
(a) Pulmonary venous congestion, pulmonary edema and dyspnoea of left ventricular failure, and
(b) Systemic venous congestion, liver enlargement and peripheral edema of right ventricular failure.</p>
<p>The important event in heart failure is the loss of functioning cardiac tissue. To compensate for this loss, both hemodynamic and neurohumoral adaptive mechanisms are activated to improve the force of ventricular contraction (Fig 31.1). The compensatory mechanisms involved are:</p>
<p><img src="assets/images/image-20251214-6f621351.jpeg" alt="img-27.jpeg"></p>
<ul>
<li>Increase in diastolic tension (preload) which in early stages enhances the force of contraction according to Frank-Starling principle.</li>
<li>Activation of adrenergic nervous system, leading to increase in the circulating NA; chronic stimulation of the adrenergic system, however, causes increased afterload.</li>
<li>Activation of renin-angiotensin-aldosterone system;</li>
<li>Atrial stretch, stimulating secretion of Atrial Natriuretic Peptide - ANP (Chapter 37);</li>
<li>Release of endothelin</li>
</ul>
<p>In response to these mechanisms, ventricular remodeling occurs: the ventricle hypertrophies, and in severe cases there is loss of myocytes with interstitial fibrosis. The atrial stretch stimulates the baroreceptors to produce bradycardia which counteracts the effects of sympathetic outflow. The atrial distention stimulates the release of ANP, which causes vasodilatation, and natriuresis, thus opposing the actions of angiotensin II and aldosterone (Chapter 37). Thus, the cardiac output is maintained and the cardiac tissue is protected to a certain extent from the adverse effects of ventricular dilatation and sympathetic activation. However, prolonged ventricular distension leads to progressive dilatation of the ventricles and to a gradual loss of inhibitory control over the adrenergic stimulation leading to decompensated heart failure. The failing heart is not able to maintain the cardiac output. Further, activation of adrenergic system causes peripheral vasoconstriction, which increases the load on the ventricles (afterload).</p>
<p>When the cardiac output falls, systemic perfusion pressure is maintained by two mechanisms:
(a) Peripheral vasoconstriction caused by activation of adrenergic system early in the disease, and
(b) Sodium retention caused by activation of renin-angiotensin-aldosterone system which causes increase in aldosterone production. In the terminal phases of cardiac disease, vasopressin is also released (decompensated heart failure). Thus, the heart failure is not only a disease of the heart (a systolic dysfunction of the left ventricle), but is also a disorder of the circulation, involving both hemodynamic and neurohumoral factors.</p>
<p>Heart failure (HF) is a complex clinical syndrome, which arises from abnormalities of cardiac structure, function or both that impair the ability of the heart to fill or eject blood. The major symptoms of HF are dyspnoea, decreased exercise tolerance, fatigue and fluid retention, which may result in pulmonary and/or systemic congestion. Some patients, however, do not show signs and symptoms of overload (congestion). Hence the term congestive heart failure is now replaced by the term heart failure.</p>
<p>Patients with HF show wide variation in LV functional abnormalities of both systolic and diastolic functions. Clinical LV dysfunction can occur with normal heart size and preserved EF or dilated heart and/or markedly reduced ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ) EF. Hence, HF can be clinically classified as
(1) HF with preserved <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">P</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{EF}\left(\mathrm{HF}_{\mathrm{P}} \mathrm{EF}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">P</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> or
(2) HF with reduced <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">R</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mo fence="true">)</mo></mrow></mrow><annotation encoding="application/x-tex">\mathrm{EF}\left(\mathrm{HF}_{\mathrm{R}} \mathrm{EF}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">R</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span>. Patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">R</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{HF}_{\mathrm{R}} \mathrm{EF}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">R</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span></span></span></span></span> have evidence of abnormal LV systolic dysfunction and marked reduction in LVEF ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> ).</p>
<p>Patients with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">F</mi></mrow><mi mathvariant="normal">P</mi></msub><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{HF}_{\mathrm{P}} \mathrm{EF}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">HF</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3283em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathrm mtight">P</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm">EF</span></span></span></span></span></span>, on the other hand, have evidence of abnormal LV diastolic dysfunction and near normal EF ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&gt;50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> ). Commonly it is caused by disorders that chronically increase the cardiac workload e.g, previous history of MI, high blood pressure. The myocardial responses to such stresses involve remodeling of cardio-myocytes and the non-myocytes. Such responses are initially adaptive and beneficial but later progress to contractile dysfunction, ventricular dilatation and arrhythmias.</p>
<p>Diastolic cardiac dysfunction involves an abnormality of diastolic distensibility, filling or relaxation of the left ventricle. The patient may be symptomatic or asymptomatic. Doppler echocardiography plays a critical diagnostic role in such patients, partly because the physical examination, chest X-ray and ECG do not provide definite information. It is more prevalent in elderly patients and may be associated with hypertension, IHD and diabetes mellitus. The management primarily comprises the treatment of the specific underlying cause. Digitalis, diuretics and vasodilators are less effective than in systolic heart failure and must be used with great caution. Unlike systolic heart failure, verapamil and diltiazem may improve diastolic function.</p>
<p>Three important pathophysiological factors that contribute to the ventricular wall stress are:</p>
<ul>
<li>Reduced cardiac contractility.</li>
<li>Peripheral vasoconstriction due to activation of sympathetic and renin-angiotensin aldosterone systems; and</li>
<li>Sodium and water retention.</li>
</ul>
<p>In acute heart failure reduction of load (elevated LV filling pressure) and maintenance of cardiac output as well as optimal blood pressure are the immediate aims of therapy.</p>
<p>In chronic heart failure, the long term aims include:</p>
<ul>
<li>Relief of symptoms and signs;</li>
<li>Stabilisation of hemodynamics;</li>
<li>Prevention of disease progress;</li>
<li>Treatment of risk factors; and</li>
<li>Improvement in quality of life and reduction in mortality</li>
</ul>
<p>The principles of rational therapy of chronic heart failure are outlined in Table 31.1. Risk factors should be treated in all patients. Restriction of sodium intake is beneficial to all.</p>
<p>Table 31.1
Rational therapy of chronic heart failure</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>Reduction in ventricular wall stress by
</span>    - Bed rest
    - Vasodilators
    Reduction in neurohumoral activation by
    - ACE inhibitors
    - Beta blockers
    Countering sodium and fluid retention by
    - Restriction of sodiumintake (&lt;2 g/day).
    - Restriction of fluid to &lt; 1.5 L/day.
    - Promotion of sodium excretion by using a diuretic, furosemide 20-40 mg.
    Treatment of the cause e.g. hypertension, arrhythmias, anemia, thyrotoxicosis.
    Use of aldosterone antagonist: Spironolactone
    Use of an inotropic drug, e.g., Digoxin.
    Use of low dose aspirin, if evidence of ischaemic heart disease</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="Reduction in ventricular wall stress by
    - Bed rest
    - Vasodilators
    Reduction in neurohumoral activation by
    - ACE inhibitors
    - Beta blockers
    Countering sodium and fluid retention by
    - Restriction of sodiumintake (&lt;2 g/day).
    - Restriction of fluid to &lt; 1.5 L/day.
    - Promotion of sodium excretion by using a diuretic, furosemide 20-40 mg.
    Treatment of the cause e.g. hypertension, arrhythmias, anemia, thyrotoxicosis.
    Use of aldosterone antagonist: Spironolactone
    Use of an inotropic drug, e.g., Digoxin.
    Use of low dose aspirin, if evidence of ischaemic heart disease" style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="acei-and-vasodilators-in-heart-failure">ACEI and Vasodilators in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#acei-and-vasodilators-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Activation of the neurohumoral mechanisms in CHF increases the systemic vascular resistance and venous return. Thus, the body tries to maintain an adequate pressure-head to perfuse the vital organs such as brain and kidneys. However, such vasoconstriction of arterioles causes increased impedence (afterload) to left ventricular ejection and further increases the cardiac work load. Increase in venous return increases the end diastolic ventricular filling pressure (preload), which also increases the cardiac work. A reduction in either the afterload or in the preload increases the cardiac output. Hence, vasodilators, particularly ACEI, are now considered the cornerstone of the therapy of patients with heart failure.</p>
<p>Vasodilator drugs are of three types (Table 31.2):</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-2">Table 31.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="beneficial-effects-of-vasodilators-in-cardiac-failure">Beneficial effects of vasodilators in cardiac failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beneficial-effects-of-vasodilators-in-cardiac-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: left;">Vasodilator type</th><th style="text-align: left;">Preload</th><th style="text-align: left;">Afterload</th><th style="text-align: left;">VEDV</th><th style="text-align: left;">Stroke volume</th></tr></thead><tbody><tr><td style="text-align: left;">Arterial (hydralazine)</td><td style="text-align: left;">No change</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">No change</td><td style="text-align: left;">Increased</td></tr><tr><td style="text-align: left;">Venous (nitrates)</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">No change</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">No change</td></tr><tr><td style="text-align: left;">Combined (ACEI)</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">Reduced</td><td style="text-align: left;">Increased</td></tr></tbody></table>
<p>VEDV = Ventricular end diastolic volume.</p>
<ul>
<li>Arterial e.g. Hydralazine. It reduces the afterload on the heart.</li>
<li>Venous e.g. Nitrates. They reduce the preload on the heart.</li>
<li>Combined, balanced arteriolar plus venous e.g. Prazosin; ACEI, ARB, Sodium nitroprusside. They reduce both preload and afterload.
The vasodilator drugs currently used in chronic CHF are shown in Table 31.3.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-3">Table 31.3<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-3" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="vasodilators-used-in-chronic-congestive-heart-failure">Vasodilators used in chronic congestive heart failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#vasodilators-used-in-chronic-congestive-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Captopril ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6.25</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6.25-50 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6.25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> tid), enalapril ( 10 mg bid), lisinopril 5 mg od.</li>
<li>Isosorbide dinitrate ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">20-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">20</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> orally or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">2.5-10 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> sublingually, 6 hourly) or nitroglycerine ointment.</li>
<li>Hydralazine ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mn>6</mn></mrow><annotation encoding="application/x-tex">50-75 \mathrm{mg} 6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">6</span></span></span></span></span> hourly).</li>
<li>Prazosin ( 5 mg 8 hourly).</li>
</ul>
<p>Many clinicians presently treat heart failure with sinus rhythm, at least initially, with bed rest and ACEI (Chapter 30; Table 31.4)</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-4">Table 31.4<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-4" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Use of ACEI in heart failure</p>
<ul>
<li>Start with small doses (captopril 6.25 mg , enalapril 2.5 mg , lisinopril 2.5 mg or ramipril 2.5 mg a day)</li>
<li>Maximum doses are captopril 50 mg tid, enalapril 10 mg bid, lisinopril 30 mg od, or ramipril 5 mg bid.</li>
<li>Stop potassium supplements and potassium sparing diuretics before starting ACEI.</li>
<li>Stop other diuretics 24 hours before the first dose of ACEI. They may be restarted the next day.</li>
<li>Patient should be sitting or lying down for 2-4 hours, depending on the drug used, after the first dose of ACEI.</li>
</ul>
<p>ACEI has several advantages:</p>
<ul>
<li>They are beneficial clinically and hemodynamically even in resistant heart failure.</li>
<li>They control hypertension which is an important risk factor.</li>
<li>They prolong survival in CHE</li>
<li>Tolerance is rare.</li>
<li>By blocking the local generation of angiotensin II, they reduce its direct toxic effects on the myocardium (cardiac remodeling) and reduce the risk of coronary ischemic events.</li>
<li>They reduce the mortality rate and the risk of hemodynamic and clinical progression in asymptomatic patient with left ventricular dysfunction following acute MI.
All patients with asymptomatic or symptomatic LV dysfunction or LV enlargement should be treated with ACEI as a first line therapy. Patients who do not tolerate ACEI or remain symptomatic may be treated with ARB or combination of hydralazine + isosorbide dinitrate as these drugs improve exercise tolerance and increase life expectancy. Nitrates decrease the preload by venodilatation without causing decrease in blood volume and are helpful if ischaemia is also present.</li>
</ul>
<p>In the management of acute congestive heart failure due to MI, the therapy of choice is an infusion of sodium nitroprusside or nitroglycerine (Chapter 30). The use of such infusions requires the facilities of an ICCU. In their absence, NTG ointment may be used.</p>
<p>The other indications for vasodilator therapy are:</p>
<ul>
<li>Hypertensive crisis especially malignant hypertension and dissecting aortic aneurysm; and</li>
<li>Acute or chronic mitral or aortic regurgitation, and ventricular septal defect, in patients awaiting surgery.
Vasopeptidase inhibitors: These drugs inhibit both ACE and neutral endopeptidase (NEP). NEP is found mainly in the renal tubules but is also present in other tissues such as lungs, intestines, brain, heart and blood vessels. It catalyses the breakdown of atrial natriuretic peptide (ANP) and some other peptide hormones including bradykinin. Its inhibition by vasopeptidase inhibitors prevents the breakdown of ANP and causes vasodilation and sodium excretion (Fig 31.2). They also inhibit the production of angiotensin II. Thus, they may be useful in the treatment of CHF and hypertension.
<img src="assets/images/image-20251214-68373eee.jpeg" alt="img-28.jpeg"></li>
</ul>
<p>FIG. 31.2 Mechanism of action of vasopeptidase inhibitors ACE = Angiotensin converting enzyme; NEP = Neutral endopeptidase</p>
<p>OMAPATRILAT: This vasopeptidase inhibitor drug, given orally, is rapidly absorbed with plasma half life of 14-19 hrs. It causes both arterial and venous dilatation and natriuresis. It inhibits the serum ACE activity and increases the renal excretion of natriuretic peptide in a dose dependant manner. Toxicity reported includes dizziness, cough and angioedema.</p>
<p>NESIRITIDE: This, recombinant human B type natriuretic peptide (BNP), given IV binds to surface receptors on the vascular smooth muscle and endothelial cells and activates cGMP. It causes both arterial and venous vasodilatation and mild natriuresis. It also suppresses the renin-angiotensin-aldosterone system. However, it causes dose-dependant hypotension and hence should not be used routinely to treat severely decompensated heart failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="beta-adrenergic-blocking-agents-in-heart-failure">Beta-adrenergic Blocking Agents in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#beta-adrenergic-blocking-agents-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Although the beta-adrenergic blockers can block the adverse cardiac effects of catecholamines, their use in large doses can worsen the heart failure owing to their negative inotropic action. However, the use of gradually increasing doses (start low, go slow) of metoprolol/carvedilol/bisoprolol over long term improve the symptoms and reduces the all-cause mortality substantially in heart failure.</p>
<p>They attenuate the adverse effects of the activated sympathetic drive (including apoptosis) on the heart, upregulate the beta receptors and reduce the LV remodeling. They are recommended in all patients in a stable condition, in whom LVEF is less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span>, without substantial salt and water retention and without recent exacerbation of heart failure requiring digoxin. Their long term effects are uniformly beneficial. Combination of an ACEI and a beta blocker is currently the cornerstone of the treatment of patients with left ventricular systolic dysfunction. Once started, they should not be stopped abruptly.</p>
<p>Beta blockers are not indicated in heart failure after acute MI nor in those with heart failure and normal LVEF (i.e. diastolic heart failure). They are also not indicated in patients with heart rate less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo separator="true">,</mo><mi mathvariant="normal">A</mi><mo>−</mo><mi mathvariant="normal">V</mi></mrow><annotation encoding="application/x-tex">60 / \mathrm{min}, \mathrm{A}-\mathrm{V}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord mathrm">A</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathrm" style="margin-right: 0.01389em;">V</span></span></span></span></span> block, asthma or COPD and severe or unstable heart failure. The therapy is initiated with very small doses, increased every 2 weeks. As beta blockers and ACEI can worsen the fluid retention, it is necessary to optimise the diuretic drugs before starting beta blockers.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="diuretics-in-heart-failure">Diuretics in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diuretics-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Diuretics are used in heart failure to relieve sodium and water accumulation (volume overload) and thus reduce peripheral edema, and dyspnoea due to pulmonary congestion. This gives quick symptomatic relief. But, their use alone has limitations:
(a) They do not increase cardiac output nor do they improve ventricular function.
(b) With the excessive use of diuretics, cardiac output and renal perfusion may diminish, with resultant fatigue, hypotension and impairment of renal function.
(c) They do not improve the survival rate.
(d) They can cause electrolyte disturbances.</p>
<p>Therefore, diuretics alone are not recomended; they are combined with either ACEI or digoxin. Diuretics have no place in the absence of overt heart failure. Table 31.5 outlines the principles of safe diuretic therapy of heart failure. For pharmacology of diuretics, see Chapter 39.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-5">Table 31.5<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-5" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="diuretic-therapy-of-chronic-heart-failure">Diuretic therapy of Chronic heart failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#diuretic-therapy-of-chronic-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-4" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="aldosterone-antagonists-in-heart-failure">Aldosterone Antagonists in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#aldosterone-antagonists-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>It is known that ACEI in therapeutic doses do not completely abolish the secretion of aldosterone. In addition to its classic mineralocorticoid properties, excess aldosterone causes coronary and renovascular remodeling, endothelial cell and baroreceptor dysfunction, potassium excretion and inhibition of myocardial noradrenaline uptake (Chapter 66). Morphological studies indicate that chronic excess of aldosterone and salt loading cause fibrosis in the atria, ventricles, kidney and other organs. The aldosterone antagonist spironolactone (Chapter 39) in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12.5</mn><mo>−</mo><mn>25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12.5-25 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> OD has been shown to decrease the hospitalisation and mortality rates in patients with severe CHF who are already on the drugs discussed earlier. Further, the risk of hyperkalemia is very low when such small doses of spironolactone are used in combination with ACEI. It also probably helps to conserve magnesium and thus prevent arrythmias. Monitoring of renal function and serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>is mandatory. For eplerenone, see Chapter 39.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="digitalis-and-other-inotropic-agents-in-heart-failure">Digitalis and Other Inotropic Agents in Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#digitalis-and-other-inotropic-agents-in-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>In 1776, William Withering, the master physician and botanist from Birmingham, identified digitalis as the active ingredient from a mixture of twenty different herbs used by an old woman in Shropshire for the treatment of dropsy. In 1785, Withering published his treatise entitled 'An Account of the Foxglove and Some of its Medical Uses: with Practical Remarks on Dropsy and other Diseases', which remains a classic even today. He, however, thought it to be a diuretic. Later a number of active glycosides were identified and shown to possess potent inotropic actions on the heart (cardiac glycosides).</p>
<p>Chemistry of the cardiac glycosides: Besides the plant Digitalis purpurea or foxglove, many other plants also serve as a source of cardiac glycosides. The glycoside strophanthin is obtained from the seeds of Strophanthus kombe or hispidus and another glycoside ouabain is derived from the seeds of Strophanthus gratus. Other less important and less prevalent sources include squill, the dried fleshy bulb of the 'sea onion' and the plants Convallaria majalis and Thevetia neriifolia (yellow oleander).</p>
<p>The cardiac glycosides exist in plants as precursors, which have to be hydrolysed for the release of the active glycosides. The seeds of Strophanthus gratus, however, yield the glycosides directly. Each glycoside represents the combination of an aglycone or genin, with a sugar (Table 31.6). If the sugar is glucose, the glycoside is called as a glucoside, e.g., strophanthin. Structurally, the aglycone has a steroid nucleus (CPP ring) with an attached lactone ring (Fig. 31.3). Acid hydrolysis of the glycoside results in separation of the aglycone and the sugar. The pharmacological activity is contained in the aglycone and the sugars ensure increased water solubility, cell penetrability and potency of the aglycones.</p>
<p>Table 31.6
Important cardiac glycosides</p>
<table><thead><tr><th style="text-align: left;">Source</th><th style="text-align: center;">Glycoside</th><th style="text-align: center;">Aglycone or Genin</th></tr></thead><tbody><tr><td style="text-align: left;">Digitalis purpurea</td><td style="text-align: center;">Digitoxin</td><td style="text-align: center;">Digitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Gitoxin</td><td style="text-align: center;">Gitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Gitalin</td><td style="text-align: center;">Gitaligenin</td></tr><tr><td style="text-align: left;">Digitalis lanata</td><td style="text-align: center;">Digitoxin</td><td style="text-align: center;">Digitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Gitoxin</td><td style="text-align: center;">Gitoxigenin</td></tr><tr><td style="text-align: left;"></td><td style="text-align: center;">Digoxin</td><td style="text-align: center;">Digoxigenin</td></tr></tbody></table>
<p><img src="assets/images/image-20251214-e8cd1ca1.jpeg" alt="img-29.jpeg"></p>
<p>FIG. 31.3 Structure of digitalis aglycone, digitoxigenin</p>
<p>Mechanism of action: Sarcolemmal membrane structures that regulate calcium entry into the cell include the slow (L type) calcium channel, the sodium-calcium exchanger, calcium ATPase, and (indirectly) the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>activated ATPase, and the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mi mathvariant="normal">H</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{H}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">H</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>exchanger. Digitalis acts as a potent positive inotropic agent by directly inhibiting the membrane bound <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mord">−</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">K^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>ATPase which acts as a digitalis receptor (direct action). This prevents extrusion of sodium and hastens the entry of sodium into the cell during the resting phase (diastolic depolarisation). Along with sodium, some calcium also moves in and remains intracellularly because of the depressed function of the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">N</mi><mi mathvariant="normal">a</mi></mrow><mo lspace="0em" rspace="0em">+</mo></msup><mo>−</mo><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Na}^{+}-\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9279em; vertical-align: -0.0833em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Na</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>exchange pump. The accumulated intracellular sodium exchanges for the extracellular calcium thus increasing the cytoplasmic calcium concentration. The increased calcium is stored within the sarcoplasmic reticulum sacs. This permits faster release and dispersal of calcium from these sacs into the cytoplasm. Increase in intracellular calcium activates the light chain of myosin, which combines with actin to form actomyosin, and the muscle contracts. Digitalis thus enhances the contractility, automaticity and ectopic pacemaker activity in the heart.</p>
<p>As inhibition of the sodium pump also prevents reentry of potassium into the cell after repolarisation is complete, digitalis causes depletion of intracellular potassium. This potassium depleting action is not confined to the cardiac muscle but also involves the skeletal muscle and the liver.</p>
<p>Digitalis also exerts indirect action on the heart, mainly by enhancing the vagal activity and thus influencing the activity of the SA node, the atria and the AV node (see below).</p>
<p>Pharmacological actions of digitalis: These can be divided into
I Cardiovascular actions; and
II Extracardiac actions
Cardiovascular actions: These are explained by an indirect and a direct actions of digitalis on the heart.</p>
<p>In the presence of CHF, digitalis has the following actions:</p>
<ul>
<li>Contractility: By direct action, it:
(i) Increases the force of contraction thus increasing the stroke output.
(ii) Shortens the duration of the systole, allowing greater time for both ventricular filling. and cardiac rest; and
(iii) Reduces diastolic size of the heart. Since the oxygen consumption is a function of the initial diastolic fibre length, such a reduction in size diminishes the oxygen consumption for a given work output. The digitalised heart, thus, can do the same work with less energy expenditure (oxygen utilisation) or more work for the same energy expenditure, than before digitalisation. Digitalis, therefore, is called a 'cardiotonic' (and not merely a cardiac stimulant like adrenaline). Such increase in the cardiac output following digoxin also occurs in cases with 'latent' (asymptomatic) heart failure.</li>
<li>Heart rate (HR): In an individual with CHF the heart rate diminishes. However, digitalis is not effective in tachycardia without cardiac decompensation as in sinus tachycardia due to fever or thyrotoxicosis.
Small doses of digitalis reduce the HR predominantly by stimulation of the vagus (the vagal effect), which can be abolished by atropine and exercise.
Full digitalising dose reduces the HR by direct cardiac action; this effect cannot be abolished by exercise or atropine. In an individual with CHF, an increased sympathetic</li>
</ul>
<p>activity causes tachycardia and increased venous pressure. Digitalis, by improving the circulation, decreases the sympathetic tone and thus, helps to reduce the heart rate and venous pressure.</p>
<ul>
<li>Refractory period (RP): Digitalis exerts varying effects on the RP of different cardiac tissues.
(a) It shortens the atrial RP with small doses (vagal action) and prolongs it with larger doses (direct action).
(b) It prolongs the effective RP of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>V</mi></mrow><annotation encoding="application/x-tex">A V</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.22222em;">V</span></span></span></span></span> node through the vagus and directly. This leads to a decrease in the transmission of the number of stimuli arising from the supraventricular pacemakers to the ventricle. This action is of major importance in slowing the rapid ventricular rate in a patient with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>A</mi><mi>F</mi></mrow><annotation encoding="application/x-tex">A F</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal">A</span><span class="mord mathnormal" style="margin-right: 0.13889em;">F</span></span></span></span></span>.
(c) In contrast, digitalis shortens the ventricular RP by direct action, as observed in ECG as a shortening in the Q-T interval.</li>
<li>Conduction velocity: The resultant effects of the 'vagal' and the direct cardiac actions on conduction are:
(a) The conduction velocity is slightly increased in the atria and the ventricles by small doses of digitalis (vagal action) while therapeutic doses depress the conduction velocity (direct action).
(b) Conduction through the AV node is depressed by both vagal and direct actions, this effect being therapeutically useful. The action of digitalis on A-V conduction and refractory period is mainly due to increased vagal tone and only to a minimal extent due to its direct effect.
(c) Conduction through the Purkinje fibre system of the ventricles is depressed by the direct action.</li>
<li>Automaticity: Digitalis increases the ability of the Purkinje cells and the ventricular muscle to initiate impulses. This leads to the development of ventricular extrasystoles, bigeminy, and if accompanied by depression of the conduction velocity, even to VF.</li>
<li>Blood pressure: IV injection of a digitalis glycoside in normal humans increases the mean arterial pressure while persons with CHF show no such increase. The effects of oral digitalis upon arterial pressure in patients with failure are secondary to improvement in the circulation.</li>
<li>Coronary circulation: Improvement in coronary flow is secondary to the improvement in cardiac output and slowing of the heart.</li>
<li>Venous system: The decrease in venous pressure in individuals with CHF is secondary to the improvement of circulation.</li>
<li>Digitalis and potassium: Discussed later.</li>
<li>Digitalis and calcium: Calcium ions increase the force of cardiac contraction. Digitalis acts synergistically with calcium. Its toxicity is enhanced by excess of calcium ions. IV calcium should be avoided in individuals on digoxin.</li>
<li>Effect of digitalis on the electrocardiogram (ECG): The characteristic ECG changes are:
(a) Changes in the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>T</mi></mrow><annotation encoding="application/x-tex">T</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">T</span></span></span></span></span> wave and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi><mi>T</mi></mrow><annotation encoding="application/x-tex">S T</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.13889em;">ST</span></span></span></span></span> segments. These include depression or 'scooping out' of ST segment, and inversion of the first portion of T wave. The changes, however, are no guide to its adequacy or toxicity.
(b) The PR interval is prolonged.
(c) The Q-T interval is shortened by digitalis, an indication that the drug shortens</li>
</ul>
<p>ventricular systole. Large doses may produce extrasystoles, various degrees of A-V block and ventricular fibrillation as the terminal event.
Almost every type of ECG abnormality associated with cardiac disease has been seen in patients on digitalis. However, QRS widening in the presence of sinus rhythm is not caused by digitalis; it is due to the concurrent heart disease.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="extracardiac-actions">Extracardiac actions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#extracardiac-actions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Kidney: The increased urinary output observed following digitalis in edematous patients is due to:
(a) Decrease in the venous pressure bringing about shifting of the edema fluid into the circulation.
(b) Improvement in renal circulation and increased excretion of sodium; and
(c) Inhibition of renin release from the kidney because of the decreased activity of the renal sodium pump.</li>
<li>Gastrointestinal tract: Digitalis, can produce anorexia, nausea, vomiting and diarrhoea.</li>
</ul>
<p>The nausea and vomiting are of central origin due to stimulation of the CTZ.
Absorption, fate and excretion: There are no qualitative differences among the digitalis glycosides in their effects on heart; the dissimilarities encountered are quantitative and related to the differences in pharmacokinetics. These drugs are usually administered orally or IV. Absorption is mostly from the small intestine. Absorption after SC or IM administration is unreliable.</p>
<p>The pharmacokinetics of the two digitalis glycosides is summarised in Table 31.7. Digitoxin, a non polar compound, is absorbed almost completely and rapidly from the gut whereas the more polar digoxin is absorbed to the extent of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span>. Further, absorption of digoxin is slowed by the presence of food in the GI tract and by malabsorption syndrome.</p>
<p>Table 31.7
Pharmacokinetics of oral digoxin and digitoxin</p>
<table><thead><tr><th style="text-align: left;"></th><th style="text-align: left;">Digoxin</th><th style="text-align: left;">Digitoxin</th></tr></thead><tbody><tr><td style="text-align: left;">Absorption</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">70</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>100</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90-100 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">100%</span></span></span></span></span></td></tr><tr><td style="text-align: left;">Plasma Protein binding</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> or more</td></tr><tr><td style="text-align: left;">Disposal</td><td style="text-align: left;">Renal excretion of unchanged drug 50-75%</td><td style="text-align: left;">Metabolised in liver</td></tr><tr><td style="text-align: left;">Enterophepatic recycling</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>8</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6-8 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">8%</span></span></span></span></span></td><td style="text-align: left;">Extensive</td></tr><tr><td style="text-align: left;">Plasma half-life</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>24</mn><mo>−</mo><mn>48</mn></mrow><annotation encoding="application/x-tex">24-48</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">24</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">48</span></span></span></span></span> hours</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">5-7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span> days</td></tr><tr><td style="text-align: left;">Therapeutic plasma concentration</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-2 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span></td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>35</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-35 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">35</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span></td></tr><tr><td style="text-align: left;">Time for max. effect of a single dose</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mo>−</mo><mn>12</mn></mrow><annotation encoding="application/x-tex">6-12</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">6</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">12</span></span></span></span></span> hours</td></tr><tr><td style="text-align: left;">Persistence of effect after stopping drug</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">3-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">3</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> days</td><td style="text-align: left;">18 days</td></tr><tr><td style="text-align: left;">Time for digitalisation without loading dose</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>7</mn></mrow><annotation encoding="application/x-tex">5-7</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">7</span></span></span></span></span> days</td><td style="text-align: left;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mo>−</mo><mn>30</mn></mrow><annotation encoding="application/x-tex">25-30</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">25</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">30</span></span></span></span></span> days</td></tr></tbody></table>
<p>Liquid filled capsules of digoxin (Lanoxicaps) have higher bioavailability.
One of the metabolites is digoxin.
Corresponding figures after IV dose are 1.5-3 hours (digoxin) and 4-8 hours (digitoxin).
As about 50-75% of digoxin is excreted by the kidneys, its excretion is prolonged in renal insufficiency and needs dose adjustment.</p>
<p>The body eliminates per day not a fixed quantity of digoxin and digitoxin but a fixed proportion of that present in the body at the beginning of the day (exponential elimination). The figure is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> in the case of digoxin and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> in the case of digitoxin. Therefore, on repeated daily administration, these compounds accumulate in the body until the daily dose equals the amount eliminated by the body per day. After this, a steady</p>
<p>state is reached. It is reached much faster if initial loading dose is employed but is eventually reached even with the use of a daily maintenance dose right from the first day without any initial loading dose; only it takes longer. Thus, a patient can be digitalised without using any loading dose.</p>
<p>Adverse reactions: Digoxin can cause cardiac and extracardiac adverse effects:
Cardiac toxicity: Digoxin produces cardiac arrhythmias either due to:</p>
<ul>
<li>Disturbed impulse formation</li>
<li>Disturbed impulse conduction; or</li>
<li>Both</li>
</ul>
<p>The disorders of impulse formation are due to ectopic pacemaker activity. The commonest are multifocal extrasystoles and bigeminy, followed by partial or complete A-V block. Less common are A-V dissociation, sinoatrial block, paroxysmal atrial tachycardia with block (PATB), sinoatrial arrest, ventricular tachycardia and VF. Any arrhythmia occurring in a patient receiving digoxin should be assumed to be due to drug toxicity until proved otherwise.</p>
<p>Pre-existing extrasystoles in themselves, however, do not constitute a contraindication to digoxin.</p>
<p>Several factors can modify the of digitalis cardiotoxicity. Recent MI, hypoxemia and acidosis increase the liability to digoxin induced arrhythmias.</p>
<p>Hypokalemia enhances digoxin toxicity. The serum potassium level, however, is not a reliable guide to the severity of depletion of myocardial potassium.</p>
<p>Vigorous therapy of cor pulmonale with digoxin without correction of the other abnormalities with measures such as diuretics, bronchodilators, oxygen and antibiotics can precipitate cardiac toxicity. Cor pulmonale produces hypoxia which results in tachycardia and an increased blood volume due to compensatory polycythemia. Hypoxia also produces pulmonary vasoconstriction resulting in pulmonary hypertension. The right ventricle has to force an increased volume of blood against an increased vascular resistance (because of pulmonary hypertension)into a grossly reduced pulmonary vascular bed (due to emphysema). Inability of the right ventricle to achieve this results in right ventricular failure. Such patients might become worse following the administration of digoxin, as increase in the right ventricular stroke volume may further increase the load on the already compromised pulmonary circulation.</p>
<p>In patients with AF and CHF, slowing down of the ventricular rate provides a good guide to digoxin therapy. But, this is not so in patients with sinus rhythm, in whom improvement in the cardiac status can occur without much reduction in the heart rate; increasing the dose of digoxin in order to slow down the heart rate to an arbitrary level in such patients can lead to digoxin toxicity. Persistence of tachycardia and cardiac failure can be due to such factors as myocarditis, pulmonary infarcts or emboli, or a mechanical problem such as very tight mitral stenosis. Increasing digoxin dose in such cases may lead to toxicity.</p>
<p>Adrenergic drugs enhance the digoxin cardiotoxicity.
A common cause of digoxin toxicity is the use of increasing doses of digoxin for noncardiac dyspnoea.</p>
<p>Gastrointestinal toxicity: Although anorexia, nausea and vomiting are generally the earliest toxic effects, cardiotoxicity can occur without them. It is necessary to distinguish vomiting due to digoxin from that due to CHF.</p>
<p>Neurological toxicity: Vertigo, visual disturbances including blurring, photophobia and disturbances of colour vision and headache are fairly common. Lassitude, confusion, disorientation, delirium, neuralgic pains, and psychotic behaviour may appear.</p>
<p>Miscellaneous toxicity: Includes skin rashes and gynecomastia; cardiac glycosides have a structural resemblance to estrogens.</p>
<p>Digoxin crosses the placental barrier, producing foetal concentration higher than the maternal concentration. Large doses to the mother, therefore, may lead to premature delivery, and the newborn may present with ECG abnormalities.</p>
<p>Drug interactions: See Table 31.8. About 10% of patients convert large amounts of digoxin to inactive metabolites in the gut; in such patients oral antibiotics can cause a sudden increase in serum digoxin level.</p>
<p>Table 31.8</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drug-interactions-of-digoxin">Drug interactions of digoxin<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drug-interactions-of-digoxin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Drugs which increase serum digoxin levels: Quinidine; Verapamil; Methyldopa; Indomethacin. Antibiotics (see text); Amiodarone.
(b) Drugs which reduce serum digoxin levels:</p>
<ul>
<li>By induction of hepatic microsomal enzymes: Rifampicin.</li>
<li>By reducing the bioavailability: Antacids; Kaolin-pectin preparations; Neomycin; Cholestyramine</li>
<li>Drugs acting indirectly by interfering with serum <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow><mi mathvariant="normal">C</mi><mi mathvariant="normal">a</mi></mrow><mrow><mo>+</mo><mo>+</mo></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{Ca}^{++}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8446em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">Ca</span></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8446em;"><span style="top: -3.1362em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">++</span></span></span></span></span></span></span></span></span></span></span></span></span>levels, e.g., diuretics and IV calcium.</li>
</ul>
<p>Recognition of overdigitalisation: Over-digitalisation is to be suspected when any of the aforementioned symptoms or signs arise in a patient on digitalis therapy. The usual symptoms and signs of digoxin toxicity are:
(a) Anorexia, nausea and vomiting.
(b) Decrease in the pulse rate below 60 per minute, presence of extrasystoles, especially bigeminy or any other arrhythmia.</p>
<p>A detailed analysis of the clinical situation, with special reference to past digitalisation, the amount and the speed of digoxin administration during the present illness, the nature of the disease process, and the patient's electrolyte and renal status, is necessary because the ECG may not be of help in diagnosing digoxin toxicity.</p>
<p>Determination of plasma digoxin level is valuable in
(a) Pharmacokinetic studies;
(b) Adjusting the maintenance dose of digoxin; and
(c) Detecting such unsuspected factors as poor patient compliance or poor bioavailability.</p>
<p>Higher than expected levels suggest renal failure. Therapeutic serum levels of digoxin generally range from 0.5 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2.0</mn><mrow><mi mathvariant="normal">n</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">2.0 \mathrm{ng} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">ng</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span>. Although levels are higher in patients showing toxicity than in those without it, plasma level alone for the diagnosis of digoxin toxicity is unreliable.</p>
<p>Treatment of digoxin toxicity: See Table 31.9. Tachyarrhythmias and ectopic impulse generation caused by digoxin are associated with intracellular loss of potassium and can be corrected by potassium administration.</p>
<p>Table 31.9
Principles of treatment of digoxin toxicity</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>- Stop digoxin
</span>    - Stop diuretics
    - Estimate serum potassium
    - Bradycardia: atropine
    - Mildtoxicity: oral potassium
    - Supraventricular tachyarrhythmiaes oral/IV propranolol. Verapamil is contraindicated as it elevatesserum digoxin concentration
    - Ventricular tachycardia: lignocaine or phenytoin, IV
    - Severe toxicity: antidi goxin antibodies.
    - Potassium is contraindicated in the presence of A-V block, hyperkalemia or severe renal insufficiency.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="- Stop digoxin
    - Stop diuretics
    - Estimate serum potassium
    - Bradycardia: atropine
    - Mildtoxicity: oral potassium
    - Supraventricular tachyarrhythmiaes oral/IV propranolol. Verapamil is contraindicated as it elevatesserum digoxin concentration
    - Ventricular tachycardia: lignocaine or phenytoin, IV
    - Severe toxicity: antidi goxin antibodies.
    - Potassium is contraindicated in the presence of A-V block, hyperkalemia or severe renal insufficiency." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Mild toxicity (stable, ventricular premature beats especially bigemini) can be treated by administration of potassium salts, 5 to 7.5 g of potassium chloride orally, daily, in divided doses. In more serious arrhythmias a solution containing 40 mEq of potassium chloride in 500 ml . of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> glucose can be administered IV over 2-4 hours with ECG as a guide.</p>
<p>Potassium loss does not appear to be related to the other cardiac toxic actions of digoxin. Potassium has little effect on the myocardial binding of digoxin that has already occurred; it can only reduce further uptake of the glycoside by the heart. Since <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">K</mi><mo lspace="0em" rspace="0em">+</mo></msup></mrow><annotation encoding="application/x-tex">\mathrm{K}^{+}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7713em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.7713em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">+</span></span></span></span></span></span></span></span></span></span></span></span></span>itself prolongs the refractory period of the AV node, it is contraindicated in the presence of A-V block. It is usually preferred, even in the presence of normal serum potassium level, when there is an evidence of ventricular irritability. However, it should be avoided in the presence of severe renal impairment. The administration of a potassium salt for treating digoxin toxicity does not counteract the positive inotropic properties of the glycoside.</p>
<p>The supraventricular tachyarrhythmias complicating digoxin therapy are best treated with a beta adrenergic blocking drug. Propranolol is used orally in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>40</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">10-40 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">40</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> every 6 hours or 0.5 to 1 mg IV.</p>
<p>Ventricular tachycardia is best treated with either lignocaine hydrochloride or phenytoin sodium IV. In the case of lignocaine, an initial dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> is followed either by similar doses at 20-30 minute intervals or by drip at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><mn>2</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">1-2 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">2</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> per minute. Phenytoin sodium is injected IV in the dose of 250 mg well diluted, over 3-5 minutes. Phenytoin sodium has the added advantage of countering the depression of A-V conduction by digitalis.</p>
<p>In severe digoxin toxicity (which usually involves suicidal overdose), hyperkalemia is commonly present and administration of an antiarrhythmic agent may cause cardiac arrest. Such patients are best treated with antidigoxin specific antibodies (Digibind).</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="preparations">Preparations:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#preparations" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(i) Digoxin tablet (Lanoxin) 0.125 or 0.25 mg
(ii) Digoxin injection 0.25 mg per ml .
(iii) Digitoxin tablet 0.1 mg . Digitoxin injection 0.2 mg per ml .
(iv) Liquid-filled capsules of digoxin (Lanoxicaps) 100 mcg and 200 mcg .
(v) Elixir Digoxin 1 ml equivalent to 0.05 mg of digoxin.</p>
<p>Therapeutic uses:</p>
<ul>
<li>Heart failure: see below and</li>
<li>Cardiac arrythmias for its action on the conducting system of the heart. Larger doses of digoxin are required to control arrhythmias than CHF.
Table 31.10 summarises the therapeutic usefulness of digoxin in various cardiac</li>
</ul>
<p>conditions.</p>
<p>Table 31.10
Therapeutic usefulness of digoxin</p>
<ul>
<li>Very useful in heart failure associated with atrial fibrillation and rapid ventricular rate.</li>
<li>Useful in low output failure in valvular, hypertensive, ischemic and congenital heart disease.</li>
<li>Of limited value in high output failure in anemia, thyrotoxicosis, beriberi and arterio-venous fistula; and in heart failure due to myocarditis and cor pulmonale.</li>
<li>Not effective in mitral stenosis, constrictive pericarditis and restrictive cardiomyopathy.</li>
<li>Contraindicated in patients with A-V block and in those with dynamic outflow block such as hypertrophic cardiomyopathy. (Refer text for details).
(1) Congestive heart failure (CHF): Digoxin, by increasing the cardiac output, brings about more complete emptying of the ventricles during systole. This reduces pulmonary congestion and edema (relief from orthopnea, disappearance of basal rales) and reduces systemic venous pressure (disappearance of hepatojugular reflux). As a result of improved cardiac output, the compensatory circulation changes abate, providing further clinical relief. Thus, tachycardia improves and diuresis is established as a result of diminution in the augmented sympathetic drive and reduction in various hormonal levels in the blood.</li>
</ul>
<p>Digoxin has no place in treatment of acute heart failure associated with acute MI, acute onset mitral regurgitation and papillary muscle dysfunction. These conditions are best treated by reduction of afterload.</p>
<p>Studies have reconfirmed that although digoxin is not the first drug of choice in CHF, it is useful in improving the clinical status and LV dysfunction. The consensus is that:</p>
<ul>
<li>Digoxin (in maintenance doses <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.125</mn><mo>−</mo><mn>0.25</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">0.125-0.25 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.125</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.25</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day) is an effective, generally safe and inexpensive drug for the relief of symptoms of CHE It prevents worsening of heart failure, improves exercise tolerance and reduces the repeated hospitalisation.</li>
<li>However, it does not alter the natural history of the disease nor does it substantially increase survival, in contrast to ACEI; and</li>
<li>Maintenance of lower serum digoxin level ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> ) is as effective as and much safer than higher levels.
Digoxin may be prescribed particularly in patients with persistent symptoms even after the ACEI, therapy.
(2) Left ventricular failure (LVF): Digoxin is helpful in the treatment of chronic, pure, left ventricular failure in patients with hypertensive or ischemic heart disease and aortic valve disease. It relieves orthopnoea. Hypertension if present, is treated with an antihypertensive drug. For acute LVF, see later.
(3) Atrial fibrillation (AF): Digoxin is indicated in (a) patients of AF with rapid ventricular rate; and (b) those with AF and cardiac failure, even if the heart rate is not rapid.</li>
</ul>
<p>The aim of digoxin therapy in patients with AF is to reduce the ventricular rate. If failure is present, digoxin relieves it. In the absence of failure, digoxin can protect the ventricles from too rapid atrial impulses by depressing conduction across the AV node and the AV bundle. The dosage should be adjusted to maintain a ventricular rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">60-80 / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">80/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> at rest and less than 100/min during physical activity. Verapamil or diltiazem IV is now preferred to digoxin in the absence of heart failure (28).</p>
<p>Electrical cardioversion is dangerous in patients with overt digoxin toxicity, who can develop fatal ventricular arrhythmias.</p>
<p>Digoxin is not indicated in patients with AF with normal ventricular rate. In such patients, warfarin is indicated to prevent stroke particularly in presence of risk factors</p>
<p>such as history of transient ischemic attacks, clinical heart failure, enlarged left atrium or impaired left ventricular function (Chapter 28).
(4) Atrial flutter: Digoxin corrects any associated cardiac failure and slows the ventricular rate. Propranolol can be added in patients resistant to digoxin. Atrial flutter is often converted into atrial fibrillation by digoxin, and its withdrawal at this stage may restore sinus rhythm.
(5) Paroxysmal atrial tachycardia (PAT): Digoxin is the drug of choice in the treatment of PAT - associated with heart failure. In patients without heart failure, other drugs such as verapamil/diltiazem/adenosine is preferred (Chapter 28). Physical measures such as pressure on the carotid sinus may occasionally be helpful. Digoxin terminates PAT probably by its indirect (vagal) action. It should be noted that digoxin therapy itself sometimes converts AF into PATB and hence, it is imperative to enquire about previous digitalisation before the institution of therapy. Spontaneous PAT without obvious cause could be benign but PATB induced by digoxin is a serious complication.</p>
<p>Digitalisation: The patient should be digitalised, avoiding even the mildest digoxin toxicity. This, however, may not always be possible. The important determinant of daily digoxin dose is the renal function. The therapeutic benefit, though proportionately smaller, comes even from partial digitalisation, because there is a linear dose-response relationship in the case of digoxin and there is no threshold for the positive inotropic effect of digoxin. Hence, except in special circumstances, the use of initial, large loading dose of digoxin should be avoided.</p>
<p>The recommended schedules for digoxin therapy are summarised in Table 31.11.</p>
<p>Table 31.11
Digoxin dosage (mg) in adults in heart failure</p>
<p>For routine, oral digitalisation: 0.25 mg once in 24 hours (maintenance dose); smaller doses in the the elderly and in those in renal failure; digitalisation occurs in 5-7 days. For rapid, oral digitalisation: Loading dose of 0.75 mg in 24 hours, followed by maintenance dose.
For IV digitalisation: <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mo>−</mo><mn>1.0</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">0.5-1.0 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">0.5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">1.0</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>.</p>
<p>In a patient with mild cardiac failure, especially when he is treated on an out-patient or domiciliary basis, digoxin should be administered in maintenance dose from the first day. Estimation of serum level may be useful for dose adjustment in renal failure.</p>
<p>A loading dose should be used only when it is necessary to digitalise a patient rapidly (in 24-36 hours) as in:</p>
<ul>
<li>Severe LVF; or</li>
<li>Acute heart failure due to paroxysmal atrial fibrillation with rapid ventricular rate.</li>
</ul>
<p>The loading dose, if used, should be three times the expected maintenance dose and should be given in divided doses in the first 24 hours. History of digoxin therapy should be enquired into before using the loading dose. A baseline ECG should be recorded.</p>
<p>IV digitalisation is a potentially dangerous procedure, to be employed only in emergency. The preparation to be administered should be diluted with normal saline and injected slowly over 10-15 min.</p>
<p>Bioavailability of digoxin may vary among different brands of tablets because of differences in the dissolution rates. Change to a different brand may suddenly increase the plasma level of digoxin and precipitate toxicity.</p>
<p>Once started, digoxin therapy is generally required for life in most patients.</p>
<p>Contraindications to digoxin therapy: The only absolute contraindication to digoxin therapy is digoxin toxicity. Except for partial and complete heart block and perhaps paroxysmal ventricular tachycardia, no other cardiac arrhythmia, unless digoxin induced, is a contraindication to digoxin therapy, and even in these cases, it may be used if CHF is present.</p>
<p>Ouabain (Strophanthin - G): Ouabain is a pure crystalline glycoside derived from the plant Strophanthus gratus. It is now rarely used.</p>
<p>Other inotropic agents: These agents stimulate the myocardium either by stimulating the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi>β</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\beta_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord"><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.0528em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors or inhibiting the breakdown of cAMP by phosphodiesterase (aminophylline). Their usefulness is limited.</p>
<p>Beta-adrenergic agonists, dopamine and dobutamine increase myocardial contractility, particularly in selected patients with severe heart failure (Chapter 32).</p>
<p>AMRINONE: This bipyridine derivative is a non-adrenergic, positive inotropic agent. It acts by inhibiting cardiac phosphodiesterase activity. It increases the force of contraction and rate of shortening of the cardiac muscle. It is a vasodilator and, reduces peripheral resistance (ionodilator effect). It has been used in patients with refractory HF. A common adverse effect is dose related thrombocytopenia. The drug has no clear benefits over digoxin.</p>
<p>Milrinone has similar action as amrinone.
The inotropes such as dobutamine, dopamine and milrinone improve myocardial contractility by raising cardiac myocyte intracellular calcium. The heart rate and myocardial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> consumption increased, which can exacerbate cardiac ischemia in CHF and may precipitate cardiac arrhythmias. Although, these agents increase the velocity and force of contraction, they do not increase but often shorten the duration of systole. Hence a new inotropic agent with novel mechanism of action has been developed.</p>
<p>Omecamtiv mecarbil: This new sarcomere directed drug, is a selective cardiac myosin activator. It increases myocardial contractility and stroke volume without increasing the calcium transit in myocytes and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> consumption, thereby improving myocardial efficiency. The effect is dose dependent. The duration of left ventricular systole is increased. As the heart rate is decreased, the duration of diastole is not much altered. As a result, the coronary flow and left ventricular filling is not much altered. Thus, omecamtiv mecarbil may be an useful inotropic agent in the treatment of chronic HF caused by left ventricular dysfunction. It is under evaluation.</p>
<p>Table 31.12 describes one of the proposed protocols for the management of heart failure. The effectiveness of therapy can be monitored by observing the following:</p>
<p>Table 31.12
Protocol for management of heart failure</p>
<table><thead><tr><th style="text-align: center;">Stage <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">§</mi></mrow><annotation encoding="application/x-tex">\S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord">§</span></span></span></span></span></th><th style="text-align: center;">Risk factors for heart failure*</th><th style="text-align: center;">Symptoms of heart failure**</th><th style="text-align: center;">Structural abnormalities in the heart <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo><mo>∗</mo></mrow></msup></mrow><annotation encoding="application/x-tex">{ }^{* * *}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗∗</span></span></span></span></span></span></span></span></span></span></span></span></span></th><th style="text-align: center;">Treatment recommended</th></tr></thead><tbody><tr><td style="text-align: center;">A: High risk only</td><td style="text-align: center;">Present</td><td style="text-align: center;">Never</td><td style="text-align: center;">None</td><td style="text-align: center;">Treat risk factors &lt;br&gt; Patient education. ACEI or ARB in some patients</td></tr><tr><td style="text-align: center;">B: Asymptomatic LV dysfunction</td><td style="text-align: center;"></td><td style="text-align: center;">Never</td><td style="text-align: center;">Detectable</td><td style="text-align: center;">ACEI/ARB &lt;br&gt; + beta blockers for all.</td></tr><tr><td style="text-align: center;">C: Symptomatic heart failure</td><td style="text-align: center;"></td><td style="text-align: center;">Currently present or H/O such symptoms</td><td style="text-align: center;">Detectable</td><td style="text-align: center;">ACEI + beta blockers in all <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Diuretics <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Digoxin, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> ARB <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Aldosterone antagonist <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mi mathvariant="normal">/</mi><mo>−</mo></mrow><annotation encoding="application/x-tex">+/-</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">+</span><span class="mord">/</span><span class="mord">−</span></span></span></span></span> Vasodilator</td></tr><tr><td style="text-align: center;">D: End stage heart failure Advanced (HF)</td><td style="text-align: center;"></td><td style="text-align: center;">Refractory heart failure with marked symptoms at rest ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">E</mi><mi mathvariant="normal">F</mi></mrow><mo>&lt;</mo></mrow><annotation encoding="application/x-tex">\mathrm{EF}&lt;</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7224em; vertical-align: -0.0391em;"></span><span class="mord"><span class="mord mathrm">EF</span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">&lt;</span></span></span></span></span> <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">30 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">30%</span></span></span></span></span> ) resistant to maximal therapy</td><td style="text-align: center;">Obvious</td><td style="text-align: center;">Difficult to treat &lt;br&gt; No beta blockers &lt;br&gt; May use inotropes &lt;br&gt; Ventricular assist device/Surgery</td></tr></tbody></table>
<p>Risk factor treatment and patient education is for all (A-D) groups.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo><mover><mo><mo>=</mo></mo><mn>5</mn></mover></mo><mo>=</mo></mrow><annotation encoding="application/x-tex">\stackrel{5}{=}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1.118em;"></span><span class="mrel"><span class="mop op-limits"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 1.118em;"><span style="top: -3em;"><span class="pstrut" style="height: 3em;"></span><span><span class="mop">=</span></span></span><span style="top: -3.5669em; margin-left: 0em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">5</span></span></span></span></span></span></span></span></span></span><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Stages as per the guidelines of the American College of Cardiology and The American Heart Assocition.
*= Hypertension; Diabetes mellitus; Ischemic heart disease; Chronic lung disease; Heavy smoking/alcohol consumption; H/O rheumatic fever.
" <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>=</mo></mrow><annotation encoding="application/x-tex">=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.3669em;"></span><span class="mrel">=</span></span></span></span></span> Symptoms (current or past) of either left or right sided heart failure.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mrow><mo>∗</mo><mo>∗</mo></mrow></msup><mo>=</mo></mrow><annotation encoding="application/x-tex">{ }^{* *}=</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗∗</span></span></span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">=</span></span></span></span></span> Cardiac chamber enlargement; Valvular heart disease; H/O myocardial infarction; Signs of left or right ventricular hypertrophy/failure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="symptoms-and-signs-of-improvement">Symptoms and signs of improvement:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#symptoms-and-signs-of-improvement" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>(a) Increased urinary output.
(b) Relief from fatigue, insomnia, orthopnoea and disappearance of basal rates.
(c) Improved exercise tolerance.
(d) Diminution in jugular venous pressure, hepatojugular reflux and in liver size.
(e) Disappearance of tachycardia and ventricular gallop; and
(f) Change of dry and paper like skin to normal, moist and elastic type.</p>
<p>Table 31.13 lists important points to remember in the management of systolic LV dysfunction.</p>
<p>Table 31.13
Points to remember in management of left ventricular systolic dysfunction</p>
<p><sup><a href="#user-content-fn-0" id="user-content-fnref-0-5" data-footnote-ref="true" aria-describedby="footnote-label">1</a></sup></p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="management-of-acute-lvf">Management of Acute LVF<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#management-of-acute-lvf" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Acute left ventricular failure with pulmonary edema is a medical emergency and is treated with IV furosemide, nitrate and ACEI (Table 31.14). Management of acute HF has to be tailor-made guided by several factors such as concomitant diseases, left ventricular filling pressure and cardiac output and hence is better left to specialist.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-14">Table 31.14<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-14" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Management of acute LVF with pulmonary edema
<img src="assets/images/image-20251214-6bbb11d0.jpeg" alt="img-30.jpeg">
(a) The patient without hypotension is made to lie in a semi-upright position either by raising the head end of the bed or by using a back-rest, preferably with the legs hanging over the edge of the bed. Application of tourniquets to three limbs at a time, with rotation of the free limb every 15-20 minutes. This helps to pool the blood in the limbs to reduce venous return and the preload.
(b) Oxygen is administered at the rate of 6-8 litres a minute.
(c) Furosemide is injected IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">40-60 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span>, repeated every 30 minutes until diuresis sets in. It acts by causing venodilatation, in addition to diuresis.
(d) Morphine IV 2 to 4 mg every 15 mins to a total of 15 mg is used. In addition to allaying anxiety and improving patient comfort, morphine also brings about peripheral pooling of blood by central reduction in sympathetic activity (Chapter 10).
(e) If the patient has associated bronchospasm, aminophylline is given IV in the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>250</mn><mo>−</mo><mn>500</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">250-500 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">250</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">500</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> over 15 minutes, followed by an infusion.
(f) Sublingual NTG <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>0.4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(0.4 \mathrm{mg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">0.4</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mclose">)</span></span></span></span></span> is a first line therapy in acute HF. It temporarily reduces the pulmonary capillary pressure by producing venodilatation and may be repeated every 5 minutes three times. As NTG may cause severe hypotension in some patients BP, must be monitored regularly. In resistant cases, IV NTG (5-10 mcg/min) is administered provided there is no hypotension. Careful use of sodium nitroprusside infusion (as a balanced preload and afterload reducer) may be helpful in these patients but it requires the facilities of an intensive care unit.
(g) Low dose of short acting ACEI is initiated in hypertensive patients and those with acute MI with HF.
(h) If inotropic effect is desired, drugs such as dopamine or dobutamine may be preferred to digoxin. However, IV digoxin, 0.5 mg injected over 15 minutes, can be valuable in patients with atrial fibrillation or supraventricular tachycardia.</p>
<p>After resolution of acute heart failure, the patient should be investigated for possible cause of heart failure and treated accordingly.</p>
<p>Table 31.15 lists drugs to be avoided/used cautiously in CHF.</p>
<p>Table 31.15
Drugs to be avoided in CHF</p>
<ul>
<li>Antiarrhythmics except beta blockers and antiodarone</li>
<li>Calciumchannel blockers</li>
<li>NSAID</li>
<li>Glucocorticoids</li>
<li>Glitazones</li>
<li>Metformin</li>
<li>Cilostazol</li>
<li>Sildenafil</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="nonpharmacological-treatment-of-heart-failure">Nonpharmacological Treatment of Heart Failure<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#nonpharmacological-treatment-of-heart-failure" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>This is outlined in Table 31.16.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-31-16">Table 31.16<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-31-16" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Nonpharmacological treatment of heart failure</p>
<ul>
<li>Salt and water restriction: advise sodium intake less than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>−</mo><mn>3</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">2-3 \mathrm{~g} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">3</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span></span></span></span></span> day.</li>
<li>Weight reduction in the obese.</li>
<li>Cessation of smoking and alcohol consumption.</li>
<li>Limit physical activity in the acute phase of illness.</li>
<li>Stop any drug contributing to heart failure,
(Table 31.15).</li>
<li>Influenza and pneumococcal vaccination has been recommended.</li>
<li>Supervised rehabilitation therapy including regular graded physical exercise which improves peak exercise capacity and the quality of life.</li>
<li>Surgical treatment, when appropriate.</li>
</ul>
<p>Chronic heart failure in many cases is preventable by:</p>
<ul>
<li>Controlling risk factors such as hypertension, DM and correcting the structural anomalies like valve damage/stenosis</li>
<li>Controlling body weight and the sodium intake</li>
<li>Use of ACEI after MI and in patients with asymptomatic LV dysfunction</li>
<li>Avoidance of certain drugs</li>
</ul>
<p>32</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="pharmacotherapy-of-shock">Pharmacotherapy of Shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacotherapy-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Shock may be defined as complex acute systemic circulatory failure associated with hypoperfusion of tissues, which is incompatible with life if untreated and persisting for more than a short time. It may be initiated by trauma, acute blood loss, depletion of body fluids, severe infection or acute myocardiac dysfunction. In these conditions, it may be mediated by one or more of the following mechanisms; of these, hypovolemia is the most important.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="mechanisms-of-shock">Mechanisms of shock:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#mechanisms-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Hypovolemic: This may be defined as a reduction in the circulating blood volume, and can arise in many different ways. It evokes, through the baroreceptors, a generalised, compensatory sympatho-adrenal discharge and peripheral vasoconstriction. The latter is responsible for many of the clinical manifestations of shock. Though it helps to maintain the cardiac output and is important in short-term survival, it aggravates the hypovolemia by making the microcirculation very sluggish, pooling the blood in the periphery and thus reducing the effective intravascular volume.
The excessive sympatho-adrenal discharge causes a redistribution of the cardiac output with reduction in the blood flow to the skin, the intestines and the kidneys. The BP is stabilised but the tissue perfusion is impaired. Excessive vasoconstriction results in slowing of the blood flow, local hemoconcentration from loss of fluid from the capillaries into the tissues and in local formation of thrombi in the microcirculation. This causes tissue hypoxia leading to acidosis and to liberation of substances such as histamine, kinins, prostaglandins and cardiodepressant peptides into the circulation. Tissue hypoxia damages intracellular structures. The coronary filling is mainly diastolic and excessive fall in diastolic BP (together with cardiodepressant peptides) adds a cardiogenic element to any other variety of shock. Inadequate cerebral blood flow causes mental changes. Microcirculatory changes in the lungs lead to pulmonary odema (shock lung); this is abetted by neurogenic and mechanical factors leading to ventilatory failure and multiorgan dysfunction. Oligemic acute renal shut down completes the devastating picture.</li>
<li>Cardiogenic: This is due to failure of the heart as a pump as in acute myocardial infarction (MI). Rarely, in some cases, there is complete failure of the compensatory sympathoadrenal discharge.</li>
<li>Obstructive: Extracardiac obstructive diseases impair cardiac filling.</li>
<li>Distributive: In shock due to sepsis and burns, the peripheral resistance is initially low (warm shock); the cardiac output is elevated but is maldistributed exactly as in shock with low cardiac output, with all the disastrous consequences detailed above. In the later stages, the cardiac output falls and the peripheral resistance rises markedly.
The septic shock is initiated by the toxins released by the micro-organisms: exotoxins (as in the case of Toxic Shock Syndrome (TSS) due to staphylococci or streptococci); or endotoxins (as with Gram-negative bacilli). These toxins cause the release of tumour necrosis factor alpha (TNF alpha) and a variety of interleukins especially IL-1 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>β</mi></mrow><annotation encoding="application/x-tex">\beta</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8889em; vertical-align: -0.1944em;"></span><span class="mord mathnormal" style="margin-right: 0.05278em;">β</span></span></span></span></span>, and the platelet activating factor (PAF) from the mononuclear phagocytes and the endothelial cells. These cytokines cause a further cascade of synthesis and release of substances</li>
</ul>
<p>such as leukotrienes, PGs and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. They injure the vascular endothelium, increase its permeability, and cause fluid loss from the circulation leading to
hypovolemia. They also depress the myocardium. Diffuse cell injury results in multiple organ failure. Many patients with septic shock have partial adrenocortical insufficiency. Distributive shock may also occur following anaphylaxis and spinal cord or neurologic injury.
The clinical picture of shock is variable but generally consists of pallor, sweating, cold extremities, rapid and thready pulse and air hunger, all due to the sympatho-adrenal discharge. Cyanosis of the extremities may be present. Rarely, the extremities are warm (even in the absence of fever) whereas the circulation to the vital organs may be critically compromised. Oliguria (urine output less than 25 ml per hour for 4 hours or less than 500 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mn>24</mn></mrow><annotation encoding="application/x-tex">\mathrm{ml} / 24</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/24</span></span></span></span></span> hours in adults), mental changes (somnolence, confusion, restlessness), acidosis and a marked difference in the temperature between the rectum and the skin are all indicators of reduced cardiac output and reduced tissue perfusion. Central venous pressure (CVP) is the best guide to hypovolemia. If it is low to begin with and fails to rise during intravenous infusion of fluid at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo>−</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10-20 \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">10</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6944em;"></span><span class="mord">20</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> per minute for 10-15 minutes, hypovolemia can be diagnosed. If during such infusion, the CVP exceeds 15 cm of water or rises more than 5 cm of water over the basal level, pump failure is a major component of the shock. In patients with chronic lung disease and after acute MI, CVP does not truthfully reflect left ventricular filling pressure. In such patients monitoring of pulmonary artery occlusive pressure (PAOP) is a better index of left ventricular filling pressure.</p>
<p>By the time the BP falls, there is already a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> deficit in the effective intravascular volume and hence an attempt should be made to diagnose and treat shock before the BP falls significantly. The femoral pulses are the best guide to the level of arterial pressure, since they are weak in hypotension but bounding in the presence of peripheral vasoconstriction with adequate arterial pressure. On the other hand, thready or absent radial or brachial pulses may be due to either severe hypotension or to reduction in extremity blood flow due to peripheral vasoconstriction. A low BP recorded by means of a blood pressure cuff has the same significance as weak brachial or radial pulses.</p>
<p>Arterial hypoxemia (reduced <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">a</mi><mi mathvariant="normal">O</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PaO}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PaO</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ), lactic acidosis and acidemia are the biochemical reflections of severe tissue hypoxia. It is customary to talk about 'irreversible' shock when the latter does not respond easily to treatment. It may be better to give up this term which admits defeat and call it 'refractory'.</p>
<p>Successful management of circulatory failure aims at:</p>
<ul>
<li>Early recognition of the shock state.</li>
<li>Correction of the initiating insult (defibrillation, antibiotics, hemostasis, IV fluids, surgical removal of necrotic tissue).</li>
<li>Treatment of secondary consequences of shock (e.g., acidosis, hypoxemia).</li>
<li>Maintenance of function of vital organs (e.g., cardiac output, B.P., urine output); and</li>
<li>Identification and treatment of aggravating factors.</li>
</ul>
<p>All the five factors must be handled concurrently.
Hemodynamic and biochemical monitoring of the patients response to treatment is critical to success of the treatment and need repeated monitoring.</p>
<p>Restoration of blood volume: Since increased blood flow to vital organs increases the likelihood of survival, therapy should augment cardiac output. This is best achieved by</p>
<p>restoring the intravascular blood volume as quickly as possible and may be the only treatment necessary, except in shock due to MI where the function of the heart itself is impaired. Fluid administration should be monitored by measurement of CVP and mean arterial BP. Rise in CVP without a corresponding rise in arterial blood pressure during IV fluid therapy denotes an overloading of the circulation. To avoid such overloading, CVP should be maintained below 15 cm of water.</p>
<p>Fluids used for volume replacement are:
I Whole blood and plasma
II Colloidal plasma substitutes: Dextran, Hydroxyethyl starches, Polyvinylpyrrolidone and Oxypolygelatin.
III Crystalloid plasma substitutes: Normal saline (sodium chloride solution) and 5% Dextrose solution.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="whole-blood-plasma-and-plasma-fractions">Whole Blood, Plasma and Plasma Fractions<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#whole-blood-plasma-and-plasma-fractions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>BLOOD obtained from donors by aseptic technique, is preserved with either CPD (citrate-phosphate-dextrose) or CPDA (citrate-phosphate-dextrose-adenine) solution. Blood is stored at a constant temperature between <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span>; storage below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">2^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> damages the RBC. It is vital to maintain the temperature constantly below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> to prevent the multiplication of bacterial contaminants. However, some bacilli can multiply even at a temperature below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> if they have previously been stimulated by exposure to a higher temperature. As the degree of hemolysis produced by such organisms is too insignificant for detection, a bottle once taken out from the refrigerator and exposed to room temperature for 30 minutes or more should be discarded.</p>
<p>The straw colour of the supernatant plasma serves as a convenient indicator to judge the suitability of blood sample for use. Pink or red stained plasma indicates hemolysis.</p>
<p>The expiry date for blood preserved in CPD solution is 21 days and that for blood stored in CPDA solution is 35 days; however, the local FDA regulations must be followed in this matter. Blood should not be used after the stipulated period as the fragility of the erythrocytes increases after that period. Supernatant plasma, however, is stable and can be used. In the absence of an unusual hemolytic state or factor, the transfused erythrocytes have an average life of 4 months.</p>
<p>While transfusing whole blood, care must be taken to use only blood belonging to the same ABO blood group but preferably not from a genetically related donor (see GVHD below). While using packed red blood cells, it is permissible to transfuse cells from an O group person (universal donor) into a person with any ABO group; similarly a person with AB group may receive packed RBCs from a donor of any ABO group. Rh positive blood should not be given to Rh negative individual if it can be avoided; at least, it should not be repeated in a Rh negative individual who has received Rh positive blood transfusion previously.</p>
<p>Autologous blood transfusion: Blood collected from a patient awaiting elective surgery which is likely to require a blood transfusion, can be infused back into the donor, when the need arises. The main advantages of this procedure are avoidance of immunological mismatch and/or disease transmission; and conservation of the available blood resources. The disadvantages are reinfusion of contaminants, dilutional coagulopathy and undesired infusion of anticoagulants; further, hemolysed red cells in the blood may cause renal insufficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="indications-for-blood-transfusion">Indications for blood transfusion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#indications-for-blood-transfusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(1) Acute hemorrhage: Assessment of blood loss is relatively easy in case of external injuries or gynaecological emergencies. Many times, however, one has to rely mainly on clinical signs such as pallor, tachycardia and hypotension to gauge the degree of blood loss.</p>
<p>While treating acute blood loss, an attempt should be made to maintain:
(a) Blood volume at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">90 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">90%</span></span></span></span></span> or more of normal;
(b) Hemoglobin level of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">10 \mathrm{~g} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm" style="margin-right: 0.01389em;">g</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span>;
(c) Total serum proteins level of at least <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span> of normal;
(d) Platelets above 50,000/cu mm; and
(e) Plasma coagulation factors above <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>35</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">35 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">35%</span></span></span></span></span> of normal. When the blood loss is mild ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> or less of the total blood volume) a crystalloid solution (see later) should be infused in</p>
<p>amounts 3-4 times the estimated blood loss. For moderate blood loss (26-50% of the total blood volume), colloid plasma expanders may be adequate. For larger estimated blood losses, either packed blood cells or whole blood are needed to achieve adequate tissue oxygenation; this may be in addition to crystalloid and colloid solutions.
Adequacy of transfusion can be judged clinically from the reappearance of colour and warmth in the patient, filling of veins and the improvement in pulse and BP.
(2) To provide leucocytes in cases of agranulocytosis: Fresh blood is preferred as the leucocytes deteriorate on storage.
(3) Anaemia: See later
(4) Intrauterine transfusion: To reduce mortality in erythroblastosis foetalis.</p>
<p>In the past, whole blood transfusions were used to provide RBCs, platelets and clotting factors as indicated e.g. anaemia, thrombocytopenia or bleeding disorders. However, all these uses have been superseded by use of multiple components like packed red cells, platelet concentrates and clotting factors isolated from whole blood. Thus the donated blood can be used optimally on fractionation.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="complications-of-blood-transfusion">Complications of blood transfusion:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#complications-of-blood-transfusion" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Nonhemolytic pyrexial reaction: Rigor, a common manifestation, is mostly due to imperfect sterilisation of the apparatus. In the event of a rigor, the transfusion should be stopped. The patient is covered with blankets. In severe cases aspirin, anti-histaminics and glucocorticoids are employed. Usually, it is due to pyrogens but occasionally it can be caused by antibodies against antigens on donor leucocytes or platelets, stimulated by a previous transfusion or pregnancy.</li>
<li>Allergy: It is mandatory to enquire about previous history of urticaria in the donor to prevent this complication. Antihistaminics and adrenaline are used to treat this manifestation.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="air-embolism">- Air embolism.<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#air-embolism" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>
<p>Heart failure due to hypervolemia and circulatory overload.</p>
</li>
<li>
<p>Transmission of disease: (i) Acute viral hepatitis B or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="bold">C</mi></mrow><annotation encoding="application/x-tex">\mathbf{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6861em;"></span><span class="mord mathbf">C</span></span></span></span></span> is one of the most serious adverse reactions. Type C virus is the infective agent most frequently transmitted by blood. (ii) Acquired immuno-deficiency syndrome (AIDS) due to HIV. (iii) Syphilis. Treponema pallidum does not survive refrigeration for more than three days. In an emergency, prophylactic use of penicillin can prevent this complication. (iv) Malaria.
There is also the possibility of the recipient being harmed if the donor has received certain medications in recent or remote past. Blood for homologous transfusion should not be collected if the prospective donor has been given:
(a) A blood transfusion or a blood product or any hormone derived from the human pituitary, ever in the past;
(b) Isotretinoin or etretinate (Chapter 71) in the past 3 years;
(c) Rabies vaccine in the past one year;
(d) Any other vaccine in the past 4 weeks;
(e) An antiplatelet agent such as aspirin or another NSAID (Chapter 11), clopidogrel or ticlopidine (Chapter 33), in the past 7 days, especially if the recipient requires platelets;
(f) An androgen or a antiandrogen, especially one with long half life (danazol or cyproterone acetate); or
(g) Is currently taking any drug.</p>
</li>
<li>
<p>Hemolytic reaction due to mismatched transfusion is characterised by rigor, pain in loins, jaundice, hemoglobinuria, oliguria, bleeding and coma. The treatment of an acute hemolytic reaction is aimed at prevention of acute renal shut down. Mannitol 20 g (20%) should be administered rapidly, to initiate diuresis. If diuresis occurs, it should be maintained at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">100 \mathrm{ml} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span></span></span></span></span> hour by giving normal saline, and IV furosemide, and by maintaining BP above 100 mm systolic. Alkalinising the urine with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>50</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">E</mi></mrow></mrow><annotation encoding="application/x-tex">40-50 \mathrm{mE}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord">50</span><span class="mord"><span class="mord mathrm">mE</span></span></span></span></span></span> moles of sodium bicarbonate, given IV, helps to hasten the excretion of free hemoglobin. If diuresis fails to occur, patient is treated for acute renal failure.</p>
</li>
<li>
<p>Hyperkalemia: Storing of blood at a temperature below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> causes an efflux of potassium from erythrocytes into the plasma. When the blood is brought back to room temperature, potassium re-enters the erythrocytes. Failure to re-warm the blood to room temperature may lead to hyperkalemia.</p>
</li>
<li>
<p>Graft-versus-host disease (GVHD) in which the donor lymphocytes attack and damage the host immune system. The mortality rate is high. It may be prevented either by avoiding transfusing blood from a genetically related donor or by irradiating such blood before transfusing it.</p>
</li>
<li>
<p>Iron overload can occur in an adult after he/she has received 60-210 (mean 120) units of blood. It is successfully treated by iron chelation (Chapter 34).</p>
</li>
<li>
<p>Citrate intoxication leading to cardiac irregularities and metabolic alkalosis due to metabolic conversion of citrate to bicarbonate, is a rare complication seen only after massive blood transfusions (more than 5 units of blood).
Other complications after massive blood transfusion are: hypocalcemia; hyperkalemia; pulmonary insufficiency with adult respiratory distress syndrome (due to debris comprising of platelets, leucocytes and fibrin, in the stored blood); hypothermia (if blood is transfused without warming it to body temperature); and hemorrhagic diathesis (due to dilution of platelets and clotting factors in patient's own blood or due to disseminated intravascular coagulation).
Due to these complications of whole blood transfusion, when oxygen replacement is required, RBC replacement is always preferable to whole blood.
PACKED RED CELLS can be transfused when it is desired to increase the oxygen carrying capacity of blood without increasing its volume. A packed red cell preparation is made by removal of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> of the supernatant plasma. The red cell content of the remaining packed cells should be at least 5.5 million cmm . Concentrated red cells have to be infused within twelve hours of preparation. There are less blood group antibodies in packed cells, so non-group specific blood i.e. O negative blood can be given to patients with other groups. In addition, chances of anaphylactic reactions are less.
Indications for packed red cell transfusion:</p>
</li>
<li>
<p>Anaemia:
(a) Symptomatic anaemia with haemoglobin below <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>20</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">20 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">20%</span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&lt;</mo><mn>8</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">&lt;8 \mathrm{gm} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&lt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">%</span></span></span></span></span> )
(b) Aplastic and refractory anemias.
(c) Thalassemia and other haemolytic anemias.
(d) Cases of dyshaemopoiesis.
(e) As a pre-operative measure.</p>
</li>
</ul>
<p>One unit of packed red cells has haematocrit of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>65</mn><mo>−</mo><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">65-70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">65</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span> which raises haematocrit of the recipient by approx. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3%</span></span></span></span></span> and and Hb by <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mrow><mi mathvariant="normal">g</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \mathrm{gm} \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.9444em; vertical-align: -0.1944em;"></span><span class="mord">1</span><span class="mord"><span class="mord mathrm">gm</span></span><span class="mord">%</span></span></span></span></span>. The amount of packed cells administered</p>
<p>should not exceed 500 ml at a time. In chronic severe anemia and in sepsis, the myocardium is on the verge of ischemia, and the rate of transfusion should not exceed 1015 drops per minute. Failure to observe this precaution may result in heart failure. The amount administered in children under 25 kg is usually <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">15 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of body weight while 10 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> are administered in premature infants.</p>
<p>When selective component replacement is necessary then plasma fractions are preferred; however, plasma also can be used.</p>
<p>PLASMA: Fresh plasma is prepared by separating a single unit ( 350 ml ) of blood immediately after collection, for immediate infusion; and fresh-frozen plasma (FFP) is prepared by separating a single unit of blood within 6 hours of collection and then storing the plasma at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>−</mo><msup><mn>30</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">-30^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7667em; vertical-align: -0.0833em;"></span><span class="mord">−</span><span class="mord">3</span><span class="mord"><span class="mord">0</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> or lower. Fresh plasma and FFP contain all the stable proteins (albumin, globulin) and the coagulation factors including Factor VIII, factor IX and vWF; their main use is to treat/prevent bleeding due to deficiencies of coagulation factors.</p>
<p>FFP is administered as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>12</mn><mo>−</mo><mn>15</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">12-15 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">12</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">15</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span>. It should be transfused immediately after thawing or else it should be stored at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mo>−</mo><msup><mn>6</mn><mo lspace="0em" rspace="0em">∘</mo></msup><mi mathvariant="normal">C</mi></mrow><annotation encoding="application/x-tex">1-6^{\circ} \mathrm{C}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">1</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6741em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∘</span></span></span></span></span></span></span></span></span><span class="mord mathrm">C</span></span></span></span></span> after thawing but should be used within 24 hours. Ideally, ABO compatibility of FFP should be matched with the recipient. However, Group AB plasma is a neutral plasma and hence is considered as universal for all the blood groups. Prothrombin time or partial thromboplastin time should be monitored and should not be allowed to go beyond 1.5 times the normal.</p>
<p>Plasma can also be prepared by separating stored blood within five days after its expiry date; it may be prepared by separating single units of blood individually; or by first mixing together blood of many donors (preferably small in number, say 10-12), and then separating that mixture. Such plasma may then be freeze dried and stored. Plasma prepared in this last manner lacks the labile coagulation factors but has the advantage of easy and prolonged storage upto 5 years. The use of pooled plasma is, however, discouraged because of the statutory requirement of sterilising it free of viruses. The use of plasma merely to maintain blood volume is not recommended.</p>
<p>NORMAL HUMAN SERUM ALBUMIN: This sterile preparation is obtained from human whole blood. It is used to raise the serum protein and reduce edema level in hypoproteinemia, in hypovolemic shock, and as a vehicle for transfusing packed red cells. It is usually non-toxic and does not interfere with normal coagulation. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> solution is given undiluted usually at a rate of 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">4 \mathrm{ml} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">4</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span>. The <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> solution can be administered undiluted or diluted with sterile saline or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose. Undiluted solution is used to treat the presence of edema. In patients with low cardiac reserve, the rate of administration should be slow, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>1</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(1 \mathrm{ml} / \mathrm{min})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">1</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span><span class="mclose">)</span></span></span></span></span>.</p>
<p>PLASMA FRACTIONS: Plasma may also be used, by fractionating it, to prepare:</p>
<ul>
<li>Individual coagulation factor concentrates, such as prothrombin complex concentrate, Factor VIII concentrate, to treat deficiencies of specific factors;</li>
<li>Human gamma globulin;</li>
<li>Fibrinogen;</li>
<li>Human and bovine thrombin, and</li>
<li>Human fibrin foam</li>
</ul>
<p>These are discussed elsewhere.</p>
<ul>
<li>Platelet concentrates are discussed in Chapter 35.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="colloidal-plasma-expanders">Colloidal Plasma Expanders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#colloidal-plasma-expanders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Colloidal plasma expanders are substances of relatively high molecular weight, which, when infused, remain in circulation and augment the blood volume by increasing its oncotic pressure.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="requirements-of-an-ideal-plasma-expander">Requirements of an ideal plasma expander:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#requirements-of-an-ideal-plasma-expander" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>(a) It should have an oncotic pressure comparable to that of plasma.
(b) It should remain in the circulation for an adequate period and yet be eventually disposed of by metabolic degradation/excretion.
(c) It should not affect any visceral function adversely and should not have antigenic, allergenic or pyrogenic effects.
(d) It should not interfere with blood grouping or cross-matching.
(e) It should remain stable over a long period and at usual variations in environmental temperature. It should be easily sterilised and have a viscosity suitable for infusion. (f) It should be easily available.</p>
<p>The plasma expanders are used to treat oligemic shock when blood and plasma are not available immediately. The colloidal plasma expanders are:</p>
<p>DEXTRAN: Dextran is isolated from beet root, where it is formed by the action of a contaminating bacterium Leuconstoc mesenteroides. Native dextran has a very high molecular weight ( 40 million) and from it can be prepared low molecular weight dextrans. Those used in therapeutics are Dextran 70 (Macrodex, M.W. 70,000) and Dextran 40 (Lomodex, M.W. 40,000). Dextran 70 is available as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">6 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">6%</span></span></span></span></span> solution and Dextran 40 as a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> solution, in either isotonic saline or <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose. They are infused in the dose of 10 ml per kg body weight.</p>
<p>The oncotic pressure of dextrans is similar to that of plasma proteins and they persist in the plasma with an effective half life of about 24 hours. The dextrans also inhibit rouleaux formation by RBCs and have an antisludging effect on blood; they are claimed to improve the microcirculation independently of volume expansion. They may not interfere with typing, crossmatching or Rh determination. However, they coat the platelets and coagulation factors, and interfere with their function. In large doses, dextrans can cause widespread hemorrhages.</p>
<p>Dextran 70 tends to be retained in the body especially in the liver and the reticuloendothelial system. Dextran 40 is rapidly excreted by the kidneys; as much as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> is excreted in 24 hours and the remainder in 4-7 days. Dextran molecules not excreted are slowly degraded enzymatically to glucose over a period of weeks. Dextrans are potent antigens especially when administered SC in small doses. However, administration of massive doses IV does not induce antibody formation, probably because of immunological paralysis. Allergic reactions including fatal shock are seen in about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> of persons, including those who have never received it in the past.</p>
<p>During its excretion through the renal tubules, dextran 40 can clog them and is known to precipitate acute oliguric renal failure which is gradual in onset (3-6 days) and hence may be missed initially. In order to guard against such possibility; dextran should not be used: (a) In quantities larger than 1 litre <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo stretchy="false">(</mo><mn>20</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mo stretchy="false">)</mo></mrow><annotation encoding="application/x-tex">(20 \mathrm{ml} / \mathrm{kg})</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mopen">(</span><span class="mord">20</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mclose">)</span></span></span></span></span> on day one and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">10 \mathrm{ml} / \mathrm{kg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span></span></span></span></span> day on subsequent days.
(b) If the urine output is less than 1500 ml per day or the blood urea is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">d</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">60 \mathrm{mg} / \mathrm{dl}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">60</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">dl</span></span></span></span></span></span> or higher.</p>
<p>(c) If the urine output drops further or the specific gravity of the urine rises above 1045 during its administration; in such cases an attempt may be made to keep the urine output high with the use of diuretics and a high fluid intake; and
(d) For more than 5 days.</p>
<p>They are contraindicated in those who are known to be allergic to them; in patients in heart failure; in existing or threatened acute oliguric renal failure; and in patients with hypofibrino-genemia or marked thrombocytopenia.</p>
<p>Dextrans can be easily sterilised by either filtration or autoclaving. They can be stored without any special precautions for upto 10 years and thus can be stockpiled for emergency use.</p>
<p>HYDROXYETHYL STARCHES: Addition of hydroxyethyl groups to starch molecules makes them resistant to hydrolysis by amylase and prolongs their intravascular half-life. One preparation (Hetastarch, Expan, MW 450,000) of hydroxyethyl starch has been extensively tried in treating shock. Compared to dextrans, hetastarch:</p>
<ul>
<li>Maintains blood volume longer</li>
<li>Is non-allergenic; and</li>
<li>Does not cause acute renal failure or coagulation disturbances</li>
</ul>
<p>POLYVINYLPYRROLIDONE (PVP): This is a synthetic, water soluble, hydrophilic polymer of heterogenous molecular sizes with a molecular weight between 35,000 and 40,000. It is given IV, as a clear, amber coloured, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">40%</span></span></span></span></span> solution in buffered normal saline.</p>
<p>It is rapidly excreted; 50 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">75 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">75%</span></span></span></span></span> of the dose is recovered from the urine within 48 to 72 hours. About <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">10 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">10%</span></span></span></span></span> is excreted in bile. The remainder (fraction of molecular weight above 120,000 ) is not metabolised and is stored in the skin, skeletal muscle and the reticuloendothelial system.</p>
<p>PVP may interfere with antibody formation. It can bind to drugs like penicillin and insulin and has a tendency to produce agglutination of erythrocytes. Hence, it interferes with blood grouping. It is now less used.</p>
<p>GELATIN POLYMERS: Various gelatin polymers have been investigated as plasma substitutes. One such polymer of degraded gelatin available commercially (Haemaccel) is a polypeptide with molecular weight of about <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo separator="true">,</mo><mn>000</mn><mo>−</mo><mn>35</mn><mo separator="true">,</mo><mn>000</mn></mrow><annotation encoding="application/x-tex">30,000-35,000</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">35</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span></span></span></span></span>. It is dissolved in an electrolyte solution with the final pH of the infusion 7.2-7.3. In this state, it can remain stable for 3 years at room temperature. Given IV, its mean serum half life is 4 to 5 hours. Approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>60</mn><mo>−</mo><mn>80</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">60-80 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">60</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">80%</span></span></span></span></span> of the gelatin is excreted unchanged by the kidneys. The preparation exerts osmotic activity similar to that of albumin.</p>
<p>It does not interfere with coagulation, blood grouping and cross matching and is nonantigenic. Occasionally, it may cause flushing, urticaria and rigors. Bronchospasm and hypotension can occur. It is available as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>3.5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">3.5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">3.5%</span></span></span></span></span> gelatin polymer in 500 ml .</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="crystalloid-plasma-expanders">Crystalloid Plasma Expanders<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#crystalloid-plasma-expanders" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Crystalloids are solutions containing salts or other water-miscible agents. They can freely cross biological barriers to enter interstitial tissue and hence, their effects are not restricted within vessels.</p>
<p>NORMAL SALINE, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span>, is the most widely used IV preparation. As its osmolality (308 <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">O</mi><mi mathvariant="normal">s</mi><mi mathvariant="normal">m</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{mOsm} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord"><span class="mord mathrm">mOsm</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> ) matches that of serum, it is an excellent fluid for volume replacement. It distributes itself in the extracellular space, and infusion of 1 litre of normal saline raises the blood volume by about 300 ml . It is mainly useful to replace lost sodium, chloride and water, particularly in cases of dehydration for emergency correction of hypovolemia e.g. hemorrhage, burns, diarrhoea. It is also used as a vehicle for giving IV drugs by drip. Though it is adequate to raise the effective blood volume and BP in emergencies, it leaves the blood rapidly and hence, has a short duration of effect. Too rapid administration of large amounts can produce pulmonary edema. The febrile reaction that occur is usually due to the presence of pyrogens.</p>
<p>It is important to note that noradrenaline is unstable at the neutral pH of normal saline but is stable at the acidic pH of dextrose solution.</p>
<p>Hypertonic Saline: see Chapter 37
Hypotonic Saline ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.45%</span></span></span></span></span> ): it is used to treat:
(a) Hypernatremia with extracellular volume depletion and
(b) Hyperosmolar state with severe hyperglycemia ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.45</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.45 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.45%</span></span></span></span></span> saline with <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">5 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">5%</span></span></span></span></span> dextrose).</p>
<p>DEXTROSE 5% in water: When the glucose metabolism is normal, this solution is equivalent to administration of water alone. As its osmolality is lower than that of serum, it is not optimum for volume replacement. Water distributes itself in the total body water, and infusion of 1 litre of dextrose in water raises the blood volume by about 100 ml only. It is particularly useful when the kidney function is impaired. It supplies nutrition. It can be used as a vehicle for drugs, especially noradrenaline. However, phenytoin should not be infused in glucose-containing fluids.</p>
<p>In general, colloids are superior to crystalloids in maintaining blood volume. But they are expensive and they may not always be available. Hence <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.9</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">0.9 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">0.9%</span></span></span></span></span> sodium chloride or Ringerlactate is used commonly.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="cardiovascular-drugs-in-shock">Cardiovascular Drugs in Shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#cardiovascular-drugs-in-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>The major cardiovascular drugs used in shock are summarised in Tables 32.1 and 32.2.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-32-1">Table 32.1<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-32-1" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="actions-of-drugs-used-in-shock">Actions of drugs used in shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#actions-of-drugs-used-in-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Drug</th><th style="text-align: center;">Receptors</th><th style="text-align: center;"></th><th style="text-align: center;"></th><th style="text-align: center;"></th></tr></thead><tbody><tr><td style="text-align: center;"></td><td style="text-align: center;">Dopamine</td><td style="text-align: center;">Beta,</td><td style="text-align: center;">Beta,</td><td style="text-align: center;">Alpha</td></tr><tr><td style="text-align: center;">Adrenaline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Noradrenaline <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;">(small doses)</td><td style="text-align: center;"></td><td style="text-align: center;">(large doses)</td></tr><tr><td style="text-align: center;">Dopamine</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo></mrow><annotation encoding="application/x-tex">+</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Dobutamine</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo><mrow><mo fence="true">∣</mo><mtext> </mtext><mfrac><mn>101</mn><mn>2</mn></mfrac></mrow></mrow><annotation encoding="application/x-tex">++\left\lvert\, \frac{101}{2}\right.</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">+</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1.2em; vertical-align: -0.35em;"></span><span class="minner"><span class="mopen"><span class="delimsizing mult"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.85em;"><span style="top: -2.85em;"><span class="pstrut" style="height: 3.2em;"></span><span style="width: 0.333em; height: 1.2em;"><svg xmlns="http://www.w3.org/2000/svg" width="0.333em" height="1.200em" viewBox="0 0 333 1200"><path d="M145 15 v585 v0 v585 c2.667,10,9.667,15,21,15
c10,0,16.667,-5,20,-15 v-585 v0 v-585 c-2.667,-10,-9.667,-15,-21,-15
c-10,0,-16.667,5,-20,15z M188 15 H145 v585 v0 v585 h43z"></path></svg></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.35em;"><span></span></span></span></span></span></span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord"><span class="mopen nulldelimiter"></span><span class="mfrac"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.8451em;"><span style="top: -2.655em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span><span style="top: -3.23em;"><span class="pstrut" style="height: 3em;"></span><span class="frac-line" style="border-bottom-width: 0.04em;"></span></span><span style="top: -3.394em;"><span class="pstrut" style="height: 3em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">101</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.345em;"><span></span></span></span></span></span><span class="mclose nulldelimiter"></span></span><span class="mclose nulldelimiter"></span></span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>±</mo></mrow><annotation encoding="application/x-tex">\pm</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">±</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Phenylephrine</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td></tr><tr><td style="text-align: center;">Isoprenaline</td><td style="text-align: center;">-</td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;"><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>+</mo><mo>+</mo></mrow><annotation encoding="application/x-tex">++</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6667em; vertical-align: -0.0833em;"></span><span class="mord">+</span><span class="mord">+</span></span></span></span></span></td><td style="text-align: center;">-</td></tr><tr><td style="text-align: center;">Glucagon: Positive inotropic and chronotropic action independent of beta-adrenergic receptors.</td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td><td style="text-align: center;"></td></tr></tbody></table>
<p><span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mi>a</mi></msup></mrow><annotation encoding="application/x-tex">{ }^{a}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mathnormal mtight">a</span></span></span></span></span></span></span></span></span></span></span></span></span> Low doses elevate systolic and decrease diastolic pressure; higher doses elevate both.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mtext>a&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">{ }^{\text {a }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6644em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6644em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">a&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> Both systolic and diastolic pressures elevated.
The action of dopamine varies with the dose. See Table 18.6 in Chapter 17.
Dobutamine is a more potent ionotropic agent than isoprenaline.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="table-32-2">Table 32.2<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-32-2" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="principles-of-management-of-shock">Principles of management of shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#principles-of-management-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<table><thead><tr><th style="text-align: center;">Treatment</th><th style="text-align: center;">Hypovolemic shock</th><th style="text-align: center;">Endotonic shock</th><th style="text-align: center;">Cardiogenic shock</th><th style="text-align: center;">Anaphylactic shock</th></tr></thead><tbody><tr><td style="text-align: center;">Volume replacement</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Usually no</td><td style="text-align: center;">Possibly</td></tr><tr><td style="text-align: center;">Dopamine</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Possibly</td></tr><tr><td style="text-align: center;">Dobutamine</td><td style="text-align: center;">Possibly</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td></tr><tr><td style="text-align: center;">Noradrenaline (only if severely hypotensive)</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td><td style="text-align: center;">Yes</td></tr><tr><td style="text-align: center;">Adrenaline</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">Drug of choice</td></tr><tr><td style="text-align: center;">Vasodilators (Sodium nitroprusside, nitroglycerine)</td><td style="text-align: center;">Possibly</td><td style="text-align: center;">No</td><td style="text-align: center;">Possibly</td><td style="text-align: center;">No</td></tr><tr><td style="text-align: center;">Phenylephrine <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mo lspace="0em" rspace="0em">∗</mo></msup></mrow><annotation encoding="application/x-tex">{ }^{*}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6887em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.6887em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">∗</span></span></span></span></span></span></span></span></span></span></span></span></span></td><td style="text-align: center;">No</td><td style="text-align: center;">Sometimes</td><td style="text-align: center;">No</td><td style="text-align: center;">Sometimes</td></tr><tr><td style="text-align: center;">Glucocorticoids</td><td style="text-align: center;">In Addison's disease</td><td style="text-align: center;">Yes</td><td style="text-align: center;">No</td><td style="text-align: center;">Yes</td></tr><tr><td style="text-align: center;">Antihistaminics</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">No</td><td style="text-align: center;">Yes</td></tr></tbody></table>
<p>Isoprenaline is useful in toxicity due to beta blockers if bradycardia is the main problem (atropine may also be used for the same purpose); glucagon, dopamine and dobutamine are useful if hypotension is the main problem.
<span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mrow></mrow><mn>7</mn></msup></mrow><annotation encoding="application/x-tex">{ }^{7}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8141em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8141em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">7</span></span></span></span></span></span></span></span></span></span></span></span></span> May also be used along with dopamine.
"Also useful in spinal shock.
Dopamine is indicated for reversing hypotension following MI, trauma, sepsis, kidney failure, overt heart failure and chronic CHF, when volume resuscitation is unsuccessful. For dobutamine, see Chapter 18. Noradrenaline may be required for severe hypotension. The other drugs used are mephentermine, metara-minol and methoxamine (Chapter 18).</p>
<p>Mephentermine acts chiefly by increasing the cardiac output. Metaraminol acts like NA but is less potent. As it acts by releasing NA from the nerve endings, prior treatment with reserpine (which depletes catecholamine stores) makes the patient unresponsive to this drug. Methoxamine, being a pure alpha adrenergic stimulant, is useful only in neurogenic shock. Correction of acidosis restores sensitivity to the sympathomimetics.</p>
<p>The main problem with sympathomimetics is the loss of responsiveness to them, apparently due to downregulation of adrenergic receptors, which may become evident within 8 hours of continuous infusion. Therefore, some workers recommend their intermittent use in shock.</p>
<p>Except as a desperate resuscitative measure, the use of vasopressors should be preceded by expansion of intravascular volume. The systolic blood pressure should be maintained around <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>90</mn><mo>−</mo><mn>100</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">m</mi></mrow><mrow><mi mathvariant="normal">H</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">90-100 \mathrm{~mm} \mathrm{Hg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">90</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">mm</span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">Hg</span></span></span></span></span></span> (or in previously hypertensive patients, 30 mm Hg below their usual pressure) during vasopressor infusion, as at infusion rates needed to raise the pressure higher, peripheral resistance rises disproportionately and compromises tissue perfusion. Use of isoprenaline should be monitored by PAOP measurement and measurement of arterial BP; heart rate over 120/minute may cause cardiac arrhythmias and should be avoided.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="treatment-of-shock">Treatment of Shock<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#treatment-of-shock" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Clinically, shock can be classified as:
I Hypovolemic or oligemic shock due to
(a) Acute loss of plasma or blood as in burns and hemorrhage; or
(b) Due to dehydration and sodium depletion as in excessive vomiting, diarrhoea, diabetic ketoacidosis and Addison's disease.
II Bacteremic endotoxic or septic shock produced as a result of severe infection usually with gram negative bacteria like E. coli. Gram positive organisms, particularly resistant staphylococci, can also produce shock by releasing an exotoxin called toxic shock syndrome toxin-1 (TSST-1) into the circulation. Deficiency of adrenal gland function and vasopressin production occurs in about half and one-third patients respectively. The mortality is still <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>40</mn><mo>−</mo><mn>60</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">40-60 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">40</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">60%</span></span></span></span></span>.
III Cardiogenic shock due to acute heart failure e.g., myocardial infarction, acute myocarditis or severe paroxysmal tachycardia.
IV Anaphylactic shock which is due to release of histamine and other mediators (Chapters 2 and 23).
V Neurogenic shock due to pooling of blood in post-capillary capacitance blood vessels, e.g. shock encountered with spinal anaesthesia, spinal cord injury, abdominal and testicular trauma and perforation of a hollow viscus. In fact, it is a form of distributive shock.
VI Haemo-obstructive shock produced as a result of obstruction of a main vascular channel, e.g. shock due to massive pulmonary embolism.
I Hypovolemic shock:</p>
<ul>
<li>Immediate treatment is directed towards restoration of effective blood volume by suitable fluids given IV. Hypovolemic shock is usually associated with metabolic acidosis as tissue hypoxia increases the production of lactic acid. This can be corrected by administration of sodium bicarbonate. Associated diseases such as diabetes or Addison's disease must be treated.</li>
<li>Abnormalities of electrolyte balance should be corrected.</li>
<li>As soon as the clinical state of the patient permits, the causative factor should be corrected, if possible.</li>
<li>Morphine is administered IV to relieve pain if shock is not associated with head injury or suspected acute abdomen.</li>
<li>Vasopressor agents (DA or NA see Table 32.2) may be employed to correct hypotension. However, fluid deficit must be corrected before using vasopressors. Without such correction, the use of vasopressor agents may worsen the patient's condition by reducing renal and cerebral blood flow and by increasing the oxygen consumption of the myocardium.</li>
<li>Oxygen administration to correct arterial hypoxemia. Central venous <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">O</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{O}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">O</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> saturation should be maintained at more than <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>70</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">70 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">70%</span></span></span></span></span>.
II Bacteremic shock (Endotoxic shock): This is caused by severe infection and tissue hypoperfusion, leading to organ dysfunction. Emergency treatment comprises the use of appropriate antibiotic, surgical intervention (if necessary), correction of acidosis, blood volume expansion, and therapy for hypotension and for associated hypoglycemia. As active lung injury often complicates severe sepsis, lung-protective ventilation, meaning the</li>
</ul>
<p>use of relatively low tidal volumes ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>6</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">6 \mathrm{ml} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">6</span><span class="mord"><span class="mord mathrm">ml</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> of ideal body weight), is reported to be beneficial in reducing mortality. Excessive tidal volume causes lung injury. Use of antiendotoxin and monoclonal antibodies to TNF- <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>α</mi></mrow><annotation encoding="application/x-tex">\alpha</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal" style="margin-right: 0.0037em;">α</span></span></span></span></span> are under evaluation for the treatment of endotoxic shock.
III Shock due to acute myocardial infarction (MI): see Chapter 29.
IV Anaphylactic shock: See Chapters 2 and 23.
V Neurogenic shock: This should be treated like hypovolemic shock. Use of a vasopressor IV (Tables 32.1 and 32.2) is indicated. Alternatively, ephedrine hydrochloride 0.5 to 1 ml of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>45</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">l</mi></mrow></mrow><annotation encoding="application/x-tex">45 \mathrm{mg} / \mathrm{ml}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">45</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">ml</span></span></span></span></span></span> solution may be injected IM prophylactically.
VI Hemo-obstructive shock: This should be treated like cardiogenic shock.
Vasodilators in shock: Their use is restricted to the treatment of continued ischemic pain or cardiogenic shock in acute MI. Nitroglycerin IV infusion, along with dobutamine infusion is the preferred regimen.</p>
<p>Glucocorticoids in shock: Glucocorticoids are of definite value in shock due to adrenocortical insufficiency and anaphylaxis. As many patients in septic shock may have partial, adrenocortical insufficiency, early administration of low doses of a glucocorticoid ( 200 mg hydrocortisone per 24 hours by continuous IV infusion, or equivalent doses IM of methylprednisolone, betamethasone, or dexamethasone) for 5-7 days may be helpful. The first dose should be administered as soon as septic shock is suspected. Treatment of septic shock with corticosteroids is, however, not accepted by all experts. It is of no value in cardiogenic, hypovolemic and traumatic shock.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="section-viii-drugs-acting-on-blood-and-blood-forming-organs">SECTION VIII Drugs Acting on Blood and Blood Forming Organs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#section-viii-drugs-acting-on-blood-and-blood-forming-organs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="outline">OUTLINE<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#outline" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Chapter 33: Drugs and Blood Coagulation
Chapter 34: Drugs Effective in Iron Deficiency and Other Related Anemias
Chapter 35: Drugs Effective in Megaloblastic Anemias and Neutropenia
Chapter 36: Drug-Induced Blood Dyscrasias</p>
<p>33</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="drugs-and-blood-coagulation">Drugs and Blood Coagulation<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#drugs-and-blood-coagulation" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Drugs are often used in therapeutics to prevent blood coagulation and to arrest blood loss. They do that by acting on various stages of coagulation:</p>
<ul>
<li>Platelet aggregation</li>
<li>Clot or fibrin formation; or</li>
<li>Fibrinolysis</li>
</ul>
<p>Hemostasis is the spontaneous arrest of bleeding from damaged blood vessels. When cut, the precapillary vessels constrict. Platelets adhere (platelet adhesion) to the exposed collagen fibrils in the subendothelium of the injured vessel via a specific, platelet-collagen receptor, glycoprotein Ia/IIa. This causes platelet activation and release of preformed platelet granule constituents ( 5 HT ) and de novo generation of mediators of coagulation including adenosine diphosphate (ADP). This promotes platelet aggregation (more platelets sticking to each other), thus forming a primary hemostatic plug. Activated platelets lose their individual membranes, form a viscous mass and promote the assembly of clotting factors, thereby amplifying thrombin formation. Activated platelets generate thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{A}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, a potent platelet agonist that also stimulates additional platelets. The other platelet agonists include collagen, ADP, adrenaline and thrombin. ADP elicits its effects on the platelet through <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> receptors while thrombin interacts with protease activated receptors PAR -1 and -4 .</p>
<p>Circulating fibrinogen binds to an activated platelet receptor glycoprotein IIb/IIIa (Integrin) and is converted to fibrin. The process of deposition of fibrin is called coagulation.</p>
<p>The process of coagulation involves a series of interactions among various protein factors and other substances (Kallekrein, calcium, platelet factor) present in the plasma. The clotting factors (Table 33.1) are synthesised by the liver. Some of the factors (II or prothrombin; VII, IX and X) are vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>K</mi></mrow><annotation encoding="application/x-tex">K</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.07153em;">K</span></span></span></span></span> dependent for their synthesis. During the process of clotting, each factor undergoes partial proteolysis to form an enzyme (activated factor labelled by the subscript ' <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>a</mi></mrow><annotation encoding="application/x-tex">a</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4306em;"></span><span class="mord mathnormal">a</span></span></span></span></span> ' after the Roman number indicating the factor e.g. Xa). The activated factor then brings about similar proteolysis of the next factor in the cascade of coagulation, leading ultimately to conversion of fibrinogen into soluble fibrin (friable clot) and finally, conversion of soluble fibrin into insoluble fibrin (firm clot). Figure 33.1.</p>
<p>Table 33.1
Blood clotting factors</p>
<table><thead><tr><th style="text-align: center;">Factor No.</th><th style="text-align: left;">Common name</th></tr></thead><tbody><tr><td style="text-align: center;">I</td><td style="text-align: left;">Fibrinogen</td></tr><tr><td style="text-align: center;">II</td><td style="text-align: left;">Prothrombin</td></tr><tr><td style="text-align: center;">III</td><td style="text-align: left;">Thromboplastin</td></tr><tr><td style="text-align: center;">IV</td><td style="text-align: left;">Ionic calcium</td></tr><tr><td style="text-align: center;">V</td><td style="text-align: left;">Hereditary labile factor, Activator (AC) globulin, Proaccelerin.</td></tr><tr><td style="text-align: center;">VI</td><td style="text-align: left;">Accelerin, supposed to be active form of Factor V</td></tr><tr><td style="text-align: center;">VII</td><td style="text-align: left;">Proconvertin; Serum prothrombin conversion accelerator (SPCA)</td></tr><tr><td style="text-align: center;">VIII</td><td style="text-align: left;">Antihemophilic factor (AHF)</td></tr><tr><td style="text-align: center;">IX</td><td style="text-align: left;">Plasma thromboplastin component (PTC; Christmas factor)</td></tr><tr><td style="text-align: center;">X</td><td style="text-align: left;">Stuart-Prower factor</td></tr><tr><td style="text-align: center;">XI</td><td style="text-align: left;">Plasma thromboplastin antecedent (PTA)</td></tr><tr><td style="text-align: center;">XII</td><td style="text-align: left;">Hageman factor</td></tr><tr><td style="text-align: center;">XIII</td><td style="text-align: left;">Fibrin stabilising factor, Fibrinase</td></tr><tr><td style="text-align: center;">XIV</td><td style="text-align: left;">Prekallekrein</td></tr><tr><td style="text-align: center;">XV</td><td style="text-align: left;">Kallekrein</td></tr><tr><td style="text-align: center;">XVI</td><td style="text-align: left;">Platelet factor</td></tr></tbody></table>
<p><img src="assets/images/image-20251214-f3d8d949.jpeg" alt="img-31.jpeg"></p>
<p>FIG. 33.1 Clotting factors and blood clotting</p>
<ul>
<li>Inhibited by warfarin ** Inhibited by heparin</li>
</ul>
<p>The coagulation is initiated in vitro by the intrinsic pathway whereas it is initiated in vivo by the extrinsic pathway (Fig. 33.1). These pathways merge with the generation of factor Xa. All the reactants necessary for the intrinsic pathway are already present in the blood in an inactive form.</p>
<p>The initial event in the intrinsic pathway appears to be the activation of factor XII to factor XIIa following a contact with a foreign surface such as glass. The initiators of the extrinsic pathway are not normally present in the blood; they are added following tissue injury; in their presence, factor VII converts factors IX and X to active factors IXa and Xa respectively. The two pathways have the common objective of generating factor Xa from factor X . The intrinsic pathway is slow requiring minutes for the formation of activated factor X (factor Xa ); the extrinsic pathway takes only seconds for the same.</p>
<p>Normally, the blood is kept fluid by:</p>
<ul>
<li>The rapid flow of blood, which keeps the local concentration of clotting factors low.</li>
<li>Antithrombin III which inactivates all the clotting factors in the blood as well as any thrombin formed in the circulation; and</li>
<li>Removal by fibrinolysis of traces of fibrin formed in the circulation.</li>
</ul>
<p>Disturbances in hemostasis include hypercoagulability and excessive bleeding. The latter may be due to deficiency of platelets or clotting factors. Hypercoagulability is due to:</p>
<ul>
<li>Stasis within the venous system</li>
<li>Injury to or disease of the vessel wall; and</li>
<li>A hypercoagulable state of blood</li>
</ul>
<p>Thrombogenesis is a pathological process, leading to an intravascular thrombus formation. It is normally prevented by several regulatory mechanisms such as normal vascular endothelium, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, antithrombin, protein C and heparan sulfate proteoglycans synthesised by the vascular endothelium.</p>
<p>There are two types of thrombi: (1) arterial (white thrombus); and (2) venous (red thrombus). The process of formation of an arterial thrombus is an extension of the processes of platelet adhesion, granule release and platelet aggregation. The arterial thrombus is predominantly made up of aggregated platelets and contains little thrombin. The arterial thrombus via platelet receptor glycoprotein IIb/IIIa (GpIIb/IIIa) may occlude the artery or, by disintegrating, embolise the distal arterial tree. It may lead to ischemic necrosis of the tissue such as heart. By contrast, a venous thrombus forms in an area of venous stasis (slow blood flow). It is largely a mass of fibrin with RBCs entangled in its mesh and resembles a clot formed in a test tube. It has few platelets.</p>
<p>Figure 33.2 depicts the steps in thrombosis and their inhibitors. Drugs used in the prevention and treatment of thrombosis are:
<img src="assets/images/image-20251214-abca99d3.jpeg" alt="img-32.jpeg"></p>
<p>FIG. 33.2 Mechanism of thrombosis and its inhibition by drugs (1) Aspirin; (2) Clopidogrel; and (3) Glycoprotein llb/llla antagonists. Prostacyclin is a physiological inhibitor (see text).</p>
<ul>
<li>Antiplatelet agents</li>
<li>Anticoagulants</li>
<li>Fibrinolytic agents; and</li>
<li>Hemorrheological agents (Chapter 28).</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="antiplatelet-agents">Antiplatelet Agents<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#antiplatelet-agents" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>Intravascular thrombosis is initiated by platelet adhesion and aggregation and is completed by the formation of fibrin.</p>
<p>Prostacyclin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGI}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> and thromboxane <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{TXA}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> are both derived from arachidonic acid (Chapter 25). Unlike <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which is formed by the vascular endothelium, TXA2, mostly generated by the platelets, is a potent vasoconstrictor, and promotes platelet aggregation. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> plays a major role in the natural resistance to intra-arterial thrombosis. A balance between platelet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and vascular <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> regulates the platelet aggregability. Circulating platelets normally do not adhere to the healthy endothelium, mainly because of the adequate <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formed locally.</p>
<p>Platelet cyclic AMP plays an important role in platelet adhesion/aggregation. Endothelial <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> stimulates adenylyl cyclase and the formation of cAMP. <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> within the platelets, on the other hand, inhibits adenylyl cyclase and lowers cAMP concentration. High concentration of intraplatelet cAMP inhibits, whereas low concentration accelerates, platelet aggregation. Platelet adhesion and thrombosis seen in atheromatous plaques are due to failure of local generation of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by the vascular endothelial cells (Endothelial dysfunction).</p>
<p>Apart from <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, the endothelial cells also produce NO which increases the platelet cAMP resulting in inhibition of platelet aggregation. Exposed collagen from the subendothelial matrix of damaged vessel wall initiates platelet attachment and simultaneously the release of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> and ADP from the platelets. Additional platelets are then recruited. Antagonists of platelet <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ADP receptors prevent activation of platelets, their recruitment to the site of injury, and aggregation. Prevention of platelet aggregation can prevent thrombosis.</p>
<p>Antiplatelet agents-classification:
I Prostacyclin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>.
II Inhibitors of TXA <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">{ }_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.4511em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formation e.g., Aspirin.
III ADP receptor ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) antagonists e.g., Ticlopidine, Clopidogrel, Prasugrel.
IV Phosphodiesterase inhibitors e.g., Dipyridamole.
V Glycoprotein IIb/IIIa antagonists e.g., Abciximab; and
VI Protease activated receptor (PAR-1) antagonist e.g., Vorapaxar
PROSTACYCLIN <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{PGI}_{2}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> is naturally produced by the endothelial cells lining the blood vessels. It is also present in other tissues such as the brain, the gut and the kidney. It is formed from PG-endoperoxide (Chapter 25).</p>
<p>In man, prostacyclin infusion, in addition to inhibiting platelet aggregation, causes vasodilatation, resulting in hypotension, tachycardia, headache and intense facial flushing. It causes renin release. The compound is very unstable with a short half life of 3 minutes.</p>
<p>Epoprostanol, an analogue of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>, is available for preventing platelet aggregation during hemodialysis and to treat primary pulmonary hypertension (Chapter 25).</p>
<p>ASPIRIN: Aspirin selectively acetylates platelet cyclo-oxygenase irreversibly (Chapter 11). The enzyme of vessel walls is less sensitive to aspirin than is that of platelets. Hence, small doses of aspirin selectively inhibit the synthesis of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>T</mi><mi>X</mi><msub><mi>A</mi><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">T X A_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord mathnormal" style="margin-right: 0.07847em;">TX</span><span class="mord"><span class="mord mathnormal">A</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> by platelets whereas higher doses</p>
<p>also inhibit <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> formation in the vessel. Aspirin in the oral dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mo>−</mo><mn>150</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">75-150 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">75</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">150</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> daily is useful in:</p>
<ul>
<li>Decreasing the incidence of CHD in adults with high risk factors (Primary prevention).</li>
<li>Preventing MI in patients with angina.</li>
<li>Acute coronary syndromes (ACS) such as unstable angina. As immediate platelet inhibition is desirable, the dose of aspirin should be 150-300 mg.</li>
<li>Patients undergoing coronary bypass surgery or angioplasty, or other revascularization procedures.</li>
<li>Preventing stroke in patients with cerebrovascular disease and history of transient ischemic attacks (TIA).</li>
<li>Preventing ischemic limb complications in patients with atherosclerotic peripheral vascular disease.</li>
<li>Preventing re-infarction in patients with MI and ischemic heart disease.</li>
<li>Preventing the development of preeclampsia in pregnant women at high risk of developing that condition; for this purpose, it is started between the <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>12</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">12^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>16</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">16^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">6</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> weeks of pregnancy. Its routine use in all pregnant women to prevent pre-eclampsia is, however, not recommended. It does not prevent the development of eclampsia if started after the onset of pre-eclampsia.
In hypertensive patients, aspirin therapy should not be initiated until the BP is controlled.
The low dose aspirin therapy can cause adverse effects including GI bleeding, and intracranial hemorrhage, though rarely.</li>
</ul>
<p>Dazoxiben is a substituted imidazole which selectively blocks production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">T</mi><mi mathvariant="normal">X</mi><mi mathvariant="normal">A</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{TXA}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">TXA</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> without affecting the production of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mrow><mi mathvariant="normal">P</mi><mi mathvariant="normal">G</mi><mi mathvariant="normal">I</mi></mrow><mn>2</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{PGI}_{2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord"><span class="mord mathrm">PGI</span></span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span>. However, aspirin is safer and far superior.</p>
<p>Ticlopidine, a thienopyridine derivative, is a prodrug. Its active metabolites act as ADP receptor <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo fence="true">(</mo><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub><mo fence="true">)</mo></mrow><annotation encoding="application/x-tex">\left(\mathrm{P}_{2} \mathrm{Y}_{12}\right)</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="minner"><span class="mopen delimcenter" style="top: 0em;">(</span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mclose delimcenter" style="top: 0em;">)</span></span></span></span></span></span> antagonists and inhibit platelet aggregation. Orally, the onset of action is delayed for hours to days and the effect lasts for a few days after its discontinuation. Adverse effects include neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), rash, diarrhoea and liver dysfunction.</p>
<p>Therapeutically, it is only slightly more effective but more toxic than aspirin.
CLOPIDOGREL: This prodrug, related chemically to ticlopidine, has slow onset of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>8</mn><mrow><mi mathvariant="normal">h</mi><mi mathvariant="normal">r</mi><mi mathvariant="normal">s</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 8 \mathrm{hrs}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">8</span><span class="mord"><span class="mord mathrm">hrs</span></span></span></span></span></span> ). It gets metabolised to its active form by CYP2C19 which irreversibly blocks above-mentioned ADP receptors. Its antiplatelet effect lasts for the life of the platelets (5-7 days). The usual dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>75</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">75 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">75</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day. Given alone, it is equivalent to aspirin but is much more expensive. Its superiority over aspirin remains to be established. Substitution of clopidogrel for aspirin may provide marginal benefit for the secondary prevention of serious vascular events.</p>
<p>Combination of aspirin and clopidogrel is synergistic. Such combination offers no advantage over aspirin for primary prevention of CV disease. The combination is usually used in patients with ACS (unstable angina, NSTEMI, acute MI [STEMI]), during percutaneous coronary intervention (PCI) and other vascularisation procedures. Excessive bleeding is a clear hazard of this combination.</p>
<p>Clopidogrel has several drawbacks such as delayed onset of action, large inter-individual variability in platelet response, irreversibility of its inhibitory effect on platelets, genetic polymorphisms (CYP2C19) and drug-drug interactions with CYP3A4 inhibitors like</p>
<p>atorvastatin.
Low dose aspirin still remains the relatively safe, efficacious and cost-effective antiplatelet regimen for routine use.</p>
<p>Prasugrel, a theinopyridine, is also a prodrug with properties similar to clopidogrel but with greater risk of bleeding. It is claimed to be less susceptible to genetic polymorphism. It is contraindicated in patients with history of stroke of TIA. It should be avoided in elderly <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>&gt;</mo><mn>75</mn></mrow><annotation encoding="application/x-tex">&gt;75</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.5782em; vertical-align: -0.0391em;"></span><span class="mrel">&gt;</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">75</span></span></span></span></span> years of age.</p>
<p>TICAGRELOR: This cyclopentine triazolopyrimidine reversibly inhibits <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">P</mi><mn>2</mn></msub><msub><mi mathvariant="normal">Y</mi><mn>12</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{P}_{2} \mathrm{Y}_{12}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">P</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">2</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span><span class="mord"><span class="mord mathrm" style="margin-right: 0.025em;">Y</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: -0.025em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">12</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ADP receptors. Its action is more rapid and more complete and it is effective in patients not responding to Clopidogrel. The recovery after stoppage is rapid. The drug is metabolised by CYP3A4. Adverse effects include dyspnoea, bradyarrhythmia and increase serum uric acid and creatinine level.</p>
<p>Combinations of newer antiplatelet agents with aspirin are more effective than that with clopidogrel. However, they may have higher risk of bleeding</p>
<p>DIPYRIDAMOLE: This vasodilator reversibly inhibits platelet phosphodiesterase enzyme and thus, increases cAMP. It has a weak therapeutic effect. Its main use is as an adjunct to warfarin in patients with artificial heart valves. It is used orally in the dose of 100 mg qid. By itself, it is hardly of any benefit.</p>
<p>Cilostazol (See Chapter 29)
Glycoprotein IIb/IIIa antagonists: These are:
(1) A monoclonal antibody against the platelet receptor, e.g., Abciximab.
(2) Synthetic inhibitors of glycoprotein IIb/IIIa e.g., Tirofiban - a non-peptide;</p>
<p>Eptifibatide - a cyclic heptapeptide. These agents compete with fibrinogen to occupy the glycoprotein IIb/IIIa receptors. They inhibit the final common pathway of platelet aggregation. Thus, they are effective against any platelet aggregating agent and are more potent than other anti-platelet drugs. Onset of action is rapid.</p>
<p>ABCIXIMAB: This monoclonal antibody blocks platelet receptors and inhibits platelet aggregation. Given as IV bolus, followed by infusion for 12 hours, it produces an immediate effect which lasts for 18-24 hours after stopping the infusion. Small amounts of the drug can be detected on circulating platelets for 7-14 days. It is an effective antithrombotic agent in ACS that requires percutaneous coronary intervention. It acts synergistically with aspirin and heparin. The drug is effective in refractory unstable angina and has also been used in ischemic stroke. The major adverse effect is thrombocytopenia, which is reversed by platelet transfusion; monitoring of platelet count is necessary.</p>
<p>Tirofiban and Eptifibatide are competitive inhibitors of the GpIIb/IIIa complex, with a plasma <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of 2-2.5 hrs. Their effect disappears within 4-6 hours after stopping the infusion.</p>
<p>Vorapaxar: Thrombin activates the platelets by acting on protease activated receptors (PAR-1) on platelets. Vorapaxar selectively inhibits PAR-1 and thus blocks the cellular action of thrombin and serves as modestly effective antiplatelet agent. Although it may help in the secondary prevention of thrombotic events in addition to standard care (aspirin and/or clopidogrel), it also increases the risk of bleeding.</p>
<p>The use of antiplatelet drugs may unmask an underlying defect in hemostasis.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="anticoagulants-classification">Anticoagulants - classification:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#anticoagulants-classification" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>I Those used for preventing clotting of blood inside the intact vasculature.</p>
<ul>
<li>
<p>Fast acting, e.g., Heparin, Bivalirudin, Dabigatran.</p>
</li>
<li>
<p>Slow acting, e.g., (i) Coumarin derivatives e.g. Bishydroxycoumarin, Ethyl biscoumacetate and Warfarin sodium. (ii) Indandione derivatives e.g. Phenindione. II Those used to prevent clotting of blood in vitro. (See later).
The division is necessarily arbitrary as certain drugs can be used both in vivo as well as in vitro.</p>
</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="fast-acting-anticoagulants">Fast Acting Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#fast-acting-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HEPARIN: Heparin was discovered in 1916 by McLean, a medical student, who was looking for a coagulant in the liver. It is a naturally occurring anticoagulant substance of marked molecular heterogeneity (mol. wt 5000-30,000 daltons), found in the metachromatically staining granules of mast cells. These cells are abundant in the liver (hence the name heparin), and in the lung. When released, it is rapidly degraded by macrophages and cannot be detected in normal plasma. Commercial heparin is obtained from the lung and the intestinal mucosa of pigs and cattle.</p>
<p>Purified, unfractionated (native) heparin preparations from different animals have different activities. The bioassay of heparin depends upon the capacity of heparin to prevent clotting of sheep or cattle plasma under standardized conditions. This activity is compared with that of the standard heparin powder; 1 mg of dry material obtained from the cattle lung equals 150 USP units.</p>
<p>Heparin is a mucopolysaccharide composed of a number of sulfated D-glucosamine and D-glucuronic acid units linked through an oxygen bridge (glucosaminoglycans) with more than 40-45 saccharides per chain. The content of esterified sulfuric acid is very high, which makes heparin a strongly electronegative compound. It is thus the strongest organic acid occurring in the body. The anticoagulant activity is attributed to its strong electronegative charge. It is used as the sodium salt.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="pharmacological-actions-of-heparin">Pharmacological actions of heparin:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#pharmacological-actions-of-heparin" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<ul>
<li>Blood coagulation: Heparin prevents the clotting of blood both, in vivo and in vitro. Heparin binds to and activates antithrombin III which then inactivates factor IXa, Xa, and thrombin. The heparin binding changes conformation of antithrombin and the complex becomes almost 1000 fold more active inhibitor than antithrombin alone, producing instantaneous action.
At least 5 saccharide units of heparin are needed to bind to antithrombin. This facilitates binding of the complex to serine protease of factor Xa. Attachment of heparinantithrombin complex to thrombin (factor II) requires at least 18 saccharide units. These units serve as a template on which both, antithrombin and thrombin bind. Antifactor Xa: antifactor IIa activity of unfractionated heparin is 1:1. Even small doses of heparin that have much less antithrombin activity inhibit factor Xa which is a critical moiety in coagulation system. This may explain the usefulness of small dose heparin given SC for prophylaxis. It has no action on thrombin bound to fibrin.
The therapeutic doses prolongs the clotting time ( 2 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>2</mn><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">2^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> times the control) and activated partial thromboplastin time (aPTT) to 1.5 to 2 times the control. Because of its varied distribution, its elimination from plasma involves both first and zero order kinetic. Thus clinically, the dose-response relation is not linear; instead, the anticoagulant respons increases disproportionately in intensity and duration with increasing doses.</li>
</ul>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="heparin-and-lipoprotein-lipase">- Heparin and lipoprotein lipase:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#heparin-and-lipoprotein-lipase" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<p>Heparin abolishes the cloudiness of the hyperlipemic plasma (Tyndall effect) within minutes after its administration. This action occurs only in vivo and is attributed to an enzyme called lipoprotein lipase activated by heparin.</p>
<ul>
<li>Miscellaneous actions: Heparin inhibits aldosterone secretion and causes hyperkalemia. Heparin inhibits the growth of many cells such as vascular muscle and endothelium in</li>
</ul>
<p>culture. It also has some antiinflammatory action.
Absorption, fate and excretion: Heparin is poorly absorbed orally. It is well absorbed after SC injection. Usually, it is given IV. It circulates bound to plasma proteins. The mast cells take up heparin in their granules and act as a storage depot for exogenously administered heparin. It is also taken up by the endothelial cells.
The onset of anticoagulant action with an IV dose is almost immediate and reaches peak within 5 to 10 minutes; whereas after SC administration, it is delayed upto 1 hour. The clotting time returns to normal within 2 to 4 hours with a <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> of about 60 minutes. The aqueous preparation is, therefore, administered at 2 to 4 hourly interval.
Heparin is metabolised mainly by a liver enzyme termed heparinase. Following IV administration, 25 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">50 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">50%</span></span></span></span></span> of a single dose may appear in the urine in active form. Heparin does not cross the placental barrier and is not secreted in the milk.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Allergic and anaphylactoid reactions are rare and include asthma, urticaria, rhinitis, and fever. It is advisable to give a trial dose of 1000 units of heparin.</li>
<li>Bleeding: Excessive or injudicious use of heparin may produce hemorrhage from various sites such as peptic ulcer, kidneys and hemorrhoids, and may cause hemarthrosis or wound hematoma. Patients can bleed with even normal aPTT value. It is advisable to avoid aspirin and other drugs which interfere with platelet function during heparin therapy.</li>
<li>Thrombocytopenia: Heparin causes transient, mild thrombocytopenia in <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>25</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">25 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">25%</span></span></span></span></span> of patients and severe thrombocytopenia in a few. The mild reaction results from heparin induced platelet aggregation. The severe form, which occurs on <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>8</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">8^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord"><span class="mord">8</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mn>12</mn><mtext>th&nbsp;</mtext></msup></mrow><annotation encoding="application/x-tex">12^{\text {th }}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8491em;"></span><span class="mord">1</span><span class="mord"><span class="mord">2</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.8491em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord text mtight"><span class="mord mtight">th&nbsp;</span></span></span></span></span></span></span></span></span></span></span></span></span></span> day of treatment, is due to the formation of heparin dependent antiplatelet antibodies; this can result in tolerance to its anticoagulant action and recurrent thromboembolic disease. The thrombocytopenia improves after its discontinuation. The incidence is less with low molecular weight (LMW) heparins which interact less readily with platelets than unfractionated heparin. It is recommended that a platelet count should be obtained before starting the therapy and frequently during the therapy. Heparin should be discontinued if platelet count falls below 1,00,000/cu mm.</li>
<li>Alopecia: Transient alopecia may occur after prolonged heparin therapy.</li>
<li>Osteoporosis: Use of heparin in the dose of 15,000 units daily for a period of 6 months or more has been reported to cause osteoporosis.</li>
<li>Miscellaneous: SGOT and SGPT levels may rise during therapy with heparin.</li>
</ul>
<p>Preparations and dosage: Heparin is available as sodium or calcium heparin. Since the commercial preparations of heparin vary in their potency (as units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> ), the dosage of heparin must be prescribed in units.</p>
<p>Small fixed doses of heparin are given deep SC to prevent venous thromboembolism. Larger doses are needed either SC or IV to prevent the propagation of an established thrombus; still larger doses may be necessary in acute pulmonary embolism. When large doses are used, they must be adjusted according to the results of clotting time and activated partial thromboplastin time (aPTT) (see below).</p>
<p>Heparin is not injected IM as it can cause a hematoma.
(i) Low fixed dose, SC regimen (Prophylactic): 5,000 U given every 8-12 hours, starting 1-2 hours before the operation and continuing till the patient is discharged. Injection is given</p>
<p>with a small needle and the smallest possible volume is employed, to prevent local hematoma. Determination of aPTT is not needed.
(ii) Dose adjusted SC regimen (Therapeutic): This regimen employs either 8000-10,000 U hourly or 15,000-20,000 U 12 hourly, the actual dose being adjusted in either instance according to the results of aPTT.
(iii) IV Intermittent regimen (Therapeutic): 10,000 U initially (in a 70 kg man) followed by 5000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>10</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">U</mi></mrow><annotation encoding="application/x-tex">10,000 \mathrm{U}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">10</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord mathrm">U</span></span></span></span></span> every <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>−</mo><mn>6</mn></mrow><annotation encoding="application/x-tex">4-6</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">6</span></span></span></span></span> hours. In children, the dose is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{U} / \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">100</span><span class="mord mathrm">U</span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> initially, followed by a similar dose every 4 hours.
(iv) IV infusion (Therapeutic): Initially, 5000 U into the tubing of infusion, followed by 20,000 to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>30</mn><mo separator="true">,</mo><mn>000</mn><mi mathvariant="normal">U</mi></mrow><annotation encoding="application/x-tex">30,000 \mathrm{U}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8778em; vertical-align: -0.1944em;"></span><span class="mord">30</span><span class="mpunct">,</span><span class="mspace" style="margin-right: 0.1667em;"></span><span class="mord">000</span><span class="mord mathrm">U</span></span></span></span></span> daily at the rate of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>0.5</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">0.5 \mathrm{U} / \mathrm{kg} / \mathrm{min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">0.5</span><span class="mord mathrm">U</span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span><span class="mord">/</span><span class="mord"><span class="mord mathrm">min</span></span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1000</mn><mi mathvariant="normal">U</mi><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">1000 \mathrm{U} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">1000</span><span class="mord mathrm">U</span><span class="mord">/</span></span></span></span></span> hour in a 70 kg man) in isotonic saline. Not more than 25,000 units of heparin should be added to one bag for IV infusion.</p>
<p>Low molecular weight heparins (LMWH) are prepared by fractionation of native heparin; they are more homogeneous molecularly with molecular weight between 4000 and 6500 and have 15-17 saccharide chains. Given SC once or twice daily, these compounds have at least as much antithrombotic activity as native heparin. Their advantages are that, they:</p>
<ul>
<li>Are absorbed more uniformly than the native heparin after SC administration.</li>
<li>Have a longer duration of action ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>4</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">h</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 4 \mathrm{~h}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">4</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">h</span></span></span></span></span></span> ).</li>
<li>Inactivate factor Xa selectively; their action against thrombin is minimal. (ratio of anti-Xa to anti-IIa activity is <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>2</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">2: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> to <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>4</mn><mo>:</mo><mn>1</mn></mrow><annotation encoding="application/x-tex">4: 1</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">4</span><span class="mspace" style="margin-right: 0.2778em;"></span><span class="mrel">:</span><span class="mspace" style="margin-right: 0.2778em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">1</span></span></span></span></span> )</li>
<li>Have a predictable anticoagulant effect because they bind less avidly to cells and to heparin binding proteins.</li>
<li>Interact relatively less with platelets and lead to fewer bleeding episodes; and</li>
<li>Are less antigenic and cause thrombocytopenia and osteoporosis less frequently.</li>
</ul>
<p>These properties would make their use attractive for outpatient and domiciliary use. However, they are expensive and their routine post-operative use in all cases is not recommended.</p>
<p>Examples of LMW heparins are enoxaparin, dalteparin sodium, tinzaparin, pamaparin and reviparin. They vary in their pharmacokinetic properties and dose. Their uses are similar to those of native heparin. (Table 33.2). However, native heparin still remains the parenteral anticogualant of choice in cardiopulmonary bypass and DIC.</p>
<p>Table 33.2
Doses of commonly used LMWH</p>
<table><thead><tr><th style="text-align: left;">Preparation For prophylaxis of deep vein thrombosis (DVT)</th><th style="text-align: left;">For treatment of DVT and pulmonary embolism</th></tr></thead><tbody><tr><td style="text-align: left;">Enoxaparin 2000 units SC 2 hrs before surgery; then 2000 units every 24 hrs for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days</td><td style="text-align: left;">100 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> SC every 12 hrs for 5 days</td></tr><tr><td style="text-align: left;">Dalteparin 2500 units SC 1-2 hrs before surgery; then 2500 units every 24 hrs for 5-7 days</td><td style="text-align: left;">100 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> SC twice daily for 5 days</td></tr><tr><td style="text-align: left;">Tinzaparin 3500 units SC 2 hrs before surgery; then 3500 units every 24 hrs for <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>7</mn><mo>−</mo><mn>10</mn></mrow><annotation encoding="application/x-tex">7-10</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">7</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">10</span></span></span></span></span> days</td><td style="text-align: left;">175 units <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">/</mi><mrow><mi mathvariant="normal">k</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">/ \mathrm{kg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">/</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">kg</span></span></span></span></span></span> SC once daily for 6 days</td></tr></tbody></table>
<p>Table 33.3 lists the methods of monitoring heparin therapy. Small doses of heparin SC, for prophylaxis, and LMWH do not generally require monitoring of blood samples.</p>
<p>Table 33.3
Monitoring heparin therapy</p>
<ul>
<li>Whole blood clotting time (Lee-White), which should be kept at 2-3 times the normal; and</li>
<li>Activated partial thromboplastin time (aPTT) which should be kept at <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>11</mn><mi mathvariant="normal">/</mi><mn>2</mn><mo>−</mo><mn>2</mn></mrow><annotation encoding="application/x-tex">11 / 2-2</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">11/2</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.6444em;"></span><span class="mord">2</span></span></span></span></span> times the normal.</li>
</ul>
<p>FONDAPARINUX is a synthetic pentasaccharide unit of heparin that binds to antithrombin and enhances inactivation of Factor Xa. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi>t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">t^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathnormal">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 17 hrs . It is excreted by the kidney. It does not cause heparin induced thrombocytopenia. It is not neutralised by protamine. It is given as 2.5 mg SC once daily.</p>
<p>Heparin antagonists: The anticoagulant effects of heparin can be promptly arrested by the administration of strongly basic compounds which react with the strongly acidic groups of heparin, thereby abolishing the anticoagulant activity e.g. protamine sulfate.</p>
<p>PROTAMINE SULFATE: Protamine is a mixture of simple, low molecular weight polypeptides, found in the sperms of certain fish. It binds firmly to heparin and inactivates it. Protamine sulfate as <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>1</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">1 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">1%</span></span></span></span></span> solution, is administered slowly, IV, not more than 50 mg over a 10 minute period. One mg of protamine sulfate neutralises the anti-coagulant effect of 100 units of heparin activity. If more than 30 minutes have elapsed after heparin administration half of this dosage is required. A patient given protamine should be observed for recurrence of bleeding as protamine sulfate itself has anticoagulant activity and the action of heparin lasts longer than that of protamine.</p>
<p>It is considered unsafe to exceed the dose of <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>50</mn><mo>−</mo><mn>100</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow></mrow><annotation encoding="application/x-tex">50-100 \mathrm{mg}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">50</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 0.8389em; vertical-align: -0.1944em;"></span><span class="mord">100</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span></span></span></span></span> over a short period. Protamine IV injection may cause a sudden fall in BP, bradycardia, dyspnoea and transitory flushing. Protamine only partially neutralises LMWH.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="other-factor-xa-inhibitors">Other Factor Xa inhibitors:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#other-factor-xa-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>RIVAROXABAN: It is an orally acting, direct, reversible selective Factor Xa inhibitor used for prevention and treatment of arterial and venous thromboembolism. It does not require monitoring. There is no specific antidote (Table 33.6). Others are, Apixaban and Edoxaban.</p>
<p>Table 33.6
Advantages and disadvantages of different classes of oral anticoagulants</p>
<table><thead><tr><th style="text-align: center;">Drug class</th><th style="text-align: center;">Advantages</th><th style="text-align: center;">Disadvantages</th></tr></thead><tbody><tr><td style="text-align: center;">Vit. K antagonists (Warfarin)</td><td style="text-align: center;">- Large data on therapeutic utility and adverse effects &lt;br&gt; - Once daily dosing &lt;br&gt; - Antidote available &lt;br&gt; - Cost effective</td><td style="text-align: center;">- Marked variability in dose requirements &lt;br&gt; - Dietary restrictions &lt;br&gt; - INR monitoring required &lt;br&gt; - Numeous drug interactions</td></tr><tr><td style="text-align: center;">Factor Xa inhibitors (Rivaroxaban)</td><td style="text-align: center;">- INR monitoring not required &lt;br&gt; - Once daily dosing &lt;br&gt; - Appeas to have lessincidence of intraconial and fatal bleeding &lt;br&gt; - No dietary restrictions</td><td style="text-align: center;">- No specific antidote &lt;br&gt; - Missing a dose can predispose to thrombotic risk. &lt;br&gt; - No method to evaluate extent of anticoagulant effect &lt;br&gt; - Dose adjustment required in renal impairment &lt;br&gt; - Non dialyzable</td></tr><tr><td style="text-align: center;">Thrombin inhibitors (Dabigatran)</td><td style="text-align: center;">- INR monitoring not required &lt;br&gt; - Dialyzable &lt;br&gt; - Appeas to have lessincidence of intraconial and fatal bleeding</td><td style="text-align: center;">- No specific antidote &lt;br&gt; - No method to evaluate extent of anticoagulant effect &lt;br&gt; - Dose adjustment required in renal impairment &lt;br&gt; - Twice daily dosing and must be stored in original container</td></tr></tbody></table>
<p>Danaparoid: This heparinoid, obtained from porcine intestinal mucosa, is a mixture of glucosaminoglycans. It inhibits Xa. It is given SC twice a day, for prophylaxis. It does not</p>
<p>cause thrombocytopenia. It has no antidote.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="direct-thrombin-inhibitors">Direct Thrombin Inhibitors<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#direct-thrombin-inhibitors" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>HIRUDIN: This is a potent antithrombin polypeptide obtained from the leech Hirudo medicinalis. It has now been synthesised by recombinant DNA technique (lepirudin,). Unlike heparin, it binds irreversibly to thrombin and inactivate free as well as fibrin-bound thrombin. Its effect does not require antithrombin or other co-factors. It not only prevents conversion of fibrinogen to fibrin, but also blocks thrombin-catalysed platelet aggregation, and activation of other clotting factors. Its activity is monitored by the same tests as that of heparin. It has a short duration of action and hence it is given by IV infusion. There is no antidote. It inhibits disseminated intravascular coagulation, and venous and arterial thrombosis.</p>
<p>Bivalirudin is a synthetic analogue of hirudin, with rapid onset and offset of action (due to reversible binding; <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup><mn>25</mn><mrow><mtext>&nbsp;</mtext><mi mathvariant="normal">m</mi><mi mathvariant="normal">i</mi><mi mathvariant="normal">n</mi></mrow></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2} 25 \mathrm{~min}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span><span class="mord">25</span><span class="mord"><span class="mspace nobreak">&nbsp;</span><span class="mord mathrm">min</span></span></span></span></span></span> ). It does not form antihirudin antibodies. Desirudin is also an analogue of hirudin.</p>
<p>Argatroban: is also a reversible direct thrombin inhibitor, given as IV infusion. Its <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msup><mi mathvariant="normal">t</mi><mrow><mn>1</mn><mi mathvariant="normal">/</mi><mn>2</mn></mrow></msup></mrow><annotation encoding="application/x-tex">\mathrm{t}^{1 / 2}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.888em;"></span><span class="mord"><span class="mord mathrm">t</span><span class="msupsub"><span class="vlist-t"><span class="vlist-r"><span class="vlist" style="height: 0.888em;"><span style="top: -3.063em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1/2</span></span></span></span></span></span></span></span></span></span></span></span></span> is 45 min . It is used as an alternative to lepirudin.</p>
<p>DABIGATRAN: Dabigatran etexilate is a prodrug. Given orally, it is converted to the active agent dabigatran which is a direct inhibitor of thrombin. Given once daily, it is claimed to be as effective as enoxaparin for the treatment and prevention of venous thromboembolism. The drug appears to have an ADR profile similar to that of enoxaparin. The major advantage of this drug is that it is effective orally without the need for coagulation monitoring.</p>
<p>All the direct thrombin inhibitors are used in patients with or at risk of developing heparin induced thrombocytopenia.</p>
<p>HUMAN ANTITHROMBIN CONCENTRATE: This is prepared from pooled human plasma or by recombinant technology. It is used either alone or along with heparin to treat patients with a rare hereditary disorder, antithrombin III deficiency.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="slow-acting-anticoagulants">Slow Acting Anticoagulants<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#slow-acting-anticoagulants" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<p>These drugs are known as oral anticoagulants because, in contrast to heparin, they are effective orally. They have a slow onset of action.</p>
<p>COUMARIN DERIVATIVES: Bishydroxycoumarin or dicoumarol, the first coumarin compound (Fig 33.3), was isolated from spoilt sweet clover in 1943-1944 and was proved to be the causative factor in a cattle disease termed 'Sweet Clover Disease', characterised by a severe haemorrhagic tendency. The most commonly used drug is warfarin sodium.
<img src="assets/images/image-20251214-51ef5f7a.jpeg" alt="img-33.jpeg"></p>
<p>FIG. 33.3 Coumarin ring
Pharmacological actions: The various coumarin drugs exert qualitatively similar pharmacological actions (Fig 33.4).
<img src="assets/images/image-20251214-26bbb17e.jpeg" alt="img-34.jpeg"></p>
<p>FIG. 33.4 Vitamin K cycle and site of action of Coumarin anticoagulants</p>
<ul>
<li>Anticoagulant action: Coagulation factors prothrombin, VII, IX and X are synthesised in the liver but are biologically inactive until they are carboxylated. Carboxylation is directly coupled to the oxidation of vitamin K to its epoxide. To sustain the carboxylation, the epoxide is converted back to the reduced form of vitamin K by the enzymes vitamin K epoxide reductase and vitamin K reductase (Fig. 33.4). Coumarin being structurally similar to vitamin K, competitively inhibits vitamin K epoxide reductase. This prevents regeneration of reduced form of vitamin K and therefore to inhibition of carboxylation. Thus coumarins inhibit vitamin K dependent synthesis of coagulation factors. In contrast to heparin, there is a considerable lag (usually 24 to 48 hours) between the</li>
</ul>
<p>time of peak plasma level of coumarins and the therapeutic response. This is because they prevent the formation of active essential clotting factors by the liver but do not destroy the circulating ones. It takes 3-7 days for prothrombin time to return to normal after cessation of therapy. As coumarins have no direct action on coagulation factors they are not effective in vitro.
Coumarin therapy is controlled by estimating prothrombin time which is expressed as International Normalised Ratio (INR). Bleeding time is unaltered.
Absorption, fate and excretion: The intestinal absorption of coumarin is slow and incomplete. The drugs are extensively bound to plasma proteins. They cross the placental barrier and are also secreted in milk. They are mainly metabolised in the liver. There is a considerable individual variation (as much as 14 fold) in the rate of detoxification.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="adverse-reactions">Adverse reactions:<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#adverse-reactions" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<ul>
<li>Bleeding: The incidence of hemorrhage is 5-6%. There is no correlation between the onset and degree of hemorrhage and the dose, or the prothrombin, levels. In fact, similar degree of hypoprothrombinemia may be found in patients who bleed and those who do not.
The hemorrhage induced by coumarins can be treated by large doses of vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>1</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{1}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">1</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> which enables the liver to synthesise active clotting factors. However, even the IV administration of vitamin K is associated with a latent period of several hours. Therefore, in the immediate treatment of severe hemorrhage, prompt administration of fresh whole blood is necessary. Menadione (synthetic Vitamin K, Vitamin <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><msub><mi mathvariant="normal">K</mi><mn>3</mn></msub></mrow><annotation encoding="application/x-tex">\mathrm{K}_{3}</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8333em; vertical-align: -0.15em;"></span><span class="mord"><span class="mord mathrm">K</span><span class="msupsub"><span class="vlist-t vlist-t2"><span class="vlist-r"><span class="vlist" style="height: 0.3011em;"><span style="top: -2.55em; margin-left: 0em; margin-right: 0.05em;"><span class="pstrut" style="height: 2.7em;"></span><span class="sizing reset-size6 size3 mtight"><span class="mord mtight"><span class="mord mtight">3</span></span></span></span></span><span class="vlist-s">​</span></span><span class="vlist-r"><span class="vlist" style="height: 0.15em;"><span></span></span></span></span></span></span></span></span></span></span> ) is ineffective in countering the bleeding caused by coumarins.</li>
<li>Fetal toxicity: Coumarin anticoagulants may cause fatal hemorrhage in the fetus; further they are teratogenic (Chapter 80).</li>
<li>Cutaneous gangrene: Petechiae that coalesce to painful ecchymoses, hemorrhagic bullae and finally to necrosis/gangrene occur occasionally within 3-8 days after starting treatment with large doses of warfarin. The lesions affect women more often than men and involve the adipose tissue of breasts, buttocks, thighs and the distal lower extremities.</li>
<li>Miscellaneous: Rarely, coumarins may cause urticaria, anorexia, vomiting and diarrhoea. WARFARIN SODIUM: This coumarin (Fig 33.5), originally employed as a rodent poison, is the most widely used coumarin anticoagulant and is considered to be the drug of choice. It is a racemic mixture of two isomers, <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>S</mi></mrow><annotation encoding="application/x-tex">S</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.05764em;">S</span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><mn>235</mn></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 235</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/235</span></span></span></span></span> hours) and <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi>R</mi></mrow><annotation encoding="application/x-tex">R</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.6833em;"></span><span class="mord mathnormal" style="margin-right: 0.00773em;">R</span></span></span></span></span> ( <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mi mathvariant="normal">t</mi><mn>1</mn><mi mathvariant="normal">/</mi><mn>250</mn></mrow><annotation encoding="application/x-tex">\mathrm{t} 1 / 250</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord mathrm">t</span><span class="mord">1/250</span></span></span></span></span> hours), in almost equal proportions. After initiating therapy with the maintenance dose <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>5</mn><mo>−</mo><mn>10</mn><mrow><mi mathvariant="normal">m</mi><mi mathvariant="normal">g</mi></mrow><mi mathvariant="normal">/</mi></mrow><annotation encoding="application/x-tex">5-10 \mathrm{mg} /</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.7278em; vertical-align: -0.0833em;"></span><span class="mord">5</span><span class="mspace" style="margin-right: 0.2222em;"></span><span class="mbin">−</span><span class="mspace" style="margin-right: 0.2222em;"></span></span><span class="base"><span class="strut" style="height: 1em; vertical-align: -0.25em;"></span><span class="mord">10</span><span class="mord"><span class="mord mathrm" style="margin-right: 0.01389em;">mg</span></span><span class="mord">/</span></span></span></span></span> day (no loading dose is used), therapeutic INR level is usually achieved in 36 hours but clinical effect is seen within 4-5 days. Its advantages are:</li>
</ul>
<p><img src="assets/images/image-20251214-8a686a79.jpeg" alt="img-35.jpeg"></p>
<ul>
<li>It is almost <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>99</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">99 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">99%</span></span></span></span></span> absorbed and gives more steady plasma levels; approximately <span class="math math-inline"><span class="katex"><span class="katex-mathml"><math xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>97</mn><mi mathvariant="normal">%</mi></mrow><annotation encoding="application/x-tex">97 \%</annotation></semantics></math></span><span class="katex-html" aria-hidden="true"><span class="base"><span class="strut" style="height: 0.8056em; vertical-align: -0.0556em;"></span><span class="mord">97%</span></span></span></span></span> of the drug is bound to plasma albumin.</li>
<li>It has rapid onset and predictable duration of action; therefore, the therapy is easier to regulate; and</li>
<li>It is water soluble and can be given parenterally. Parenteral administration, however, does not accelerate the speed of anticoagulation.
If warfarin is employed for long-term anticoagulant therapy, it takes about 3 days for the prothrombin time to return to normal after drug discontinuation.</li>
</ul>
<p>Adverse reactions: Comparatively few toxic effects other than haemorrhage have been reported. These include alopecia, urticaria and dermatitis. It can cross the placenta but is not secreted in the milk. It is contraindicated during pregnancy. Women on long term warfarin therapy should avoid pregnancy. The major drawback of this drug is the possibility of multiple drug interactions (Table 33.4).</p>
<p>Table 33.4
Drug interactions of coumarin anticoagulants</p>
<ul>
<li>Drugs which prolong prothrombin time and may cause bleeding: Aspirin, phenylbutazone, other NSAID, heparin, clofibrate, thyroxine, amiodarone, anabolic steroids, cimetidine, omeprazole, metronidazole, co-trimoxazole, high doses of penicillins, erythromycin, some cephalosporins, moxalactam.</li>
<li>Drugs which shorten prothrombin time: Barbiturates, chloral hydrate, meprobamate, rifampicin, griseofulvin, cholestyramine, carbamazepine. When these drugs are stopped, bleeding may occur in a patient on oral anticoagulants.</li>
</ul>
<p>The action of warfarin can be antagonised by vitamin K (see later).
Other preparations used are: Fresh frozen plasma, recombinant factor VIIa and prothrombin complex concentrate, which act more rapidly than vitamin K.</p>
<p>Preparation and dosage: Warfarin sodium 5 mg . It is used once a day in the dose of 2.510 mg . It has a cumulative action and the maintenance dose may have to be gradually decreased after the first week or so. No loading dose is used to initiate therapy. Its haemostatic effect varies within individuals depending upon the vitamin K intake and polymorphism of vitamin K reductase and liver CYP2C9.</p>
<p>The dose of warfarin is adjusted by measuring INR, which is generally maintained between 2.0 and 3.5 .</p>
<p>Drug interactions: See Table 33.4. Coumarins can cause drug interactions by:</p>
<ul>
<li>Inhibiting the platelet function (aspirin, NSAID).</li>
<li>Stimulating hepatic microsomal catabolism of warfarin (barbiturates, rifampicin, griseofulvin, carbamazepine).</li>
<li>Displacing warfarin from protein binding (sulfonamides, phenylbutazone, chlorpropamide); or</li>
<li>Inhibiting the metabolic clearance of warfarin (cimetidine, omeprazole, amiodarone). Drugs like tolbutamide and phenytoin may accumulate in the body following coumarins</li>
</ul>
<p>and hence, doses of these drugs must be reduced.
Indandione Derivatives: Such as phenindione have anticoagulant activity similar to the coumarin compounds. Because of their toxicity, they are now almost obsolete.</p>
<p>Factors affecting the dosage and activity of the oral anticoagulants are listed in Table 33.5 .</p>
<p>Table 33.5
Factors affecting the dosage of oral anticoagulants</p>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>* Genetic differences in the rate of drug metabolism.
</span>* Age and ses.
* Vitamin K deficiency caused by poordiet, bowel disease or biliary disease enhances the response to oral anticoagulants
* Chronic alcoholism, liver disease, kidney disease and vitamin C deficiency enhance the response.
* Hypermetabolic states.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="* Genetic differences in the rate of drug metabolism.
* Age and ses.
* Vitamin K deficiency caused by poordiet, bowel disease or biliary disease enhances the response to oral anticoagulants
* Chronic alcoholism, liver disease, kidney disease and vitamin C deficiency enhance the response.
* Hypermetabolic states." style="top: 0px; right: 0px;" class="st-emotion-cache-1lyayqq e1xss9yb5"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><rect x="9" y="9" width="13" height="13" rx="2" ry="2"></rect><path d="M5 15H4a2 2 0 0 1-2-2V4a2 2 0 0 1 2-2h9a2 2 0 0 1 2 2v1"></path></svg></button></div></div></div>
<p>Advantages and disadvantages of different classes of oral anticoagulants is presented in Table 33.6.</p>
<p>Table 33.7 summarises the main actions of anticoagulant drugs.</p>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h1 level="1" id="table-33-7">Table 33.7<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#table-33-7" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h1></div>
<div data-testid="stHeadingWithActionElements" class="st-emotion-cache-1p9ibxm e1icttdg2"><h2 level="2" id="main-actions-of-anticoagulant-drugs">Main actions of anticoagulant drugs<span data-testid="stHeaderActionElements" class="st-emotion-cache-gi0tri e1icttdg3"><a href="#main-actions-of-anticoagulant-drugs" class="st-emotion-cache-yinll1 e1icttdg1"><svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M15 7h3a5 5 0 0 1 5 5 5 5 0 0 1-5 5h-3m-6 0H6a5 5 0 0 1-5-5 5 5 0 0 1 5-5h3"></path><line x1="8" y1="12" x2="16" y2="12"></line></svg></a></span></h2></div>
<div data-testid="stMarkdownPre" class="st-emotion-cache-acwcvw e1icttdg5"><div class="stCode st-emotion-cache-6ml83 e1xss9yb4" data-testid="stCode"><pre class="st-emotion-cache-1nqbjoj e1xss9yb2"><div style="background-color: transparent;"><code style="white-space: pre;"><span>* Heparin accelerates inactivation of thrombin by antithrombin III.
</span>* LMWHs, mainly, inactivate factor Xa (activated factor X).
* Rivaroxaban inhibits factor Xa
* Hirudin, Lepuridin and Dabigatran inactivate thrombin.
* Warfarin inhibits the synthesis of several active coagulation factors, including prothrombin.</code></div></pre><div class="st-emotion-cache-chk1w8 e1xss9yb3"><button data-testid="stCodeCopyButton" title="Copy to clipboard" data-clipboard-text="* Heparin accelerates inactivation of thrombin by antithrombin III.
* LMWHs, mainly, inactivate factor Xa (activated factor X).
* Rivaroxaban inhibits factor Xa
* Hirudin, Lepuridin and Dabigatran inactivate thrombin.
